WO2023028341A1 - Compounds, compositions and methods for histone lysine demethylase inhibition - Google Patents
Compounds, compositions and methods for histone lysine demethylase inhibition Download PDFInfo
- Publication number
- WO2023028341A1 WO2023028341A1 PCT/US2022/041742 US2022041742W WO2023028341A1 WO 2023028341 A1 WO2023028341 A1 WO 2023028341A1 US 2022041742 W US2022041742 W US 2022041742W WO 2023028341 A1 WO2023028341 A1 WO 2023028341A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mmol
- alkyl
- cycloalkyl
- heterocyclyl
- aryl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 263
- 238000000034 method Methods 0.000 title claims abstract description 65
- 239000000203 mixture Substances 0.000 title claims description 260
- 108010074870 Histone Demethylases Proteins 0.000 title claims description 19
- 102000008157 Histone Demethylases Human genes 0.000 title claims description 19
- 230000005764 inhibitory process Effects 0.000 title abstract description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 19
- 230000000694 effects Effects 0.000 claims abstract description 9
- -1 -N3 Chemical group 0.000 claims description 641
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 136
- 125000000623 heterocyclic group Chemical group 0.000 claims description 123
- 125000003118 aryl group Chemical group 0.000 claims description 114
- 125000001072 heteroaryl group Chemical group 0.000 claims description 105
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 96
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 87
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 60
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 57
- 229910052739 hydrogen Inorganic materials 0.000 claims description 53
- 239000001257 hydrogen Substances 0.000 claims description 53
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 44
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 38
- 150000003839 salts Chemical class 0.000 claims description 34
- 229940002612 prodrug Drugs 0.000 claims description 28
- 239000000651 prodrug Substances 0.000 claims description 28
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 27
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 26
- 150000002431 hydrogen Chemical group 0.000 claims description 25
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 24
- 229910052757 nitrogen Inorganic materials 0.000 claims description 22
- 125000000217 alkyl group Chemical group 0.000 claims description 21
- 206010028980 Neoplasm Diseases 0.000 claims description 19
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 15
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 14
- 125000003342 alkenyl group Chemical group 0.000 claims description 14
- 125000000304 alkynyl group Chemical group 0.000 claims description 14
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 14
- 208000036142 Viral infection Diseases 0.000 claims description 12
- 125000002947 alkylene group Chemical group 0.000 claims description 12
- 125000004419 alkynylene group Chemical group 0.000 claims description 12
- 235000010290 biphenyl Nutrition 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 230000009385 viral infection Effects 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 11
- 125000001188 haloalkyl group Chemical group 0.000 claims description 9
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 9
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 7
- 125000004429 atom Chemical group 0.000 claims description 7
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 7
- 125000004474 heteroalkylene group Chemical group 0.000 claims description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims description 6
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 claims description 6
- 125000006591 (C2-C6) alkynylene group Chemical group 0.000 claims description 6
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims description 6
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims description 6
- 125000003070 2-(2-chlorophenyl)ethyl group Chemical group [H]C1=C([H])C(Cl)=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims description 6
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims description 6
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims description 6
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims description 6
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims description 6
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims description 6
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 6
- 125000004861 4-isopropyl phenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 6
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 6
- 125000004863 4-trifluoromethoxyphenyl group Chemical group [H]C1=C([H])C(OC(F)(F)F)=C([H])C([H])=C1* 0.000 claims description 6
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 208000014018 liver neoplasm Diseases 0.000 claims description 6
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims description 6
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 6
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims description 6
- 125000004043 oxo group Chemical group O=* 0.000 claims description 6
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 6
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 208000032839 leukemia Diseases 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 201000001441 melanoma Diseases 0.000 claims description 5
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 claims description 4
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 208000032612 Glial tumor Diseases 0.000 claims description 4
- 206010018338 Glioma Diseases 0.000 claims description 4
- 206010061598 Immunodeficiency Diseases 0.000 claims description 4
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 229910019999 S(O)2O Inorganic materials 0.000 claims description 4
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 241000700605 Viruses Species 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 4
- 241001529453 unidentified herpesvirus Species 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- 206010003571 Astrocytoma Diseases 0.000 claims description 3
- 241000701022 Cytomegalovirus Species 0.000 claims description 3
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 3
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims description 3
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 3
- 241000700721 Hepatitis B virus Species 0.000 claims description 3
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims description 3
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 3
- 241001502974 Human gammaherpesvirus 8 Species 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 3
- 206010057644 Testis cancer Diseases 0.000 claims description 3
- 230000004663 cell proliferation Effects 0.000 claims description 3
- 229910052805 deuterium Inorganic materials 0.000 claims description 3
- 201000002313 intestinal cancer Diseases 0.000 claims description 3
- 201000008968 osteosarcoma Diseases 0.000 claims description 3
- 230000007420 reactivation Effects 0.000 claims description 3
- 201000003120 testicular cancer Diseases 0.000 claims description 3
- 125000000464 thioxo group Chemical group S=* 0.000 claims description 3
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims description 2
- 206010062016 Immunosuppression Diseases 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 208000035269 cancer or benign tumor Diseases 0.000 claims description 2
- 206010014599 encephalitis Diseases 0.000 claims description 2
- 230000001506 immunosuppresive effect Effects 0.000 claims description 2
- 206010023332 keratitis Diseases 0.000 claims description 2
- 208000008798 osteoma Diseases 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 8
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 201000002434 Alpha-thalassemia-X-linked intellectual disability syndrome Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 206010006550 Bulimia nervosa Diseases 0.000 claims 1
- 241000399988 Carinoma Species 0.000 claims 1
- 206010012335 Dependence Diseases 0.000 claims 1
- 208000001914 Fragile X syndrome Diseases 0.000 claims 1
- 101000904868 Homo sapiens Transcriptional regulator ATRX Proteins 0.000 claims 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 206010068871 Myotonic dystrophy Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 201000010769 Prader-Willi syndrome Diseases 0.000 claims 1
- 208000006289 Rett Syndrome Diseases 0.000 claims 1
- 206010039281 Rubinstein-Taybi syndrome Diseases 0.000 claims 1
- 206010040108 Serotonin syndrome Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 102100023931 Transcriptional regulator ATRX Human genes 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 208000022246 craniosynostosis-fibular aplasia syndrome Diseases 0.000 claims 1
- 230000028252 learning or memory Effects 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 102100033247 Lysine-specific demethylase 5B Human genes 0.000 abstract description 12
- 101001088883 Homo sapiens Lysine-specific demethylase 5B Proteins 0.000 abstract description 11
- 108010033040 Histones Proteins 0.000 abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract description 7
- 239000004472 Lysine Substances 0.000 abstract description 7
- 201000010099 disease Diseases 0.000 abstract description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 838
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 321
- 235000019439 ethyl acetate Nutrition 0.000 description 282
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 159
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 122
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 121
- 229910052938 sodium sulfate Inorganic materials 0.000 description 121
- 235000011152 sodium sulphate Nutrition 0.000 description 118
- 238000006243 chemical reaction Methods 0.000 description 114
- 239000000243 solution Substances 0.000 description 112
- 239000012267 brine Substances 0.000 description 100
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 100
- 239000012043 crude product Substances 0.000 description 88
- 239000000463 material Substances 0.000 description 85
- 239000011541 reaction mixture Substances 0.000 description 84
- 238000003818 flash chromatography Methods 0.000 description 83
- 239000000284 extract Substances 0.000 description 74
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 70
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 63
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 63
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 60
- 239000012044 organic layer Substances 0.000 description 60
- 238000001816 cooling Methods 0.000 description 53
- 239000010410 layer Substances 0.000 description 49
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 48
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 48
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 46
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 42
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 41
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 38
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 38
- 239000012299 nitrogen atmosphere Substances 0.000 description 38
- 238000003756 stirring Methods 0.000 description 38
- 239000007864 aqueous solution Substances 0.000 description 37
- 238000004440 column chromatography Methods 0.000 description 35
- 239000000706 filtrate Substances 0.000 description 35
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 34
- 239000003480 eluent Substances 0.000 description 33
- 238000000605 extraction Methods 0.000 description 28
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 26
- 125000005843 halogen group Chemical group 0.000 description 24
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 24
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 23
- WFKAJVHLWXSISD-UHFFFAOYSA-N anhydrous dimethyl-acetamide Natural products CC(C)C(N)=O WFKAJVHLWXSISD-UHFFFAOYSA-N 0.000 description 23
- 229920006395 saturated elastomer Polymers 0.000 description 23
- GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 23
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 22
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 18
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 18
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 18
- 125000004432 carbon atom Chemical group C* 0.000 description 17
- 235000017557 sodium bicarbonate Nutrition 0.000 description 17
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 17
- 239000000725 suspension Substances 0.000 description 16
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 15
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 15
- 239000000741 silica gel Substances 0.000 description 14
- 229910002027 silica gel Inorganic materials 0.000 description 14
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 14
- VNFWTIYUKDMAOP-UHFFFAOYSA-N sphos Chemical compound COC1=CC=CC(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 VNFWTIYUKDMAOP-UHFFFAOYSA-N 0.000 description 14
- 208000024172 Cardiovascular disease Diseases 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 13
- 239000008177 pharmaceutical agent Substances 0.000 description 13
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 13
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 12
- 235000019798 tripotassium phosphate Nutrition 0.000 description 12
- 229960000583 acetic acid Drugs 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 10
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 10
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 10
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 10
- 235000019270 ammonium chloride Nutrition 0.000 description 9
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 9
- HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 9
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- 238000001914 filtration Methods 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 8
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 8
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 8
- UHWMYQZIMKZKBL-UHFFFAOYSA-N 1-o,1-o-ditert-butyl 2-o-ethyl ethane-1,1,2-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OC(C)(C)C)C(=O)OC(C)(C)C UHWMYQZIMKZKBL-UHFFFAOYSA-N 0.000 description 7
- 206010006187 Breast cancer Diseases 0.000 description 7
- 208000026310 Breast neoplasm Diseases 0.000 description 7
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 7
- 229910000024 caesium carbonate Inorganic materials 0.000 description 7
- 239000012362 glacial acetic acid Substances 0.000 description 7
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 7
- 235000010265 sodium sulphite Nutrition 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 7
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 6
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 6
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 125000000524 functional group Chemical group 0.000 description 6
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 5
- 206010025323 Lymphomas Diseases 0.000 description 5
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 5
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 150000002367 halogens Chemical class 0.000 description 5
- 239000011777 magnesium Substances 0.000 description 5
- 229910052749 magnesium Inorganic materials 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000012312 sodium hydride Substances 0.000 description 5
- 229910000104 sodium hydride Inorganic materials 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 4
- JQJPBYFTQAANLE-UHFFFAOYSA-N Butyl nitrite Chemical compound CCCCON=O JQJPBYFTQAANLE-UHFFFAOYSA-N 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 208000017604 Hodgkin disease Diseases 0.000 description 4
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 4
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 4
- 101001088887 Homo sapiens Lysine-specific demethylase 5C Proteins 0.000 description 4
- 229910010084 LiAlH4 Inorganic materials 0.000 description 4
- 102100033246 Lysine-specific demethylase 5A Human genes 0.000 description 4
- 102100033249 Lysine-specific demethylase 5C Human genes 0.000 description 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 239000007832 Na2SO4 Substances 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000001212 derivatisation Methods 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- UHKVUBKBFDPSDM-UHFFFAOYSA-N ethyl 3-amino-7-bromoquinoline-2-carboxylate Chemical compound BrC1=CC=C2C=C(N)C(C(=O)OCC)=NC2=C1 UHKVUBKBFDPSDM-UHFFFAOYSA-N 0.000 description 4
- VICYTAYPKBLQFB-UHFFFAOYSA-N ethyl 3-bromo-2-oxopropanoate Chemical compound CCOC(=O)C(=O)CBr VICYTAYPKBLQFB-UHFFFAOYSA-N 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 4
- 239000012280 lithium aluminium hydride Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 201000005962 mycosis fungoides Diseases 0.000 description 4
- 206010028537 myelofibrosis Diseases 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 4
- ZPCQHOKATFHJST-UHFFFAOYSA-N (2-amino-3-bromophenyl)methanol Chemical compound NC1=C(Br)C=CC=C1CO ZPCQHOKATFHJST-UHFFFAOYSA-N 0.000 description 3
- JHLFDAZFHWATIS-UHFFFAOYSA-N (2-amino-4-bromophenyl)methanol Chemical compound NC1=CC(Br)=CC=C1CO JHLFDAZFHWATIS-UHFFFAOYSA-N 0.000 description 3
- GDCWZYRWKSOYGQ-UHFFFAOYSA-N (2-amino-5-bromophenyl)methanol Chemical compound NC1=CC=C(Br)C=C1CO GDCWZYRWKSOYGQ-UHFFFAOYSA-N 0.000 description 3
- OGWBVTDYXWQJSM-UHFFFAOYSA-N (2-amino-6-bromophenyl)methanol Chemical compound NC1=CC=CC(Br)=C1CO OGWBVTDYXWQJSM-UHFFFAOYSA-N 0.000 description 3
- WLBVFJUXKRSWJC-UHFFFAOYSA-N 2-amino-3-bromobenzaldehyde Chemical compound NC1=C(Br)C=CC=C1C=O WLBVFJUXKRSWJC-UHFFFAOYSA-N 0.000 description 3
- ZZVUOSVSPAPBEJ-UHFFFAOYSA-N 2-amino-4-bromobenzaldehyde Chemical compound NC1=CC(Br)=CC=C1C=O ZZVUOSVSPAPBEJ-UHFFFAOYSA-N 0.000 description 3
- VBYZWJMZASVGNB-UHFFFAOYSA-N 2-amino-5-bromobenzaldehyde Chemical compound NC1=CC=C(Br)C=C1C=O VBYZWJMZASVGNB-UHFFFAOYSA-N 0.000 description 3
- JGCRWLRUZUXAAN-UHFFFAOYSA-N 2-amino-6-bromobenzaldehyde Chemical compound NC1=CC=CC(Br)=C1C=O JGCRWLRUZUXAAN-UHFFFAOYSA-N 0.000 description 3
- TYEYBOSBBBHJIV-UHFFFAOYSA-M 2-oxobutanoate Chemical compound CCC(=O)C([O-])=O TYEYBOSBBBHJIV-UHFFFAOYSA-M 0.000 description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 3
- AQYWNRHTFJHMPQ-UHFFFAOYSA-N CCOC(C(C(O)=CC1=C2)=NC1=CC=C2Br)=O Chemical compound CCOC(C(C(O)=CC1=C2)=NC1=CC=C2Br)=O AQYWNRHTFJHMPQ-UHFFFAOYSA-N 0.000 description 3
- 101001088892 Homo sapiens Lysine-specific demethylase 5A Proteins 0.000 description 3
- 101001088879 Homo sapiens Lysine-specific demethylase 5D Proteins 0.000 description 3
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 3
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 3
- 102100033143 Lysine-specific demethylase 5D Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000014767 Myeloproliferative disease Diseases 0.000 description 3
- YNHIGQDRGKUECZ-UHFFFAOYSA-L PdCl2(PPh3)2 Substances [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 3
- 208000015634 Rectal Neoplasms Diseases 0.000 description 3
- 208000000453 Skin Neoplasms Diseases 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- VONWDASPFIQPDY-UHFFFAOYSA-N dimethyl methylphosphonate Chemical compound COP(C)(=O)OC VONWDASPFIQPDY-UHFFFAOYSA-N 0.000 description 3
- NXRQJVHRJPEQBP-UHFFFAOYSA-N ethyl 3-amino-5-bromoquinoline-2-carboxylate Chemical compound NC=1C(=NC2=CC=CC(=C2C=1)Br)C(=O)OCC NXRQJVHRJPEQBP-UHFFFAOYSA-N 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 238000007306 functionalization reaction Methods 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- 208000025750 heavy chain disease Diseases 0.000 description 3
- 239000008240 homogeneous mixture Substances 0.000 description 3
- 125000001183 hydrocarbyl group Chemical group 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 239000005414 inactive ingredient Substances 0.000 description 3
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 3
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 208000003476 primary myelofibrosis Diseases 0.000 description 3
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 3
- 206010038038 rectal cancer Diseases 0.000 description 3
- 201000001275 rectum cancer Diseases 0.000 description 3
- 239000012047 saturated solution Substances 0.000 description 3
- 201000000849 skin cancer Diseases 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 3
- 238000001665 trituration Methods 0.000 description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 3
- 229920002554 vinyl polymer Polymers 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- WRSWIWOVJBYZAW-UHFFFAOYSA-M zinc;methanidylbenzene;bromide Chemical compound Br[Zn+].[CH2-]C1=CC=CC=C1 WRSWIWOVJBYZAW-UHFFFAOYSA-M 0.000 description 3
- NSJVYHOPHZMZPN-UHFFFAOYSA-N (2-methylphenyl)boronic acid Chemical compound CC1=CC=CC=C1B(O)O NSJVYHOPHZMZPN-UHFFFAOYSA-N 0.000 description 2
- BJQCPCFFYBKRLM-UHFFFAOYSA-N (3-methylphenyl)boronic acid Chemical compound CC1=CC=CC(B(O)O)=C1 BJQCPCFFYBKRLM-UHFFFAOYSA-N 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- ASSKVPFEZFQQNQ-UHFFFAOYSA-N 2-benzoxazolinone Chemical compound C1=CC=C2OC(O)=NC2=C1 ASSKVPFEZFQQNQ-UHFFFAOYSA-N 0.000 description 2
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 201000003076 Angiosarcoma Diseases 0.000 description 2
- 206010073360 Appendix cancer Diseases 0.000 description 2
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 201000004085 CLL/SLL Diseases 0.000 description 2
- 206010007275 Carcinoid tumour Diseases 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 208000006332 Choriocarcinoma Diseases 0.000 description 2
- 208000002330 Congenital Heart Defects Diseases 0.000 description 2
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 101100477411 Dictyostelium discoideum set1 gene Proteins 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- 208000032027 Essential Thrombocythemia Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000001258 Hemangiosarcoma Diseases 0.000 description 2
- 102000006947 Histones Human genes 0.000 description 2
- 101001050886 Homo sapiens Lysine-specific histone demethylase 1A Proteins 0.000 description 2
- 206010048643 Hypereosinophilic syndrome Diseases 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010070999 Intraductal papillary mucinous neoplasm Diseases 0.000 description 2
- 208000009164 Islet Cell Adenoma Diseases 0.000 description 2
- 206010023347 Keratoacanthoma Diseases 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- 206010023825 Laryngeal cancer Diseases 0.000 description 2
- 208000018142 Leiomyosarcoma Diseases 0.000 description 2
- 102100024985 Lysine-specific histone demethylase 1A Human genes 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 2
- 208000032271 Malignant tumor of penis Diseases 0.000 description 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 2
- 208000000172 Medulloblastoma Diseases 0.000 description 2
- 206010027406 Mesothelioma Diseases 0.000 description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 2
- 150000001204 N-oxides Chemical class 0.000 description 2
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 208000009905 Neurofibromatoses Diseases 0.000 description 2
- 208000033755 Neutrophilic Chronic Leukemia Diseases 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 2
- 208000002471 Penile Neoplasms Diseases 0.000 description 2
- 206010034299 Penile cancer Diseases 0.000 description 2
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 2
- 208000031839 Peripheral nerve sheath tumour malignant Diseases 0.000 description 2
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 2
- 206010034811 Pharyngeal cancer Diseases 0.000 description 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 206010057846 Primitive neuroectodermal tumour Diseases 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 201000000582 Retinoblastoma Diseases 0.000 description 2
- 201000010208 Seminoma Diseases 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical class [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 2
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 2
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 2
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 208000008383 Wilms tumor Diseases 0.000 description 2
- LXGQHDUCNDGTDB-PAMNCVQHSA-N [2-[(8s,9r,10s,13s,14s,16s,17r)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate;[2-[(8s,9r,10s,13s,14s,16s,17r)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11, Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(C)=O)(O)[C@@]1(C)CC2O.C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COP(O)(O)=O)(O)[C@@]1(C)CC2O LXGQHDUCNDGTDB-PAMNCVQHSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 208000017733 acquired polycythemia vera Diseases 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 150000001371 alpha-amino acids Chemical class 0.000 description 2
- 235000008206 alpha-amino acids Nutrition 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 208000021780 appendiceal neoplasm Diseases 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 208000002458 carcinoid tumor Diseases 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 208000023738 chronic lymphocytic leukemia/small lymphocytic lymphoma Diseases 0.000 description 2
- 201000010903 chronic neutrophilic leukemia Diseases 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 208000028831 congenital heart disease Diseases 0.000 description 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 208000017055 digestive system neuroendocrine neoplasm Diseases 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000001973 epigenetic effect Effects 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- SXRUTUFTJVVQGD-UHFFFAOYSA-N ethyl 3-amino-6-bromoquinoline-2-carboxylate Chemical compound NC=1C(=NC2=CC=C(C=C2C=1)Br)C(=O)OCC SXRUTUFTJVVQGD-UHFFFAOYSA-N 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 201000009277 hairy cell leukemia Diseases 0.000 description 2
- 239000007887 hard shell capsule Substances 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 206010023841 laryngeal neoplasm Diseases 0.000 description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 description 2
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 201000004931 neurofibromatosis Diseases 0.000 description 2
- 208000029974 neurofibrosarcoma Diseases 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 description 2
- RDOWQLZANAYVLL-UHFFFAOYSA-N phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 208000037244 polycythemia vera Diseases 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 201000002314 small intestine cancer Diseases 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000007886 soft shell capsule Substances 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 150000003457 sulfones Chemical class 0.000 description 2
- 150000003462 sulfoxides Chemical class 0.000 description 2
- 229910052717 sulfur Chemical group 0.000 description 2
- 239000011593 sulfur Chemical group 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- 208000008732 thymoma Diseases 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- PYMPTRMDPJYTDF-UHFFFAOYSA-N tributyl(2-phenylethynyl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C#CC1=CC=CC=C1 PYMPTRMDPJYTDF-UHFFFAOYSA-N 0.000 description 2
- 229940086542 triethylamine Drugs 0.000 description 2
- 231100000588 tumorigenic Toxicity 0.000 description 2
- 230000000381 tumorigenic effect Effects 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- CVCLJVVBHYOXDC-IAZSKANUSA-N (2z)-2-[(5z)-5-[(3,5-dimethyl-1h-pyrrol-2-yl)methylidene]-4-methoxypyrrol-2-ylidene]indole Chemical compound COC1=C\C(=C/2N=C3C=CC=CC3=C\2)N\C1=C/C=1NC(C)=CC=1C CVCLJVVBHYOXDC-IAZSKANUSA-N 0.000 description 1
- BIWQNIMLAISTBV-UHFFFAOYSA-N (4-methylphenyl)boronic acid Chemical compound CC1=CC=C(B(O)O)C=C1 BIWQNIMLAISTBV-UHFFFAOYSA-N 0.000 description 1
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
- SRIZNTFPBWRGPB-UHFFFAOYSA-N 2-amino-3-bromobenzoic acid Chemical compound NC1=C(Br)C=CC=C1C(O)=O SRIZNTFPBWRGPB-UHFFFAOYSA-N 0.000 description 1
- CUKXRHLWPSBCTI-UHFFFAOYSA-N 2-amino-5-bromobenzoic acid Chemical compound NC1=CC=C(Br)C=C1C(O)=O CUKXRHLWPSBCTI-UHFFFAOYSA-N 0.000 description 1
- BNQPROAXWQCNKO-UHFFFAOYSA-N 2-amino-6-bromobenzoic acid Chemical compound NC1=CC=CC(Br)=C1C(O)=O BNQPROAXWQCNKO-UHFFFAOYSA-N 0.000 description 1
- CTRPRMNBTVRDFH-UHFFFAOYSA-N 2-n-methyl-1,3,5-triazine-2,4,6-triamine Chemical class CNC1=NC(N)=NC(N)=N1 CTRPRMNBTVRDFH-UHFFFAOYSA-N 0.000 description 1
- VLRSADZEDXVUPG-UHFFFAOYSA-N 2-naphthalen-1-ylpyridine Chemical compound N1=CC=CC=C1C1=CC=CC2=CC=CC=C12 VLRSADZEDXVUPG-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- CBKDCOKSXCTDAA-UHFFFAOYSA-N 4,5,6,7-tetrahydro-1-benzothiophene Chemical compound C1CCCC2=C1C=CS2 CBKDCOKSXCTDAA-UHFFFAOYSA-N 0.000 description 1
- GDRVFDDBLLKWRI-UHFFFAOYSA-N 4H-quinolizine Chemical compound C1=CC=CN2CC=CC=C21 GDRVFDDBLLKWRI-UHFFFAOYSA-N 0.000 description 1
- YHHFKWKMXWRVTJ-XLNRJJMWSA-N 5-chloro-n-[(z)-[phenyl(pyridin-2-yl)methylidene]amino]pyridin-2-amine Chemical compound N1=CC(Cl)=CC=C1N\N=C(C=1N=CC=CC=1)\C1=CC=CC=C1 YHHFKWKMXWRVTJ-XLNRJJMWSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- IRBAWVGZNJIROV-SFHVURJKSA-N 9-(2-cyclopropylethynyl)-2-[[(2s)-1,4-dioxan-2-yl]methoxy]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(C#CC4CC4)C=C3CCN2C(=O)N=C1OC[C@@H]1COCCO1 IRBAWVGZNJIROV-SFHVURJKSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000036832 Adenocarcinoma of ovary Diseases 0.000 description 1
- 206010001197 Adenocarcinoma of the cervix Diseases 0.000 description 1
- 208000034246 Adenocarcinoma of the cervix uteri Diseases 0.000 description 1
- 208000036764 Adenocarcinoma of the esophagus Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000012791 Alpha-heavy chain disease Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical class C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 239000012664 BCL-2-inhibitor Substances 0.000 description 1
- 108700020463 BRCA1 Proteins 0.000 description 1
- 101150072950 BRCA1 gene Proteins 0.000 description 1
- 108700020462 BRCA2 Proteins 0.000 description 1
- 102000052609 BRCA2 Human genes 0.000 description 1
- 108091005625 BRD4 Proteins 0.000 description 1
- 208000029862 Barrett adenocarcinoma Diseases 0.000 description 1
- 229940122035 Bcl-XL inhibitor Drugs 0.000 description 1
- 229940123711 Bcl2 inhibitor Drugs 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 101150008921 Brca2 gene Proteins 0.000 description 1
- 102100025401 Breast cancer type 1 susceptibility protein Human genes 0.000 description 1
- 102100029895 Bromodomain-containing protein 4 Human genes 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- RAPBNVDSDCTNRC-UHFFFAOYSA-N Chlorobenzilate Chemical compound C=1C=C(Cl)C=CC=1C(O)(C(=O)OCC)C1=CC=C(Cl)C=C1 RAPBNVDSDCTNRC-UHFFFAOYSA-N 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
- 208000009798 Craniopharyngioma Diseases 0.000 description 1
- 102100024457 Cyclin-dependent kinase 9 Human genes 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-STHAYSLISA-N D-threonine Chemical compound C[C@H](O)[C@@H](N)C(O)=O AYFVYJQAPQTCCC-STHAYSLISA-N 0.000 description 1
- 229930182822 D-threonine Natural products 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 229940122680 Demethylase inhibitor Drugs 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 108010028143 Dioxygenases Proteins 0.000 description 1
- 102000016680 Dioxygenases Human genes 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- MBYXEBXZARTUSS-QLWBXOBMSA-N Emetamine Natural products O(C)c1c(OC)cc2c(c(C[C@@H]3[C@H](CC)CN4[C@H](c5c(cc(OC)c(OC)c5)CC4)C3)ncc2)c1 MBYXEBXZARTUSS-QLWBXOBMSA-N 0.000 description 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 208000002460 Enteropathy-Associated T-Cell Lymphoma Diseases 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 102100038595 Estrogen receptor Human genes 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010026389 Gramicidin Proteins 0.000 description 1
- 229940125497 HER2 kinase inhibitor Drugs 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010019972 Herpes viral infections Diseases 0.000 description 1
- 101000980930 Homo sapiens Cyclin-dependent kinase 9 Proteins 0.000 description 1
- 101100118549 Homo sapiens EGFR gene Proteins 0.000 description 1
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 description 1
- 101000615488 Homo sapiens Methyl-CpG-binding domain protein 2 Proteins 0.000 description 1
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 1
- 101000755643 Homo sapiens RIMS-binding protein 2 Proteins 0.000 description 1
- 101000756365 Homo sapiens Retinol-binding protein 2 Proteins 0.000 description 1
- 241000701041 Human betaherpesvirus 7 Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 208000007866 Immunoproliferative Small Intestinal Disease Diseases 0.000 description 1
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 201000003803 Inflammatory myofibroblastic tumor Diseases 0.000 description 1
- 206010067917 Inflammatory myofibroblastic tumour Diseases 0.000 description 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 1
- 206010061252 Intraocular melanoma Diseases 0.000 description 1
- DNVXATUJJDPFDM-KRWDZBQOSA-N JQ1 Chemical compound N([C@@H](CC(=O)OC(C)(C)C)C1=NN=C(N1C=1SC(C)=C(C)C=11)C)=C1C1=CC=C(Cl)C=C1 DNVXATUJJDPFDM-KRWDZBQOSA-N 0.000 description 1
- 229960005549 JQ1 Drugs 0.000 description 1
- 102000016624 JmjC domains Human genes 0.000 description 1
- 108050006228 JmjC domains Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010062038 Lip neoplasm Diseases 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 101710105712 Lysine-specific demethylase 5B Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229930126263 Maytansine Natural products 0.000 description 1
- 208000009018 Medullary thyroid cancer Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 102100021299 Methyl-CpG-binding domain protein 2 Human genes 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 208000010190 Monoclonal Gammopathy of Undetermined Significance Diseases 0.000 description 1
- 208000012799 Mu-heavy chain disease Diseases 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 208000002231 Muscle Neoplasms Diseases 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 201000004404 Neurofibroma Diseases 0.000 description 1
- 206010029461 Nodal marginal zone B-cell lymphomas Diseases 0.000 description 1
- 108091093105 Nuclear DNA Proteins 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 206010031096 Oropharyngeal cancer Diseases 0.000 description 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
- 206010061328 Ovarian epithelial cancer Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 239000012270 PD-1 inhibitor Substances 0.000 description 1
- 239000012668 PD-1-inhibitor Substances 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 208000017459 Paget disease of the penis Diseases 0.000 description 1
- 208000025610 Paget disease of the vulva Diseases 0.000 description 1
- 206010061332 Paraganglion neoplasm Diseases 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 201000008199 Pleuropulmonary blastoma Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010036524 Precursor B-lymphoblastic lymphomas Diseases 0.000 description 1
- 208000032758 Precursor T-lymphoblastic lymphoma/leukaemia Diseases 0.000 description 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 229910019891 RuCl3 Inorganic materials 0.000 description 1
- AUVVAXYIELKVAI-UHFFFAOYSA-N SJ000285215 Natural products N1CCC2=CC(OC)=C(OC)C=C2C1CC1CC2C3=CC(OC)=C(OC)C=C3CCN2CC1CC AUVVAXYIELKVAI-UHFFFAOYSA-N 0.000 description 1
- 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 208000006938 Schwannomatosis Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000009359 Sezary Syndrome Diseases 0.000 description 1
- 208000021388 Sezary disease Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000010502 Subcutaneous panniculitis-like T-cell lymphoma Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 201000008736 Systemic mastocytosis Diseases 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000026651 T-cell prolymphocytic leukemia Diseases 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 206010043515 Throat cancer Diseases 0.000 description 1
- 201000009365 Thymic carcinoma Diseases 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 1
- 206010046431 Urethral cancer Diseases 0.000 description 1
- 206010046458 Urethral neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 201000005969 Uveal melanoma Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 208000014070 Vestibular schwannoma Diseases 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- GQCMNJDKRLXFTM-UHFFFAOYSA-M [Br-].CC1=CC=CC=C1C[Zn+] Chemical compound [Br-].CC1=CC=CC=C1C[Zn+] GQCMNJDKRLXFTM-UHFFFAOYSA-M 0.000 description 1
- GOPYZMJAIPBUGX-UHFFFAOYSA-N [O-2].[O-2].[Mn+4] Chemical class [O-2].[O-2].[Mn+4] GOPYZMJAIPBUGX-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 208000004064 acoustic neuroma Diseases 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 208000025751 alpha chain disease Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 206010002449 angioimmunoblastic T-cell lymphoma Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- RGHILYZRVFRRNK-UHFFFAOYSA-N anthracene-1,2-dione Chemical compound C1=CC=C2C=C(C(C(=O)C=C3)=O)C3=CC2=C1 RGHILYZRVFRRNK-UHFFFAOYSA-N 0.000 description 1
- 239000003817 anthracycline antibiotic agent Substances 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940045687 antimetabolites folic acid analogs Drugs 0.000 description 1
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 201000008274 breast adenocarcinoma Diseases 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 201000000135 breast papillary carcinoma Diseases 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 201000005200 bronchus cancer Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 201000011529 cardiovascular cancer Diseases 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 201000007455 central nervous system cancer Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 201000006662 cervical adenocarcinoma Diseases 0.000 description 1
- NDAYQJDHGXTBJL-MWWSRJDJSA-N chembl557217 Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 NDAYQJDHGXTBJL-MWWSRJDJSA-N 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000010568 chiral column chromatography Methods 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000003426 co-catalyst Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 201000010918 connective tissue cancer Diseases 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 208000002445 cystadenocarcinoma Diseases 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 1
- GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 125000004982 dihaloalkyl group Chemical group 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- CLPHAYNBNTVRDI-UHFFFAOYSA-N ditert-butyl propanedioate Chemical compound CC(C)(C)OC(=O)CC(=O)OC(C)(C)C CLPHAYNBNTVRDI-UHFFFAOYSA-N 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 201000011025 embryonal testis carcinoma Diseases 0.000 description 1
- AUVVAXYIELKVAI-CKBKHPSWSA-N emetine Chemical compound N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@@H]1CC AUVVAXYIELKVAI-CKBKHPSWSA-N 0.000 description 1
- 229960002694 emetine Drugs 0.000 description 1
- AUVVAXYIELKVAI-UWBTVBNJSA-N emetine Natural products N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@H]1CC AUVVAXYIELKVAI-UWBTVBNJSA-N 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 208000001991 endodermal sinus tumor Diseases 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 208000037828 epithelial carcinoma Diseases 0.000 description 1
- 208000028653 esophageal adenocarcinoma Diseases 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical group COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 150000002224 folic acids Chemical class 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 201000003115 germ cell cancer Diseases 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
- 201000002222 hemangioblastoma Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 125000004404 heteroalkyl group Chemical group 0.000 description 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- 108010051779 histone H3 trimethyl Lys4 Proteins 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000000640 hydroxylating effect Effects 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 208000015210 hypertensive heart disease Diseases 0.000 description 1
- 201000006866 hypopharynx cancer Diseases 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- LPAGFVYQRIESJQ-UHFFFAOYSA-N indoline Chemical compound C1=CC=C2NCCC2=C1 LPAGFVYQRIESJQ-UHFFFAOYSA-N 0.000 description 1
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 201000002529 islet cell tumor Diseases 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 208000022013 kidney Wilms tumor Diseases 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 201000006721 lip cancer Diseases 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 208000037829 lymphangioendotheliosarcoma Diseases 0.000 description 1
- 208000012804 lymphangiosarcoma Diseases 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000029559 malignant endocrine neoplasm Diseases 0.000 description 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 description 1
- 208000021937 marginal zone lymphoma Diseases 0.000 description 1
- 208000008585 mastocytosis Diseases 0.000 description 1
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 1
- 208000030163 medullary breast carcinoma Diseases 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 201000008203 medulloepithelioma Diseases 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- GQJCAQADCPTHKN-UHFFFAOYSA-N methyl 2,2-difluoro-2-fluorosulfonylacetate Chemical compound COC(=O)C(F)(F)S(F)(=O)=O GQJCAQADCPTHKN-UHFFFAOYSA-N 0.000 description 1
- MMSODGJNFCCKAZ-UHFFFAOYSA-N methyl 2-amino-4-bromobenzoate Chemical compound COC(=O)C1=CC=C(Br)C=C1N MMSODGJNFCCKAZ-UHFFFAOYSA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 208000026114 mu chain disease Diseases 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 201000002077 muscle cancer Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 208000001611 myxosarcoma Diseases 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- JLYAXFNOILIKPP-KXQOOQHDSA-N navitoclax Chemical compound C([C@@H](NC1=CC=C(C=C1S(=O)(=O)C(F)(F)F)S(=O)(=O)NC(=O)C1=CC=C(C=C1)N1CCN(CC1)CC1=C(CCC(C1)(C)C)C=1C=CC(Cl)=CC=1)CSC=1C=CC=CC=1)CN1CCOCC1 JLYAXFNOILIKPP-KXQOOQHDSA-N 0.000 description 1
- 229950004847 navitoclax Drugs 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 201000009494 neurilemmomatosis Diseases 0.000 description 1
- 201000002120 neuroendocrine carcinoma Diseases 0.000 description 1
- 239000012740 non-selective inhibitor Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 229950006584 obatoclax Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- 201000002575 ocular melanoma Diseases 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 201000002740 oral squamous cell carcinoma Diseases 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 238000006053 organic reaction Methods 0.000 description 1
- 201000006958 oropharynx cancer Diseases 0.000 description 1
- 208000013371 ovarian adenocarcinoma Diseases 0.000 description 1
- 201000011029 ovarian embryonal carcinoma Diseases 0.000 description 1
- 201000006588 ovary adenocarcinoma Diseases 0.000 description 1
- RLZJFTOYCVIYLE-UHFFFAOYSA-N oxane-4-carbonitrile Chemical compound N#CC1CCOCC1 RLZJFTOYCVIYLE-UHFFFAOYSA-N 0.000 description 1
- AUONHKJOIZSQGR-UHFFFAOYSA-N oxophosphane Chemical compound P=O AUONHKJOIZSQGR-UHFFFAOYSA-N 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
- 208000007312 paraganglioma Diseases 0.000 description 1
- 208000012111 paraneoplastic syndrome Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229940121655 pd-1 inhibitor Drugs 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 208000030613 peripheral artery disease Diseases 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 208000024724 pineal body neoplasm Diseases 0.000 description 1
- 201000004123 pineal gland cancer Diseases 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 201000002511 pituitary cancer Diseases 0.000 description 1
- 208000010626 plasma cell neoplasm Diseases 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 201000006037 primary mediastinal B-cell lymphoma Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 201000005825 prostate adenocarcinoma Diseases 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000002577 pseudohalo group Chemical group 0.000 description 1
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 201000006845 reticulosarcoma Diseases 0.000 description 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 1
- YBCAZPLXEGKKFM-UHFFFAOYSA-K ruthenium(iii) chloride Chemical compound [Cl-].[Cl-].[Cl-].[Ru+3] YBCAZPLXEGKKFM-UHFFFAOYSA-K 0.000 description 1
- 210000004706 scrotum Anatomy 0.000 description 1
- 208000014956 scrotum Paget disease Diseases 0.000 description 1
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000023516 stroke disease Diseases 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 201000010965 sweat gland carcinoma Diseases 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 206010062123 testicular embryonal carcinoma Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000005207 tetraalkylammonium group Chemical group 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 239000011135 tin Substances 0.000 description 1
- 239000012929 tonicity agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 150000004654 triazenes Chemical class 0.000 description 1
- DBGVGMSCBYYSLD-UHFFFAOYSA-N tributylstannane Chemical compound CCCC[SnH](CCCC)CCCC DBGVGMSCBYYSLD-UHFFFAOYSA-N 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 125000004385 trihaloalkyl group Chemical group 0.000 description 1
- UKHQRARQNZOXRL-UHFFFAOYSA-N trimethyltin Chemical compound C[SnH](C)C UKHQRARQNZOXRL-UHFFFAOYSA-N 0.000 description 1
- 208000029387 trophoblastic neoplasm Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 208000037965 uterine sarcoma Diseases 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- 208000028010 vulval Paget disease Diseases 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
Definitions
- Histone Demethylases are a class of epigenetic enzyme that remove methyl groups from histone lysine residues, in particular lysine residues 4 (H3K4), 9 (H3K9), 27 (H3K27), 36 (H3K36), and 79 (H3K79) on histone 3, and lysine residue 20 (H4K20) on histone 4.
- HDMs lysine-specific demethylase 1
- KDM1 lysine-specific demethylase 1
- JmjC Jumonji C domain containing Fe(II)-dependent and oxoglutarate (2OG)-dependent dioxygenases.
- the JmjC domain is responsible for the demethylation activity by first hydroxylating histone lysine methylamine groups utilizing oxygen and 2-OG, which is then followed by the spontaneous loss of the unstable hydroxymethyl group.
- the KDM5, or JARID1, family of JmjC HDMs includes KDM5A (JARID1A/RBP2), KDM5B (JARID1B/PLU-1), KDM5C (JARID1C/SMCX), and KDM5D (JARID1D/SMCY).
- KDM5A has been implicated in the development of prostate, breast, and skin cancer and also has been associated with melanoma maintenance.
- KDM5B has been implicated in the development of prostate, breast, and skin cancer and also has been associated with melanoma maintenance.
- KDM5B is also overexpressed in non-small cell lung cancer (NSCLC) cells and is associated with tumor size, lymph node metastasis, advanced stages, and poor overall survival in NSCLC patients.
- NSCLC non-small cell lung cancer
- the present disclosure is directed to compounds, compositions comprising the same, and methods of using the compounds to selectively modulate the activity of histone demethylases (HDMs), in particular, histone lysine demethylase-5.
- HDMs histone demethylases
- n is 0, 1, 2, 3, or 4;
- R 1 is hydrogen, -P(O)(OR 20 )2, -CH2P(O)(OR 20 )2, -P(O)(R 20 )(OR 20 ), -CH2P(O)(R 20 )(OR 20 ), -P(O)(N(R 20 )2)(OR 20 ), -CH2P(O)(N(R 20 )2)(OR 20 ), -P(O)(R 20 )(N(R 20 )2)(OR 20 ), -P(O)(R 20 )(N(R 20 )2), -CH2P(O)(R 20 )(N(R 20 )2), -C(O)R 20 , -C(O)N(R 21 )(R 22 ), -CH2P(O)(N(R 20 )2)2, or -P(O)
- compositions comprising one or more compounds of formula I and a pharmaceutically acceptable excipient.
- This disclosure is also directed to methods for inhibiting the activity of histone lysine demethylase and treating, pretreating, or delaying onset of a condition associated with histone lysine demethylase.
- a method of treating, pretreating, or delaying onset of a condition associated with undesirable cellular proliferation is provided.
- alkyl refers to saturated monovalent straight or branched chain hydrocarbyl groups having from 1 to 10 carbon atoms, from 1 to 6 carbon atoms, or 1 to 3 carbon atoms.
- alkoxy refers to -O-alkyl, where alkyl is as defined above.
- alkynyl refers to an acetylinic unsaturated monovalent hydrocarbyl groups having from 2 to 6 carbon atoms, or 2 to 3 carbon atoms, and having at least 1, or from 1 to 2 sites of acetylenic (-C ⁇ C-) unsaturation. This group is exemplified by ethyn-1-yl, propyn-1-yl, propyn-2-yl, and the like.
- alkylene alkenylene
- alkynylene refers to divalent alkyl, alkenyl, and alkynyl groups, respectively, where each is as defined herein.
- aryl or “Ar” refers to a monovalent aromatic carbocyclic group of from 6 to 14 carbon atoms having a single ring (e.g., phenyl) or multiple condensed rings (e.g., naphthyl or anthryl) which condensed rings may or may not be aromatic (e.g., 2-benzoxazolinone, 2H-1,4-benzoxazin-3(4H)- one-7-yl, benzo[1,3]-dioxol-5-yl, 2,3-dihydro-benzo[1,4]dioxin-6-yl, 2,3-dihydro-benzofuran-5-yl, dibenzofuran-4-yl, and the like) provided that
- cycloalkyl refers to cyclic alkyl groups of from 3 to 10 carbon atoms having single or multiple cyclic rings including, by way of example, adamantyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclooctyl, and the like.
- halo refers to fluoro, chloro, bromo, and iodo, and in certain embodiments, is fluoro, chloro or bromo.
- heteroaryl refers to an aromatic group of from 1 to 15 carbon atoms, or from 1 to 10 carbon atoms, and 1 to 4 heteroatoms selected from oxygen, nitrogen, and sulfur within the ring. Such heteroaryl groups can have a single ring (e.g., pyridinyl, furyl, or thienyl) or multiple condensed rings (e.g., indolizinyl or benzothienyl).
- the nitrogen and/or sulfur ring atoms can optionally be oxidized to provide for the N-oxide or the sulfoxide, and sulfone derivatives.
- exemplary heteroaryls include pyridinyl, pyrrolyl, indolyl, thiophenyl, thienyl, and furyl.
- haloalkyl refers to an unbranched or branched alkyl group as defined above, wherein one or more (e.g., 1 to 6 or 1 to 3) hydrogen atoms are replaced by a halogen.
- Dihaloalkyl and trihaloalkyl refer to alkyl substituted with two (“di”) or three (“tri”) halo groups, which may be, but are not necessarily, the same halogen.
- haloalkyl include, e.g., trifluoromethyl, difluoromethyl, fluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1,2-difluoroethyl, 3-bromo-2-fluoropropyl, 1,2-dibromoethyl and the like.
- haloalkoxy refers to -O-haloalkyl, where haloalkyl is as defined above.
- heteroalkyl refers to a C 1-6 alkyl group in which one or two of the carbon atoms (and any associated hydrogen atoms) are each independently replaced with the same or different heteroatomic group. Heteroatomic groups include, but are not limited to, -NH-, -O-, -S-, -S(O)-, -S(O) 2 -, and the like.
- heteroalkylene refers to a linear, divalent C 1-6 alkyl group (i.e., C 1-6 alkylene) in which one or two of the carbon atoms (and any associated hydrogen atoms) are each independently replaced with the same or different heteroatomic group.
- Heteroatomic groups include, but are not limited to, -NH-, -O-, -S-, -S(O)-, -S(O)2-, and the like.
- heterocyclyl or “heterocyclic” refers to a saturated or unsaturated (but not aromatic) group having a single ring or multiple condensed rings, from 1 to 10 carbon atoms, and from 1 to 4 hetero atoms selected from nitrogen, sulfur or oxygen within the ring wherein, in fused ring systems, one or more of the rings can be aryl or heteroaryl provided that the point of attachment is at the heterocycle.
- the nitrogen and/or sulfur ring atoms can optionally be oxidized to provide for the N-oxide or the sulfoxide, and sulfone derivatives.
- substituted heterocyclyl or “substituted heterocyclic” refers to heterocycle groups that are substituted with from 1 to 3 of the same substituents as defined for substituted cycloalkyl.
- heterocycles and heteroaryls include, but are not limited to, azetidine, pyrrole, imidazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, indolizine, isoindole, indole, dihydroindole, indazole, purine, quinolizine, isoquinoline, quinoline, phthalazine, naphthylpyridine, quinoxaline, quinazoline, cinnoline, pteridine, carbazole, carboline, phenanthridine, acridine, phenanthroline, isothiazole, phenazine, isoxazole
- amino acid refers to any of the naturally occurring amino acids, as well as synthetic analogs (e.g., D-stereoisomers of the naturally occurring amino acids, such as D-threonine), and derivatives thereof.
- ⁇ -Amino acids comprise a carbon atom to which is bonded an amino group, a carboxyl group, a hydrogen atom, and a distinctive group referred to as a “side chain.”
- the side chains of naturally occurring amino acids are well known in the art, and include, for example, hydrogen (e.g., as in glycine), alkyl (e.g., as in alanine, valine, leucine, isoleucine, proline), substituted alkyl (e.g., as in threonine, serine, methionine, cysteine, aspartic acid, asparagine, glutamic acid, glutamine, arginine, and lysine), arylalkyl (e.g., as in phenylalanine, and tryptophan), substituted arylalkyl (e.g., as in tyrosine), and heteroarylalkyl (e.g., as in histidine).
- hydrogen e.g
- Unnatural amino acids are also known in the art, as set forth in, for example, Williams, ed. (1989) Synthesis of Optically Active ⁇ -Amino Acids, Pergamon Press; Evans et al. (1990) J. Amer. Chem. Soc.112:4011-4030; Pu et al. (1991) J. Amer. Chem. Soc.56:1280-1283; Williams et al. (1991) J. Amer. Chem. Soc.113:9276-9286; and all references cited therein.
- pharmaceutically acceptable salt refers to a pharmaceutically acceptable salt of a compound, which salt can be derived from a variety of organic, and inorganic counter ions well known in the art, and include, by way of example only, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, and the like; and when the molecule contains a basic functionality, a salt of an organic or inorganic acid, such as hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, oxalate, and the like.
- excipient means an inert or inactive substance used in the production of pharmaceutical products or other tablets, including without limitation any substance used as a binder, disintegrant, coating, compression/encapsulation aid, cream or lotion, lubricant, parenteral, sweetener or flavoring, suspending/gelling agent, or wet granulation agent.
- substituents as defined herein are not intended to include impermissible substitution patterns (e.g., methyl substituted with 5 fluoro groups or a hydroxy group attached to an ethenylic or acetylenic carbon atom). Such impermissible substitution patterns are well known to the skilled artisan. 2.
- n is 0, 1, 2, 3, or 4;
- R 1 is hydrogen, -P(O)(OR 20 ) 2 , -CH 2 P(O)(OR 20 ) 2 , -P(O)(R 20 )(OR 20 ), -CH 2 P(O)(R 20 )(OR 20 ), -P(O)(N(R 20 )2)(OR 20 ), -CH2P(O)(N(R 20 )2)(OR 20 ), -P(O)(R 20 )(N(R 20 )2), -CH2P(O)(R 20 )(N(R 20 )2), -CH2P(O)(R 20 )(N(R 20 )2), -C(O)R 20 , -C(O)N(R 21 )(R 22 ), -CH2P(O)(N(R 20 )
- n is 0 or 1. In certain embodiments, n is 1. In certain embodiments, n is 0. [0039] In certain embodiments, provided herein is a compound of Formula IA: or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, where each of R 1 , R 2 , R 3 , R 4 , R 6 , R 7 , R 8 , and R 9 are independently as defined herein.
- a compound of Formula IB or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, where each of R 1 , R 2 , R 3 , R 4 , R 6 , R 7 , R 8 , and R 9 are independently as defined herein.
- a compound of Formula IC or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, where each of R 1 , R 2 , R 3 , R 4 , R 6 , R 7 , R 8 , and R 9 are independently as defined herein.
- R 3 is halo, cyano, or C1-6 haloalkyl. In certain embodiments, R 3 is hydrogen, cyano, or C1-6 haloalkyl.
- n is 0 or 1. In certain embodiments, n is 1. In certain embodiments, n is 0.
- a compound of Formula IIA or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, where each of R 1 , R 2 , R 4 , R 6 , R 7 , R 8 , and R 9 are independently as defined herein.
- a compound of Formula IIB or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, where each of R 1 , R 2 , R 4 , R 6 , R 7 , R 8 , and R 9 are independently as defined herein.
- a compound of Formula IIC or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, where each of R 1 , R 2 , R 4 , R 6 , R 7 , R 8 , and R 9 are independently as defined herein.
- a compound of Formula IID or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, where each of R 1 , R 2 , R 4 , R 6 , R 7 , R 8 , and R 9 are independently as defined herein.
- R 1 is hydrogen.
- a compound of Formula IIIA or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, where each of R 2 , R 4 , R 6 , R 7 , R 8 , and R 9 are independently as defined herein.
- a compound of Formula IIIB or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, where each of R 2 , R 4 , R 6 , R 7 , R 8 , and R 9 are independently as defined herein.
- a compound of Formula IIIC or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, where each of R 2 , R 4 , R 6 , R 7 , R 8 , and R 9 are independently as defined herein.
- a compound of Formula IIID or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, where each of R 2 , R 4 , R 6 , R 7 , R 8 , and R 9 are independently as defined herein.
- R 2 is -OH, -OR 5 , -OCH2P(O)(OR 20 )2, -OCH2P(O)(R 20 )(N(R 20 )2), -OCH2P(O)(R 20 )(OR 20 ), -OCH2P(O)(N(R 20 )2)(OR 20 ), or -OCH2P(O)(N(R 20 )2)2.
- R 2 is -N(R 21 )(R 22 ), -N(R 20 )C(O)R 20 , -N(R 20 )C(O)OR 20 , -N(R 20 )C(O)N(R 21 )(R 21 ), -N(R 20 )S(O)2(R 20 ), -NR 20 S(O) 2 N(R 21 )(R 22 ), or -NR 20 S(O) 2 O(R 20 ).
- R 2 is -OH, -OR 5 , or -N(R 21 )(R 22 ).
- R 2 is -OH or -OR 5 .
- R 2 is -OH. In certain embodiments, R 2 is -OR 5 or -N(R 21 )(R 22 ). In certain embodiments, R 2 is -OR 5 . In certain embodiments, R 2 is -N(R 21 )(R 22 ). [0057] In certain embodiments, provided herein is a compound of Formula IVA: or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, where each of R 4 , R 6 , R 7 , R 8 , and R 9 are independently as defined herein.
- a compound of Formula IVB or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, where each of R 4 , R 6 , R 7 , R 8 , and R 9 are independently as defined herein.
- a compound of Formula IVC or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, where each of R 4 , R 6 , R 7 , R 8 , and R 9 are independently as defined herein.
- R 6 is hydrogen.
- R 7 is hydrogen.
- R 8 is hydrogen.
- R 9 is hydrogen.
- R 6 and R 7 are hydrogen.
- R 8 and R 9 are hydrogen.
- R 6 , R 7 , R 8 , and R 9 are hydrogen.
- provided herein is a compound of Formula VA: or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, where each of R 2 and R 4 are independently as defined herein.
- a compound of Formula VC or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, where each of R 2 and R 4 are independently as defined herein.
- a compound of Formula VD or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, where each of R 2 and R 4 are independently as defined herein.
- R 4 is cyano, -L-C 3-10 cycloalkyl, -L-heterocyclyl, -L-aryl, or -L-heteroaryl; wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl of R 4 is optionally substituted with 1-3 R 14 .
- R 4 is cyano, -L-cycloalkyl, -L-aryl, or -L-heteroaryl; wherein the cycloalkyl, aryl, or heteroaryl of R 4 is optionally substituted with 1-3 R 14 .
- R 4 is cyano or -L-aryl; wherein the aryl of R 4 is optionally substituted with 1-3 R 14 .
- R 4 is cyano.
- R 4 is -L-cycloalkyl optionally substituted with 1-3 R 14 .
- R 4 is -L-aryl optionally substituted with 1-3 R 14 .
- R 4 is -L-heteroaryl optionally substituted with 1-3 R 14 .
- L is a bond, C1-2 alkylene, C2 alkynylene, -O-, -S-, or -S(O)2-.
- L is a bond, C 1-2 alkylene, C 2 alkynylene, -O-, -S-, or -S(O) 2 -.
- L is a bond.
- L is a C1-2 alkylene.
- L is C2 alkynylene.
- L is -O-, -S-, or -S(O)2-.
- L is -O-.
- L is -S-.
- L is -S(O) 2 -.
- R 4 is cyano, -L-cycloalkyl, -L-aryl, or -L-heteroaryl; wherein the cycloalkyl, aryl, or heteroaryl of R 4 is optionally substituted with 1-3 R 14 ; and L is a bond, C1-2 alkylene, C2 alkynylene, -O-, -S-, or -S(O)2-.
- R 4 is cycloalkyl optionally substituted with 1-3 R 14 .
- R 4 is aryl optionally substituted with 1-3 R 14 .
- R 4 is heteroaryl optionally substituted with 1-3 R 14 .
- each R 14 is independently selected from the group consisting of halo, cyano, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, and aryl.
- R 4 is cyano, -L-cycloalkyl, -L-aryl, or -L-heteroaryl; wherein the cycloalkyl, aryl, or heteroaryl of R 4 is optionally substituted with 1-3 R 14 independently selected from the group consisting of halo, cyano, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, and C 1-6 haloalkoxy; and L is a bond, C 1-2 alkylene, C 2 alkynylene, -O-, -S-, or -S(O) 2 -.
- R 4 is cyano or -L-aryl; wherein the aryl of R 4 is optionally substituted with 1-3 R 14 ; and L is a bond, C1-2 alkylene, C2 alkynylene, -O-, -S-, or -S(O)2-.
- each R 14 is independently selected from the group consisting of halo, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, and C1-6 haloalkoxy.
- R 4 is cyano or -L-aryl; wherein the aryl of R 4 is optionally substituted with 1-3 R 14 independently selected from the group consisting of halo, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, and C1-6 haloalkoxy; and L is a bond, C1-2 alkylene, C2 alkynylene, -O-, -S-, or -S(O)2-.
- R 4 is cyano, phenyl, 2-fluorophenyl, 3-fluorophenyl, 4- fluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-methylphenyl, 3-methylphenyl, 4- methylphenyl, 2,6-dimethylphenyl, 3,5-dimethylphenyl, 2-trifluoromethylphenyl, 3- trifluoromethylphenyl, 4-trifluoromethylphenyl, 2-isopropylphenyl, 3-isopropylphenyl, 4- isopropylphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2-trifluoromethoxyphenyl, 3- trifluoromethoxyphenyl, 4-trifluoromethoxyphenyl, naphthalen-1-yl, 4-fluoro-3-methylphenyl, 2-fluoro- 3-methylphenyl
- R 4 is cyano, phenyl, 2-fluorophenyl, 3-fluorophenyl, 4- fluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-methylphenyl, 3-methylphenyl, 4- methylphenyl, 2,6-dimethylphenyl, 3,5-dimethylphenyl, 2-trifluoromethylphenyl, 3- trifluoromethylphenyl, 4-trifluoromethylphenyl, 2-isopropylphenyl, 3-isopropylphenyl, 4- isopropylphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2-trifluoromethoxyphenyl, 3- trifluoromethoxyphenyl, 4-trifluoromethoxyphenyl, naphthalen-1-yl, 4-fluoro-3-methylphenyl, 2-fluoro- 3-methylphenyl
- R 1 is hydrogen; R 2 is -OH; R 3 is hydrogen, cyano, or C1-6 haloalkyl; and each of R 6 , R 7 , R 8 , and R 9 is hydrogen.
- R 1 is hydrogen; R 2 is -OH; R 3 is hydrogen, cyano, or C1-6 haloalkyl; each of R 6 , R 7 , R 8 , and R 9 is hydrogen; R 4 is cyano, -L-cycloalkyl, -L-aryl, or -L-heteroaryl; wherein the cycloalkyl, aryl, or heteroaryl of R 4 is optionally substituted with 1-3 R 14 independently selected from the group consisting of halo, cyano, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, and C1-6 haloalkoxy; and L is a bond, C1-2 alkylene, C2 alkyn
- each R 14 is independently selected from the group consisting of halo, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, and C1-6 haloalkoxy.
- R 1 is hydrogen;
- R 2 is -OH;
- R 3 is hydrogen, cyano, or C 1-6 haloalkyl;
- each of R 6 , R 7 , R 8 , and R 9 is hydrogen;
- R 4 is cyano, phenyl, 2-fluorophenyl, 3- fluorophenyl, 4-fluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-methylphenyl, 3- methylphenyl, 4-methylphenyl, 2,6-dimethylphenyl, 3,5-dimethylphenyl, 2-trifluoromethylphenyl, 3- trifluoromethylphenyl, 4-trifluoromethylphenyl, 2-isopropylphenyl, 3-iso
- R 1 is hydrogen;
- R 2 is -OH;
- R 3 is hydrogen, cyano, or C 1-6 haloalkyl; each of R 6 , R 7 , R 8 , and R 9 is hydrogen; and
- R 4 is cyano, phenyl, 2-fluorophenyl, 3- fluorophenyl, 4-fluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-methylphenyl, 3- methylphenyl, 4-methylphenyl, 2,6-dimethylphenyl, 3,5-dimethylphenyl, 2-trifluoromethylphenyl, 3- trifluoromethylphenyl, 4-trifluoromethylphenyl, 2-isopropylphenyl, 3-isopropylphenyl, 4- isopropylphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2-trifluoromethoxyphenyl,
- compositions and Methods [0086] This disclosure provides compounds, compositions and methods of inhibiting the activity of a histone lysine demethylase-5 (KDM5) enzyme, as well as compounds and compositions for the manufacture of a medicament, for use in treating various conditions or disorders as described herein.
- the compound or composition can be used in methods to treat, pretreat, or delay progression or onset of a condition associated with a KDM5, particularly KDM5B.
- the composition is a pharmaceutical composition comprising a pharmaceutically acceptable excipient or carrier, and a therapeutically effective amount of one or more compounds of formula I.
- each of the various embodiments above also relate to a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug of the compound (e.g., a compound of formula I).
- a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug of the compound e.g., a compound of formula I.
- provided is a method of inhibiting the activity of a KDM5, particularly KDM5B, comprising bringing into contact the KDM5 and an inhibitory-effective amount of a compound or pharmaceutical composition disclosed herein.
- a method of treating, pretreating, or delaying onset of a condition associated with KDM5, particularly KDM5B the method comprising administering to a patient a therapeutically effective amount of a compound or pharmaceutical composition disclosed herein.
- a method of treating, pretreating, or delaying onset of a condition associated with undesirable cellular proliferation comprising administering to a patient a therapeutically effective amount of a compound or pharmaceutical composition disclosed herein.
- the condition is cancer.
- Exemplary cancers include, but are not limited to, acoustic neuroma; adenocarcinoma; adrenal gland cancer; anal cancer; angiosarcoma (e.g., lymphangio sarcoma, lymphangioendotheliosarcoma, hemangiosarcoma); appendix cancer; benign monoclonal gammopathy; biliary cancer (e.g., cholangiocarcinoma); bladder cancer; breast cancer (e.g., adenocarcinoma of the breast, papillary carcinoma of the breast, mammary cancer, medullary carcinoma of the breast); brain cancer (e.g., meningioma, glioblastomas, glioma (e.g., astrocytoma, oligodendroglioma), medulloblastoma); bronchus cancer; carcinoid tumor; cervical cancer (e.g., cervical adenocarcinoma); chorio
- Wilms tumor, renal cell carcinoma); liver cancer (e.g., hepatocellular cancer (HCC), malignant hepatoma); lung cancer (e.g., bronchogenic carcinoma, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), adenocarcinoma of the lung); leiomyosarcoma (LMS); mastocytosis (e.g., systemic mastocytosis); muscle cancer; myelodysplastic syndrome (MDS); mesothelioma; myeloproliferative disorder (MPD) (e.g., polycythemia vera (PV), essential thrombocytosis (ET), agnogenic myeloid metaplasia (AMM), myelofibrosis (MF), chronic idiopathic myelofibrosis, chronic myelocytic leukemia (CML), chronic neutrophilic leukemia (CNL), hypereosinophilic syndrome (HES)); neuroblastoma;
- the condition is a neoplasm, a tumor, or leukemia.
- the condition is histocytoma, glioma, astrocytoma, osteoma, lung cancer, small cell lung cancer, gastrointestinal cancer, bowel cancer, colon cancer, breast carcinoma, ovarian carcinoma, prostate cancer, testicular cancer, liver cancer, kidney cancer, bladder cancer, pancreas cancer, brain cancer, sarcoma, osteosarcoma, Kaposi's sarcoma, or melanoma.
- the cancer is embryonic carcinoma, teratoma, seminoma, germ cell tumors, prostate cancer, breast cancer, stomach cancer, gastrointestinal cancer, neuroblastoma, choriocarcinoma, yolk sac tumors, ovarian cancer, endometrial cancer, cervical cancer, retinoblastoma, kidney cancer, liver cancer, gastric cancer, brain cancer, medulloblastoma, medulloepithelioma, glioma, glioblastoma, multiple myeloma, lung cancer, bronchial cancer, mesothelioma, skin cancer, colon and rectal cancer, bladder cancer, pancreatic cancer, lip and oral cancer, laryngeal and pharyngeal cancer, melanoma, pituitary cancer, penile cancer, parathyroid cancer, thyroid cancer, pheochromocytoma and paraganglioma, thymoma and thymic carcinoma, leukemia, lymphoma,
- B-ALL B-cell acute lymphocytic leukemia
- NSCLC non-small cell lung cancer
- ER+ estrogen receptor positive
- provided is a method of preventing or treating a viral infection the method comprising administering to a patient a therapeutically effective amount of a compound or pharmaceutical composition disclosed herein.
- the patient has a viral infection or is at risk for viral infection but is free from cancer.
- the viral infection may be due to a nuclear DNA viral infection such as a herpes viral infection.
- the herpesvirus may be, e.g., herpes simplex virus (HSV) type 1, herpes simplex virus type 2, varicella zoster virus (VZV), or cytomegalovirus (CMV).
- the herpesvirus may be Epstein-Barr virus (EBV), Kaposi's Sarcoma-Associated herpesvirus, herpes simiae virus, herpes lymphotropic virus, human herpesvirus-7 (HHMV-7), or human herpesvirus-8 (HHMV-8).
- EBV Epstein-Barr virus
- HHMV-7 herpesvirus-7
- HHMV-8 human herpesvirus-8
- Viral infections especially pose a threat to individuals that have suppressed (immunosuppressed) or otherwise compromised (immunocompromised) immune systems.
- the viral infection involves reactivation of a virus after latency in the patient.
- the patient has undergone, is undergoing, or will undergo, immunosuppression.
- the method prevents or treats viral-induced encephalitis, viral-induced keratitis, or reduces the severity of infection.
- the patient is an immunocompromised mammal.
- a method for treating a hepatitis B virus (HBV) infection comprising administering a therapeutically effective amount of a compound or composition disclosed herein to a patient in need thereof.
- a method for treating a hepatocellular carcinoma derived from persistent HBV or HCV infection comprising administering a therapeutically effective amount of a compound or composition disclosed herein to a patient in need thereof.
- the condition is cardiovascular disease.
- the cardiovascular disease is heart disease.
- the cardiovascular disease is coronary heart disease.
- the cardiovascular disease is stroke or cerebrovascular disease.
- the cardiovascular disease is a congenital heart defect.
- the cardiovascular disease is peripheral artery disease. In certain embodiments, the cardiovascular disease is heart disease associated with atherosclerosis. In certain embodiments, the cardiovascular disease is ischemic heart disease. In certain embodiments, the cardiovascular disease is hypertensive heart disease. In certain embodiments, the cardiovascular disease is cardiac arrhythmia. In certain embodiments, the cardiovascular disease is heart failure or congenital heart disease. In certain embodiments, the cardiovascular disease is inflammatory heart disease. In certain embodiments, the cardiovascular disease is cardiomyopathy. [0098] In certain embodiments, the compound is administered in combination with one or more additional pharmaceutical agents described herein. The additional pharmaceutical agent may be an anti- proliferative agent. In certain embodiments, the additional pharmaceutical agent is an anti-cancer agent.
- the additional pharmaceutical agent may also be a kinase inhibitor.
- the additional pharmaceutical agent is an inhibitor of histone lysine demethylase.
- the additional pharmaceutical agent includes an anti-cancer agent, anti-inflammatory agent, steroids, immunosuppressant, radiation therapy, or other agents.
- the additional pharmaceutical agent is an anti-proliferative agent.
- the additional pharmaceutical agent is a non-selective inhibitor of a histone demethylase.
- the additional pharmaceutical agent is an immunotherapy agent.
- the additional pharmaceutical agent is an immune checkpoint inhibitor.
- the anti-cancer agent is a chemotherapeutic.
- the immunotherapy agent is a PD1 inhibitor. In certain embodiments, the immunotherapy agent is a PDL1 inhibitor. In certain embodiments, the additional pharmaceutical agent is a topoisomerase inhibitor, a MCL1 inhibitor, a BCL-2 inhibitor, a BCL-xL inhibitor, a BRD4 inhibitor, a BRCA1 inhibitor, BRCA2 inhibitor, HER1 inhibitor, HER2 inhibitor, a CDK9 inhibitor, a Jumonji histone demethylase inhibitor, or a DNA damage inducer.
- the additional pharmaceutical agent is etoposide, obatoclax, navitoclax, JQ1, 4-(((5’- chloro-2’-(((lR,4R)-4- (((R)-l-methoxypropan-2-yl)amino)cyclohexyl)amino)-[2,4’-bipyridin]-6- yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile, JIB04, or cisplatin.
- chemotherapeutic agents include alkylating agents such as nitrogen mustards, ethylenimines, methylmelamines, alkyl sulfonates, nitrosoureas, and triazenes; antimetabolites such as folic acid analogs, pyrimidine analogs, in particular fluorouracil and cytosine arabinoside, and purine analogs; natural products such as vinca alkaloids epi-podophyllotoxins, antibiotics, enzymes, and biological response modifiers; and miscellaneous products such as platinum coordination complexes, anthracenedione, substituted urea such as hydroxyurea, methyl hydrazine derivatives, and adrenocorticoid suppressant.
- alkylating agents such as nitrogen mustards, ethylenimines, methylmelamines, alkyl sulfonates, nitrosoureas, and triazenes
- antimetabolites such as folic acid analogs, pyrim
- chemotherapeutic agents also include anthracycline antibiotics, actinomycin D, plicamycin, puromycin, gramicidin D, paclitaxel, colchicine, cytochalasin B, emetine, maytansine, amsacrine, cisplatin, carboplatin, mitomycin, altretamine, cyclophosphamide, lomustine, and carmustine.
- a pharmaceutical composition described herein further comprises a combination of the additional pharmaceutical agents described herein. 4. Formulations and Administration [0099]
- the compositions of the present disclosure can be delivered directly or in pharmaceutical compositions along with suitable carriers or excipients, as is well known in the art.
- Present methods of treatment can comprise administration of an effective amount of a compound of the disclosure to a subject in need; e.g., a subject having or at risk for a hyperproliferative disease or cancer.
- the subject is a mammalian subject.
- the subject is a human subject.
- An effective amount of such agents can readily be determined by routine experimentation, as can the most effective and convenient route of administration and the most appropriate formulation.
- formulations and drug delivery systems are available in the art. See, e.g., Gennaro, A.R., ed. (1995) Remington’s Pharmaceutical Sciences, supra.
- Suitable routes of administration may, for example, include oral, rectal, topical, nasal, pulmonary, ocular, intestinal, and parenteral administration.
- Pharmaceutical compositions are often composed of the drug and an excipient(s).
- Pharmaceutical dosage forms are often composed of the drug, an excipient(s), and a container/closure system.
- One or multiple excipients, also referred to as inactive ingredients can be added to a compound of the disclosure to improve or facilitate manufacturing, stability, administration, and safety of the drug, and can provide a means to achieve a desired drug release profile.
- excipient(s) to be added to the drug can depend on various factors, such as, for example, the physical and chemical properties of the drug, the route of administration, and the manufacturing procedure.
- Pharmaceutically acceptable excipients are available in the art and include those listed in various pharmacopoeias. (See, e.g., the U.S. Pharmacopeia (USP), Japanese Pharmacopoeia (JP), European Pharmacopoeia (EP), and British pharmacopeia (BP); the U.S. Food and Drug Administration (fda.gov) Center for Drug Evaluation and Research (CEDR) publications, e.g., Inactive Ingredient Guide (1996); Ash and Ash, Eds.
- compositions of the present disclosure can include one or more physiologically acceptable inactive ingredients that facilitate processing of active molecules into preparations for pharmaceutical use.
- Proper formulation is dependent upon the desired route of administration.
- the composition may be formulated in aqueous solution, if necessary using physiologically compatible buffers, including, for example, phosphate, histidine, or citrate for adjustment of the formulation pH, and a tonicity agent, such as, for example, sodium chloride or dextrose.
- physiologically compatible buffers including, for example, phosphate, histidine, or citrate for adjustment of the formulation pH
- a tonicity agent such as, for example, sodium chloride or dextrose.
- semisolid, liquid formulations, or patches may be desired, possibly containing penetration enhancers.
- penetration enhancers are generally known in the art.
- the compounds can be formulated in liquid or solid dosage forms, and as instant or controlled/sustained release formulations.
- Suitable dosage forms for oral ingestion by a subject include tablets, pills, dragees, hard and soft shell capsules, liquids, gels, syrups, slurries, suspensions, and emulsions.
- the compounds may also be formulated in rectal compositions, such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.
- Solid oral dosage forms can be obtained using excipients, which may include fillers, disintegrants, binders (dry and wet), dissolution retardants, lubricants, glidants, antiadherants, cationic exchange resins, wetting agents, antioxidants, preservatives, coloring, and flavoring agents.
- excipients can be of synthetic or natural source.
- excipients include cellulose derivatives, citric acid, dicalcium phosphate, gelatine, magnesium carbonate, magnesium/sodium lauryl sulfate, mannitol, polyethylene glycol, polyvinyl pyrrolidone, silicates, silicium dioxide, sodium benzoate, sorbitol, starches, stearic acid or a salt thereof, sugars (i.e. dextrose, sucrose, lactose, etc.), talc, tragacanth mucilage, vegetable oils (hydrogenated), and waxes. Ethanol and water may serve as granulation aides.
- a therapeutically effective dose can be estimated initially using a variety of techniques well-known in the art. Initial doses used in animal studies may be based on effective concentrations established in cell culture assays. Dosage ranges appropriate for human subjects can be determined, for example, using data obtained from animal studies and cell culture assays.
- an effective amount or a therapeutically effective amount or dose of an agent refers to that amount of the agent or compound that results in amelioration of symptoms or a prolongation of survival in a subject.
- Toxicity and therapeutic efficacy of such molecules can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., by determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population).
- the dose ratio of toxic to therapeutic effects is the therapeutic index, which can be expressed as the ratio LD 50 /ED 50 . Agents that exhibit high therapeutic indices are generally desired.
- the effective amount or therapeutically effective amount is the amount of the compound or pharmaceutical composition that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by the researcher, veterinarian, medical doctor or other clinician. Dosages typically fall within a range of circulating concentrations that includes the ED 50 with little or no toxicity. Dosages may vary within this range depending upon the dosage form employed and/or the route of administration utilized. Dosages are typically expressed as a number of milligrams of a compound described herein per kilogram of the subject’s body weight (mg/kg). Dosages of between about 0.1 and 900 mg/kg may be appropriate. In some embodiments, about 1 and 500 mg/kg may be appropriate.
- a dosage of between 10 and 250 mg/kg may be appropriate.
- a dosage of from about 1 to about 100 mg per kg of body weight, from about 1 to about 50 mg of compound per kg of body weight, or from about 1 to about 10 mg of compound per kg of body weight may be appropriate.
- a dosage of from about 25 to about 500 mg per kg of body weight, from about 50 to about 500 mg of compound per kg of body weight, or from about 25 to about 250 mg of compound per kg of body weight may be appropriate.
- the exact formulation, route of administration, dosage, and dosage interval should be chosen according to methods known in the art, in view of the specifics of a subject’s condition.
- the amount of agent or composition administered may be dependent on a variety of factors, including the sex, age, and weight of the subject being treated, the severity of the affliction, the manner of administration, and the judgment of the prescribing physician. [0110] These and other embodiments of the present disclosure will readily occur to those of ordinary skill in the art in view of the disclosure herein and are specifically contemplated. 5. General Synthetic Methods [0111] The compounds of this disclosure can be prepared from readily available starting materials using, for example, the following general methods, and procedures. It will be appreciated that where certain process conditions (i.e., reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are given, other process conditions can also be used unless otherwise stated.
- process conditions i.e., reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.
- Optimum reaction conditions may vary with the reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimization procedures.
- conventional protecting groups may be necessary to prevent certain functional groups from undergoing undesired reactions.
- Suitable protecting groups for various functional groups as well as suitable conditions for protecting and deprotecting certain functional groups are well known in the art. For example, numerous protecting groups are described in T. W. Greene and G. M. Wuts (1999) Protecting Groups in Organic Synthesis, 3rd Edition, Wiley, New York, and references cited therein.
- the compounds of this disclosure may contain one or more chiral centers.
- stereoisomers i.e., as individual enantiomers or diastereomers, or as stereoisomer-enriched mixtures. All such stereoisomers (and enriched mixtures) are included within the scope of this disclosure, unless otherwise indicated.
- Pure stereoisomers (or enriched mixtures) may be prepared using, for example, optically active starting materials or stereoselective reagents well-known in the art. Alternatively, racemic mixtures of such compounds can be separated using, for example, chiral column chromatography, chiral resolving agents, and the like.
- the starting materials for the following reactions are generally known compounds or can be prepared by known procedures or obvious modifications thereof.
- Scheme I illustrates a general method which can be employed for the synthesis of compounds described herein, where n, R 1 , R 2 , R 3 , R 4 , R 6 , R 7 , R 8 , and R 9 are defined herein, Z is halo (such as Cl, Br, or I), PG is a suitable protecting group (e.g., benzyl), and R 52 and R 53 are independently C1-6 alkoxy, -O-C2-6 alkenyl, -O-C2-6 alkynyl, -O-C1-6 haloalkyl, -O-C3-10 cycloalkyl, -O-C3-10 cycloalkenyl, -O-heterocyclyl, -O-aryl, or –O-heteroaryl.
- Z is halo (such as Cl, Br, or I)
- PG is a suitable protecting group (e.g., benzyl)
- R 52 and R 53 are independently C
- Compounds of Formula I, where R 3 is other than hydrogen can be provided by functionalization of Formula I-1 (e.g., compounds of Formula I where R 3 is hydrogen).
- halogenation of Formula I-1 provides Formula I-2 (e.g., compounds of Formula I where R 3 is halo).
- Formula I-2 such as with a compound of formula B-C 1-6 haloalkyl or M-CN, where B is a suitable functional group such as, but not limited to, a boronic acid or a derivative thereof, such as a boronic ester, zinc or magnesium halide, an organotin compound, and M is a metal, such as zinc or magnesium halide, provides compounds of Formula I where R 3 is cyano or C1-6 haloalkyl.
- B is a suitable functional group such as, but not limited to, a boronic acid or a derivative thereof, such as a boronic ester, zinc or magnesium halide, an organotin compound
- M is a metal, such as zinc or magnesium halide
- Formula I-4 For example, contacting appropriately substituted Formula I-3 with oxalyl chloride in the presence of DMF, followed by 2-tert- butoxycarbonyl-succinic acid 1-tert-butyl ester 4-ethyl ester provides Formula I-4.
- Formula I-1 is then provided from Formula I-4 using an acid (e.g., p-toluenesulfonic acid) followed by appropriate deprotection and/or functionalization, such as at R 1 .
- an acid e.g., p-toluenesulfonic acid
- R 1 e.g., p-toluenesulfonic acid
- compounds of Formula I-1 where one or more of R 6 -R 9 are other than hydrogen can be provided from Formula I-3.
- various compounds of Formula I can be prepared by contacting compounds where one or more R 4 is a leaving group (e.g., halo, such as Cl, Br, or I, or a pseudohalide, such as a triflate, sulfonate, or phosphate), with a compound of Formula R 4 -B, wherein B is a suitable functional group such as, but not limited to, a boronic acid or a derivative thereof, such as a boronic ester, zinc or magnesium halide, an organotin compound, such as tributylstannane or trimethylstannane, fluorosulfonyl esters, tin, sodium, hydrogen, and the like.
- a leaving group e.g., halo, such as Cl, Br, or I, or a pseudohalide, such as a triflate, sulfonate, or phosphate
- B is a suitable functional group such as, but not limited to, a boronic acid or a derivative
- Such reactions are commonly utilized for aromatic functionalization, and are typically conducted in the presence of suitable catalyst such as, but not limited to, a palladium catalyst including [1,1’-bis(diphenylphosphino)ferrocene]palladium(II) dichloride, Pd(OAc)2, Pd(PPh3)4, PdCl2(PPh3)2 or tris(dibenzylideneacetone)dipalladium(0), and the like, or a copper catalyst such as CuCl or CuI, and if required suitable mediator, co-catalyst and/or base known to one skilled in the art using suitable solvents/solvent mixtures.
- a palladium catalyst including [1,1’-bis(diphenylphosphino)ferrocene]palladium(II) dichloride, Pd(OAc)2, Pd(PPh3)4, PdCl2(PPh3)2 or tris(dibenzylideneacetone)dipalladium(0), and the like
- compounds of Formula I can be recovered by conventional techniques such as neutralization, extraction, precipitation, chromatography, filtration and the like.
- the various substituents of Formula I-1, I-2, I-3, I-4, I-5, I-6, I-7, or I-8 e.g., n, R 1 , R 2 , R 3 , R 4 , R 6 , R 7 , R 8 , R 9 , Z, R 52 , and R 53 ) are as defined herein.
- Example 1 4-(4-Cyano-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid a) (2-Amino-4-bromo-phenyl)-methanol [0122] To an ice cooled solution of LiAlH4 (5.2 g, 0.135 mol) in THF (125 mL), methyl 2- amino-4-bromobenzoate (25 g, 0.108 mol) in THF (125 mL) was added at 0 0 C and stirred at RT for 4h. The reaction mixture was slowly quenched using saturated aqueous solution of sodium thiosulfate and filtered.
- the mixture was diluted with 2 mL of cold THF and the solid was isolated by filtration and dried under high vacuum for several hours.
- glacial acetic acid 80 mL was heated to 115 o C.
- the solid from above was suspended in glacial acetic acid (80 mL) and added to the pre-heated acetic acid, and the resulting homogeneous mixture was then stirred at 115-120 o C for 16 h.
- the reaction was completed.
- the mixture was allowed to come to room temperature and concentrated to dryness.
- the residue was re-dissolved in absolute EtOH (35 mL) and placed in ice bath.
- Example 2 4-(4-Cyano-3-hydroxy-7-phenyl-quinolin-2-yl)-4-oxo-butyric acid a) 3-Hydroxy-7-phenyl-quinoline-2-carboxylic acid ethyl ester
- 7-Bromo-3-hydroxy-quinoline-2-carboxylic acid ethyl ester 930 mg, 3.0 mmol
- phenylboronic acid 550 mg, 4.5 mmol, 1.5 eq
- S-Phos 98 mg, 0.24 mmol, 0.08 eq
- palladium acetate 40.3 mg, 0.18 mmol, 0.06 eq
- tripotassium phosphate (1.27 g, 6.0 mmol, 2.0 eq).
- Example 3 4-(3-Hydroxy-7-phenyl-quinolin-2-yl)-4-oxo-butyric acid a) 4-(3-hydroxy-7-phenyl-quinolin-2-yl)-4-oxo-butyric acid [0143] At room temperature, to a solution of 4-(3-hydroxy-7-phenyl-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (50 mg, 0.14 mmol) in THF/H 2 O (3 mL/1 mL) was added lithium hydroxide monohydrate (24 mg, 0.57 mmol).
- Example 4 4-(4-Cyano-3-hydroxy-5-phenyl-quinolin-2-yl)-4-oxo-butyric acid a) (2-Amino-6-bromo-phenyl)-methanol [0144] To a solution of 2-amino-6-bromo benzoic acid (10 g, 46.2 mmol) in THF (100 mL), LiAlH 4 (2.5 g, 69.3 mmol) was added at 0 o C and stirred at RT for 8 h, water (7.7 mL) was added, followed by 15% NaOH (7.7 mL) and water (23 mL). The slurry was stirred at room temperature for 1h.
- the mixture was diluted with 10 mL of cold THF and the solid was isolated by filtration and dried under high vacuum for several hours.
- glacial acetic acid (8 mL) was heated to 115 o C.
- the solid from above was suspended in glacial acetic acid (7 mL) and added to the pre-heated acetic acid, and the resulting homogeneous mixture was then stirred at 115-120 o C for 16 h.
- the reaction mixture was allowed to come to room temperature and concentrated to dryness.
- the residue was re- dissolved in absolute EtOH (58 mL) and placed in ice bath.
- Thionyl chloride (1.66 mL) was added, and the mixture was warmed to room temperature and refluxed for 16h.
- Example 5 4-(3-Hydroxy-5-phenyl-4-trifluoromethyl-quinolin-2-yl)-4-oxo-butyric acid a) 4-(3-Benzyloxy-4-bromo-5-phenyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0157] Benzyl bromide (0.036 mL, 52 mg, 0.3 mmol) was added to a mixture of 4-(4-Bromo-3- hydroxy-5-phenyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (86 mg, 0.2 mmol) and cesium carbonate (78 mg, 0.24 mmol) in anhydrous DMF (3 mL) at room temperature.
- Example 6 4-(5-Cyano-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid a) 2-tert-Butoxycarbonyl-succinic acid 1-tert-butyl ester 4-ethyl ester [0161] A solution of di-tert-butyl malonate (9.66 g, 44.7 mmol) in anhydrous tetrahydrofuran (15 mL) was added to a suspension of sodium hydride (1.8 g, 45 mmol, 60% dispersion) in anhydrous tetrahydrofuran (50 mL) at room temperature. After stirring for 2 hours at room temperature, the suspension mixture was further heated at 60°C for 16 hours.
- Example 7 4-(4-Cyano-3-hydroxy-6-phenyl-quinolin-2-yl)-4-oxo-butyric acid a) (2-Amino-5-bromo-phenyl)-methanol [0170] To a solution of 2-amino-5-bromo benzoic acid (10 g, 46.2 mmol) in THF (100 ml), LiAlH4 (2.5 g, 69.3 mmol) was added at 0 o C and stirred at RT for 8h, The reaction was quenched using saturated solution of sodium sulfate and filtered through celite bed to yield 6 g of title compound. MS: (+) m/z 202, 204 (M+1).
- Example 8 4-(6-Benzyl-4-cyano-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid a) 4-(6-Benzyl-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0184] At 0°C, to a solution of 4-(6-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (110 mg, 0.32 mmol), Pd(OAc)2 (7.2 mg, 0.032 mmol) and S-Phos (26 mg, 0.064 mmol) in dry THF (3 mL) was added dropwise a solution of benzylzinc(II) bromide in THF (0.8 mmol, 1.6 mL, 0.5 M) under nitrogen atmosphere.
- Example 10 4-(4-Cyano-3-hydroxy-7-phenylsulfanyl-quinolin-2-yl)-4-oxo-butyric acid a) 4-(3-Hydroxy-7-phenylsulfanyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0197] To a round-bottom-flask were added 4-(7-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (352mg, 1.0 mmol), Pd2(dba)3 (35.4 mg, 0.05 mmol), Xantphos (58 mg, 0.1 mmol), benzenethiol (165 mg, 1.5 mmol), and N,N-Diisopropylethylamine (0.35 mL, 2.0 mmol) in anhydrous 1,4-dioxane (5 mL).
- Example 11 4-(7-Benzenesulfonyl-4-cyano-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid a) 4-(7-Benzenesulfonyl-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0201] At 0 o C, RuCl3.XH2O (0.02 mmol, 4 mg) was added to the mixture of 4-(3-Hydroxy-7- phenylsulfanyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (150 mg, 0.39 mmol) and NaIO4 (247 mg, 1.17 mmol) in CH3CN (10mL)/H2O (5mL).
- Example 12 4-[4-Cyano-3-hydroxy-7-(2-methyl-benzyl)-quinolin-2-yl]-4-oxo-butyric acid a) 4-[3-Hydroxy-7-(2-methyl-benzyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0205] At 0°C, to a solution of 4-(7-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (176 mg, 0.45 mmol), Pd(OAc)2 (22.4 mg, 0.10 mmol) and S-Phos (61 mg, 0.15 mmol) in dry THF (3 mL) was added dropwise a solution of 2-methylbenzyl zinc(II) bromide in THF (1.25 mmol, 2.5 mL, 0.5 M) under nitrogen atmosphere.
- Example 13 4-(4-Cyano-3-hydroxy-8-phenyl-quinolin-2-yl)-4-oxo-butyric acid a) (2-Amino-3-bromo-phenyl)-methanol [0209] To a solution of 2-amino-3-bromo benzoic acid (10 g, 46.2 mmol) in THF (100 mL), LiAlH 4 (2.5 g, 69.3 mmol) was added at 0 o C and stirred at RT for 8 h, The reaction was quenched using saturated solution of sodium sulfate and filtered through celite bed to yield 7 g of title compound after trituration with hexane.
- the mixture was diluted with 10 mL of cold THF and the solid was isolated by filtration and dried under high vacuum for several hours.
- glacial acetic acid (20 mL) was heated to 115 o C.
- the solid from above was suspended in glacial acetic acid (20 mL) and added to the pre-heated acetic acid, and the resulting homogeneous mixture was then stirred at 115-120 o C for 16 h.
- the reaction mixture was allowed to come to room temperature and concentrated to dryness.
- the residue was re- dissolved in absolute EtOH (30 mL) and placed in ice bath. Thionyl chloride (1 mL) was added, and the mixture was warmed to room temperature and refluxed for 16 h.
- Example 14 4-[4-Cyano-7-(2,6-dimethyl-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid a) 4-[7-(2,6-Dimethyl-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0223] A round bottom flask was charged with 4-(7-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (210 mg, 0.6 mmol), 2,6-dimethylphenylboronic acid (125 mg, 0.9 mmol, 1.5 eq), S-Phos (20 mg, 0.048 mmol, 0.08 eq), palladium acetate (8.1 mg, 0.036 mmol, 0.06 eq), and tripotassium phosphate (254 mg, 1.2 mmol, 2.0 eq).
- Example 15 4-(4-Cyano-3-hydroxy-7-phenoxy-quinolin-2-yl)-4-oxo-butyric acid a) 4-(3-Benzyloxy-7-phenoxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0227] To a round-bottom-flask were added 4-(3-benzyloxy-7-bromo-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (221mg, 0.5 mmol), Pd(OAc)2 (11.2 mg, 0.05 mmol), t-BuXPhos (32 mg, 0.075 mmol), phenol (71 mg, 0.75 mmol), and K3PO4 (212 mg, 1.0 mmol) in anhydrous toluene (4 mL).
- Example 16 4-(8-Benzyl-4-cyano-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid a) 4-(8-Benzyl-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0232] At 0°C, to a solution of 4-(8-bromo-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (176 mg, 0.5 mmol), Pd(OAc)2 (22.4 mg, 0.1 mmol) and S-Phos (61 mg, 0.15 mmol) in dry THF (3 mL) was added dropwise a solution of benzylzinc(II) bromide in THF (1.25 mmol, 2.5 mL, 0.5 M) under nitrogen atmosphere.
- Example 17 4-(4-Cyano-3-hydroxy-7-o-tolyl-quinolin-2-yl)-4-oxo-butyric acid a) 4-(3-Hydroxy-7-o-tolyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0236] A round bottom flask was charged with 4-(7-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (176 mg, 0.5 mmol), 2-methylphenylboronic acid (136 mg, 1.0 mmol), S-Phos (16.5 mg, 0.04 mmol), palladium acetate (6.7 mg, 0.03 mmol), and tripotassium phosphate (212 mg, 1.0 mmol).
- Example 18 4-(4-Cyano-3-hydroxy-7-m-tolyl-quinolin-2-yl)-4-oxo-butyric acid a) 4-(3-Hydroxy-7-m-tolyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0240] A round bottom flask was charged with 4-(7-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (176 mg, 0.5 mmol), 3-methylphenylboronic acid (136 mg, 1.0 mmol), S-Phos (16.5 mg, 0.04 mmol), palladium acetate (6.7 mg, 0.03 mmol), and tripotassium phosphate (212 mg, 1.0 mmol).
- Example 19 4-(4-Cyano-3-hydroxy-7-p-tolyl-quinolin-2-yl)-4-oxo-butyric acid a) 4-(3-Hydroxy-7-p-tolyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0244] A round bottom flask was charged with 4-(7-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (176 mg, 0.5 mmol), 4-methylphenylboronic acid (136 mg, 1.0 mmol), S-Phos (16.5 mg, 0.04 mmol), palladium acetate (6.7 mg, 0.03 mmol), and tripotassium phosphate (212 mg, 1.0 mmol).
- Example 20 4-(4-Cyano-3-hydroxy-6-phenoxy-quinolin-2-yl)-4-oxo-butyric acid a) 4-(3-Benzyloxy-6-phenoxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0248] To a round-bottom-flask were added 4-(3-Benzyloxy-6-bromo-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (221mg, 0.5 mmol), Pd(OAc)2 (11.2 mg, 0.05 mmol), t-BuXPhos (32 mg, 0.075 mmol), phenol (71 mg, 0.75 mmol), and K 3 PO 4 (212 mg, 1.0 mmol) in anhydrous toluene (4 mL).
- Example 21 4-(4-Cyano-3-hydroxy-6-phenylsulfanyl-quinolin-2-yl)-4-oxo-butyric acid a) 4-(3-Hydroxy-6-phenylsulfanyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0253] To a round-bottom-flask were added 4-(6-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (352mg, 1.0 mmol), Pd2(dba)3 (35.4 mg, 0.05 mmol), Xantphos (58 mg, 0.1 mmol), benzenethiol (165 mg, 1.5 mmol), and N,N-Diisopropylethylamine (0.35 mL, 2.0 mmol) in anhydrous 1,4-dioxane (5 mL).
- Example 22 4-(6-Benzenesulfonyl-4-cyano-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid a) 4-(6-Benzenesulfonyl-4-cyano-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0257] To a solution of 4-(4-Cyano-3-hydroxy-6-phenylsulfanyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (70 mg, 0.17 mmol) in DCM (6 mL) was added meta-chloroperoxybenzoic acid (88 mg, 0.51 mmol).
- Example 23 4-[4-Cyano-6-(2,6-dimethyl-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid a) 4-[6-(2,6-Dimethyl-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0259] A round bottom flask was charged with 4-(6-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (176 mg, 0.5 mmol), 2,6-dimethylphenylboronic acid (136 mg, 1.0 mmol), S- Phos (16.5 mg, 0.04 mmol), palladium acetate (6.7 mg, 0.03 mmol), and tripotassium phosphate (212 mg, 1.0 mmol).
- Example 24 4-(4-Cyano-3-hydroxy-7-phenethyl-quinolin-2-yl)-4-oxo-butyric acid a) 4-(3-Hydroxy-7-phenylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0263] To a round-bottom-flask were added 4-(7-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (71 mg, 0.20 mmol), PdCl2(PPh3)2 (28 mg, 0.04 mmol), and tributyl- phenylethynyl-stannane (0.12 mL, 0.32 mmol) in anhydrous DMF (3 mL).
- Example 25 4-(4-Cyano-3-hydroxy-6-phenethyl-quinolin-2-yl)-4-oxo-butyric acid a) 4-(3-Hydroxy-6-phenylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0268] To a round-bottom-flask were added 4-(6-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (176 mg, 0.50 mmol), PdCl 2 (PPh 3 ) 2 (71 mg, 0.2 mmol), and tributyl- phenylethynyl-stannane (0.31 mL, 0.8 mmol) in anhydrous DMF (5 mL).
- Example 26 4-(4-Cyano-3-hydroxy-6-o-tolyl-quinolin-2-yl)-4-oxo-butyric acid a) 4-(3-Hydroxy-6-o-tolyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0273] A round bottom flask was charged with 4-(6-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (176 mg, 0.5 mmol), 2-methylphenylboronic acid (136 mg, 1.0 mmol), S-Phos (16.5 mg, 0.04 mmol), palladium acetate (6.7 mg, 0.03 mmol), and tripotassium phosphate (212 mg, 1.0 mmol).
- Example 27 4-(4-Cyano-3-hydroxy-6-m-tolyl-quinolin-2-yl)-4-oxo-butyric acid a) 4-(3-Hydroxy-6-m-tolyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0277] A round bottom flask was charged with 4-(6-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (176 mg, 0.5 mmol), 3-methylphenylboronic acid (136 mg, 1.0 mmol), S-Phos (16.5 mg, 0.04 mmol), palladium acetate (6.7 mg, 0.03 mmol), and tripotassium phosphate (212 mg, 1.0 mmol).
- Example 28 4-(4-Cyano-3-hydroxy-6-p-tolyl-quinolin-2-yl)-4-oxo-butyric acid a) 4-(3-Hydroxy-6-p-tolyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0281] A round bottom flask was charged with 4-(6-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (106 mg, 0.3 mmol), 4-methylphenylboronic acid (82 mg, 0.6 mmol), S-Phos (9.8 mg, 0.024 mmol), palladium acetate (4.0 mg, 0.018 mmol), and tripotassium phosphate (127 mg, 0.6 mmol).
- Example 29 4-(4-Cyano-3-hydroxy-8-o-tolyl-quinolin-2-yl)-4-oxo-butyric acid a) 4-(3-Hydroxy-8-o-tolyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0285] A round bottom flask was charged with 4-(8-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (106 mg, 0.3 mmol), 2-methylphenylboronic acid (82 mg, 0.6 mmol), S-Phos (9.8 mg, 0.024 mmol), palladium acetate (4.0 mg, 0.018 mmol), and tripotassium phosphate (127 mg, 0.6 mmol).
- Example 30 4-(4-Cyano-3-hydroxy-8-m-tolyl-quinolin-2-yl)-4-oxo-butyric acid a) 4-(3-Hydroxy-8-m-tolyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0289] A round bottom flask was charged with 4-(8-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (106 mg, 0.3 mmol), 3-methylphenylboronic acid (82 mg, 0.6 mmol), S-Phos (9.8 mg, 0.024 mmol), palladium acetate (4.0 mg, 0.018 mmol), and tripotassium phosphate (127 mg, 0.6 mmol).
- Example 31 4-(4-Cyano-3-hydroxy-8-p-tolyl-quinolin-2-yl)-4-oxo-butyric acid a) 4-(3-Hydroxy-8-p-tolyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0293] A round bottom flask was charged with 4-(8-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (106 mg, 0.3 mmol), 4-methylphenylboronic acid (82 mg, 0.6 mmol), S-Phos (9.8 mg, 0.024 mmol), palladium acetate (4.0 mg, 0.018 mmol), and tripotassium phosphate (127 mg, 0.6 mmol).
- Example 32 4-[4-Cyano-3-hydroxy-7-(2-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid a) 4-[3-Hydroxy-7-(2-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0297] A round bottom flask was charged with 4-(7-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (176 mg, 0.5 mmol), 2-trifluoromethylphenylboronic acid (190 mg, 1.0 mmol), S- Phos (33 mg, 0.08 mmol), palladium acetate (13.4 mg, 0.06 mmol), and tripotassium phosphate (212 mg, 1.0 mmol).
- Example 33 4-[4-Cyano-3-hydroxy-7-(4-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid a) 4-[3-Hydroxy-7-(4-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0301] A round bottom flask was charged with 4-(7-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (106 mg, 0.3 mmol),4-trifluoromethylphenylboronic acid (114 mg, 0.6 mmol), S- Phos (19.7 mg, 0.048 mmol), palladium acetate (8.1 mg, 0.036 mmol), and tripotassium phosphate (127 mg, 0.6 mmol).
- Example 34 4-[4-Cyano-3-hydroxy-7-(3-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid a) 4-[3-Hydroxy-7-(3-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0305] A round bottom flask was charged with 4-(7-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (176 mg, 0.5 mmol), 3-trifluoromethylphenylboronic acid (190 mg, 1.0 mmol), S- Phos (33 mg, 0.08 mmol), palladium acetate (13.4 mg, 0.06 mmol), and tripotassium phosphate (212 mg, 1.0 mmol).
- Example 35 4-[4-Cyano-3-hydroxy-7-(2-isopropyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid a) 4-[3-Hydroxy-7-(2-isopropyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0309] A round bottom flask was charged with 4-(7-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (176 mg, 0.5 mmol), 2-isopropylphenylboronic acid (164 mg, 1.0 mmol), S-Phos (33 mg, 0.08 mmol), palladium acetate (13.4 mg, 0.06 mmol), and tripotassium phosphate (212 mg, 1.0 mmol).
- Example 36 4-[4-Cyano-3-hydroxy-7-(3-isopropyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid a) 4-[3-Hydroxy-7-(3-isopropyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0313] A round bottom flask was charged with 4-(7-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (176 mg, 0.5 mmol), 3-isopropylphenylboronic acid (164 mg, 1.0 mmol), S-Phos (33 mg, 0.08 mmol), palladium acetate (13.4 mg, 0.06 mmol), and tripotassium phosphate (212 mg, 1.0 mmol).
- Example 37 4-[4-Cyano-3-hydroxy-7-(4-isopropyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid a) 4-[3-Hydroxy-7-(4-isopropyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0317] A round bottom flask was charged with 4-(7-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (176 mg, 0.5 mmol), 4-isopropylphenylboronic acid (164 mg, 1.0 mmol), S-Phos (33 mg, 0.08 mmol), palladium acetate (13.4 mg, 0.06 mmol), and tripotassium phosphate (212 mg, 1.0 mmol).
- Example 38 4-[4-Cyano-8-(2,6-dimethyl-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid a) 4-[8-(2,6-Dimethyl-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0321] A round bottom flask was charged with 4-(8-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (142 mg, 0.4 mmol), 2,6-dimethylphenylboronic acid (120 mg, 0.8 mmol), S- Phos (26 mg, 0.064 mmol), palladium acetate (11 mg, 0.048 mmol), and tripotassium phosphate (170 mg, 0.8 mmol).
- Example 39 4-[4-Cyano-7-(3,5-dimethyl-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid a) 4-[7-(3,5-Dimethyl-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0325] A round bottom flask was charged with 4-(7-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (530 mg, 1.5 mmol), 3,5-dimethylphenylboronic acid (450 mg, 3.0 mmol), S- Phos (98 mg, 0.24 mmol), palladium acetate (41 mg, 0.18 mmol), and tripotassium phosphate (636 mg, 3.0 mmol).
- Example 40 4-(4-Cyano-3-hydroxy-8-phenylsulfanyl-quinolin-2-yl)-4-oxo-butyric acid a) 4-(3-Hydroxy-7-phenylsulfanyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0329] To a round-bottom-flask were added 4-(8-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (246 mg, 0.7 mmol), Pd2(dba)3 (50 mg, 0.07 mmol), Xantphos (81 mg, 0.14 mmol), benzenethiol (154 mg, 1.4 mmol), and N,N-Diisopropylethylamine (0.25 mL, 1.4 mmol) in anhydrous 1,4-dioxane (5 mL).
- Example 41 4-(8-Benzenesulfonyl-4-cyano-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid a) 4-(8-Benzenesulfonyl-4-cyano-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0333] To a solution of 4-(4-Cyano-3-hydroxy-8-phenylsulfanyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (75 mg, 0.19 mmol) in DCM (6 mL) was added meta-chloroperoxybenzoic acid (99 mg, 0.57 mmol).
- Example 42 4-[7-(3,5-Dimethyl-phenyl)-3-hydroxy-4-trifluoromethyl-quinolin-2-yl]-4-oxo-butyric acid a) 4-[3-Benzyloxy-4-bromo-7-(3,5-dimethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0335] Benzyl bromide (0.13 mL, 185 mg, 1.05 mmol) was added to a mixture of 4-[4-Bromo- 7-(3,5-dimethyl-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester (321 mg, 0.7 mmol) and potassium carbonate (145 mg, 1.05 mmol) in anhydrous DMF (7 mL) at room temperature.
- Example 43 4-(4-Cyano-3-hydroxy-7-phenylethynyl-quinolin-2-yl)-4-oxo-butyric acid a) 4-(3-Hydroxy-7-phenylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0339] To a round-bottom-flask were added 4-(7-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (353 mg, 1.0 mmol), PdCl2(PPh3)2 (142 mg, 0.2 mmol), and tributyl- phenylethynyl-stannane (626 mg, 1.6 mmol) in anhydrous DMF (8 mL).
- Example 44 4-(4-Cyano-3-hydroxy-7-o-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid a) 4-(3-Hydroxy-7-o-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0343] To a round-bottom-flask were added 4-(7-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (530 mg, 1.5 mmol), PdCl 2 (PPh 3 ) 2 (53 mg, 0.075 mmol), CuI (29 mg, 015 mmol), Et 3 N (757 mg, 7.5 mmol), and 1-ethynyl-2-methyl-benzene (348 mg, 3.0 mmol) in anhydrous DMF (8 mL).
- Example 45 4-[4-Cyano-3-hydroxy-7-(2-o-tolyl-ethyl)-quinolin-2-yl]-4-oxo-butyric acid a) 4-(4-Cyano-3-hydroxy-7-o-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0347] To a solution of 4-(4-Bromo-3-hydroxy-7-o-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (200 mg, 0.47 mmol) in ethyl acetate (20 mL) was added Pd/C (25 mg, 0.025eq, 10 wt.%, wet, contains ⁇ 51% water).
- Example 46 4-(4-Cyano-3-hydroxy-7-m-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid a) 4-(3-Hydroxy-7-m-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0349] To a round-bottom-flask were added 4-(7-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (530 mg, 1.5 mmol), PdCl2(PPh3)2 (53 mg, 0.075 mmol), CuI (29 mg, 015 mmol), Et3N (757 mg, 7.5 mmol), and 1-ethynyl-3-methyl-benzene (348 mg, 3.0 mmol) in anhydrous DMF (8 mL).
- Example 47 4-[7-(2-Chloro-phenyl)-4-cyano-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid a) (2-Amino-4-bromo-phenyl)-methanol [0353] To a solution of 2-amino-4-bromo benzoic acid (10 g, 46.2 mmol) in THF (100 ml), LAH (2.5 g, 69.3 mmol) was added at 0 o C and stirred at room temperature for 8 h. The reaction was quenched using saturated solution of sodium sulfate and filtered through Celite bed to yield 7 g of the title compound after trituration with hexane.
- the mixture was diluted with 10 mL of cold THF and the solid was isolated by filtration and dried under high vacuum for several hours.
- glacial acetic acid (20 mL) was heated to 115 o C.
- the solid from above was suspended in glacial acetic acid (20 mL) and added to the pre-heated acetic acid, and the resulting homogeneous mixture was then stirred at 115-120 o C for 16 h.
- the reaction mixture was cooled to room temperature and concentrated to dryness. The residue was re-dissolved in absolute EtOH (30 mL) and placed in ice bath. Thionyl chloride (1 mL) was added, and the mixture was warmed to room temperature and refluxed for 16h.
- Example 48 4-[7-(3-Chloro-phenyl)-4-cyano-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid a) 4-[7-(3-Chloro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0366] The title compound was prepared from 4-(7-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from Example 47i) and 3-chlorophenylboronic acid in analogy to Example 47j. MS (m/z) 384.0 (M+1) + .
- Example 49 4-[7-(4-Chloro-phenyl)-4-cyano-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid a) 4-[7-(4-Chloro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0370] The title compound was prepared from 4-(7-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from Example 47i) and 4-chlorophenylboronic acid in analogy to Example 47j. MS (m/z) 384.0 (M+1) + .
- Example 50 4-[4-Cyano-7-(4-fluoro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid a) 4-[7-(4-Fluoro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0374] The title compound was prepared from 4-(7-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from Example 47i) and 4-fluorophenylboronic acid in analogy to Example 47j. MS (m/z) 368.0 (M+1) + .
- Example 51 4-[4-Cyano-7-(3-fluoro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid a) 4-[7-(3-Fluoro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0378] The title compound was prepared from 4-(7-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from Example 47i) and 3-fluorophenylboronic acid in analogy to Example 47j. MS (m/z) 368.1 (M+1) + .
- Example 52 4-[4-Cyano-7-(2-fluoro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid a) 7-Bromo-3-hydroxy-4-iodo-quinoline-2-carboxylic acid ethyl ester [0382] To a solution of 7-bromo-3-hydroxy-quinoline-2-carboxylic acid ethyl ester (1.31 g, 4.42 mmol, prepared from Example 47d) in CH 2 Cl 2 (44 mL) at room temperature was added I(collidine)PF 6 (2.5 g, 4.86 mmol) to give a suspension.
- Example 53 4-[4-Cyano-3-hydroxy-7-(2-methoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid a) 4-[3-Hydroxy-7-(2-methoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0391] The title compound was prepared from 4-(7-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from 47i) and 2-methoxyphenylboronic acid to give the title compound in analogy to Example 47j. MS (m/z) 380.0 (M+1) + .
- Example 54 4-[4-Cyano-3-hydroxy-7-(4-methoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid a) 4-[3-Hydroxy-7-(4-methoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0395] The title compound was prepared from 4-(7-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from 47i) and 4-methoxyphenylboronic acid to give the title compound in analogy to Example 47j. MS (m/z) 380.1 (M+1) + .
- Example 55 4-[4-Cyano-8-(4-fluoro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid a) (2-Amino-3-bromo-phenyl)-methanol [0399] To a solution of 2-amino-3-bromo benzoic acid (10g, 46.2 mmol) in THF (100ml), LAH (2.5 g, 69.3 mmol) was added at 0 o C and stirred at room temperature for 8h. The reaction was quenched using saturated solution of sodium sulfate and filtered through Celite bed to yield 7 g of the title compound after trituration with hexane.
- the mixture was diluted with 10 mL of cold THF and the solid was isolated by filtration and dried under high vacuum for several hours.
- glacial acetic acid (20 mL) was heated to 115 o C.
- the solid from above was suspended in glacial acetic acid (20 mL) and added to the pre-heated acetic acid, and the resulting homogeneous mixture was then stirred at 115-120 o C for 16 h.
- the reaction mixture was allowed to come to room temperature and concentrated to dryness.
- the residue was re-dissolved in absolute EtOH (30 mL) and placed in ice bath. Thionyl chloride (1 mL) was added, and the mixture was warmed to room temperature and refluxed for 16h.
- Example 56 4-[4-Cyano-8-(3-fluoro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid a) 4-[8-(3-Fluoro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0412] The title compound was prepared from 4-(8-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from Example 55i) and 3-fluorophenylboronic acid in analogy to Example 47j. MS (m/z) 368.1 (M+1) + .
- Example 57 4-[4-Cyano-8-(2-fluoro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid a) 4-[8-(2-Fluoro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0416] The title compound was prepared from 4-(8-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from Example 55i) and 2-fluorophenylboronic acid in analogy to Example 47j. MS (m/z) 368.0 (M+1) + .
- Example 58 4-[8-(4-Chloro-phenyl)-4-cyano-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid a) 4-[8-(4-Chloro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0420] The title compound was prepared from 4-(8-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from Example 55i) and 4-chlorophenylboronic acid in analogy to Example 47j. MS (m/z) 384.0 (M+1) + .
- Example 59 4-[8-(3-Chloro-phenyl)-4-cyano-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid a) 4-[8-(3-Chloro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0424] The title compound was prepared from 4-(8-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from Example 55i) and 3-chlorophenylboronic acid in analogy to Example 47j. MS (m/z) 384.0 (M+1) + .
- Example 60 4-[8-(2-Chloro-phenyl)-4-cyano-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid a) 4-[8-(2-Chloro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0428] The title compound was prepared from 4-(8-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from Example 55i) and 2-chlorophenylboronic acid in analogy to Example 47j. MS (m/z) 384.0 (M+1) + .
- Example 61 4-[4-Cyano-3-hydroxy-8-(4-methoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid a) 4-[3-Hydroxy-8-(4-methoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0432] The title compound was prepared from 4-(8-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from Example 55i) and 4-methoxyphenylboronic acid in analogy to Example 47j. MS (m/z) 380.0 (M+1) + .
- Example 62 4-[4-Cyano-3-hydroxy-8-(2-methoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid a) 4-[3-Hydroxy-8-(2-methoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0436] The title compound was prepared from 4-(8-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from Example 55i) and 2-methoxyphenylboronic acid in analogy to Example 47j. MS (m/z) 380.1 (M+1) + .
- Example 63 4-[4-Cyano-3-hydroxy-8-(3-methoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid a) 4-[3-Hydroxy-8-(3-methoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0440] The title compound was prepared from 4-(8-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from Example 55i) and 3-methoxyphenylboronic acid in analogy to Example 47j. MS (m/z) 384.0 (M+1) + .
- Example 64 4-[4-Cyano-3-hydroxy-7-(3-methoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid a) 4-[3-Hydroxy-7-(3-methoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0444] The title compound was prepared from 4-(7-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from 47i) and 3-methoxyphenylboronic acid in analogy to Example 47j. MS (m/z) 380.1 (M+1) + .
- Example 65 4-[4-Cyano-3-hydroxy-7-(4-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid a) 4-[3-Hydroxy-7-(4-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0448] The title compound was prepared from 4-(7-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from 47i) and 4-trifluoromethylphenylboronic acid in analogy to Example 47j. MS (m/z) 418.0 (M+1) + .
- Example 66 4-[4-Cyano-3-hydroxy-7-(3-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid a) 4-[3-Hydroxy-7-(3-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0452] The title compound was prepared from 4-(7-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from 47i) and 3-trifluoromethylphenylboronic acid in analogy to Example 47j. MS (m/z) 418.0 (M+1) + .
- Example 67 4-[4-Cyano-3-hydroxy-7-(2-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid a) 4-[3-Hydroxy-7-(2-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0456] The title compound was prepared from 4-(7-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from 47i) and 2-trifluoromethylphenylboronic acid in analogy to Example 47j. MS (m/z) 418.1 (M+1) + .
- Example 68 4-[4-Cyano-3-hydroxy-7-(2-m-tolyl-ethyl)-quinolin-2-yl]-4-oxo-butyric acid a) 4-(4-Cyano-3-hydroxy-7-m-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0460] To a solution of 4-(4-Bromo-3-hydroxy-7-m-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (170 mg, 0.41 mmol) in ethyl acetate (20 mL) was added Pd/C (25 mg, 0.025eq, 10 wt.%, wet, contains ⁇ 51% water).
- Example 69 4-(4-Cyano-3-hydroxy-7-p-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid a) 4-(3-Hydroxy-7-p-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0462] To a round-bottom-flask were added 4-(7-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (530 mg, 1.5 mmol), PdCl2(PPh3)2 (53 mg, 0.075 mmol), CuI (29 mg, 015 mmol), Et3N (757 mg, 7.5 mmol), and 1-ethynyl-4-methyl-benzene (348 mg, 3.0 mmol) in anhydrous DMF (8 mL).
- Example 70 4-[4-Cyano-3-hydroxy-7-(2-p-tolyl-ethyl)-quinolin-2-yl]-4-oxo-butyric acid a) 4-(4-Cyano-3-hydroxy-7-p-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0466] To a solution of 4-(4-Bromo-3-hydroxy-7-p-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (125 mg, 0.3 mmol) in ethyl acetate (6 mL) was added Pd/C (32 mg, 0.04eq, 10 wt.%, wet, contains ⁇ 51% water).
- Example 71 4-(4-Cyano-3-hydroxy-8-phenylethynyl-quinolin-2-yl)-4-oxo-butyric acid a) 4-(3-Hydroxy-8-phenylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0468] To a round-bottom-flask were added 4-(8-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (530 mg, 1.5 mmol), PdCl2(PPh3)2 (53 mg, 0.075 mmol), CuI (29 mg, 015 mmol), Et3N (757 mg, 7.5 mmol), and ethynyl-benzene (306 mg, 3.0 mmol) in anhydrous DMF (8 mL).
- Example 72 4-(4-Cyano-3-hydroxy-8-phenethyl-quinolin-2-yl)-4-oxo-butyric acid a) 4-(4-Cyano-3-hydroxy-8-phenethyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0472] To a solution of 4-(4-Cyano-3-hydroxy-8-phenylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (82 mg, 0.2 mmol) in ethyl acetate (10 mL) was added Pd/C (21 mg, 0.04eq, 10 wt.%, wet, contains ⁇ 51% water).
- Example 73 4-[4-Cyano-3-hydroxy-7-(4-trifluoromethoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid a) 4-[3-Hydroxy-7-(4-trifluoromethoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0474] The title compound was prepared from 4-(7-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from 47i) and 4-trifluoromethoxyphenylboronic acid in analogy to Example 47j. MS (m/z) 434.0 (M+1) + .
- Example 74 4-[4-Cyano-3-hydroxy-7-(3-trifluoromethoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid a) 4-[3-Hydroxy-7-(3-trifluoromethoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0478] The title compound was prepared from 4-(7-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from 47i) and 3-trifluoromethoxyphenylboronic acid in analogy to Example 47j. MS (m/z) 384.0 (M+1) + .
- Example 75 4-[4-Cyano-3-hydroxy-7-(2-trifluoromethoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid a) 4-[3-Hydroxy-7-(2-trifluoromethoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0482] The title compound was prepared from 4-(7-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from 47i) and 2-trifluoromethoxyphenylboronic acid in analogy to Example 47j. MS (m/z) 434.0 (M+1) + .
- Example 76 4-(4-Cyano-3-hydroxy-7-naphthalen-1-yl-quinolin-2-yl)-4-oxo-butyric acid a) 4-(3-Hydroxy-7-naphthalen-1-yl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0486] The title compound was prepared from 4-(7-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from 47i) and 1-naphthaleneboronic acid to give the title compound in analogy to Example 47j. MS (m/z) 400.0 (M+1) + .
- Example 77 4-(4-Cyano-3-hydroxy-8-o-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid a) 4-(3-Hydroxy-8-o-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0490] To a round-bottom-flask were added 4-(8-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (530 mg, 1.5 mmol), PdCl 2 (PPh 3 ) 2 (53 mg, 0.075 mmol), CuI (29 mg, 015 mmol), Et 3 N (757 mg, 7.5 mmol), and 1-ethynyl-2-methyl-benzene (348 mg, 3.0 mmol) in anhydrous DMF (8 mL).
- Example 78 4-[4-Cyano-3-hydroxy-8-(2-o-tolyl-ethyl)-quinolin-2-yl]-4-oxo-butyric acid a) 4-[4-Cyano-3-hydroxy-8-(2-o-tolyl-ethyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0494] To a solution of 4-(4-Cyano-3-hydroxy-8-o-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (120 mg, 0.3 mmol) in ethyl acetate (10 mL) was added Pd/C (16 mg, 0.02eq, 10 wt.%, wet, contains ⁇ 51% water).
- Example 79 4-(4-Cyano-3-hydroxy-8-m-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid a) 4-(3-Hydroxy-8-m-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0496] To a round-bottom-flask were added 4-(8-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (530 mg, 1.5 mmol), PdCl 2 (PPh 3 ) 2 (53 mg, 0.075 mmol), CuI (29 mg, 015 mmol), Et 3 N (757 mg, 7.5 mmol), and 1-ethynyl-3-methyl-benzene (348 mg, 3.0 mmol) in anhydrous DMF (8 mL).
- Example 80 4-[4-Cyano-3-hydroxy-8-(2-m-tolyl-ethyl)-quinolin-2-yl]-4-oxo-butyric acid a) 4-[4-Cyano-3-hydroxy-8-(2-m-tolyl-ethyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0501] To a solution of 4-(4-Cyano-3-hydroxy-8-m-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (120 mg, 0.3 mmol) in ethyl acetate (10 mL) was added Pd/C (16 mg, 0.02eq, 10 wt.%, wet, contains ⁇ 51% water).
- Example 81 4-(4-Cyano-3-hydroxy-8-p-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid a) 4-(3-Hydroxy-8-p-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0503] To a round-bottom-flask were added 4-(8-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (530 mg, 1.5 mmol), PdCl2(PPh3)2 (53 mg, 0.075 mmol), CuI (29 mg, 015 mmol), Et3N (757 mg, 7.5 mmol), and 1-ethynyl-4-methyl-benzene (348 mg, 3.0 mmol) in anhydrous DMF (8 mL).
- Example 82 4-[4-Cyano-7-(4-fluoro-3-methyl-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid a) 4-[7-(4-Fluoro-3-methyl-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0507] The title compound was prepared from 4-(7-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from 47i) and 4-fluoro-3-methylphenylboronic acid in analogy to Example 47j. MS (m/z) 382.1 (M+1) + .
- Example 83 4-[4-Cyano-7-(2-fluoro-3-methyl-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid a) 4-[7-(2-Fluoro-3-methyl-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0511] The title compound was prepared from 4-(7-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from 47i) and 2-fluoro-3-methylphenylboronic acid in analogy to Example 47j. MS (m/z) 382.1 (M+1) + .
- Example 84 4-[4-Cyano-7-(2-fluoro-5-methyl-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid a) 4-[7-(2-Fluoro-5-methyl-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0515] The title compound was prepared from 4-(7-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from 47i) and 2-fluoro-5-methylphenylboronic acid in analogy to Example 47j. MS (m/z) 382.1 (M+1) + .
- Example 85 4-[4-Cyano-3-hydroxy-8-(4-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid a) 4-[3-Hydroxy-8-(4-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0519] The title compound was prepared from 4-(8-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from Example 55i) and 4-trifluoromethylphenylboronic acid in analogy to Example 47j. MS (m/z) 418.0 (M+1) + .
- Example 86 4-[4-Cyano-3-hydroxy-8-(3-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid a) 4-[3-Hydroxy-8-(3-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0523] The title compound was prepared from 4-(8-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from Example 55i) and 3-trifluoromethylphenylboronic acid in analogy to Example 47j. MS (m/z) 418.0 (M+1) + .
- Example 87 4-[4-Cyano-3-hydroxy-8-(2-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid a) 4-[3-Hydroxy-8-(2-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0527] The title compound was prepared from 4-(8-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from Example 55i) and 2-trifluoromethylphenylboronic acid in analogy to Example 47j. MS (m/z) 418.0 (M+1) + .
- Example 88 4-[4-Cyano-3-hydroxy-8-(2-p-tolyl-ethyl)-quinolin-2-yl]-4-oxo-butyric acid a) 4-[4-Cyano-3-hydroxy-8-(2-p-tolyl-ethyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0531] To a solution of 4-(4-Cyano-3-hydroxy-8-p-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (40 mg, 0.1 mmol) in ethyl acetate (5 mL) was added Pd/C (5 mg, 0.03eq, 10 wt.%, wet, contains ⁇ 51% water).
- Example 89 4-[8-(2-Chloro-phenylethynyl)-4-cyano-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid a) 4-[8-(2-Chloro-phenylethynyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0533] To a round-bottom-flask were added 4-(8-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (530 mg, 1.5 mmol), PdCl2(PPh3)2 (53 mg, 0.075 mmol), CuI (29 mg, 015 mmol), Et3N (757 mg, 7.5 mmol), and 1-Chloro-2-ethynyl-benzene (411 mg, 3.0 mmol) in anhydrous DMF (8 mL).
- Example 90 4- ⁇ 8-[2-(2-Chloro-phenyl)-ethyl]-4-cyano-3-hydroxy-quinolin-2-yl ⁇ -4-oxo-butyric acid a) 4- ⁇ 8-[2-(2-Chloro-phenyl)-ethyl]-4-cyano-3-hydroxy-quinolin-2-yl ⁇ -4-oxo-butyric acid ethyl ester [0537] To a solution of 4-[8-(2-Chloro-phenylethynyl)-4-cyano-3-hydroxy-quinolin-2-yl]-4- oxo-butyric acid ethyl ester (130 mg, 0.3 mmol) in ethyl acetate (10 mL) was added Pd/C (24 mg, 0.03eq, 10 wt.%, wet, contains ⁇ 51% water).
- Example 91 4-[4-Cyano-3-hydroxy-8-(4-trifluoromethoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid a) 4-[3-Hydroxy-8-(4-trifluoromethoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0539] The title compound was prepared from 4-(8-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from Example 55i) and 4-trifluoromethoxyphenylboronic acid in analog to Example 47j : MS (m/z) 433.9 (M+1) + .
- Example 92 4-[4-Cyano-3-hydroxy-8-(3-trifluoromethoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid a) 4-[3-Hydroxy-8-(3-trifluoromethoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0543] The title compound was prepared from 4-(8-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from Example 55i) and 3-trifluoromethoxyphenylboronic acid in analog to Example 47j : MS (m/z) 434.0 (M+1) + .
- Example 93 4-[4-Cyano-3-hydroxy-8-(2-trifluoromethoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid a) 4-[3-Hydroxy-8-(2-trifluoromethoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0547] The title compound was prepared from 4-(8-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from Example 55i) and 2-trifluoromethoxyphenylboronic acid in analog to Example 47j : MS (m/z) 434.0 (M+1) + .
- Example 94 4-[4-Cyano-8-(2-fluoro-4-methoxy-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid a) 4-[8-(2-Fluoro-4-methoxy-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0551] The title compound was prepared from 4-(8-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from Example 55i) and 2-Fluoro-4-methoxyphenylboronic acid in analog to Example 47j : MS (m/z) 398.1 (M+1) + .
- Example 95 4-[4-Cyano-8-(2,4-difluoro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid a) 4-[8-(2,4-Difluoro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0555] The title compound was prepared from 4-(8-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from Example 55i) and 2,4-difluorophenylboronic acid in analog to Example 47j : MS (m/z) 386.0 (M+1) + .
- Example 96 4-[4-Cyano-8-(2,5-difluoro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid a) 4-[8-(2,5-Difluoro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0559] The title compound was prepared from 4-(8-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from Example 55i) and 2,5-difluorophenylboronic acid in analog to Example 47j: MS (m/z) 386.1 (M+1) + .
- Example 118 4-(4-cyano-8-(3-fluoropyridin-4-yl)-3-hydroxyquinolin-2-yl)-4-oxobutanoic acid a) ethyl 4-[3-(benzyloxy)-8-(3-fluoropyridin-4-yl)quinolin-2-yl]-4-oxobutanoate [0564] A mixture of ethyl 4-[3-(benzyloxy)-8-bromoquinolin-2-yl]-4-oxobutanoate (2.40 g, 5.43 mmol, 1 equiv), 3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (1.82 g, 8.13 mmol, 1.5 equiv), K3PO4 (3.46 g, 16.3 mmol, 3.0 equiv) and Pd(dppf)Cl2 (0.401 g, 0.541
- Example 119 4-(4-cyano-8-(3,5-difluoropyridin-4-yl)-3-hydroxyquinolin-2-yl)-4-oxobutanoic acid a) 3-(benzyloxy)-2-(4-ethoxy-4-oxobutanoyl)quinolin-8-ylboronic acid [0569] Into a 100 mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, were added ethyl 4-[3-(benzyloxy)-8-bromoquinolin-2-yl]-4-oxobutanoate (1 g, 2.26 mmol, 1.0 equiv.), Pin 2 B 2 (860 mg, 3.390 mmol, 1.5 equiv.) KOAc (670 mg, 6.780 mmol, 3.0 equiv.) and Pd(dppf)Cl 2 (170 mg, 0.226 mmol, 0.1 equiv.), diox
- the mixture was stirred for 6 h at 75°C under nitrogen atmosphere. After cooling to room temperature, the mixture was diluted with water (50 mL) and extracted with EtOAc (3 x 25 mL). The combined organic layers were dried over anhydrous Na 2 SO 4 . After filtration, the filtrate was concentrated under reduced pressure.
- Example 120 4-(4-cyano-3-hydroxy-8-(6-(trifluoromethoxy)pyridin-3-yl)quinolin-2-yl)-4-oxobutanoic acid a) ethyl 4-[3-(benzyloxy)-8-[6-(trifluoromethoxy)pyridin-3-yl]quinolin-2-yl]-4-oxobutanoate [0575] Into a 100 mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, were added 3-(benzyloxy)-2-(4-ethoxy-4-oxobutanoyl)quinolin-8-ylboronic acid (500 mg, 1.22 mmol, 1 equiv.), 5-bromo-2-(trifluoromethoxy)pyridine (356 mg, 1.47 mmol, 1.2 equiv.), K2CO3 (509 mg, 3.68 mmol, 3.0 equiv.), 1,4-di
- [1- 14 C] alphaketoglutarate ( ⁇ KG) was from Perkin-Elmer, H3K4me3 and H3K9me3 peptides were from Mimotopes. All other reagents were from Sigma. Reaction mixtures included the following components: Fe(SO 4 ), [1- 14 C] ⁇ KG, non-labeled ⁇ KG, ascorbate, peptide-substrate (H3K4me3: H- ARTK(me3)QTARKSTGGKAPRKQLA-OH. H3K9me3: H-ARTKQTARK(me3)STGGKAPRKQLA- OH), NaCl, Tween-20 and catalase in 25 mM HEPES buffer, pH 7.4.
- the enzymatic reactions were initiated by addition of recombinant human KDM5B or KDM4A enzyme (truncated enzyme produced in house by method and using sequence disclosed in Ng et al, Nature 448:87-91, 2007).
- the reactions were performed in 96-well microtiter plates (20 ⁇ L total assay volume) (Greiner #650201). 14 CO2 was captured on a glass fiber filter paper (Cat. No. IH-201-A, Inotech Biosystems International) soaked with saturated Ba(OH) 2 that was laid on top of the 96-well plate.
- a microtiter plate sealer film (Thermal Seal cat# T7961100) was applied to the filter paper.
- the plate and filter paper were sandwiched between two custom made aluminum plates (Advanced Component Manufacturing, Burlingame, CA) and transferred to a 37 °C oven and allowed to incubate for 1 hour. After incubation, the filter paper was dried in a 103 °C oven for 40-60 minutes. To determine percent turnover, aliquots of the reaction mixture were spotted onto the filter paper and the filter paper was dried again. The dry filter paper was exposed to a storage phosphor screen for 24-72 hours and the images recorded using a Typhoon FLA 7000 Imager (Amersham Biosciences, Piscataway, NJ). Integrated spot intensities corresponding to control reactions lacking the enzyme were subtracted from integration results for enzyme containing reactions and data were converted to enzyme dependent percent 14 CO2 release.
- Biological Example 2 a) Cell-Based Assay for KDM5 inhibitors
- COS-7 monkey kidney fibroblasts ATCC, Manassas VA
- standard culture medium e.g., Dulbecco's Modified Eagle Medium containing 10% fetal bovine serum.
- cells were transfected with an expression plasmid for Myc-His-tagged KDM5B (Origene, Rockville MD) for 3h before replacing the transfection medium with fresh culture medium and treating with vehicle or compound.
- the cell culture treatment medium was removed and cell layers were fixed using 4% formaldehyde in Dulbecco’s Phosphate Buffered Saline (DPBS), then permeabilized with 0.25% Triton X-100, and then blocked using a suitable blocking agent e.g., Odyssey Blocking Buffer (LICOR, Lincoln NE). Cell layers were then incubated overnight with primary antibodies for detection of MYC (Thermo Fisher Scientific, Waltham MA) and tri-methylated Lysine 4 of Histone 3 (H3K4me3) (Cell Signaling Technology, Danvers MA). The next day cell layers were washed and incubated with appropriate fluorescently labeled secondary antibodies.
- DPBS Dulbecco’s Phosphate Buffered Saline
- LICOR Odyssey Blocking Buffer
- MYC Thermo Fisher Scientific, Waltham MA
- H3K4me3 tri-methylated Lysine 4 of Histone 3
- DAPI 4′,6-diamidino-2-phenylindole
- Mean fold increases in H3K4me3 in compound-treated cells relative to vehicle- treated cells were calculated for each MYC-KDM5B expressing bin (low, medium, or high).
- the percentages of MYC-KDM5B-overexpressing cells with H3K4me3 levels above a pre-determined threshold were calculated.
- a suitable cell imaging system e.g., Incucyte ZOOM (Sartorius, Germany) was used to scan cell layers that had been immunostained for MYC-KDM5B and H3K4me3.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present disclosure relates generally to compounds and pharmaceutical compositions for the selective inhibition of histone lysine demethylase5 (KDM5), particularly KDM5B, and methods of their use in treating conditions and diseases associated with KDM5 activity.
Description
COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION CROSS REFERENCE TO RELATED APPLICATIONS [0001] This application claims the benefit under 35 U.S.C. §119(e) to U.S. Provisional Application Number 63/238,042, filed August 27, 2021, which is incorporated by reference in its entirety. FIELD [0002] Provided herein are compounds and pharmaceutical compositions suitable for the selective inhibition of histone lysine demethylase-5 (KDM5), particularly KDM5B, and methods for their use in treating conditions and diseases modulated by KDM5 activity. BACKGROUND [0003] Epigenetic enzymes modify DNA or histones by adding or removing chemical markers including methylation, acetylation, phosphorylation, and ubiquitination. These alterations modify the interactions between histones and DNA and lead to local changes in chromatin structure that silence or activate local genes. Histone Demethylases (HDMs) are a class of epigenetic enzyme that remove methyl groups from histone lysine residues, in particular lysine residues 4 (H3K4), 9 (H3K9), 27 (H3K27), 36 (H3K36), and 79 (H3K79) on histone 3, and lysine residue 20 (H4K20) on histone 4. Although there is some literature on the roles of HDMs in non-cancer settings (e.g. inflammation and wound healing), the vast majority of the current HDM literature is in cancer where HDMs are frequently over-expressed and where genetic approaches support pro-tumorigenic HDM functions. [0004] At least 17 different HDMs have been identified so far. While the first and most studied HDMs belong to the lysine-specific demethylase 1 (LSD1; also known as KDM1) family of amine oxidases, the remainder are all Jumonji C (JmjC) domain containing Fe(II)-dependent and oxoglutarate (2OG)-dependent dioxygenases. The JmjC domain is responsible for the demethylation activity by first hydroxylating histone lysine methylamine groups utilizing oxygen and 2-OG, which is then followed by the spontaneous loss of the unstable hydroxymethyl group. (See, e.g., Loenarz and Schofield (2008) Nat Chem Biol 4(3):152-6; Ozer et al (2007) Nat Chem Biol 3(3):144-53.) [0005] The KDM5, or JARID1, family of JmjC HDMs includes KDM5A (JARID1A/RBP2), KDM5B (JARID1B/PLU-1), KDM5C (JARID1C/SMCX), and KDM5D (JARID1D/SMCY). These enzymes can act on di- and trimethylated H3K4 and demethylate H3K4me3/me2/me. There are numerous reports of pro-tumorigenic functions for KDM5A, KDM5B, and KDM5C. (See, e.g., Tang et al (2015) Oncotarget 6(14):12723-39.) For example, KDM5B has been implicated in the development of prostate, breast, and skin cancer and also has been associated with melanoma maintenance. (See, e.g., Han et al. (2017) Oncotarget 8(5):8980-8991.) KDM5B is also overexpressed in non-small cell lung cancer (NSCLC) cells and is associated with tumor size, lymph node metastasis, advanced stages, and poor overall survival in NSCLC patients. (Kuo et al. (2018) Clin Epigenetics 10(1):107.)
[0006] There remains a need for compounds that are effective in the treatment and prevention of conditions and disorders associated with KDM5 and, in particular KDM5B, including various cancers. The compounds provided herein inhibit KDM5 activity and can be used to treat and prevent KDM5- associated disorders such as cancer. SUMMARY [0007] The present disclosure is directed to compounds, compositions comprising the same, and methods of using the compounds to selectively modulate the activity of histone demethylases (HDMs), in particular, histone lysine demethylase-5. In one aspect, provided are compounds of Formula I:
or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, wherein: n is 0, 1, 2, 3, or 4; R1 is hydrogen, -P(O)(OR20)2, -CH2P(O)(OR20)2, -P(O)(R20)(OR20), -CH2P(O)(R20)(OR20), -P(O)(N(R20)2)(OR20), -CH2P(O)(N(R20)2)(OR20), -P(O)(R20)(N(R20)2), -CH2P(O)(R20)(N(R20)2), -C(O)R20, -C(O)N(R21)(R22), -CH2P(O)(N(R20)2)2, or -P(O)(N(R20)2)2; R2 is -OH, -OR5, -OCH2P(O)(OR20)2, -OCH2P(O)(R20)(N(R20)2), -OCH2P(O)(R20)(OR20), -OCH2P(O)(N(R20)2)(OR20), -OCH2P(O)(N(R20)2)2, -N(R21)(R22), -N(R20)C(O)R20, -N(R20)C(O)OR20, -N(R20)C(O)N(R21)(R21), -N(R20)S(O)2(R20), -NR20S(O)2N(R21)(R22), or -NR20S(O)2O(R20); R3 is hydrogen, halo, cyano, or C1-6 haloalkyl; each R4 is independently halo, cyano, -L-C1-6 alkyl, -L-C2-6 alkenyl, -L-C2-6 alkynyl, -L-C1-6 haloalkyl, -L-C3-10 cycloalkyl, -L-heterocyclyl, -L-aryl, or -L-heteroaryl; wherein each alkyl, alkenyl, alkynyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl of R4 is independently optionally substituted with 1-5 R14; L is a bond, C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, C1-6 heteroalkylene, -O-, -S-, -S(O)-, -S(O)2-, -NR16-, -C(O)NR16-, -NR16C(O)-, -C(O)-, -OC(O)-, -C(O)O-, -NR16S(O)-, -S(O)NR16-, -NR16S(O)NR16-, -NR16S(O)2-, -S(O)2NR16-, -NR16S(O)2NR16-, -NR16C(O)NR16-, -OC(O)NR16-, or -NR16C(O)O-; wherein each C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, or C1-6 heteroalkylene of L is independently optionally substituted with 1-5 R14; each R5 is independently C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, heterocyclyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl of R5 is independently optionally substituted with 1-5 R15;
each of R6, R7, R8, and R9 are independently hydrogen, deuterium, C1-6 alkyl, or C1-6 haloalkyl; each R14 and R15 are independently hydroxy, halo, cyano, -NO2, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-10 cycloalkyl, heterocyclyl, aryl, benzyl, heteroaryl, -N(R16)2, -C(O)R16, -C(O)OR16, -S-R16, S(O)R16, -NR16S(O)R16, -S(O)N(R16)2, -NR16S(O)N(R16)2, -S(O)2R16, -NR16S(O)2R16, -S(O)2N(R16)2, -NR16S(O)2N(R16)2, -NR16C(O)N(R16)2, -C(O)N(R16)2, -NR16C(O)R16, -OC(O)N(R16)2, or -NR16C(O)OR16; each R16 is independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 heteroalkyl, C3-10 cycloalkyl, heterocyclyl, aryl, or heteroaryl; wherein each C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 heteroalkyl, C3-10 cycloalkyl, heterocyclyl, aryl, or heteroaryl of R16 is independently optionally substituted with 1-5 halo, cyano, -NO2, oxo, -SF5, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-10 cycloalkyl, aryl, benzyl, heteroaryl, or heterocyclyl; or two R16 together with the atom to which they are attached form a heterocyclyl; wherein said heterocyclyl is independently optionally substituted with 1-5 R30; each R20 is independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, aryl, heteroaryl, or heterocyclyl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl is independently optionally substituted with 1-5 R30; or two R20together with the atom to which they are attached form a heterocyclyl; wherein said heterocyclyl is independently optionally substituted with 1-5 R30; each R21 and R22 is independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl is independently optionally substituted with 1-5 R30 groups; or R20and R21 together with the nitrogen to which they are attached form a heterocyclyl; wherein said heterocyclyl is independently optionally substituted with 1-5 R30; or R21and R22 together with the nitrogen to which they are attached form a heterocyclyl; wherein said heterocyclyl is independently optionally substituted with 1-5 R30; each R30 is independently oxo, thioxo, hydroxy, halo, -NO2, -N3, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C1-6 haloalkyl, aryl, heteroaryl, heterocyclyl, -O(C1-6 alkyl), -O(C2-6 alkenyl), -O(C2-6 alkynyl), -O(C3-10 cycloalkyl), -O(C1-6 haloalkyl), -O(aryl), -O(heteroaryl), -O(heterocyclyl), -NH2, -NH(C1-6 alkyl), -NH(C2-6 alkenyl), -NH(C2-6 alkynyl), -NH(C3-10 cycloalkyl), -NH(C1-6 haloalkyl), -NH(aryl), -NH(heteroaryl), -NH(heterocyclyl), -N(C1-6 alkyl)2, -N(C3-10 cycloalkyl)2, -N(C2-6 alkenyl)2, -N(C2-6 alkynyl)2, -N(C3-10 cycloalkyl)2, -N(C1-6 haloalkyl)2, -N(aryl)2, -N(heteroaryl)2, -N(heterocyclyl)2, -N(C1-6 alkyl)(C3-10 cycloalkyl), -N(C1-6 alkyl)(C2-6 alkenyl), -N(C1-6 alkyl)(C2-6 alkynyl), -N(C1-6 alkyl)(C3-10 cycloalkyl), -N(C1-6 alkyl)(C1-6 haloalkyl), -N(C1-6 alkyl)(aryl), -N(C1-6 alkyl)(heteroaryl), -N(C1-6 alkyl)(heterocyclyl), -C(O)(C1-6 alkyl), -C(O)(C2-6 alkenyl), -C(O)(C2-6 alkynyl), -C(O)(C3-10 cycloalkyl), -C(O)(C1-6 haloalkyl), -C(O)(aryl), -C(O)(heteroaryl), -C(O)(heterocyclyl), -C(O)O(C1-6 alkyl), -C(O)O(C2-6 alkenyl),
-C(O)O(C2-6 alkynyl), -C(O)O(C3-10 cycloalkyl), -C(O)O(C1-6 haloalkyl), -C(O)O(aryl), -C(O)O(heteroaryl), -C(O)O(heterocyclyl), -C(O)NH2, -C(O)NH(C1-6 alkyl), -C(O)NH(C2-6 alkenyl), -C(O)NH(C2-6 alkynyl), -C(O)NH(C3-10 cycloalkyl), -C(O)NH(C1-6 haloalkyl), -C(O)NH(aryl), -C(O)NH(heteroaryl), -C(O)NH(heterocyclyl), -C(O)N(C1-6 alkyl)2, -C(O)N(C3-10 cycloalkyl)2, -C(O)N(C2-6 alkenyl)2, -C(O)N(C2-6 alkynyl)2, -C(O)N(C3-10 cycloalkyl)2, -C(O)N(C1-6 haloalkyl)2, -C(O)N(aryl)2, -C(O)N(heteroaryl)2, -C(O)N(heterocyclyl)2, -NHC(O)(C1-6 alkyl), -NHC(O)(C2-6 alkenyl), -NHC(O)(C2-6 alkynyl), -NHC(O)(C3-10 cycloalkyl), -NHC(O)(C1-6 haloalkyl), -NHC(O)(aryl), -NHC(O)(heteroaryl), -NHC(O)(heterocyclyl), -NHC(O)O(C1-6 alkyl), -NHC(O)O(C2-6 alkenyl), -NHC(O)O(C2-6 alkynyl), -NHC(O)O(C3-10 cycloalkyl), -NHC(O)O(C1-6 haloalkyl), -NHC(O)O(aryl), -NHC(O)O(heteroaryl), -NHC(O)O(heterocyclyl), -NHC(O)NH(C1-6 alkyl), -NHC(O)NH(C2-6 alkenyl), -NHC(O)NH(C2-6 alkynyl), -NHC(O)NH(C3-10 cycloalkyl), -NHC(O)NH(C1-6 haloalkyl), -NHC(O)NH(aryl), -NHC(O)NH(heteroaryl), -NHC(O)NH(heterocyclyl), -SH, -S(C1-6 alkyl), -S(C2-6 alkenyl), -S(C2-6 alkynyl), -S(C3-10 cycloalkyl), -S(C1-6 haloalkyl), -S(aryl), -S(heteroaryl), -S(heterocyclyl), -NHS(O)(C1-6 alkyl), -N(C1-6 alkyl)(S(O)(C1-6 alkyl), -S(O)N(C1-6 alkyl)2, -S(O)(C1-6 alkyl), -S(O)(NH)(C1-6 alkyl), -S(O)(C2-6 alkenyl), -S(O)(C2-6 alkynyl), -S(O)(C3-10 cycloalkyl), -S(O)(C1-6 haloalkyl), -S(O)(aryl), -S(O)(heteroaryl), -S(O)(heterocyclyl), -S(O)2(C1-6 alkyl), -S(O)2(C2-6 alkenyl), -S(O)2(C2-6 alkynyl), -S(O)2(C3-10 cycloalkyl), -S(O)2(C1-6 haloalkyl), -S(O)2(aryl), -S(O)2(heteroaryl), -S(O)2(heterocyclyl), -S(O)2NH(C1-6 alkyl), or -S(O)2N(C1-6 alkyl)2; wherein each alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl of R30 is optionally substituted with one to four substituents independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, -OH, -NH2, -NH(C1-6 alkyl), -NH(C3-10 cycloalkyl), -NH(C1-6 haloalkyl), -NH(aryl), -NH(heteroaryl), -NH(heterocyclyl), -N(C1-6 alkyl)2, -N(C3-10 cycloalkyl)2, -NHC(O)(C3-10 cycloalkyl), -NHC(O)(C1-6 haloalkyl), -NHC(O)(aryl), -NHC(O)(heteroaryl), -NHC(O)(heterocyclyl), -NHC(O)O(C1-6 alkyl), -NHC(O)O(C2-6 alkynyl), -NHC(O)O(C3-10 cycloalkyl), -NHC(O)O(C1-6 haloalkyl), -NHC(O)O(aryl), -NHC(O)O(heteroaryl), -NHC(O)O(heterocyclyl), -NHC(O)NH(C1-6 alkyl), -S(O)(NH)(C1-6 alkyl), S(O)2(C1-6 alkyl), -S(O)2(C3-10 cycloalkyl), -S(O)2(C1-6 haloalkyl), -S(O)2(aryl), -S(O)2(heteroaryl), -S(O)2(heterocyclyl), -S(O)2NH(C1-6 alkyl), -S(O)2N(C1-6 alkyl)2, -O(C1-6 alkyl), -O(C3-10 cycloalkyl), -O(C1-6 haloalkyl), -O(aryl), -O(heteroaryl), or -O(heterocyclyl). [0008] This disclosure also provides pharmaceutical compositions comprising one or more compounds of formula I and a pharmaceutically acceptable excipient. [0009] This disclosure is also directed to methods for inhibiting the activity of histone lysine demethylase and treating, pretreating, or delaying onset of a condition associated with histone lysine demethylase. In one aspect, provided is a method of treating, pretreating, or delaying onset of a condition associated with undesirable cellular proliferation.
DETAILED DESCRIPTION [0010] Before the present compounds and methods are described, it is to be understood that the disclosure is not limited to the methodologies, protocols, cell lines, assays, and reagents described, as these may vary. It is also to be understood that the terminology used herein is intended to describe embodiments of the present disclosure, and is in no way intended to limit the scope of the present disclosure as set forth in the appended claims. 1. Definitions [0011] It must be noted that as used herein, and in the appended claims, the singular forms “a,” “an,” and “the” include plural references unless the context clearly dictates otherwise. [0012] Unless defined otherwise, all technical, and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this disclosure pertains. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, exemplary methods, devices, and materials are now described. All publications cited herein are incorporated herein by reference in their entirety for the purpose of describing and disclosing the methodologies, reagents, and tools reported in the publications that might be used in connection with the disclosure. [0013] The practice of the present disclosure will employ, unless otherwise indicated, conventional methods of chemistry, biochemistry, molecular biology, cell biology, genetics, immunology, and pharmacology, within the skill of the art. Such techniques are explained fully in the literature. (See, e.g., Gennaro, A.R., ed. (1990) Remington’s Pharmaceutical Sciences, 18th ed., Mack Publishing Co.; Colowick, S. et al., eds., Methods In Enzymology, Academic Press, Inc.; D.M. Weir, and C.C. Blackwell, eds. (1986) Handbook of Experimental Immunology, Vols. I-IV, Blackwell Scientific Publications; Maniatis, T. et al., eds. (1989) Molecular Cloning: A Laboratory Manual, 2nd edition, Vols. I-III, Cold Spring Harbor Laboratory Press; Ausubel, F. M. et al., eds. (1999) Short Protocols in Molecular Biology, 4th edition, John Wiley & Sons; Ream et al., eds. (1998) Molecular Biology Techniques: An Intensive Laboratory Course, Academic Press; Newton & Graham eds. (1997) PCR (Introduction to Biotechniques Series), 2nd ed., Springer Verlag. [0014] The terms “disorders,” “diseases,” and “conditions” are used inclusively and refer to any condition deviating from normal. [0015] The term “alkyl” refers to saturated monovalent straight or branched chain hydrocarbyl groups having from 1 to 10 carbon atoms, from 1 to 6 carbon atoms, or 1 to 3 carbon atoms. This term is exemplified by groups such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, t-butyl, n-pentyl, and the like. [0016] The term “alkoxy” refers to -O-alkyl, where alkyl is as defined above.
[0017] The term “alkenyl” refers to a vinyl unsaturated monovalent hydrocarbyl group having from 2 to 6 carbon atoms, or from 2 to 4 carbon atoms, and having at least 1, or from 1 to 2 sites of vinyl (>C=C<) unsaturation. Such groups are exemplified by vinyl (ethen-1-yl), allyl, but-3-enyl and the like. [0018] The term “alkynyl” refers to an acetylinic unsaturated monovalent hydrocarbyl groups having from 2 to 6 carbon atoms, or 2 to 3 carbon atoms, and having at least 1, or from 1 to 2 sites of acetylenic (-C≡C-) unsaturation. This group is exemplified by ethyn-1-yl, propyn-1-yl, propyn-2-yl, and the like. [0019] The terms “alkylene,” “alkenylene,” and “alkynylene” refer to divalent alkyl, alkenyl, and alkynyl groups, respectively, where each is as defined herein. [0020] The term “aryl” or “Ar” refers to a monovalent aromatic carbocyclic group of from 6 to 14 carbon atoms having a single ring (e.g., phenyl) or multiple condensed rings (e.g., naphthyl or anthryl) which condensed rings may or may not be aromatic (e.g., 2-benzoxazolinone, 2H-1,4-benzoxazin-3(4H)- one-7-yl, benzo[1,3]-dioxol-5-yl, 2,3-dihydro-benzo[1,4]dioxin-6-yl, 2,3-dihydro-benzofuran-5-yl, dibenzofuran-4-yl, and the like) provided that the point of attachment is the aryl group. [0021] The term “cycloalkyl” refers to cyclic alkyl groups of from 3 to 10 carbon atoms having single or multiple cyclic rings including, by way of example, adamantyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclooctyl, and the like. [0022] The term “cycloalkenyl” refers to cyclic alkenyl (but not aromatic) groups of from 5 to 10 carbon atoms having single or multiple cyclic rings and having at least one site of vinyl (>C=C<) unsaturation within the ring including, by way of example, cyclopentenyl, cyclooctenyl, and the like. [0023] The term “halo” or “halogen” refers to fluoro, chloro, bromo, and iodo, and in certain embodiments, is fluoro, chloro or bromo. [0024] The term “heteroaryl” refers to an aromatic group of from 1 to 15 carbon atoms, or from 1 to 10 carbon atoms, and 1 to 4 heteroatoms selected from oxygen, nitrogen, and sulfur within the ring. Such heteroaryl groups can have a single ring (e.g., pyridinyl, furyl, or thienyl) or multiple condensed rings (e.g., indolizinyl or benzothienyl). The nitrogen and/or sulfur ring atoms can optionally be oxidized to provide for the N-oxide or the sulfoxide, and sulfone derivatives. Exemplary heteroaryls include pyridinyl, pyrrolyl, indolyl, thiophenyl, thienyl, and furyl. [0025] The term “haloalkyl” refers to an unbranched or branched alkyl group as defined above, wherein one or more (e.g., 1 to 6 or 1 to 3) hydrogen atoms are replaced by a halogen. For example, where a residue is substituted with more than one halogen, it may be referred to by using a prefix corresponding to the number of halogen moieties attached. Dihaloalkyl and trihaloalkyl refer to alkyl substituted with two (“di”) or three (“tri”) halo groups, which may be, but are not necessarily, the same halogen. Examples of haloalkyl include, e.g., trifluoromethyl, difluoromethyl, fluoromethyl,
trichloromethyl, 2,2,2-trifluoroethyl, 1,2-difluoroethyl, 3-bromo-2-fluoropropyl, 1,2-dibromoethyl and the like. [0026] The term “haloalkoxy” refers to -O-haloalkyl, where haloalkyl is as defined above. [0027] The term “heteroalkyl” refers to a C1-6 alkyl group in which one or two of the carbon atoms (and any associated hydrogen atoms) are each independently replaced with the same or different heteroatomic group. Heteroatomic groups include, but are not limited to, -NH-, -O-, -S-, -S(O)-, -S(O)2-, and the like. [0028] The term “heteroalkylene” refers to a linear, divalent C1-6 alkyl group (i.e., C1-6 alkylene) in which one or two of the carbon atoms (and any associated hydrogen atoms) are each independently replaced with the same or different heteroatomic group. Heteroatomic groups include, but are not limited to, -NH-, -O-, -S-, -S(O)-, -S(O)2-, and the like. [0029] The term “heterocyclyl” or “heterocyclic” refers to a saturated or unsaturated (but not aromatic) group having a single ring or multiple condensed rings, from 1 to 10 carbon atoms, and from 1 to 4 hetero atoms selected from nitrogen, sulfur or oxygen within the ring wherein, in fused ring systems, one or more of the rings can be aryl or heteroaryl provided that the point of attachment is at the heterocycle. The nitrogen and/or sulfur ring atoms can optionally be oxidized to provide for the N-oxide or the sulfoxide, and sulfone derivatives. [0030] The term “substituted heterocyclyl” or “substituted heterocyclic” refers to heterocycle groups that are substituted with from 1 to 3 of the same substituents as defined for substituted cycloalkyl. [0031] Examples of heterocycles and heteroaryls include, but are not limited to, azetidine, pyrrole, imidazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, indolizine, isoindole, indole, dihydroindole, indazole, purine, quinolizine, isoquinoline, quinoline, phthalazine, naphthylpyridine, quinoxaline, quinazoline, cinnoline, pteridine, carbazole, carboline, phenanthridine, acridine, phenanthroline, isothiazole, phenazine, isoxazole, phenoxazine, phenothiazine, imidazolidine, imidazoline, piperidine, piperazine, indoline, phthalimide, 1,2,3,4-tetrahydroisoquinoline, 4,5,6,7- tetrahydrobenzo[b]thiophene, thiazole, thiazolidine, thiophene, benzo[b]thiophene, morpholinyl, thiomorpholinyl (also referred to as thiamorpholinyl), piperidinyl, pyrrolidine, tetrahydrofuranyl, and the like. [0032] The term “oxo” refers to the atom (=O) or (-O-). [0033] The term “amino acid” refers to any of the naturally occurring amino acids, as well as synthetic analogs (e.g., D-stereoisomers of the naturally occurring amino acids, such as D-threonine), and derivatives thereof. α-Amino acids comprise a carbon atom to which is bonded an amino group, a carboxyl group, a hydrogen atom, and a distinctive group referred to as a “side chain.” The side chains of naturally occurring amino acids are well known in the art, and include, for example, hydrogen (e.g., as in glycine), alkyl (e.g., as in alanine, valine, leucine, isoleucine, proline), substituted alkyl (e.g., as in
threonine, serine, methionine, cysteine, aspartic acid, asparagine, glutamic acid, glutamine, arginine, and lysine), arylalkyl (e.g., as in phenylalanine, and tryptophan), substituted arylalkyl (e.g., as in tyrosine), and heteroarylalkyl (e.g., as in histidine). Unnatural amino acids are also known in the art, as set forth in, for example, Williams, ed. (1989) Synthesis of Optically Active α-Amino Acids, Pergamon Press; Evans et al. (1990) J. Amer. Chem. Soc.112:4011-4030; Pu et al. (1991) J. Amer. Chem. Soc.56:1280-1283; Williams et al. (1991) J. Amer. Chem. Soc.113:9276-9286; and all references cited therein. [0034] The term “pharmaceutically acceptable salt” refers to a pharmaceutically acceptable salt of a compound, which salt can be derived from a variety of organic, and inorganic counter ions well known in the art, and include, by way of example only, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, and the like; and when the molecule contains a basic functionality, a salt of an organic or inorganic acid, such as hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, oxalate, and the like. [0035] The term “excipient” as used herein means an inert or inactive substance used in the production of pharmaceutical products or other tablets, including without limitation any substance used as a binder, disintegrant, coating, compression/encapsulation aid, cream or lotion, lubricant, parenteral, sweetener or flavoring, suspending/gelling agent, or wet granulation agent. [0036] It is understood that the substituents as defined herein are not intended to include impermissible substitution patterns (e.g., methyl substituted with 5 fluoro groups or a hydroxy group attached to an ethenylic or acetylenic carbon atom). Such impermissible substitution patterns are well known to the skilled artisan. 2. Compounds [0037] Provided herein are compounds of Formula I:
or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, wherein: n is 0, 1, 2, 3, or 4; R1 is hydrogen, -P(O)(OR20)2, -CH2P(O)(OR20)2, -P(O)(R20)(OR20), -CH2P(O)(R20)(OR20), -P(O)(N(R20)2)(OR20), -CH2P(O)(N(R20)2)(OR20), -P(O)(R20)(N(R20)2), -CH2P(O)(R20)(N(R20)2), -C(O)R20, -C(O)N(R21)(R22), -CH2P(O)(N(R20)2)2, or -P(O)(N(R20)2)2;
R2 is -OH, -OR5, -OCH2P(O)(OR20)2, -OCH2P(O)(R20)(N(R20)2), -OCH2P(O)(R20)(OR20), -OCH2P(O)(N(R20)2)(OR20), -OCH2P(O)(N(R20)2)2, -N(R21)(R22), -N(R20)C(O)R20, -N(R20)C(O)OR20, -N(R20)C(O)N(R21)(R21), -N(R20)S(O)2(R20), -NR20S(O)2N(R21)(R22), or -NR20S(O)2O(R20); R3 is hydrogen, halo, cyano, or C1-6 haloalkyl; each R4 is independently halo, cyano, -L-C1-6 alkyl, -L-C2-6 alkenyl, -L-C2-6 alkynyl, -L-C1-6 haloalkyl, -L-C3-10 cycloalkyl, -L-heterocyclyl, -L-aryl, or -L-heteroaryl; wherein each alkyl, alkenyl, alkynyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl of R4 is independently optionally substituted with 1-5 R14; L is a bond, C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, -C1-6 heteroalkylene, -O-, -S-, -S(O)-, -S(O)2-, -NR16-, -C(O)NR16-, -NR16C(O)-, -C(O)-, -OC(O)-, -C(O)O-, -NR16S(O)-, -S(O)NR16-, -NR16S(O)NR16-, -NR16S(O)2-, -S(O)2NR16-, -NR16S(O)2NR16-, -NR16C(O)NR16-, -OC(O)NR16-, or -NR16C(O)O-; wherein each C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, or -C1-6 heteroalkylene of L is independently optionally substituted with 1-5 R14; each R5 is independently C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, heterocyclyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl of R5 is independently optionally substituted with 1-5 R15; each of R6, R7, R8, and R9 are independently hydrogen, deuterium, C1-6 alkyl, or C1-6 haloalkyl; each R14 and R15 are independently hydroxy, halo, cyano, -NO2, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-10 cycloalkyl, heterocyclyl, aryl, benzyl, heteroaryl, -N(R16)2, -C(O)R16, -C(O)OR16, -S-R16, S(O)R16, -NR16S(O)R16, -S(O)N(R16)2, -NR16S(O)N(R16)2, -S(O)2R16, -NR16S(O)2R16, -S(O)2N(R16)2, -NR16S(O)2N(R16)2, -NR16C(O)N(R16)2, -C(O)N(R16)2, -NR16C(O)R16, -OC(O)N(R16)2, or -NR16C(O)OR16; each R16 is independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 heteroalkyl, C3-10 cycloalkyl, heterocyclyl, aryl, or heteroaryl; wherein each C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 heteroalkyl, C3-10 cycloalkyl, heterocyclyl, aryl, or heteroaryl of R16 is independently optionally substituted with 1-5 halo, cyano, -NO2, oxo, -SF5, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-10 cycloalkyl, aryl, benzyl, heteroaryl, or heterocyclyl; or two R16 together with the atom to which they are attached form a heterocyclyl; wherein said heterocyclyl is independently optionally substituted with 1-5 R30; each R20 is independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, aryl, heteroaryl, or heterocyclyl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl is independently optionally substituted with 1-5 R30; or two R20together with the atom to which they are attached form a heterocyclyl; wherein said heterocyclyl is independently optionally substituted with 1-5 R30;
each R21 and R22 is independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl is independently optionally substituted with 1-5 R30 groups; or R20and R21 together with the nitrogen to which they are attached form a heterocyclyl; wherein said heterocyclyl is independently optionally substituted with 1-5 R30; or R21and R22 together with the nitrogen to which they are attached form a heterocyclyl; wherein said heterocyclyl is independently optionally substituted with 1-5 R30; each R30 is independently oxo, thioxo, hydroxy, halo, -NO2, -N3, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C1-6 haloalkyl, aryl, heteroaryl, heterocyclyl, -O(C1-6 alkyl), -O(C2-6 alkenyl), -O(C2-6 alkynyl), -O(C3-10 cycloalkyl), -O(C1-6 haloalkyl), -O(aryl), -O(heteroaryl), -O(heterocyclyl), -NH2, -NH(C1-6 alkyl), -NH(C2-6 alkenyl), -NH(C2-6 alkynyl), -NH(C3-10 cycloalkyl), -NH(C1-6 haloalkyl), -NH(aryl), -NH(heteroaryl), -NH(heterocyclyl), -N(C1-6 alkyl)2, -N(C3-10 cycloalkyl)2, -N(C2-6 alkenyl)2, -N(C2-6 alkynyl)2, -N(C3-10 cycloalkyl)2, -N(C1-6 haloalkyl)2, -N(aryl)2, -N(heteroaryl)2, -N(heterocyclyl)2, -N(C1-6 alkyl)(C3-10 cycloalkyl), -N(C1-6 alkyl)(C2-6 alkenyl), -N(C1-6 alkyl)(C2-6 alkynyl), -N(C1-6 alkyl)(C3-10 cycloalkyl), -N(C1-6 alkyl)(C1-6 haloalkyl), -N(C1-6 alkyl)(aryl), -N(C1-6 alkyl)(heteroaryl), -N(C1-6 alkyl)(heterocyclyl), -C(O)(C1-6 alkyl), -C(O)(C2-6 alkenyl), -C(O)(C2-6 alkynyl), -C(O)(C3-10 cycloalkyl), -C(O)(C1-6 haloalkyl), -C(O)(aryl), -C(O)(heteroaryl), -C(O)(heterocyclyl), -C(O)O(C1-6 alkyl), -C(O)O(C2-6 alkenyl), -C(O)O(C2-6 alkynyl), -C(O)O(C3-10 cycloalkyl), -C(O)O(C1-6 haloalkyl), -C(O)O(aryl), -C(O)O(heteroaryl), -C(O)O(heterocyclyl), -C(O)NH2, -C(O)NH(C1-6 alkyl), -C(O)NH(C2-6 alkenyl), -C(O)NH(C2-6 alkynyl), -C(O)NH(C3-10 cycloalkyl), -C(O)NH(C1-6 haloalkyl), -C(O)NH(aryl), -C(O)NH(heteroaryl), -C(O)NH(heterocyclyl), -C(O)N(C1-6 alkyl)2, -C(O)N(C3-10 cycloalkyl)2, -C(O)N(C2-6 alkenyl)2, -C(O)N(C2-6 alkynyl)2, -C(O)N(C3-10 cycloalkyl)2, -C(O)N(C1-6 haloalkyl)2, -C(O)N(aryl)2, -C(O)N(heteroaryl)2, -C(O)N(heterocyclyl)2, -NHC(O)(C1-6 alkyl), -NHC(O)(C2-6 alkenyl), -NHC(O)(C2-6 alkynyl), -NHC(O)(C3-10 cycloalkyl), -NHC(O)(C1-6 haloalkyl), -NHC(O)(aryl), -NHC(O)(heteroaryl), -NHC(O)(heterocyclyl), -NHC(O)O(C1-6 alkyl), -NHC(O)O(C2-6 alkenyl), -NHC(O)O(C2-6 alkynyl), -NHC(O)O(C3-10 cycloalkyl), -NHC(O)O(C1-6 haloalkyl), -NHC(O)O(aryl), -NHC(O)O(heteroaryl), -NHC(O)O(heterocyclyl), -NHC(O)NH(C1-6 alkyl), -NHC(O)NH(C2-6 alkenyl), -NHC(O)NH(C2-6 alkynyl), -NHC(O)NH(C3-10 cycloalkyl), -NHC(O)NH(C1-6 haloalkyl), -NHC(O)NH(aryl), -NHC(O)NH(heteroaryl), -NHC(O)NH(heterocyclyl), -SH, -S(C1-6 alkyl), -S(C2-6 alkenyl), -S(C2-6 alkynyl), -S(C3-10 cycloalkyl), -S(C1-6 haloalkyl), -S(aryl), -S(heteroaryl), -S(heterocyclyl), -NHS(O)(C1-6 alkyl), -N(C1-6 alkyl)(S(O)(C1-6 alkyl), -S(O)N(C1-6 alkyl)2, -S(O)(C1-6 alkyl), -S(O)(NH)(C1-6 alkyl), -S(O)(C2-6 alkenyl), -S(O)(C2-6 alkynyl), -S(O)(C3-10 cycloalkyl), -S(O)(C1-6 haloalkyl), -S(O)(aryl), -S(O)(heteroaryl), -S(O)(heterocyclyl), -S(O)2(C1-6 alkyl), -S(O)2(C2-6 alkenyl), -S(O)2(C2-6 alkynyl), -S(O)2(C3-10 cycloalkyl), -S(O)2(C1-6 haloalkyl), -S(O)2(aryl), -S(O)2(heteroaryl), -S(O)2(heterocyclyl), -S(O)2NH(C1-6 alkyl), or -S(O)2N(C1-6 alkyl)2;
wherein each alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl of R30 is optionally substituted with one to four substituents independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, -OH, -NH2, -NH(C1-6 alkyl), -NH(C3-10 cycloalkyl), -NH(C1-6 haloalkyl), -NH(aryl), -NH(heteroaryl), -NH(heterocyclyl), -N(C1-6 alkyl)2, -N(C3-10 cycloalkyl)2, -NHC(O)(C3-10 cycloalkyl), -NHC(O)(C1-6 haloalkyl), -NHC(O)(aryl), -NHC(O)(heteroaryl), -NHC(O)(heterocyclyl), -NHC(O)O(C1-6 alkyl), -NHC(O)O(C2-6 alkynyl), -NHC(O)O(C3-10 cycloalkyl), -NHC(O)O(C1-6 haloalkyl), -NHC(O)O(aryl), -NHC(O)O(heteroaryl), -NHC(O)O(heterocyclyl), -NHC(O)NH(C1-6 alkyl), -S(O)(NH)(C1-6 alkyl), S(O)2(C1-6 alkyl), -S(O)2(C3-10 cycloalkyl), -S(O)2(C1-6 haloalkyl), -S(O)2(aryl), -S(O)2(heteroaryl), -S(O)2(heterocyclyl), -S(O)2NH(C1-6 alkyl), -S(O)2N(C1-6 alkyl)2, -O(C1-6 alkyl), -O(C3-10 cycloalkyl), -O(C1-6 haloalkyl), -O(aryl), -O(heteroaryl), or -O(heterocyclyl). [0038] In certain embodiments, n is 0 or 1. In certain embodiments, n is 1. In certain embodiments, n is 0. [0039] In certain embodiments, provided herein is a compound of Formula IA:
or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, where each of R1, R2, R3, R4, R6, R7, R8, and R9 are independently as defined herein. [0040] In certain embodiments, provided herein is a compound of Formula IB:
or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, where each of R1, R2, R3, R4, R6, R7, R8, and R9 are independently as defined herein. [0041] In certain embodiments, provided herein is a compound of Formula IC:
or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, where each of R1, R2, R3, R4, R6, R7, R8, and R9 are independently as defined herein. [0042] In certain embodiments, provided herein is a compound of Formula ID:
or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, where each of R1, R2, R3, R4, R6, R7, R8, and R9 are independently as defined herein. [0043] In certain embodiments, R3 is halo, cyano, or C1-6 haloalkyl. In certain embodiments, R3 is hydrogen, cyano, or C1-6 haloalkyl. [0044] In certain embodiments, provided herein is a compound of Formula II:
or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, where each of R1, R2, R4, n, R6, R7, R8, and R9 are independently as defined herein. [0045] In certain embodiments, n is 0 or 1. In certain embodiments, n is 1. In certain embodiments, n is 0. [0046] In certain embodiments, provided herein is a compound of Formula IIA:
or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, where each of R1, R2, R4, R6, R7, R8, and R9 are independently as defined herein. [0047] In certain embodiments, provided herein is a compound of Formula IIB:
or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, where each of R1, R2, R4, R6, R7, R8, and R9 are independently as defined herein. [0048] In certain embodiments, provided herein is a compound of Formula IIC:
or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, where each of R1, R2, R4, R6, R7, R8, and R9 are independently as defined herein. [0049] In certain embodiments, provided herein is a compound of Formula IID:
or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, where each of R1, R2, R4, R6, R7, R8, and R9 are independently as defined herein. [0050] In certain embodiments, R1 is hydrogen. [0051] In certain embodiments, provided herein is a compound of Formula IIIA:
or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, where each of R2, R4, R6, R7, R8, and R9 are independently as defined herein. [0052] In certain embodiments, provided herein is a compound of Formula IIIB:
or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, where each of R2, R4, R6, R7, R8, and R9 are independently as defined herein. [0053] In certain embodiments, provided herein is a compound of Formula IIIC:
or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, where each of R2, R4, R6, R7, R8, and R9 are independently as defined herein. [0054] In certain embodiments, provided herein is a compound of Formula IIID:
or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, where each of R2, R4, R6, R7, R8, and R9 are independently as defined herein. [0055] In certain embodiments, R2 is -OH, -OR5, -OCH2P(O)(OR20)2, -OCH2P(O)(R20)(N(R20)2), -OCH2P(O)(R20)(OR20), -OCH2P(O)(N(R20)2)(OR20), or -OCH2P(O)(N(R20)2)2. In certain embodiments, R2 is -N(R21)(R22), -N(R20)C(O)R20, -N(R20)C(O)OR20, -N(R20)C(O)N(R21)(R21), -N(R20)S(O)2(R20), -NR20S(O)2N(R21)(R22), or -NR20S(O)2O(R20).
[0056] In certain embodiments, R2 is -OH, -OR5, or -N(R21)(R22). In certain embodiments, R2 is -OH or -OR5. In certain embodiments, R2 is -OH. In certain embodiments, R2 is -OR5 or -N(R21)(R22). In certain embodiments, R2 is -OR5. In certain embodiments, R2 is -N(R21)(R22). [0057] In certain embodiments, provided herein is a compound of Formula IVA:
or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, where each of R4, R6, R7, R8, and R9 are independently as defined herein. [0058] In certain embodiments, provided herein is a compound of Formula IVB:
or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, where each of R4, R6, R7, R8, and R9 are independently as defined herein. [0059] In certain embodiments, provided herein is a compound of Formula IVC:
or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, where each of R4, R6, R7, R8, and R9 are independently as defined herein. [0060] In certain embodiments, provided herein is a compound of Formula IVD:
or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, where each of R4, R6, R7, R8, and R9 are independently as defined herein. [0061] In certain embodiments, R6 is hydrogen. In certain embodiments, R7 is hydrogen. In certain embodiments, R8 is hydrogen. In certain embodiments, R9 is hydrogen. In certain embodiments, R6 and R7 are hydrogen. In certain embodiments, R8 and R9 are hydrogen. In certain embodiments, R6, R7, R8, and R9 are hydrogen. [0062] In certain embodiments, provided herein is a compound of Formula VA:
or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, where each of R2 and R4 are independently as defined herein. [0063] In certain embodiments, provided herein is a compound of Formula VB:
or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, where each of R2 and R4 are independently as defined herein. [0064] In certain embodiments, provided herein is a compound of Formula VC:
or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, where each of R2 and R4 are independently as defined herein. [0065] In certain embodiments, provided herein is a compound of Formula VD:
or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, where each of R2 and R4 are independently as defined herein. [0066] In certain embodiments, R4 is cyano, -L-C3-10 cycloalkyl, -L-heterocyclyl, -L-aryl, or -L-heteroaryl; wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl of R4 is optionally substituted with 1-3 R14. [0067] In certain embodiments, R4 is cyano, -L-cycloalkyl, -L-aryl, or -L-heteroaryl; wherein the cycloalkyl, aryl, or heteroaryl of R4 is optionally substituted with 1-3 R14. [0068] In certain embodiments, R4 is cyano or -L-aryl; wherein the aryl of R4 is optionally substituted with 1-3 R14. [0069] In certain embodiments, R4 is cyano. In certain embodiments, R4 is -L-cycloalkyl optionally substituted with 1-3 R14. In certain embodiments, R4 is -L-aryl optionally substituted with 1-3 R14. In certain embodiments, R4 is -L-heteroaryl optionally substituted with 1-3 R14. In certain embodiments, L is a bond, C1-2 alkylene, C2 alkynylene, -O-, -S-, or -S(O)2-. [0070] In certain embodiments, L is a bond, C1-2 alkylene, C2 alkynylene, -O-, -S-, or -S(O)2-. [0071] In certain embodiments, L is a bond. In certain embodiments, L is a C1-2 alkylene. In certain embodiments, L is C2 alkynylene. In certain embodiments, L is -O-, -S-, or -S(O)2-. In certain embodiments, L is -O-. In certain embodiments, L is -S-. In certain embodiments, L is -S(O)2-. [0072] In certain embodiments, R4 is cyano, -L-cycloalkyl, -L-aryl, or -L-heteroaryl; wherein the cycloalkyl, aryl, or heteroaryl of R4 is optionally substituted with 1-3 R14; and L is a bond, C1-2 alkylene, C2 alkynylene, -O-, -S-, or -S(O)2-. [0073] In certain embodiments, R4 is cycloalkyl optionally substituted with 1-3 R14. In certain embodiments, R4 is aryl optionally substituted with 1-3 R14. In certain embodiments, R4 is heteroaryl optionally substituted with 1-3 R14. [0074] In certain embodiments, each R14 is independently selected from the group consisting of halo, cyano, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, and aryl.
[0075] In certain embodiments, R4 is cyano, -L-cycloalkyl, -L-aryl, or -L-heteroaryl; wherein the cycloalkyl, aryl, or heteroaryl of R4 is optionally substituted with 1-3 R14 independently selected from the group consisting of halo, cyano, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, and C1-6 haloalkoxy; and L is a bond, C1-2 alkylene, C2 alkynylene, -O-, -S-, or -S(O)2-. [0076] In certain embodiments, R4 is cyano or -L-aryl; wherein the aryl of R4 is optionally substituted with 1-3 R14; and L is a bond, C1-2 alkylene, C2 alkynylene, -O-, -S-, or -S(O)2-. [0077] In certain embodiments, each R14 is independently selected from the group consisting of halo, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, and C1-6 haloalkoxy. [0078] In certain embodiments, R4 is cyano or -L-aryl; wherein the aryl of R4 is optionally substituted with 1-3 R14 independently selected from the group consisting of halo, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, and C1-6 haloalkoxy; and L is a bond, C1-2 alkylene, C2 alkynylene, -O-, -S-, or -S(O)2-. [0079] In certain embodiments, R4 is cyano, phenyl, 2-fluorophenyl, 3-fluorophenyl, 4- fluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-methylphenyl, 3-methylphenyl, 4- methylphenyl, 2,6-dimethylphenyl, 3,5-dimethylphenyl, 2-trifluoromethylphenyl, 3- trifluoromethylphenyl, 4-trifluoromethylphenyl, 2-isopropylphenyl, 3-isopropylphenyl, 4- isopropylphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2-trifluoromethoxyphenyl, 3- trifluoromethoxyphenyl, 4-trifluoromethoxyphenyl, naphthalen-1-yl, 4-fluoro-3-methylphenyl, 2-fluoro- 3-methylphenyl, 2-fluoro-5-methylphenyl, 2-p-tolyl-ethyl, 2-chloro-phenylethynyl, 2-(2-chloro-phenyl)- ethyl, 2-fluoro-4-methoxy-phenyl, 2,4-difluoro-phenyl, 2,5-difluoro-phenyl, 2-fluoro-3-methoxyphenyl, 1,1'-biphenyl]-2-yl, 1,1'-biphenyl]-3-yl, 1,1'-biphenyl]-4-yl, 2,4-dimethylphenyl, 2,5-dimethylphenyl, 2- chloro-4-(trifluoromethoxy)phenyl, 2-fluoro-3-methylphenyl, 2-fluoro-4-methoxyphenyl, 2-fluoro-5- methoxyphenyl, 2-fluoro-5-methylphenyl, 2-methyl-4-(trifluoromethoxy)phenyl, 3,4-dimethylphenyl, 3,5-difluorophenyl, 3,5-difluoropyridin-4-yl, 3-cyanophenyl, 3-fluoropyridin-4-yl, 4-cyanophenyl, 4- fluoro-3-methylphenyl, 6-(trifluoromethoxy)pyridin-3-yl, or cyclopropyl. [0080] In certain embodiments, R4 is cyano, phenyl, 2-fluorophenyl, 3-fluorophenyl, 4- fluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-methylphenyl, 3-methylphenyl, 4- methylphenyl, 2,6-dimethylphenyl, 3,5-dimethylphenyl, 2-trifluoromethylphenyl, 3- trifluoromethylphenyl, 4-trifluoromethylphenyl, 2-isopropylphenyl, 3-isopropylphenyl, 4- isopropylphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2-trifluoromethoxyphenyl, 3- trifluoromethoxyphenyl, 4-trifluoromethoxyphenyl, naphthalen-1-yl, 4-fluoro-3-methylphenyl, 2-fluoro- 3-methylphenyl, 2-fluoro-5-methylphenyl, 2-p-tolyl-ethyl, 2-chloro-phenylethynyl, 2-(2-chloro-phenyl)- ethyl, 2-fluoro-4-methoxy-phenyl, 2,4-difluoro-phenyl, or 2,5-difluoro-phenyl. [0081] In certain embodiments, R1 is hydrogen; R2 is -OH; R3 is hydrogen, cyano, or C1-6 haloalkyl; and each of R6, R7, R8, and R9 is hydrogen.
[0082] In certain embodiments, R1 is hydrogen; R2 is -OH; R3 is hydrogen, cyano, or C1-6 haloalkyl; each of R6, R7, R8, and R9 is hydrogen; R4 is cyano, -L-cycloalkyl, -L-aryl, or -L-heteroaryl; wherein the cycloalkyl, aryl, or heteroaryl of R4 is optionally substituted with 1-3 R14 independently selected from the group consisting of halo, cyano, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, and C1-6 haloalkoxy; and L is a bond, C1-2 alkylene, C2 alkynylene, -O-, -S-, or -S(O)2-. In certain embodiments, each R14 is independently selected from the group consisting of halo, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, and C1-6 haloalkoxy. [0083] In certain embodiments, R1 is hydrogen; R2 is -OH; R3 is hydrogen, cyano, or C1-6 haloalkyl; each of R6, R7, R8, and R9 is hydrogen; and R4 is cyano, phenyl, 2-fluorophenyl, 3- fluorophenyl, 4-fluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-methylphenyl, 3- methylphenyl, 4-methylphenyl, 2,6-dimethylphenyl, 3,5-dimethylphenyl, 2-trifluoromethylphenyl, 3- trifluoromethylphenyl, 4-trifluoromethylphenyl, 2-isopropylphenyl, 3-isopropylphenyl, 4- isopropylphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2-trifluoromethoxyphenyl, 3- trifluoromethoxyphenyl, 4-trifluoromethoxyphenyl, naphthalen-1-yl, 4-fluoro-3-methylphenyl, 2-fluoro- 3-methylphenyl, 2-fluoro-5-methylphenyl, 2-p-tolyl-ethyl, 2-chloro-phenylethynyl, 2-(2-chloro-phenyl)- ethyl, 2-fluoro-4-methoxy-phenyl, 2,4-difluoro-phenyl, 2,5-difluoro-phenyl, 2-fluoro-3-methoxyphenyl, 1,1'-biphenyl]-2-yl, 1,1'-biphenyl]-3-yl, 1,1'-biphenyl]-4-yl, 2,4-dimethylphenyl, 2,5-dimethylphenyl, 2- chloro-4-(trifluoromethoxy)phenyl, 2-fluoro-3-methylphenyl, 2-fluoro-4-methoxyphenyl, 2-fluoro-5- methoxyphenyl, 2-fluoro-5-methylphenyl, 2-methyl-4-(trifluoromethoxy)phenyl, 3,4-dimethylphenyl, 3,5-difluorophenyl, 3,5-difluoropyridin-4-yl, 3-cyanophenyl, 3-fluoropyridin-4-yl, 4-cyanophenyl, 4- fluoro-3-methylphenyl, 6-(trifluoromethoxy)pyridin-3-yl, or cyclopropyl. [0084] In certain embodiments, R1 is hydrogen; R2 is -OH; R3 is hydrogen, cyano, or C1-6 haloalkyl; each of R6, R7, R8, and R9 is hydrogen; and R4 is cyano, phenyl, 2-fluorophenyl, 3- fluorophenyl, 4-fluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-methylphenyl, 3- methylphenyl, 4-methylphenyl, 2,6-dimethylphenyl, 3,5-dimethylphenyl, 2-trifluoromethylphenyl, 3- trifluoromethylphenyl, 4-trifluoromethylphenyl, 2-isopropylphenyl, 3-isopropylphenyl, 4- isopropylphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2-trifluoromethoxyphenyl, 3- trifluoromethoxyphenyl, 4-trifluoromethoxyphenyl, naphthalen-1-yl, 4-fluoro-3-methylphenyl, 2-fluoro- 3-methylphenyl, 2-fluoro-5-methylphenyl, 2-p-tolyl-ethyl, 2-chloro-phenylethynyl, 2-(2-chloro-phenyl)- ethyl, 2-fluoro-4-methoxy-phenyl, 2,4-difluoro-phenyl, or 2,5-difluoro-phenyl. [0085] In certain embodiments, provided is a compound selected from Table 1, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof:
TABLE 1
3. Compositions and Methods [0086] This disclosure provides compounds, compositions and methods of inhibiting the activity of a histone lysine demethylase-5 (KDM5) enzyme, as well as compounds and compositions for the manufacture of a medicament, for use in treating various conditions or disorders as described herein. The compound or composition can be used in methods to treat, pretreat, or delay progression or onset of a condition associated with a KDM5, particularly KDM5B. In certain embodiments, the composition is a pharmaceutical composition comprising a pharmaceutically acceptable excipient or carrier, and a therapeutically effective amount of one or more compounds of formula I. In the present disclosure, each of the various embodiments above also relate to a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug of the compound (e.g., a compound of formula I). [0087] In certain embodiments, provided is a method of inhibiting the activity of a KDM5, particularly KDM5B, comprising bringing into contact the KDM5 and an inhibitory-effective amount of a compound or pharmaceutical composition disclosed herein. [0088] In certain embodiments, provided is a method of treating, pretreating, or delaying onset of a condition associated with KDM5, particularly KDM5B, the method comprising administering to a patient a therapeutically effective amount of a compound or pharmaceutical composition disclosed herein.
[0089] In certain embodiments, provided is a method of treating, pretreating, or delaying onset of a condition associated with undesirable cellular proliferation, the method comprising administering to a patient a therapeutically effective amount of a compound or pharmaceutical composition disclosed herein. [0090] In certain embodiments, the condition is cancer. Exemplary cancers include, but are not limited to, acoustic neuroma; adenocarcinoma; adrenal gland cancer; anal cancer; angiosarcoma (e.g., lymphangio sarcoma, lymphangioendotheliosarcoma, hemangiosarcoma); appendix cancer; benign monoclonal gammopathy; biliary cancer (e.g., cholangiocarcinoma); bladder cancer; breast cancer (e.g., adenocarcinoma of the breast, papillary carcinoma of the breast, mammary cancer, medullary carcinoma of the breast); brain cancer (e.g., meningioma, glioblastomas, glioma (e.g., astrocytoma, oligodendroglioma), medulloblastoma); bronchus cancer; carcinoid tumor; cervical cancer (e.g., cervical adenocarcinoma); choriocarcinoma; chordoma; craniopharyngioma; colorectal cancer (e.g., colon cancer, rectal cancer, colorectal adenocarcinoma); connective tissue cancer; epithelial carcinoma; ependymoma; endotheliosarcoma (e.g., Kaposi’s sarcoma, multiple idiopathic hemorrhagic sarcoma); endometrial cancer (e.g., uterine cancer, uterine sarcoma); esophageal cancer (e.g., adenocarcinoma of the esophagus, Barrett’s adenocarcinoma); Ewing’s sarcoma; eye cancer (e.g., intraocular melanoma, retinoblastoma); familiar hypereosinophilia; gall bladder cancer; gastric cancer (e.g., stomach adenocarcinoma); gastrointestinal stromal tumor (GIST); germ cell cancer; head and neck cancer (e.g., head and neck squamous cell carcinoma, oral cancer (e.g., oral squamous cell carcinoma), throat cancer (e.g., laryngeal cancer, pharyngeal cancer, nasopharyngeal cancer, oropharyngeal cancer)); hematopoietic cancers (e.g., leukemia such as acute lymphocytic leukemia (ALL) (e.g., B-cell ALL, T-cell ALL), acute myelocytic leukemia (AML) (e.g., B-cell AML, T-cell AML), chronic myelocytic leukemia (CML) (e.g., B-cell CML, T-cell CML), and chronic lymphocytic leukemia (CLL) (e.g., B-cell CLL, T-cell CLL)); lymphoma such as Hodgkin lymphoma (HL) (e.g., B-cell HL, T-cell HL) and non-Hodgkin lymphoma (NHL) (e.g., B-cell NHL such as diffuse large cell lymphoma (DLCL) (e.g., diffuse large B-cell lymphoma), follicular lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), mantle cell lymphoma (MCL), marginal zone B-cell lymphomas (e.g., mucosa-associated lymphoid tissue (MALT) lymphomas, nodal marginal zone B-cell lymphoma, splenic marginal zone B- cell lymphoma), primary mediastinal B-cell lymphoma, Burkitt lymphoma, lymphoplasmacytic lymphoma (i.e., Waldenstrom’s macroglobulinemia), hairy cell leukemia (HCL), immunoblastic large cell lymphoma, precursor B -lymphoblastic lymphoma and primary central nervous system (CNS) lymphoma; and T-cell NHL such as precursor T- lymphoblastic lymphoma/leukemia, peripheral T-cell lymphoma (PTCL) (e.g., cutaneous T-cell lymphoma (CTCL) (e.g., mycosis fungoides, Sezary syndrome), angioimmunoblastic T-cell lymphoma, extranodal natural killer T-cell lymphoma, enteropathy type T-cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma, and anaplastic large cell lymphoma); a mixture of one or more leukemia/lymphoma as described above; and multiple myeloma (MM)), heavy chain disease (e.g., alpha chain disease, gamma chain disease, mu chain disease); hemangioblastoma; hypopharynx cancer; inflammatory myofibroblastic tumors; immunocytic
amyloidosis; kidney cancer (e.g., nephroblastoma a.k.a. Wilms’ tumor, renal cell carcinoma); liver cancer (e.g., hepatocellular cancer (HCC), malignant hepatoma); lung cancer (e.g., bronchogenic carcinoma, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), adenocarcinoma of the lung); leiomyosarcoma (LMS); mastocytosis (e.g., systemic mastocytosis); muscle cancer; myelodysplastic syndrome (MDS); mesothelioma; myeloproliferative disorder (MPD) (e.g., polycythemia vera (PV), essential thrombocytosis (ET), agnogenic myeloid metaplasia (AMM), myelofibrosis (MF), chronic idiopathic myelofibrosis, chronic myelocytic leukemia (CML), chronic neutrophilic leukemia (CNL), hypereosinophilic syndrome (HES)); neuroblastoma; neurofibroma (e.g., neurofibromatosis (NF) type 1 or type 2, schwannomatosis); neuroendocrine cancer (e.g., gastroenteropancreatic neuroendocrinetumor (GEP-NET), carcinoid tumor); osteosarcoma (e.g., bone cancer); ovarian cancer (e.g., cystadenocarcinoma, ovarian embryonal carcinoma, ovarian adenocarcinoma); papillary adenocarcinoma; pancreatic cancer (e.g., pancreatic andenocarcinoma, intraductal papillary mucinous neoplasm (IPMN), Islet cell tumors); penile cancer (e.g., Paget’s disease of the penis and scrotum); pinealoma; primitive neuroectodermal tumor (PNT); plasma cell neoplasia; paraneoplastic syndromes; intraepithelial neoplasms; prostate cancer (e.g., prostate adenocarcinoma); rectal cancer; rhabdomyosarcoma; salivary gland cancer; skin cancer (e.g., squamous cell carcinoma (SCC), keratoacanthoma (KA), melanoma, basal cell carcinoma (BCC)); small bowel cancer (e.g., appendix cancer); soft tissue sarcoma (e.g., malignant fibrous histiocytoma (MFH), liposarcoma, malignant peripheral nerve sheath tumor (MPNST), chondrosarcoma, fibrosarcoma, myxosarcoma); sebaceous gland carcinoma; small intestine cancer; sweat gland carcinoma; synovioma; testicular cancer (e.g., seminoma, testicular embryonal carcinoma); thyroid cancer (e.g., papillary carcinoma of the thyroid, papillary thyroid carcinoma (PTC), medullary thyroid cancer); urethral cancer; vaginal cancer; and vulvar cancer (e.g., Paget’s disease of the vulva). [0091] In certain embodiments, the condition is a neoplasm, a tumor, or leukemia. In certain embodiments, the condition is histocytoma, glioma, astrocytoma, osteoma, lung cancer, small cell lung cancer, gastrointestinal cancer, bowel cancer, colon cancer, breast carcinoma, ovarian carcinoma, prostate cancer, testicular cancer, liver cancer, kidney cancer, bladder cancer, pancreas cancer, brain cancer, sarcoma, osteosarcoma, Kaposi's sarcoma, or melanoma. In certain embodiments, the cancer is embryonic carcinoma, teratoma, seminoma, germ cell tumors, prostate cancer, breast cancer, stomach cancer, gastrointestinal cancer, neuroblastoma, choriocarcinoma, yolk sac tumors, ovarian cancer, endometrial cancer, cervical cancer, retinoblastoma, kidney cancer, liver cancer, gastric cancer, brain cancer, medulloblastoma, medulloepithelioma, glioma, glioblastoma, multiple myeloma, lung cancer, bronchial cancer, mesothelioma, skin cancer, colon and rectal cancer, bladder cancer, pancreatic cancer, lip and oral cancer, laryngeal and pharyngeal cancer, melanoma, pituitary cancer, penile cancer, parathyroid cancer, thyroid cancer, pheochromocytoma and paraganglioma, thymoma and thymic carcinoma, leukemia, lymphoma, plasma cell neoplasms, myeloproliferative disorders, islet cell tumor, small intestine cancer, transitional cell cancer, pleuropulmonary blastoma, gestational trophoblastic cancer, esophageal cancer, central nervous system cancer, head and neck cancer, endocrine cancer,
cardiovascular cancer, rhabdomyosarcoma, soft tissue carcinomas, carcinomas of bone, cartilage, fat, vascular, neural, and hematopoietic tissues or an AIDS-related cancer. [0092] In certain embodiments, provided is a method of treating, pretreating, or delaying onset of a hematologic cancer, in particular a B-cell acute lymphocytic leukemia (B-ALL) or B-cell lymphoma, comprising administering a therapeutically effective amount of a compound or composition disclosed herein to a patient in need thereof. In certain embodiments, provided is a method of treating, pretreating, or delaying onset of a lung cancer, in particular a non-small cell lung cancer (NSCLC), comprising administering a therapeutically effective amount of a compound or composition disclosed herein to a patient in need thereof. In certain embodiments, provided is a method of treating, pretreating, or delaying onset of a breast cancer, in particular an estrogen receptor positive (ER+) breast cancer, comprising administering a therapeutically effective amount of a compound or composition disclosed herein to a patient in need thereof. [0093] In certain embodiments, provided is a method of preventing or treating a viral infection, the method comprising administering to a patient a therapeutically effective amount of a compound or pharmaceutical composition disclosed herein. [0094] In certain embodiments, the patient has a viral infection or is at risk for viral infection but is free from cancer. The viral infection may be due to a nuclear DNA viral infection such as a herpes viral infection. The herpesvirus may be, e.g., herpes simplex virus (HSV) type 1, herpes simplex virus type 2, varicella zoster virus (VZV), or cytomegalovirus (CMV). The herpesvirus may be Epstein-Barr virus (EBV), Kaposi's Sarcoma-Associated herpesvirus, herpes simiae virus, herpes lymphotropic virus, human herpesvirus-7 (HHMV-7), or human herpesvirus-8 (HHMV-8). Viral infections especially pose a threat to individuals that have suppressed (immunosuppressed) or otherwise compromised (immunocompromised) immune systems. For example, individuals with HIV/AIDS, diabetes, or cancer often have reduced ability to ward off additional and/or opportunistic viral infections due to immune systems that are adversely affected by the underlying, primary infection or condition. Therefore, preventing or treating viral infection or re-activation is especially important for these individuals. [0095] In certain embodiments, the viral infection involves reactivation of a virus after latency in the patient. In certain embodiments, the patient has undergone, is undergoing, or will undergo, immunosuppression. In certain embodiments, the method prevents or treats viral-induced encephalitis, viral-induced keratitis, or reduces the severity of infection. In certain embodiments, the patient is an immunocompromised mammal. [0096] In certain embodiments, provided is a method for treating a hepatitis B virus (HBV) infection, comprising administering a therapeutically effective amount of a compound or composition disclosed herein to a patient in need thereof. In certain embodiments, provided is a method for treating a hepatocellular carcinoma derived from persistent HBV or HCV infection, comprising administering a
therapeutically effective amount of a compound or composition disclosed herein to a patient in need thereof. [0097] In certain embodiments, the condition is cardiovascular disease. In certain embodiments, the cardiovascular disease is heart disease. In certain embodiments, the cardiovascular disease is coronary heart disease. In certain embodiments, the cardiovascular disease is stroke or cerebrovascular disease. In certain embodiments, the cardiovascular disease is a congenital heart defect. In certain embodiments, the cardiovascular disease is peripheral artery disease. In certain embodiments, the cardiovascular disease is heart disease associated with atherosclerosis. In certain embodiments, the cardiovascular disease is ischemic heart disease. In certain embodiments, the cardiovascular disease is hypertensive heart disease. In certain embodiments, the cardiovascular disease is cardiac arrhythmia. In certain embodiments, the cardiovascular disease is heart failure or congenital heart disease. In certain embodiments, the cardiovascular disease is inflammatory heart disease. In certain embodiments, the cardiovascular disease is cardiomyopathy. [0098] In certain embodiments, the compound is administered in combination with one or more additional pharmaceutical agents described herein. The additional pharmaceutical agent may be an anti- proliferative agent. In certain embodiments, the additional pharmaceutical agent is an anti-cancer agent. The additional pharmaceutical agent may also be a kinase inhibitor. In certain embodiments, the additional pharmaceutical agent is an inhibitor of histone lysine demethylase. In certain embodiments, the additional pharmaceutical agent includes an anti-cancer agent, anti-inflammatory agent, steroids, immunosuppressant, radiation therapy, or other agents. In certain embodiments, the additional pharmaceutical agent is an anti-proliferative agent. In certain embodiments, the additional pharmaceutical agent is a non-selective inhibitor of a histone demethylase. In certain embodiments, the additional pharmaceutical agent is an immunotherapy agent. In certain embodiments, the additional pharmaceutical agent is an immune checkpoint inhibitor. In certain embodiments, the anti-cancer agent is a chemotherapeutic. In certain embodiments, the immunotherapy agent is a PD1 inhibitor. In certain embodiments, the immunotherapy agent is a PDL1 inhibitor. In certain embodiments, the additional pharmaceutical agent is a topoisomerase inhibitor, a MCL1 inhibitor, a BCL-2 inhibitor, a BCL-xL inhibitor, a BRD4 inhibitor, a BRCA1 inhibitor, BRCA2 inhibitor, HER1 inhibitor, HER2 inhibitor, a CDK9 inhibitor, a Jumonji histone demethylase inhibitor, or a DNA damage inducer. In certain embodiments, the additional pharmaceutical agent is etoposide, obatoclax, navitoclax, JQ1, 4-(((5’- chloro-2’-(((lR,4R)-4- (((R)-l-methoxypropan-2-yl)amino)cyclohexyl)amino)-[2,4’-bipyridin]-6- yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile, JIB04, or cisplatin. Exemplary chemotherapeutic agents include alkylating agents such as nitrogen mustards, ethylenimines, methylmelamines, alkyl sulfonates, nitrosoureas, and triazenes; antimetabolites such as folic acid analogs, pyrimidine analogs, in particular fluorouracil and cytosine arabinoside, and purine analogs; natural products such as vinca alkaloids epi-podophyllotoxins, antibiotics, enzymes, and biological response modifiers; and miscellaneous products such as platinum coordination complexes, anthracenedione, substituted urea such
as hydroxyurea, methyl hydrazine derivatives, and adrenocorticoid suppressant. Exemplary chemotherapeutic agents also include anthracycline antibiotics, actinomycin D, plicamycin, puromycin, gramicidin D, paclitaxel, colchicine, cytochalasin B, emetine, maytansine, amsacrine, cisplatin, carboplatin, mitomycin, altretamine, cyclophosphamide, lomustine, and carmustine. In certain embodiments, a pharmaceutical composition described herein further comprises a combination of the additional pharmaceutical agents described herein. 4. Formulations and Administration [0099] The compositions of the present disclosure can be delivered directly or in pharmaceutical compositions along with suitable carriers or excipients, as is well known in the art. Present methods of treatment can comprise administration of an effective amount of a compound of the disclosure to a subject in need; e.g., a subject having or at risk for a hyperproliferative disease or cancer. In certain embodiments, the subject is a mammalian subject. In certain embodiments, the subject is a human subject. [0100] An effective amount of such agents can readily be determined by routine experimentation, as can the most effective and convenient route of administration and the most appropriate formulation. Various formulations and drug delivery systems are available in the art. See, e.g., Gennaro, A.R., ed. (1995) Remington’s Pharmaceutical Sciences, supra. [0101] Suitable routes of administration may, for example, include oral, rectal, topical, nasal, pulmonary, ocular, intestinal, and parenteral administration. The indication to be treated, along with the physical, chemical, and biological properties of the drug, dictate the type of formulation and the route of administration to be used, as well as whether local or systemic delivery would be desired. [0102] Pharmaceutical compositions are often composed of the drug and an excipient(s). Pharmaceutical dosage forms are often composed of the drug, an excipient(s), and a container/closure system. One or multiple excipients, also referred to as inactive ingredients, can be added to a compound of the disclosure to improve or facilitate manufacturing, stability, administration, and safety of the drug, and can provide a means to achieve a desired drug release profile. Therefore, the type of excipient(s) to be added to the drug can depend on various factors, such as, for example, the physical and chemical properties of the drug, the route of administration, and the manufacturing procedure. Pharmaceutically acceptable excipients are available in the art and include those listed in various pharmacopoeias. (See, e.g., the U.S. Pharmacopeia (USP), Japanese Pharmacopoeia (JP), European Pharmacopoeia (EP), and British pharmacopeia (BP); the U.S. Food and Drug Administration (fda.gov) Center for Drug Evaluation and Research (CEDR) publications, e.g., Inactive Ingredient Guide (1996); Ash and Ash, Eds. (2002) Handbook of Pharmaceutical Additives, Synapse Information Resources, Inc., Endicott NY; etc.) [0103] Pharmaceutical dosage forms of a compound of the present disclosure may be manufactured by any of the methods well-known in the art, such as, for example, by conventional mixing, sieving, dissolving, melting, granulating, dragee-making, tableting, suspending, extruding, spray-
drying, levigating, emulsifying, (nano/micro-) encapsulating, entrapping, or lyophilization processes. As noted above, the compositions of the present disclosure can include one or more physiologically acceptable inactive ingredients that facilitate processing of active molecules into preparations for pharmaceutical use. [0104] Proper formulation is dependent upon the desired route of administration. For intravenous injection, for example, the composition may be formulated in aqueous solution, if necessary using physiologically compatible buffers, including, for example, phosphate, histidine, or citrate for adjustment of the formulation pH, and a tonicity agent, such as, for example, sodium chloride or dextrose. For transmucosal or nasal administration, semisolid, liquid formulations, or patches may be desired, possibly containing penetration enhancers. Such penetrants are generally known in the art. For oral administration, the compounds can be formulated in liquid or solid dosage forms, and as instant or controlled/sustained release formulations. Suitable dosage forms for oral ingestion by a subject include tablets, pills, dragees, hard and soft shell capsules, liquids, gels, syrups, slurries, suspensions, and emulsions. The compounds may also be formulated in rectal compositions, such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides. [0105] Solid oral dosage forms can be obtained using excipients, which may include fillers, disintegrants, binders (dry and wet), dissolution retardants, lubricants, glidants, antiadherants, cationic exchange resins, wetting agents, antioxidants, preservatives, coloring, and flavoring agents. These excipients can be of synthetic or natural source. Examples of such excipients include cellulose derivatives, citric acid, dicalcium phosphate, gelatine, magnesium carbonate, magnesium/sodium lauryl sulfate, mannitol, polyethylene glycol, polyvinyl pyrrolidone, silicates, silicium dioxide, sodium benzoate, sorbitol, starches, stearic acid or a salt thereof, sugars (i.e. dextrose, sucrose, lactose, etc.), talc, tragacanth mucilage, vegetable oils (hydrogenated), and waxes. Ethanol and water may serve as granulation aides. In certain instances, coating of tablets with, for example, a taste-masking film, a stomach acid resistant film, or a release-retarding film is desirable. Natural and synthetic polymers, in combination with colorants, sugars, and organic solvents or water, are often used to coat tablets, resulting in dragees. When a capsule is desired over a tablet, the drug powder, suspension, or solution thereof can be delivered in a compatible hard or soft shell capsule. [0106] A therapeutically effective dose can be estimated initially using a variety of techniques well-known in the art. Initial doses used in animal studies may be based on effective concentrations established in cell culture assays. Dosage ranges appropriate for human subjects can be determined, for example, using data obtained from animal studies and cell culture assays. [0107] An effective amount or a therapeutically effective amount or dose of an agent, e.g., a compound of the disclosure, refers to that amount of the agent or compound that results in amelioration of symptoms or a prolongation of survival in a subject. Toxicity and therapeutic efficacy of such molecules can be determined by standard pharmaceutical procedures in cell cultures or experimental
animals, e.g., by determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population). The dose ratio of toxic to therapeutic effects is the therapeutic index, which can be expressed as the ratio LD50/ED50. Agents that exhibit high therapeutic indices are generally desired. [0108] The effective amount or therapeutically effective amount is the amount of the compound or pharmaceutical composition that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by the researcher, veterinarian, medical doctor or other clinician. Dosages typically fall within a range of circulating concentrations that includes the ED50 with little or no toxicity. Dosages may vary within this range depending upon the dosage form employed and/or the route of administration utilized. Dosages are typically expressed as a number of milligrams of a compound described herein per kilogram of the subject’s body weight (mg/kg). Dosages of between about 0.1 and 900 mg/kg may be appropriate. In some embodiments, about 1 and 500 mg/kg may be appropriate. In other embodiments, a dosage of between 10 and 250 mg/kg may be appropriate. In some embodiments, a dosage of from about 1 to about 100 mg per kg of body weight, from about 1 to about 50 mg of compound per kg of body weight, or from about 1 to about 10 mg of compound per kg of body weight may be appropriate. In some embodiments, a dosage of from about 25 to about 500 mg per kg of body weight, from about 50 to about 500 mg of compound per kg of body weight, or from about 25 to about 250 mg of compound per kg of body weight may be appropriate. The exact formulation, route of administration, dosage, and dosage interval should be chosen according to methods known in the art, in view of the specifics of a subject’s condition. [0109] The amount of agent or composition administered may be dependent on a variety of factors, including the sex, age, and weight of the subject being treated, the severity of the affliction, the manner of administration, and the judgment of the prescribing physician. [0110] These and other embodiments of the present disclosure will readily occur to those of ordinary skill in the art in view of the disclosure herein and are specifically contemplated. 5. General Synthetic Methods [0111] The compounds of this disclosure can be prepared from readily available starting materials using, for example, the following general methods, and procedures. It will be appreciated that where certain process conditions (i.e., reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are given, other process conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimization procedures. [0112] Additionally, as will be apparent to those skilled in the art, conventional protecting groups may be necessary to prevent certain functional groups from undergoing undesired reactions. Suitable protecting groups for various functional groups as well as suitable conditions for protecting and deprotecting certain functional groups are well known in the art. For example, numerous protecting
groups are described in T. W. Greene and G. M. Wuts (1999) Protecting Groups in Organic Synthesis, 3rd Edition, Wiley, New York, and references cited therein. [0113] Furthermore, the compounds of this disclosure may contain one or more chiral centers. Accordingly, if desired, such compounds can be prepared or isolated as pure stereoisomers, i.e., as individual enantiomers or diastereomers, or as stereoisomer-enriched mixtures. All such stereoisomers (and enriched mixtures) are included within the scope of this disclosure, unless otherwise indicated. Pure stereoisomers (or enriched mixtures) may be prepared using, for example, optically active starting materials or stereoselective reagents well-known in the art. Alternatively, racemic mixtures of such compounds can be separated using, for example, chiral column chromatography, chiral resolving agents, and the like. [0114] The starting materials for the following reactions are generally known compounds or can be prepared by known procedures or obvious modifications thereof. For example, many of the starting materials are available from commercial suppliers such as Aldrich Chemical Co. (Milwaukee, Wisconsin, USA), Bachem (Torrance CA USA), EMKA-Chemie Gmbh & Co. KG (Eching Germany), or Millipore Sigma (Burlington MA USA). Others may be prepared by procedures, or obvious modifications thereof, described in standard reference texts such as Fieser and Fieser's Reagents for Organic Synthesis, Volumes 1-15 (John Wiley, and Sons, 1991), Rodd's Chemistry of Carbon Compounds, Volumes 1-5, and Supplementals (Elsevier Science Publishers, 1989), Organic Reactions, Volumes 1-40 (John Wiley, and Sons, 1991), March's Advanced Organic Chemistry, (John Wiley, and Sons, 5th Edition, 2001), and Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989). [0115] Scheme I illustrates a general method which can be employed for the synthesis of compounds described herein, where n, R1, R2, R3, R4, R6, R7, R8, and R9 are defined herein, Z is halo (such as Cl, Br, or I), PG is a suitable protecting group (e.g., benzyl), and R52 and R53 are independently C1-6 alkoxy, -O-C2-6 alkenyl, -O-C2-6 alkynyl, -O-C1-6 haloalkyl, -O-C3-10 cycloalkyl, -O-C3-10 cycloalkenyl, -O-heterocyclyl, -O-aryl, or –O-heteroaryl.
[0116] Compounds of Formula I, where R3 is other than hydrogen, can be provided by functionalization of Formula I-1 (e.g., compounds of Formula I where R3 is hydrogen). For example, halogenation of Formula I-1 provides Formula I-2 (e.g., compounds of Formula I where R3 is halo). Further derivatization of Formula I-2, such as with a compound of formula B-C1-6 haloalkyl or M-CN, where B is a suitable functional group such as, but not limited to, a boronic acid or a derivative thereof, such as a boronic ester, zinc or magnesium halide, an organotin compound, and M is a metal, such as zinc or magnesium halide, provides compounds of Formula I where R3 is cyano or C1-6 haloalkyl. [0117] Compounds of Formula I-1 can be provided from Formula I-3. For example, contacting appropriately substituted Formula I-3 with oxalyl chloride in the presence of DMF, followed by 2-tert- butoxycarbonyl-succinic acid 1-tert-butyl ester 4-ethyl ester provides Formula I-4. Formula I-1 is then provided from Formula I-4 using an acid (e.g., p-toluenesulfonic acid) followed by appropriate deprotection and/or functionalization, such as at R1. Alternatively, compounds of Formula I-1 where one or more of R6-R9 are other than hydrogen can be provided from Formula I-3. [0118] Referring to Scheme I, exposing Formula I-5 to a base, for example n-butyl lithium, then with a compound of Formula I-3, produces phosphine oxide I-6. Formula I-6 can then be treated with a compound of Formula I-7, to provide compounds of Formula I-8. In certain embodiments, when control of stereochemistry is desired, proper control of reaction conditions and selection of substituents for the reagents and compounds of Formula I-6 and Formula I-7 can at least partially dictate the formation of E
or Z isomers of Formula I-7, allowing for the stereocontrol of substituents R6, R7, R8, and R9 on subsequent fully-saturated compounds of Formula I-1. Further derivatization of α,β-unsaturated dioxo compounds of Formula I-8, transformations which are known to those of skill in the art, or exposure to standard reducing conditions, provides compounds of Formula I-1. [0119] For any compound shown in Scheme I, it should be understood that various derivatives can be provided by functional group interconversion at any step. For example with R2, various compounds of Formula I can be provided via transesterification or hydrolysis using methods known to one of skill in the art. Likewise, various compounds of Formula I can be prepared by contacting compounds where one or more R4 is a leaving group (e.g., halo, such as Cl, Br, or I, or a pseudohalide, such as a triflate, sulfonate, or phosphate), with a compound of Formula R4-B, wherein B is a suitable functional group such as, but not limited to, a boronic acid or a derivative thereof, such as a boronic ester, zinc or magnesium halide, an organotin compound, such as tributylstannane or trimethylstannane, fluorosulfonyl esters, tin, sodium, hydrogen, and the like. Such reactions are commonly utilized for aromatic functionalization, and are typically conducted in the presence of suitable catalyst such as, but not limited to, a palladium catalyst including [1,1’-bis(diphenylphosphino)ferrocene]palladium(II) dichloride, Pd(OAc)2, Pd(PPh3)4, PdCl2(PPh3)2 or tris(dibenzylideneacetone)dipalladium(0), and the like, or a copper catalyst such as CuCl or CuI, and if required suitable mediator, co-catalyst and/or base known to one skilled in the art using suitable solvents/solvent mixtures. Upon reaction completion, compounds of Formula I can be recovered by conventional techniques such as neutralization, extraction, precipitation, chromatography, filtration and the like. [0120] In some embodiments, the various substituents of Formula I-1, I-2, I-3, I-4, I-5, I-6, I-7, or I-8 (e.g., n, R1, R2, R3, R4, R6, R7, R8, R9, Z, R52, and R53) are as defined herein. However, derivatization of compounds I-1, I-2, I-3, I-4, I-5, I-6, I-7, and I-8 prior to reacting in any step, and/or further derivatization of the resulting reaction product, provides various compounds of Formula I. Appropriate starting materials and reagents can be purchased or prepared by methods known to one of skill in the art. Upon each reaction completion, each of the intermediate or final compounds can be recovered, and optionally purified, by conventional techniques such as neutralization, extraction, precipitation, chromatography, filtration, and the like. Other modifications to arrive at compounds of this disclosure are within the skill of the art. EXAMPLES [0121] This disclosure is further understood by reference to the following examples, which are intended to be purely exemplary of the disclosure. The present disclosure is not limited in scope by the exemplified embodiments, which are intended as illustrations of single aspects of the disclosure only. Any methods that are functionally equivalent are within the scope of the disclosure. Various modifications of the disclosure in addition to those described herein will become apparent to those skilled in the art from the foregoing description. Such modifications fall within the scope of the appended claims.
Example 1 4-(4-Cyano-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid a) (2-Amino-4-bromo-phenyl)-methanol [0122] To an ice cooled solution of LiAlH4 (5.2 g, 0.135 mol) in THF (125 mL), methyl 2- amino-4-bromobenzoate (25 g, 0.108 mol) in THF (125 mL) was added at 00C and stirred at RT for 4h. The reaction mixture was slowly quenched using saturated aqueous solution of sodium thiosulfate and filtered. The obtained filtrate was concentrated to afford the crude product, which was purified by crystallization using ethyl acetate and hexane to yield 15.3 g of the title compound. 1H NMR (CDCl3, 400 MHz): δ = 6.93 (d, J = 8 Hz, 1H), 6.80-6.90 (m, 2H), 4.64 (s, 2H), 4.27 (br s, 2H). b) 2-Amino-4-bromo-benzaldehyde [0123] To a solution of (2-amino-4-bromo-phenyl)-methanol (15 g, 74.2 mmol) in DCM (750 mL), activated manganese (IV) oxide (64 g, 742 mmol) was added portion wise with stirring at room temperature (mechanical stirrer). The resulting reaction mixture was stirred at room temperature for 5 h. On reaction completion the mixture was filtered through a celite pad and the filter cake was washed thoroughly with DCM (1L). The combined filtrates were concentrated in vacuo to give 13 g of crude product. This material was mixed with hexane and stirred for 30 min and filtered to get 11 g of the title compound. 1H NMR (CDCl3, 400 MHz): δ = 9.83 (s, 1H), 7.34 (d, J = 8.4 Hz, 1H), 6.85-6.91 (m, 2H), 6.20 (br s, 2H). c) 3-Amino-7-bromo-quinoline-2-carboxylic acid ethyl ester [0124] A solution of ethyl bromopyruvate (3.4 mL, 26.8 mmol) in ethanol (23 mL) was added dropwise to a mixture of pyridine (2 mL, 25.4 mmol) and ethanol (23 mL) at room temperature for a period of more than 30 minutes and reaction mixture was stirred at rt for 1h to ensure the reaction was complete. The mixture was stirred at 600C for 2h and was cooled to room temperature. To the mixture was added 2-Amino-4-bromo-benzaldehyde (5 g, 25.4 mmol) and pyridine (6 mL). The mixture was refluxed at 850C for 4 hours. Pyrrolidine (5.2 mL, 63.5 mmol) was added and the mixture was refluxed at 850C for 4 hours. The reaction mixture was concentrated and purified by column chromatography using 5% ethyl acetate in DCM as eluent to yield 3.4 g of the title compounds. MS: (+) m/z 295, 297 (M+H, 79/81Br). d) 7-Bromo-3-hydroxy-quinoline-2-carboxylic acid ethyl ester [0125] 3-Amino-7-bromo-quinoline-2-carboxylic acid ethyl ester (3.4 g, 11.5 mmol) was dissolved in anhydrous THF (35 mL) and placed in an ice bath. With vigorous stirring, concentrated H2SO4 (1.4 mL, 34.5 mmol) was slowly added to give a thick suspension. Butyl nitrite (4 mL, 34.5 mmol) was then added dropwise, and the resulting suspension was stirred vigorously in the ice bath for 2 h. The mixture was diluted with 2 mL of cold THF and the solid was isolated by filtration and dried
under high vacuum for several hours. In a separate flask, glacial acetic acid (80 mL) was heated to 115oC. The solid from above was suspended in glacial acetic acid (80 mL) and added to the pre-heated acetic acid, and the resulting homogeneous mixture was then stirred at 115-120oC for 16 h. The reaction was completed. The mixture was allowed to come to room temperature and concentrated to dryness. The residue was re-dissolved in absolute EtOH (35 mL) and placed in ice bath. Thionyl chloride (3.5 mL) was added, and the mixture was warmed to room temperature and refluxed for 16 h, Ethanol was evaporated and residue was dissolved in DCM and washed with water followed by saturated solution of bicarbonate, organic layer was separated, dried over sodium sulfate and filtered, filtrate was concentrated to give crude product. This material was purified by column chromatography using 5% ethyl acetate in hexane as eluent to yield 450 mg of the title compound. MS: (+) m/z 296, 298 (M+H, 79/81Br). e) 3-Benzyloxy-7-bromo-quinoline-2-carboxylic acid ethyl ester [0126] Benzyl bromide (0.91 mL, 1.31 g, 7.5 mmol, 1.5 eq.) was added to a mixture of 7- Bromo-3-hydroxy-quinoline-2-carboxylic acid ethyl ester (1.48 g, 5.0 mmol, 1.0 eq.) and cesium carbonate (1.96 g, 6.0 mmol, 1.2 eq.) in anhydrous DMF (15 mL) at room temperature. After 3 hours at room temperature, TLC shows the completion of the reaction. The reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate (4 x 50 mL). The combined extracts were washed with brine (2 x 100 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 30%) to give the title compound. MS-(+)-ion, M+H = 387.89, 385.99. f) [2-(3-Benzyloxy-7-bromo-quinolin-2-yl)-2-oxo-ethyl]-phosphonic acid dimethyl ester [0127] At -78 °C, to a solution of dimethyl methylphosphonate (1.1 mL, 10.0 mmol, 2.2 eq.) in THF (20 mL) was added n-BuLi (2.5 M in hexanes, 3.7 mL, 9.2 mmol, 2.0 eq) over 10 min under N2 atmosphere. After 30 min, a solution of 3-Benzyloxy-7-bromo-quinoline-2-carboxylic acid ethyl ester (1.17 g, 4.6 mmol) in THF (10 mL) was added slowly over 10 min. After stirring for 2 h at -78 °C, the mixture was treated with half saturated aq. NH4Cl (20 mL) and extracted with ethyl acetate (4 x 15 mL). The combined extracts were dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with EtOAc/Hex (0% - 100%) to give 1.89 g of the title compound. MS-(+)-ion, M+H = 465.80, 463.85. g) 4-(3-Benzyloxy-7-bromo-quinolin-2-yl)-4-oxo-but-2-enoic acid ethyl ester [0128] To a solution of [2-(3-Benzyloxy-7-bromo-quinolin-2-yl)-2-oxo-ethyl]-phosphonic acid dimethyl ester (1.88 g, 4.0 mmol) in THF (20 mL) at -78 °C was added t-BuOK (1 M in THF, 5.2 mmol, 5.2 mL, 1.3 eq). After stirring at -78 °C for 10 min, ethyl glyoxalate (50 wt % in toluene, 1.63 g, 8.0 mmol, 2.0 eq.) was added dropwise over 20 min via a dropping funnel. The mixture was stirred at -78 °C for 3 h, then was treated with half saturated aq. NH4Cl (20 mL) and extracted with ethyl acetate (4 x 15 mL). The combined extracts were dried over sodium sulfate, filtered and evaporated in vacuo to afford
the crude product. This material was purified by flash chromatography eluting with EtOAc/hexane (0% - 20%) to give the title compound, 1.05 g. MS-(+)-ion, M+H = 441.85, 439.90. E/Z = 3/1. h) 4-Hydroxy-4-(3-hydroxy-quinolin-2-yl)-butyric acid ethyl ester [0129] To a solution of 4-(3-Benzyloxy-7-bromo-quinolin-2-yl)-4-oxo-but-2-enoic acid ethyl ester (0.98 g, 2.2 mmol) in ethyl acetate (20 mL) was added Pd/C (200 mg, 0.10eq, 10 wt.%, wet, contains ~51% water). The mixture was vacuumed/refilled with hydrogen gas for three times and attached to a hydrogen gas balloon. After stirring for 70 hr at room temperature, the reaction mixture was filtrated off through celite. The filtrate was evaporated in vacuo to afford the crude product. This material was purified by flash chromatography to give the title compound, 0.61 g, contains impurities. MS-(+)-ion, M+H = 275.96. i) 4-(3-Hydroxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0130] The mixture of 4-Hydroxy-4-(3-hydroxy-quinolin-2-yl)-butyric acid ethyl ester (0.61 g, 2.2 mmol) and manganese dioxide (2.9 g, 33 mmol) in anhydrous toluene (20 mL) was heated at 80 °C under N2 atmosphere for 16 hours. After cooling down to room temperature, the reaction mixture was filtrated off through celite. The filtrate was evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 20%) to give the title compound.48 mg, MS-(-)-ion, M+H = 273.96. j) 4-(4-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0131] To a solution of 4-(3-Hydroxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (48 mg, 0.18 mmol) in acetonitrile (3 mL) was added N-Bromosuccinimide (35 mg, 0.2 mmol). The mixture was stirred at room temperature for 2h. Silica gel was added to the reaction. The mixture was concentrated under vacuo to afford the crude product. This material was purified by column chromatography using 0- 10% ethyl acetate in hexane as eluent gave 45 mg of the title compound. MS-(+)-ion, M+H = 353.88, 351.93. k) 4-(4-Cyano-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0132] A mixture of 4-(4-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (45 mg, 0.13 mmol), zinc cyanide (30 mg, 0.26 mmol), tris(dibenzylideneacetone)dipalladium(0) (11.9 mg, 0.013 mmol), 1,1'-Bis(diphenylphosphino)ferrocene (dppf, 14.4 mg, 0.026 mmol), and zinc dust (2.5 mg, 0.039 mmol) in anhydrous dimethylacetamide (2 mL) was heated at 90 °C under N2 atmosphere for 2 hours. After cooling to room temperature, the reaction mixture was diluted with water (15 mL) and ethyl acetate (15 mL).1 mL of 1 N HCl was added to the mixture and it was allowed to stir for 10 min at room temperature. The organic layer was collected. The aqueous layer was further extracted with ethyl acetate (2 x 15 mL). The combined extracts were washed with brine (30 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography
eluting with ethyl acetate/hexane (0% - 30%) to give the title compound, 23 mg. MS-(+)-ion, M+H = 298.92. l) 4-(4-Cyano-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid [0133] At room temperature, to a solution of 4-(4-Cyano-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (24 mg, 0.08 mmol) in THF/H2O (2 mL/1 mL) was added lithium hydroxide monohydrate (16.4 mg, 0.4 mmol). After 20 hours at room temperature, the reaction was diluted with 15 mL of water and extracted with ethyl acetate (10 mL x 3). The resulting aqueous layer was treated with 1N HCl to pH = 4, followed by extraction with ethyl acetate (10 mL x 3). The combined organic layers were washed with brine and dried over sodium sulfate, filtered and evaporated in vacuo to afford the title compound, 15 mg. MS-(+)-ion, M+H = 270.91. Example 2 4-(4-Cyano-3-hydroxy-7-phenyl-quinolin-2-yl)-4-oxo-butyric acid a) 3-Hydroxy-7-phenyl-quinoline-2-carboxylic acid ethyl ester [0134] A round bottom flask was charged with 7-Bromo-3-hydroxy-quinoline-2-carboxylic acid ethyl ester (930 mg, 3.0 mmol), phenylboronic acid (550 mg, 4.5 mmol, 1.5 eq), S-Phos (98 mg, 0.24 mmol, 0.08 eq), palladium acetate (40.3 mg, 0.18 mmol, 0.06 eq), and tripotassium phosphate (1.27 g, 6.0 mmol, 2.0 eq). The flask was evacuated and backfilled with nitrogen three times. Anhydrous toluene (10 mL) and water (108 mg, 6.0 mmol, 2.0 eq) were added to the reaction. The reaction was heated at 100 °C for 6 hours, until TLC shows the completion of the reaction. After cooling back to room temperature, the reaction was diluted with water (50 mL) and acidified to pH=4 with 1N HCl. The mixture filtrate through celite. The filtrate was extracted with ethyl acetate (3 x 50 mL). The combined extracts were washed with brine (50 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 20%) to give the title compound, 890 mg.MS-(+)-ion, M+H = 294.02. b) 3-Benzyloxy-7-phenyl-quinoline-2-carboxylic acid ethyl ester [0135] Benzyl bromide (0.54 mL, 0.78 g, 4.5 mmol, 1.5 eq.) was added to a mixture of 3- Hydroxy-7-phenyl-quinoline-2-carboxylic acid ethyl ester (0.90 g, 3.0 mmol, 1.0 eq.) and cesium carbonate (1.17 g, 3.6 mmol, 1.2 eq.) in anhydrous DMF (20 mL) at room temperature. After 3 hours at room temperature, TLC shows the completion of the reaction. The reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate (4 x 50 mL). The combined extracts were washed with brine (2 x 100 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 30%) to give the title compound, 1.1 g. MS-(+)-ion, M+H = 384.09.
c) [2-(3-Benzyloxy-7-phenyl-quinolin-2-yl)-2-oxo-ethyl]-phosphonic acid dimethyl ester [0136] At -78 °C, to a solution of dimethyl methylphosphonate (0.67 mL, 6.2 mmol, 2.2 eq.) in THF (20 mL) was added n-BuLi (2.5 M in hexanes, 2.3 mL, 5.6 mmol, 2.0 eq.) over 10 min under N2 atmosphere. After 30 min, a solution of 3-Benzyloxy-7-phenyl-quinoline-2-carboxylic acid ethyl ester (1.1 g, 2.8 mmol) in THF (10 mL) was added slowly over 10 min. After stirring for 2 h at -78 °C, the mixture was treated with half saturated aq. NH4Cl (20 mL) and extracted with ethyl acetate (4 x 15 mL). The combined extracts were dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with EtOAc/Hex (0% - 100%) to give 1.04 g of the title compound. MS-(+)-ion, M+H = 462.10. d) 4-(3-Benzyloxy-7-phenyl-quinolin-2-yl)-4-oxo-but-2-enoic acid ethyl ester [0137] To an ice cooled solution of [2-(3-Benzyloxy-7-phenyl-quinolin-2-yl)-2-oxo-ethyl]- phosphonic acid dimethyl ester (1.04 g, 2.2 mmol) in acetonitrile was added ethyl glyoxalate (3.3 mmol, 50% in toluene) and triethyl amine (263 mg, 2.6 mmol). After 1 hour at 00C, the reaction mixture was quenched using saturated aq solution of ammonium chloride. The mixture was extracted with ethyl acetate (3x30 mL). The combined extracts were washed with brine (20 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 20%) to give the title compound, 0.84 g. MS- (+)-ion, M+H = 438.15. e) 4-(3-Benzyloxy-7-phenyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0138] To a solution of 4-(3-Benzyloxy-7-phenyl-quinolin-2-yl)-4-oxo-but-2-enoic acid ethyl ester (0.8 g, 1.8 mmol) in ethyl acetate (30 mL) was added Pd/C (38 mg, 0.01eq, 10 wt.%, wet, contains ~51% water). The mixture was vacuumed/refilled with hydrogen gas for three times and attached to a hydrogen gas balloon. After stirring for 1 hr at room temperature, the reaction mixture was filtrated off through celite. The filtrate was evaporated in vacuo to afford the crude product. This material was purified by flash chromatography to give the title compound, 0.49 g. MS-(+)-ion, M+H = 440.15. f) 4-(3-Hydroxy-7-phenyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0139] The mixture of 4-(3-Benzyloxy-7-phenyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (0.49 g, 1.1 mmol) and thioanisole (1.4 g, 11 mmol) in trifluoroacetic acid (5 mL) was heated at 80°C for 6 hours. After cooling down to room temperature, the reaction mixture was slowly quenched with sodium bicarbonate aqueous solution to pH = 7~8. The mixture was extracted with ethyl acetate (3x20 mL). The combined extracts were washed with brine (20 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 10%) to give the title compound, 0.30 g. MS-(+)-ion, M+H = 350.04.
g) 4-(4-Bromo-3-hydroxy-7-phenyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0140] To a solution of 4-(3-Hydroxy-7-phenyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (258 mg, 0.74 mmol) in acetonitrile (10 mL) was added N-Bromosuccinimide (145 mg, 0.84 mmol). The mixture was stirred at room temperature for 3h. Silica gel was added to the reaction. The mixture was concentrated under vacuo to afford the crude product. This material was purified by column chromatography using 0-10% ethyl acetate in hexane as eluent to give the title compound, 255 mg. MS- (+)-ion, M+H = 429.87, 427.92. h) 4-(4-Cyano-3-hydroxy-7-phenyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0141] A mixture of 4-(4-Bromo-3-hydroxy-7-phenyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (129 mg, 0.3 mmol), zinc cyanide (70 mg, 0.6 mmol), tris(dibenzylideneacetone)dipalladium(0) (27 mg, 0.03 mmol), 1,1'-Bis(diphenylphosphino)ferrocene (dppf, 33 mg, 0.06 mmol), and zinc dust (6.0 mg, 0.09 mmol) in anhydrous dimethylacetamide (3 mL) was heated at 90 °C under N2 atmosphere for 2 hours. After cooling to room temperature, the reaction mixture was diluted with water (15 mL) and ethyl acetate (15 mL).1 mL of 1 N HCl was added to the mixture and it was allowed to stir for 10 min at room temperature. The organic layer was collected. The aqueous layer was further extracted with ethyl acetate (2 x 15 mL). The combined extracts were washed with brine (30 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 30%) to give the title compound, 37 mg. MS-(+)-ion, M+H = 375.04. i) 4-(4-Cyano-3-hydroxy-7-phenyl-quinolin-2-yl)-4-oxo-butyric acid [0142] At room temperature, to a solution of 4-(4-Cyano-3-hydroxy-7-phenyl-quinolin-2-yl)-4- oxo-butyric acid ethyl ester (60 mg, 0.16 mmol) in THF/H2O (3 mL/1 mL) was added lithium hydroxide monohydrate (33 mg, 0.80 mmol). After 1h at room temperature, the reaction was diluted in 15 mL water and extracted with ethyl acetate (10mL x 3). The resulting aqueous layer was treated with 1N HCl to pH = 4, followed by extraction with ethyl acetate (10mL x 3). The combined organic layers were washed with brine and dried over sodium sulfate, filtered and evaporated in vacuo to afford the title compound. 35 mg. MS-(+)-ion, M+H = 346.93. Example 3 4-(3-Hydroxy-7-phenyl-quinolin-2-yl)-4-oxo-butyric acid a) 4-(3-hydroxy-7-phenyl-quinolin-2-yl)-4-oxo-butyric acid [0143] At room temperature, to a solution of 4-(3-hydroxy-7-phenyl-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (50 mg, 0.14 mmol) in THF/H2O (3 mL/1 mL) was added lithium hydroxide monohydrate (24 mg, 0.57 mmol). After 6h at room temperature, the reaction was diluted in 15 mL water and extracted with ethyl acetate (10mL x 3). The resulting aqueous layer was treated with 1N HCl to pH
= 4, followed by extraction with ethyl acetate (10mL x 3). The combined organic layers were washed with brine and dried over sodium sulfate, filtered and evaporated in vacuo to afford the title compound. 34 mg. MS-(+)-ion, M+H = 321.97. Example 4 4-(4-Cyano-3-hydroxy-5-phenyl-quinolin-2-yl)-4-oxo-butyric acid a) (2-Amino-6-bromo-phenyl)-methanol [0144] To a solution of 2-amino-6-bromo benzoic acid (10 g, 46.2 mmol) in THF (100 mL), LiAlH4 (2.5 g, 69.3 mmol) was added at 0 oC and stirred at RT for 8 h, water (7.7 mL) was added, followed by 15% NaOH (7.7 mL) and water (23 mL). The slurry was stirred at room temperature for 1h. The salts were filtered off and washed with THF. The combined filtrates were concentrated under vacuo to get crude which was purified by column chromatography using 0-40% ethyl acetate in hexane as eluent to give 5.5 g of the title compound.1H NMR (400 MHz, CDCl3): δ = 6.9-7.0 (m, 2H), 6.6-6.7 (m, 1H), 4.9 (s, 2H), 3.0 (br s). b) 2-Amino-6-bromo-benzaldehyde [0145] To a solution of (2-Amino-6-bromo-phenyl)-methanol (5.5 g, 29.46 mmol) in DCM (50 mL) at room temperature was added MnO2 (25.61 g, 294.66 mmol) in portions. Reaction mixture was stirred at room temperature for 4 h. Reaction mixture was filtered through a pad of celite and washed with DCM, filtrate was concentrated under vacuo to get crude; The obtained crude was purified by column chromatography (0-30% EtOAc/hexane) to yield 4 g of the title compound. MS: (+) m/z 200, 202 (M+1). c) 3-Amino-5-bromo-quinoline-2-carboxylic acid ethyl ester [0146] A solution of ethyl bromopyruvate (1.32 mL, 10.49 mmol) in ethanol (10 mL) was added dropwise to a mixture of pyridine (0.8 mL, 9.99 mmol) and ethanol (10 mL) at room temperature for a period of more than 30 minutes and reaction mixture was stirred at rt for 1h to ensure the reaction was complete. The mixture was stirred at 60 oC for 2h and was cooled to room temperature. To the mixture was added 2-Amino-6-bromo-benzaldehyde (2 g, 9.99 mmol) and pyridine (5 mL). The mixture was refluxed for 4 hours. Pyrrolidine (2 mL, 24.97 mmol) was added and the mixture was refluxed for 4 hours. The reaction mixture was concentrated under vacuo to remove ethanol, crude was diluted with ethyl acetate and washed with excess water. The organic layer was separated, dried over sodium sulfate and concentrated to get crude. The obtained crude was purified by column chromatography using 0-5% ethyl acetate in DCM as eluent followed by trituration from pentane to give 1.2 g of the title compound. MS: (+) m/z 295, 297 (M+1).
d) 5-Bromo-3-hydroxy-quinoline-2-carboxylic acid ethyl ester [0147] 3-Amino-5-bromo-quinoline-2-carboxylic acid ethyl ester (1.2 g, 4.06 mmol) was dissolved in anhydrous THF (12 mL) and placed in an ice bath. With vigorous stirring, concentrated H2SO4 (0.64 mL, 12.19 mmol) was slowly added to give a thick suspension. Butyl nitrite (1.42 mL, 12.19 mmol) was then added dropwise, and the resulting suspension was stirred vigorously in the ice bath for 2 h. The mixture was diluted with 10 mL of cold THF and the solid was isolated by filtration and dried under high vacuum for several hours. In a separate flask, glacial acetic acid (8 mL) was heated to 115oC. The solid from above was suspended in glacial acetic acid (7 mL) and added to the pre-heated acetic acid, and the resulting homogeneous mixture was then stirred at 115-120 oC for 16 h. The reaction mixture was allowed to come to room temperature and concentrated to dryness. The residue was re- dissolved in absolute EtOH (58 mL) and placed in ice bath. Thionyl chloride (1.66 mL) was added, and the mixture was warmed to room temperature and refluxed for 16h. The mixture was concentrated under vacuo. The crude was diluted with water and neutralized with sat. NaHCO3 solution and extracted with DCM. The organic layer was separated, dried over sodium sulfate and concentrated to get crude. The obtained crude was purified by column chromatography using 0-2% ethyl acetate in hexane as eluent followed by trituration from pentane to yield 560 mg of title compound. MS: (+) m/z 296, 298 (M+1). e) 3-Hydroxy-5-phenyl-quinoline-2-carboxylic acid ethyl ester [0148] A round bottom flask was charged with 5-Bromo-3-hydroxy-quinoline-2-carboxylic acid ethyl ester (1.55 g, 5.0 mmol), phenylboronic acid (915 mg, 7.5 mmol, 1.5 eq), S-Phos (164 mg, 0.4 mmol, 0.08 eq), palladium acetate (67 mg, 0.3 mmol, 0.06 eq), and tripotassium phosphate (2.12 g, 10 mmol, 2.0 eq). The flask was evacuated and backfilled with nitrogen three times. Anhydrous toluene (20 mL) and water (180 mg, 10 mmol, 2.0 eq) were added to the reaction. The reaction was heated at 100 °C for 6 hours, until TLC shows the completion of the reaction. After cooling back to room temperature, the reaction was diluted with water (50 mL) and acidified to pH = 4 with 1N HCl. The mixture was filtrate through celite. The filtrate was extracted with ethyl acetate (3 x 50 mL). The combined extracts were washed with brine (50 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 20%) to give the title compound, 690 mg. MS-(+)-ion, M+H = 293.97. f) 3-Benzyloxy-5-phenyl-quinoline-2-carboxylic acid ethyl ester [0149] Benzyl bromide (0.45 mL, 0.64 g, 3.7 mmol) was added to a mixture of 3-Hydroxy-5- phenyl-quinoline-2-carboxylic acid ethyl ester (0.68 g, 2.3 mmol) and cesium carbonate (0.98 g, 3.0 mmol) in anhydrous DMF (15 mL) at room temperature. After 3 hours at room temperature, TLC shows the completion of the reaction. The reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate (4 x 50 mL). The combined extracts were washed with brine (2 x 100 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified
by flash chromatography eluting with ethyl acetate/hexane (0% - 30%) to give the title compound, 0.64 g. MS-(+)-ion, M+H = 384.09. g) [2-(3-Benzyloxy-5-phenyl-quinolin-2-yl)-2-oxo-ethyl]-phosphonic acid dimethyl ester [0150] At -78 °C, to a solution of dimethyl methylphosphonate (0.38 mL, 3.5 mmol, 2.2 eq.) in THF (10 mL) was added n-BuLi (2.5 M in hexanes, 1.3 mL, 3.2 mmol, 2.0 eq) over 10 min under N2 atmosphere. After 30 min, a solution of 3-Benzyloxy-5-phenyl-quinoline-2-carboxylic acid ethyl ester (0.64 g, 1.6 mmol) in THF (10 mL) was added slowly over 10 min. After stirring for 2 h at -78 °C, the mixture was treated with half saturated aq. NH4Cl (20 mL) and extracted with ethyl acetate (4 x 15 mL). The combined extracts were dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with EtOAc/Hex (0% - 100%) to give 0.66 g of the title compound. MS-(+)-ion, M+H = 462.05. h) 4-(3-Benzyloxy-5-phenyl-quinolin-2-yl)-4-oxo-but-2-enoic acid ethyl ester [0151] To an ice cooled solution of [2-(3-Benzyloxy-5-phenyl-quinolin-2-yl)-2-oxo-ethyl]- phosphonic acid dimethyl ester (0.65 g, 1.4 mmol) in acetonitrile (15 mL) was added ethyl glyoxalate (2.1 mmol, 50% in toluene) and triethyl amine (171 mg, 1.7 mmol). After 1 hour at 00C, the reaction mixture was quenched using saturated aq solution of ammonium chloride. The mixture was extracted with ethyl acetate (3x30 mL). The combined extracts were washed with brine (20 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 20%) to give the title compound, 0.49 g. MS- (+)-ion, M+H = 438.10. i) 4-(3-Benzyloxy-5-phenyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0152] To a solution of 4-(3-Benzyloxy-5-phenyl-quinolin-2-yl)-4-oxo-but-2-enoic acid ethyl ester (0.49 g, 1.1 mmol) in ethyl acetate (20 mL) was added Pd/C (23 mg, 0.01eq, 10 wt.%, wet, contains ~51% water). The mixture was vacuumed/refilled with hydrogen gas for three times and attached to a hydrogen gas balloon. After stirring for 1 hr at room temperature, the reaction mixture was filtrated off through celite. The filtrate was evaporated in vacuo to afford the crude product. This material was purified by flash chromatography to give the title compound, 0.34 g. MS-(+)-ion, M+H = 440.05. j) 4-(3-Hydroxy-5-phenyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0153] The mixture of 4-(3-Benzyloxy-5-phenyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (0.34 g, 0.77 mmol) and thioanisole (0.96 g,7.7 mmol) in trifluoroacetic acid (5 mL) was heated at 80°C for 6 hours. After cooling down to room temperature, the reaction mixture was slowly quenched with sodium bicarbonate aqueous solution to pH = 7~8. The mixture was extracted with ethyl acetate (3x20 mL). The combined extracts were washed with brine (20 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography
eluting with ethyl acetate/hexane (0% - 10%) to give the title compound, 0.27 g. MS-(+)-ion, M+H = 350.04. k) 4-(4-Bromo-3-hydroxy-5-phenyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0154] To a solution of 4-(3-Hydroxy-5-phenyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (270 mg, 0.77 mmol) in acetonitrile (10 mL) was added N-Bromosuccinimide (151 mg, 0.85 mmol). The mixture was stirred at room temperature for 3h. Silica gel was added to the reaction. The mixture was concentrated under vacuo to get crude; purified by column chromatography using 0-10% ethyl acetate in hexane as eluent gave the title compound, 172 mg. MS-(+)-ion, M+H = 429.85, 427.95. l) 4-(4-Cyano-3-hydroxy-5-phenyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0155] A mixture of 4-(4-Bromo-3-hydroxy-5-phenyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (86 mg, 0.2 mmol), zinc cyanide (47 mg, 0.4 mmol), tris(dibenzylideneacetone)dipalladium(0) (18 mg, 0.02 mmol), 1,1'-Bis(diphenylphosphino)ferrocene (dppf, 22 mg, 0.04 mmol), and zinc dust (3.9 mg, 0.06 mmol) in anhydrous dimethylacetamide (3 mL) was heated at 90 °C under N2 atmosphere for 2 hours. After cooling to room temperature, the reaction mixture was diluted with water (15 mL) and ethyl acetate (15 mL).1 mL of 1 N HCl was added to the mixture and it was allowed to stir for 10 min at room temperature. The organic layer was collected. The aqueous layer was further extracted with ethyl acetate (2 x 15 mL). The combined extracts were washed with brine (30 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 30%) to give the title compound, 37 mg. MS-(+)-ion, M+H = 375.05. m) 4-(4-Cyano-3-hydroxy-5-phenyl-quinolin-2-yl)-4-oxo-butyric acid [0156] At room temperature, to a solution of 4-(4-Cyano-3-hydroxy-5-phenyl-quinolin-2-yl)-4- oxo-butyric acid ethyl ester (32 mg, 0.09 mmol) in THF/H2O (3 mL/1 mL) was added lithium hydroxide monohydrate (15 mg, 0.36 mmol). After 1h at room temperature, the reaction was diluted in 15 mL water and extracted with ethyl acetate (10mL x 3). The resulting aqueous layer was treated with 1N HCl to pH = 4, followed by extraction with ethyl acetate (10mL x 3). The combined organic layers were washed with brine and dried over sodium sulfate, filtered and evaporated in vacuo to afford the title compound. 25 mg. MS-(+)-ion, M+H = 346.98. Example 5 4-(3-Hydroxy-5-phenyl-4-trifluoromethyl-quinolin-2-yl)-4-oxo-butyric acid a) 4-(3-Benzyloxy-4-bromo-5-phenyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0157] Benzyl bromide (0.036 mL, 52 mg, 0.3 mmol) was added to a mixture of 4-(4-Bromo-3- hydroxy-5-phenyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (86 mg, 0.2 mmol) and cesium carbonate (78 mg, 0.24 mmol) in anhydrous DMF (3 mL) at room temperature. After 3 hours at room temperature,
TLC shows the completion of the reaction. The reaction mixture was diluted with water (15 mL) and extracted with ethyl acetate (4 x 20 mL). The combined extracts were washed with brine (2 x 20 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 30%) to give the title compound, 93 mg. MS-(+)-ion, M+H = 384.09. b) 4-(3-Benzyloxy-5-phenyl-4-trifluoromethyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0158] The mixture of 4-(3-Benzyloxy-4-bromo-5-phenyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (92 mg, 0.18 mmol), methyl 2,2-difluoro-2-(fluorosulfonyl)acetate (207 mg, 1.08 mmol), and copper(I) iodide (103 mg, 0.54 mmol), in anhydrous 1-methyl-2-pyrrolidone (3 mL) was heated at 100 °C under N2 atmosphere for 3 hours. After cooling down to room temperature, the reaction mixture was diluted with water (30 mL), quenched with 5 mL 1 N HCl and extracted with ethyl acetate (3 x 30 mL). The combined extracts were washed with brine (50 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 20%) to give the title compound.61 mg, MS-(+)-ion, M+Na = 508.11. c) 4-(3-Hydroxy-5-phenyl-4-trifluoromethyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0159] The mixture of 4-(3-Benzyloxy-5-phenyl-4-trifluoromethyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (60 mg, 0.12 mmol) and thioanisole (75 mg, 0.6 mmol) in trifluoroacetic acid (2 mL) was stirred at room temperature for 18 hours. The reaction mixture was slowly quenched with sodium bicarbonate aqueous solution to pH = 7~8. The mixture was extracted with ethyl acetate (3x20 mL). The combined extracts were washed with brine (20 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 10%) to give the title compound, 31 mg. MS-(+)-ion, M+H = 417.94. d) 4-(3-Hydroxy-5-phenyl-4-trifluoromethyl-quinolin-2-yl)-4-oxo-butyric acid [0160] At room temperature, to a solution of 4-(3-Hydroxy-5-phenyl-4-trifluoromethyl- quinolin-2-yl)-4-oxo-butyric acid ethyl ester (30 mg, 0.07 mmol) in THF/H2O (3 mL/1 mL) was added lithium hydroxide monohydrate (15 mg, 0.36 mmol). After 4h at room temperature, the reaction was diluted in 15 mL water and extracted with ethyl acetate (10mL x 3). The resulting aqueous layer was treated with 1N HCl to pH = 4, followed by extraction with ethyl acetate (10mL x 3). The combined organic layers were washed with brine and dried over sodium sulfate, filtered and evaporated in vacuo to afford the title compound.21 mg. MS-(+)-ion, M+H = 389.99.
Example 6 4-(5-Cyano-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid a) 2-tert-Butoxycarbonyl-succinic acid 1-tert-butyl ester 4-ethyl ester [0161] A solution of di-tert-butyl malonate (9.66 g, 44.7 mmol) in anhydrous tetrahydrofuran (15 mL) was added to a suspension of sodium hydride (1.8 g, 45 mmol, 60% dispersion) in anhydrous tetrahydrofuran (50 mL) at room temperature. After stirring for 2 hours at room temperature, the suspension mixture was further heated at 60°C for 16 hours. After cooling back to room temperature, a solution of ethyl bromoacetate (5.97 g, 35.7 mmol) in anhydrous tetrahydrofuran (25 mL) was added, and the mixture was stirred for 4 h. Then the mixture was poured into saturated aqueous ammonium chloride (50 mL) and extracted with ethyl acetate (50 mL x 2). The combined extract was washed with brine (50 mL), dried over sodium sulfate, and concentrated to give crude product. The obtained crude was purified by column chromatography using 5% ethyl acetate in hexane as eluent to yield 7.1 g of the title compound. 1H NMR (CDCl3, 200 MHz): δ = 1.25 (3H, t, J = 6.4 Hz), 1.46 (18H, s), 2.81 (2H, d, J = 7.4 Hz), 3.65 (1H, t, J = 7.4 Hz), 4.13 (2H, q, J = 6.4 Hz). b) 3-Benzyloxy-5-bromo-quinoline-2-carboxylic acid ethyl ester [0162] Benzyl bromide (0.91 mL, 1.31 g, 7.5 mmol) was added to a mixture of 5-Bromo-3- hydroxy-quinoline-2-carboxylic acid ethyl ester (1.48 g, 5.0 mmol) and cesium carbonate (1.96 g, 6.0 mmol) in anhydrous DMF (20 mL) at room temperature. After 3 hours at room temperature, TLC shows the completion of the reaction. The reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate (4 x 30 mL). The combined extracts were washed with brine (2 x 30 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 30%) to give the title compound, 1.86 g. MS- (+)-ion, M+H = 387.89, 385.94. c) 4-(3-Benzyloxy-5-bromo-quinolin-2-yl)-4-oxo-butyric acid [0163] At room temperature, to a solution of 4-(3-Benzyloxy-5-bromo-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (1.86 g, 4.8 mmol) in THF/H2O (15 mL/5 mL) was added lithium hydroxide monohydrate (0.59 g, 14.6 mmol). After 4h at room temperature, most of the organic solvent was evaporated off.100 mL of water was the reaction mixture, followed by treatment with 1N HCl to pH = 3. The precipitation was filtrated off and dried under vacuum for overnight to afford the title compound. 1.68 g. MS-(+)-ion, M+H = 359.78, 357.88. d) 3-Benzyloxy-5-bromo-quinoline-2-carbonyl chloride [0164] At 0 °C, to the solution of 3-Benzyloxy-5-bromo-quinoline-2-carboxylic acid (1.68 g, 4.7 mmol, 1.0 eq) in anhydrous THF (15 mL) was added oxalyl chloride (0.82 mL, 9.4 mmol, 2.0 eq), followed by 2 drops of DMF. The reaction was stirred at 0 °C for 1 hour, and then at room temperature
for 1 hour. The solvent was evaporated in vacuo and further dried under high vacuum for 1 hour. The residue was used directly in the next step. e) 4-(3-Benzyloxy-5-bromo-quinolin-2-yl)-3,3-bis-tert-butoxycarbonyl-4-oxo-butyric acid ethyl ester [0165] A solution of 2-tert-Butoxycarbonyl-succinic acid 1-tert-butyl ester 4-ethyl ester (2.13 g, 7.05 mmol) in anhydrous tetrahydrofuran (15 mL) was added to a suspension of sodium hydride (0.28 g, 7.05 mmol, 60% dispersion) in anhydrous tetrahydrofuran (30 mL) at room temperature. The mixture was then stirred at 40oC for 16 h. After cooling down to room temperature, a solution of 3-Benzyloxy-5- bromo-quinoline-2-carbonyl chloride (4.7 mmol) in anhydrous tetrahydrofuran (20 mL) was added, and the mixture was stirred at room temperature for 2 h. Then the mixture was treated with aqueous ammonium chloride (100 mL) and extracted with ethyl acetate (100 mL X 3). The combined extract was washed with brine (100 mL), dried over sodium sulfate, and concentrated to a crude residue. The obtained crude was purified by column chromatography using 0-15% ethyl acetate in hexane as eluent to yield 3.01 g of the title compound. MS-(+)-ion, M+H = 643.88, 641.98. f) 4-(3-Benzyloxy-5-bromo-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0166] p-Toluenesulfonic acid monohydrate (0.09 g, 0.47 mmol) was added to a solution of 4- (3-Benzyloxy-5-bromo-quinolin-2-yl)-3,3-bis-tert-butoxycarbonyl-4-oxo-butyric acid ethyl ester (3.0 g, 4.7 mmol) in toluene (18 mL), and the mixture was refluxed for 2 h. After cooling to room temperature, the mixture was treated with saturated aqueous sodium bicarbonate (30 mL) and extracted with ethyl acetate (30 mL X 3). The combined extract was dried over sodium sulfate, and concentrated to a crude residue. The obtained crude was purified by column chromatography using 0-15% ethyl acetate in hexane as eluent to yield 0.83 g of the title compound. MS-(+)-ion, M+H = 441.90, 443.85. g) 4-(5-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0167] The mixture of 4-(3-Benzyloxy-5-bromo-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (360 mg, 1.1 mmol) and thioanisole (682 mg, 5.5 mmol) in trifluoroacetic acid (4 mL) was heated at 80°C for 6 hours. After cooling down to room temperature, the reaction mixture was slowly quenched with sodium bicarbonate aqueous solution to pH = 7~8. The mixture was extracted with ethyl acetate (3x20 mL). The combined extracts were washed with brine (20 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 10%) to give the title compound, 245 mg. MS-(+)-ion, M+H = 353.68, 351.88. h) 4-(5-Cyano-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0168] A mixture of 4-(5-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (237 mg, 0.67 mmol), zinc cyanide (117 mg, 1.0 mmol), tris(dibenzylideneacetone)dipalladium(0) (61 mg,
0.067 mmol), 1,1'-Bis(diphenylphosphino)ferrocene (dppf, 74 mg, 0.134 mmol), and zinc dust (13 mg, 0.2 mmol) in anhydrous dimethylacetamide (5 mL) was heated at 90 °C under N2 atmosphere for 2 hours. After cooling to room temperature, the reaction mixture was diluted with water (15 mL) and ethyl acetate (15 mL).1 mL of 1 N HCl was added to the mixture and it was allowed to stir for 10 min at room temperature. The organic layer was collected. The aqueous layer was further extracted with ethyl acetate (2 x 15 mL). The combined extracts were washed with brine (30 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 30%) to give the title compound, 136 mg. MS-(+)-ion, M+H = 298.97. i) 4-(5-Cyano-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid [0169] At room temperature, to a solution of 4-(5-Cyano-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (9 mg, 0.03 mmol) in THF/H2O (1 mL/0.5 mL) was added lithium hydroxide monohydrate (6 mg, 0.15 mmol). After 3h at room temperature, the reaction was diluted in 15 mL water and extracted with ethyl acetate (10mL x 3). The resulting aqueous layer was treated with 1N HCl to pH = 4, followed by extraction with ethyl acetate (10mL x 3). The combined organic layers were washed with brine and dried over sodium sulfate, filtered and evaporated in vacuo to afford the title compound. 3.0 mg. MS-(+)-ion, M+H = 270.91. Example 7 4-(4-Cyano-3-hydroxy-6-phenyl-quinolin-2-yl)-4-oxo-butyric acid a) (2-Amino-5-bromo-phenyl)-methanol [0170] To a solution of 2-amino-5-bromo benzoic acid (10 g, 46.2 mmol) in THF (100 ml), LiAlH4 (2.5 g, 69.3 mmol) was added at 0oC and stirred at RT for 8h, The reaction was quenched using saturated solution of sodium sulfate and filtered through celite bed to yield 6 g of title compound. MS: (+) m/z 202, 204 (M+1). b) 2-Amino-5-bromo-benzaldehyde [0171] To a solution of (2-Amino-5-bromo-phenyl)-methanol (6 g, 29.7 mmol) in DCM (400 mL) at room temperature was added MnO2 (25.5 g, 297 mmol) in portions. Reaction mixture was stirred at room temperature for 4 h. Reaction mixture was filtered through a pad of celite and washed with DCM, filtrate was concentrated under vacuo to yield the crude product. The obtained crude was purified by column chromatography using 10 to 15% ethyl acetate in hexane as eluent to yield 3.8 g of the title compound. MS: (+) m/z 200, 202 (M+1). c) 3-Amino-6-bromo-quinoline-2-carboxylic acid ethyl ester [0172] A solution of ethyl bromopyruvate (2.5 mL, 20.9 mmol) in ethanol (20 mL) was added dropwise to a mixture of pyridine (1.5mL, 19 mmol) and ethanol (20 mL) at room temperature for a
period of more than 30 minutes and reaction mixture was stirred at rt for 1h to ensure the reaction was complete. The mixture was stirred at 60 oC for 2h and was cooled to room temperature. To the mixture was added 2-amino-5-bromo-benzaldehyde (3.8g, 19 mmol) and pyridine (10 mL). The mixture was refluxed at 85oC for 4 hours. Pyrrolidine (3.9 mL, 47.5 mmol) was added and the mixture was refluxed at 85 oC for 4 hours. The reaction mixture was concentrated on rotavapor, water was added to the reaction mixture and extracted with ethyl acetate. The organic layer was separated, dried over sodium sulfate and concentrated to get crude. The obtained crude was purified by column chromatography using 0-5% ethyl acetate in DCM as eluent gave 3 g of the title compound. MS: (+) m/z 295, 297 (M+1). d) 6-Bromo-3-hydroxy-quinoline-2-carboxylic acid ethyl ester [0173] 3-Amino-7-bromo-quinoline-2-carboxylic acid ethyl ester (3 g, 10.2 mmol) was dissolved in anhydrous THF (30 mL) and placed in an ice bath. With vigorous stirring, concentrated H2SO4 (1.6 mL, 30 mmol) was slowly added to give a thick suspension. Butyl nitrite (3.5 mL, 30 mmol) was then added dropwise, and the resulting suspension was stirred vigorously in the ice bath for 2 h. The mixture was diluted with 10 mL of cold THF and the solid was isolated by filtration and dried under high vacuum for several hours. In a separate flask, glacial acetic acid (20 mL) was heated to 115oC. The reaction mixture was allowed to come to room temperature and concentrated to dryness. The residue was re-dissolved in absolute EtOH (30 mL) and placed in ice bath. Thionyl chloride (3.7 mL) was added, and the mixture was warmed to room temperature and refluxed for 16h. The reaction mixture was concentrated on rotavapor. Ethyl acetate was added to the reaction mixture and extracted with water and aq. sodium bicarbonate solution. The organic layer was separated, dried over sodium sulfate and concentrated to get crude. The obtained crude was purified by column chromatography using 5% ethyl acetate in DCM as eluent to yield 1.5 g of the target compound. MS: (+) m/z 296, 298 (M+1). e) 3-Benzyloxy-6-bromo-quinoline-2-carboxylic acid ethyl ester [0174] Benzyl bromide (0.91 mL, 1.31 g, 7.5 mmol) was added to a mixture of 6-Bromo-3- hydroxy-quinoline-2-carboxylic acid ethyl ester (1.48 g, 5.0 mmol) and cesium carbonate (1.96 g, 6.0 mmol) in anhydrous DMF (20 mL) at room temperature. After 3 hours at room temperature, TLC shows the completion of the reaction. The reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate (4 x 30 mL). The combined extracts were washed with brine (2 x 30 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 30%) to give the title compound, 1.74 g. MS- (+)-ion, M+H = 385.94, 387.89. f) 3-Benzyloxy-6-bromo-quinoline-2-carboxylic acid [0175] At room temperature, to a solution of 3-Benzyloxy-6-bromo-quinoline-2-carboxylic acid ethyl ester (1.74 g, 0.45 mmol) in THF/H2O (25 mL/15 mL) was added lithium hydroxide monohydrate (0.55 g, 13.5 mmol). After 4 hours at room temperature, most of the THF was evaporated in vacuo. The
residue diluted in 150 mL water and treated with 1N HCl to pH = 3. After filtration and drying in vacuo for overnight, 1.52 g of the title compound was obtained. MS-(+)-ion, M+H = 357.83, 359.83. g) 3-Benzyloxy-6-bromo-quinoline-2-carbonyl chloride [0176] At 0 °C, to the solution of 3-Benzyloxy-6-bromo-quinoline-2-carboxylic acid (1.52 g, 4.3 mmol, 1.0 eq) in anhydrous THF (15 mL) was added oxalyl chloride (0.80 mL, 8.6 mmol, 2.0 eq), followed by 2 drops of DMF. The reaction was stirred at 0 °C for 1 hour, and then at room temperature for 1 hour. The solvent was evaporated in vacuo and further dried under high vacuum for 1 hour. The residue was used directly in the next step. h) 4-(3-Benzyloxy-6-bromo-quinolin-2-yl)-3,3-bis-tert-butoxycarbonyl-4-oxo-butyric acid ethyl ester [0177] A solution of 2-tert-Butoxycarbonyl-succinic acid 1-tert-butyl ester 4-ethyl ester (1.96 g, 6.5 mmol) in anhydrous tetrahydrofuran (15 mL) was added to a suspension of sodium hydride (0.26 g, 6.5 mmol, 60% dispersion) in anhydrous tetrahydrofuran (30 mL) at room temperature. The mixture was then stirred at 40oC for 16 h. After cooling down to room temperature, a solution of 3-Benzyloxy-6- bromo-quinoline-2-carbonyl chloride (4.3 mmol) in anhydrous tetrahydrofuran (20 mL) was added, and the mixture was stirred at room temperature for 2 h. Then the mixture was treated with aqueous ammonium chloride (100 mL) and extracted with ethyl acetate (100 mL X 3). The combined extract was washed with brine (100 mL), dried over sodium sulfate, and concentrated to a crude residue. The obtained crude was purified by column chromatography using 0-15% ethyl acetate in hexane as eluent to yield 2.41 g of the title compound. MS-(+)-ion, M+H = 643.98. i) 4-(3-Benzyloxy-6-bromo-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0178] p-Toluenesulfonic acid monohydrate (0.14 g, 0.74 mmol) was added to a solution of 4- (3-Benzyloxy-6-bromo-quinolin-2-yl)-3,3-bis-tert-butoxycarbonyl-4-oxo-butyric acid ethyl ester (2.4 g, 3.7 mmol) in toluene (18 mL), and the mixture was refluxed for 2 h. After cooling to room temperature, the mixture was treated with saturated aqueous sodium bicarbonate (30 mL) and extracted with ethyl acetate (30 mL X 3). The combined extract was dried over sodium sulfate, and concentrated to a crude residue. The obtained crude was purified by column chromatography using 0-10% ethyl acetate in hexane as eluent to yield 0.31 g of the title compound. MS-(+)-ion, M+H = 441.90, 443.85. j) 4-(6-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0179] The mixture of 4-(3-Benzyloxy-6-bromo-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (300 mg, 0.67 mmol) and thioanisole (246 mg, 2.0 mmol) in trifluoroacetic acid (4 mL) was heated at 80°C for 6 hours. After cooling down to room temperature, the reaction mixture was slowly quenched with sodium bicarbonate aqueous solution to pH = 7~8. The mixture was extracted with ethyl acetate (3x20 mL). The combined extracts were washed with brine (20 mL), dried over sodium sulfate, filtered
and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 10%) to give the title compound, 118 mg. MS-(+)-ion, M+H = 353.88, 351.88. k) 4-(3-Hydroxy-6-phenyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0180] A round bottom flask was charged with 4-(6-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (105 mg, 0.3 mmol), phenylboronic acid (55 mg, 0.45 mmol, 1.5 eq), S-Phos (9.9 mg, 0.024 mmol, 0.08 eq), palladium acetate (4.0 mg, 0.018 mmol, 0.06 eq), and tripotassium phosphate (127 mg, 0.6 mmol, 2.0 eq). The flask was evacuated and backfilled with nitrogen three times. Anhydrous toluene (3 mL) and water (10.8 mg, 0.6 mmol, 2.0 eq) were added to the reaction. The reaction was heated at 100 °C for 6 hours, until TLC shows the completion of the reaction. After cooling back to room temperature, the reaction was diluted with water (50 mL) and acidified to pH = 4 with 1N HCl. The mixture filtrate through celite. The filtrate was extracted with ethyl acetate (3 x 20 mL). The combined extracts were washed with brine (20 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 20%) to give the title compound, 99 mg. MS-(+)-ion, M+H = 350.03. l) 4-(4-Bromo-3-hydroxy-6-phenyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0181] To a solution of 4-(3-Hydroxy-6-phenyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (99 mg, 0.28 mmol) in acetonitrile (5 mL) was added N-Bromosuccinimide (55 mg, 0.31 mmol). The mixture was stirred at room temperature for 3h. Silica gel was added to the reaction. The mixture was concentrated under vacuo to yield crude product; purified by column chromatography using 0-10% ethyl acetate in hexane as eluent gave 94 mg of the title compound. MS-(+)-ion, M+H = 429.85, 427.95. m) 4-(4-Cyano-3-hydroxy-6-phenyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0182] A mixture of 4-(4-Bromo-3-hydroxy-6-phenyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (86 mg, 0.2 mmol), zinc cyanide (47 mg, 0.4 mmol), tris(dibenzylideneacetone)dipalladium(0) (18 mg, 0.02 mmol), 1,1'-Bis(diphenylphosphino)ferrocene (dppf, 22 mg, 0.04 mmol), and zinc dust (3.9 mg, 0.06 mmol) in anhydrous dimethylacetamide (3 mL) was heated at 90 °C under N2 atmosphere for 2 hours. After cooling to room temperature, the reaction mixture was diluted with water (15 mL) and ethyl acetate (15 mL).1 mL of 1 N HCl was added to the mixture and it was allowed to stir for 10 min at room temperature. The organic layer was collected. The aqueous layer was further extracted with ethyl acetate (2 x 15 mL). The combined extracts were washed with brine (30 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 30%) to give the title compound, 51 mg. MS-(+)-ion, M+H = 375.04.
n) 4-(4-Cyano-3-hydroxy-6-phenyl-quinolin-2-yl)-4-oxo-butyric acid [0183] At room temperature, to a solution of 4-(4-Cyano-3-hydroxy-6-phenyl-quinolin-2-yl)-4- oxo-butyric acid ethyl ester (48 mg, 0.13 mmol) in methanol(2 mL) was added sodium hydroxide aqueous solution (1.0 M in water, 0.39 mL, 0.39 mmol). After 2h at room temperature, the reaction was diluted in 15 mL water and extracted with ethyl acetate (10mL x 3). The resulting aqueous layer was treated with 1N HCl to pH = 4, followed by extraction with ethyl acetate (10mL x 3). The combined organic layers were washed with brine and dried over sodium sulfate, filtered and evaporated in vacuo to afford the title compound.17 mg. MS-(+)-ion, M+H = 346.98. Example 8 4-(6-Benzyl-4-cyano-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid a) 4-(6-Benzyl-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0184] At 0°C, to a solution of 4-(6-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (110 mg, 0.32 mmol), Pd(OAc)2 (7.2 mg, 0.032 mmol) and S-Phos (26 mg, 0.064 mmol) in dry THF (3 mL) was added dropwise a solution of benzylzinc(II) bromide in THF (0.8 mmol, 1.6 mL, 0.5 M) under nitrogen atmosphere. The reaction mixture was stirred at room temperature for 1 hour, then quenched by half saturated NH4Cl aqueous solution (20 mL) and extracted with ethyl acetate (20 mL X 3). The combined organic layers were dried (Na2SO4), concentrated under reduced pressure, and purified by flash column chromatography to give the 4-(6-Benzyl-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester, 79 mg. MS-(+)-ion, M+H = 364.03. b) 4-(6-Benzyl-4-bromo-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0185] To a solution of 4-(6-Benzyl-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (76 mg, 0.21 mmol) in acetonitrile (5 mL) was added N-Bromosuccinimide (61 mg, 0.34 mmol). The mixture was stirred at room temperature for 3h. Silica gel was added to the reaction. The mixture was concentrated under vacuo yield crude product, which was purified by column chromatography using 0- 10% ethyl acetate in hexane as eluent gave 74 mg of the title compound. MS-(+)-ion, M+H = 443.80, 441.85. c) 4-(6-Benzyl-4-cyano-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0186] A mixture of 4-(6-Benzyl-4-bromo-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (74 mg, 0.17 mmol), zinc cyanide (40 mg, 0.34 mmol), tris(dibenzylideneacetone)dipalladium(0) (15 mg, 0.017 mmol), 1,1'-Bis(diphenylphosphino)ferrocene (dppf, 19 mg, 0.034 mmol), and zinc dust (3.3 mg, 0.05 mmol) in anhydrous dimethylacetamide (3 mL) was heated at 90 °C under N2 atmosphere for 2 hours. After cooling to room temperature, the reaction mixture was diluted with water (15 mL) and ethyl acetate (15 mL).1 mL of 1 N HCl was added to the mixture and it was allowed to stir for 10 min at room temperature. The organic layer was collected. The aqueous layer was further extracted with ethyl
acetate (2 x 15 mL). The combined extracts were washed with brine (30 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 30%) to give the title compound, 51 mg. MS- (+)-ion, M+H = 389.04. d) 4-(6-Benzyl-4-cyano-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid [0187] At room temperature, to a solution of 4-(6-Benzyl-4-cyano-3-hydroxy-quinolin-2-yl)-4- oxo-butyric acid ethyl ester (50 mg, 0.13 mmol) in methanol(2 mL) was added sodium hydroxide aqueous solution (1.0 M in water, 0.39 mL, 0.39 mmol). After 2h at room temperature, the reaction was diluted in 15 mL water and extracted with ethyl acetate (10mL x 3). The resulting aqueous layer was treated with 1N HCl to pH = 4, followed by extraction with ethyl acetate (10mL x 3). The combined organic layers were washed with brine and dried over sodium sulfate, filtered and evaporated in vacuo to afford the title compound.31 mg. MS-(+)-ion, M+H = 361.03. Example 9 4-(7-Benzyl-4-cyano-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid a) 3-Benzyloxy-7-bromo-quinoline-2-carboxylic acid [0188] At room temperature, to a solution of 3-Benzyloxy-7-bromo-quinoline-2-carboxylic acid ethyl ester (7.7 g, 20 mmol) in THF/H2O (60 mL/30 mL) was added lithium hydroxide monohydrate (2.46 g, 60 mmol). After 4 hours at room temperature, most of the THF was evaporated in vacuo. The residue diluted in 300 mL water and treated with 1N HCl to pH = 3. After filtration and drying in vacuo for overnight, 6.92 g of the title compound was obtained. MS-(+)-ion, M+H = 359.83, 357.88. b) 3-Benzyloxy-7-bromo-quinoline-2-carbonyl chloride [0189] At 0 °C, to the solution of 3-Benzyloxy-7-bromo-quinoline-2-carboxylic acid (6.9 g, 19.3 mmol, 1.0 eq) in anhydrous THF (60 mL) was added oxalyl chloride (3.3 mL, 4.9 mmol, 2.0 eq). The reaction was then at room temperature for 2 hours. The solvent was evaporated in vacuo and further dried under high vacuum for 1 hour. The residue was used directly in the next step. c) 4-(3-Benzyloxy-7-bromo-quinolin-2-yl)-3,3-bis-tert-butoxycarbonyl-4-oxo-butyric acid ethyl ester [0190] A solution of 2-tert-Butoxycarbonyl-succinic acid 1-tert-butyl ester 4-ethyl ester (8.76 g, 29 mmol) in anhydrous tetrahydrofuran (100 mL) was added to a suspension of sodium hydride (1.16 g, 29 mmol, 60% dispersion) in anhydrous tetrahydrofuran (100 mL) at room temperature. The mixture was then stirred at 40oC for 16 h. After cooling down to room temperature, a solution of 3-Benzyloxy-7- bromo-quinoline-2-carbonyl chloride (19.3 mmol) in anhydrous tetrahydrofuran (60 mL) was added, and the mixture was stirred at room temperature for 18 h. Then the mixture was treated with aqueous ammonium chloride (100 mL) and extracted with ethyl acetate (200 mL X 3). The combined extract was
washed with brine (200 mL), dried over sodium sulfate, and concentrated to a crude residue. The obtained crude was purified by column chromatography using 0-15% ethyl acetate in hexane as eluent to yield 8.5 g of the title compound. MS-(+)-ion, M+H = 643.99, 642.04. d) 4-(3-Benzyloxy-7-bromo-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0191] p-Toluenesulfonic acid monohydrate (0.25 g, 1.32 mmol) was added to a solution of 4- (3-Benzyloxy-7-bromo-quinolin-2-yl)-3,3-bis-tert-butoxycarbonyl-4-oxo-butyric acid ethyl ester (8.5 g, 13.2 mmol) in toluene (80 mL), and the mixture was refluxed for 3 h. After cooling to room temperature, the mixture was treated with saturated aqueous sodium bicarbonate (50 mL) and extracted with ethyl acetate (100 mL X 3). The combined extract was dried over sodium sulfate, and concentrated to a crude residue. The obtained crude was purified by column chromatography using 0-15% ethyl acetate in hexane as eluent to yield 4.3 g of the title compound. MS-(+)-ion, M+H = 443.90. e) 4-(7-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0192] The mixture of 4-(3-Benzyloxy-7-bromo-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (3.95 g, 11.3 mmol) and thioanisole (6.9 g, 56 mmol) in trifluoroacetic acid (10 mL) was heated at 80°C for 6 hours. After cooling down to room temperature, the reaction mixture was slowly quenched with sodium bicarbonate aqueous solution to pH = 7~8. The mixture was extracted with ethyl acetate (3x100 mL). The combined extracts were washed with brine (100 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 10%) to give the title compound, 2.45 g. MS-(+)-ion, M+H = 353.88. f) 4-(7-Benzyl-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0193] At 0°C, to a solution of 4-(7-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (160 mg, 0.45 mmol), Pd(OAc)2 (20 mg, 0.09 mmol) and S-Phos (49 mg, 0.12 mmol) in dry THF (3 mL) was added dropwise a solution of benzylzinc(II) bromide in THF (1.15 mmol, 2.3 mL, 0.5 M) under nitrogen atmosphere. The reaction mixture was stirred at room temperature for 1 hour, then quenched by half saturated NH4Cl aqueous solution (20 mL) and extracted with ethyl acetate (20 mL X 3). The combined organic layers were dried (Na2SO4), concentrated under reduced pressure, and purified by flash column chromatography to give the 4-(7-Benzyl-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester, 151 mg. MS-(+)-ion, M+H = 364.08. g) 4-(7-Benzyl-4-bromo-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0194] To a solution of 4-(7-Benzyl-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (150 mg, 0.45 mmol) in acetonitrile (5 mL) was added N-Bromosuccinimide (121 mg, 0.68 mmol). The mixture was stirred at room temperature for 3h. Silica gel was added to the reaction. The mixture was
concentrated under vacuo to get crude; purified by column chromatography using 0-10% ethyl acetate in hexane as eluent gave 116 mg of the title compound. MS-(+)-ion, M+H = 443.90, 441.95. h) 4-(7-Benzyl-4-cyano-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0195] A mixture of 4-(7-Benzyl-4-bromo-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (110 mg, 0.25 mmol), zinc cyanide (58 mg, 0.50 mmol), tris(dibenzylideneacetone)dipalladium(0) (23 mg, 0.025 mmol), 1,1'-Bis(diphenylphosphino)ferrocene (dppf, 28 mg, 0.05 mmol), and zinc dust (4.9 mg, 0.075 mmol) in anhydrous dimethylacetamide (3 mL) was heated at 90 °C under N2 atmosphere for 2 hours. After cooling to room temperature, the reaction mixture was diluted with water (15 mL) and ethyl acetate (15 mL).1 mL of 1 N HCl was added to the mixture and it was allowed to stir for 10 min at room temperature. The organic layer was collected. The aqueous layer was further extracted with ethyl acetate (2 x 15 mL). The combined extracts were washed with brine (30 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 30%) to give the title compound, 59 mg. MS- (+)-ion, M+H = 389.14. i) 4-(7-Benzyl-4-cyano-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid [0196] At room temperature, to a solution of 4-(7-Benzyl-4-cyano-3-hydroxy-quinolin-2-yl)-4- oxo-butyric acid ethyl ester (58 mg, 0.15 mmol) in methanol(2 mL) was added sodium hydroxide aqueous solution (1.0 M in water, 0.45 mL, 0.45 mmol). After 18h at room temperature, the reaction was diluted in 15 mL water and extracted with ethyl acetate (10mL x 3). The resulting aqueous layer was treated with 1N HCl to pH = 4, followed by extraction with ethyl acetate (10mL x 3). The combined organic layers were washed with brine and dried over sodium sulfate, filtered and evaporated in vacuo to afford the title compound.11 mg. MS-(+)-ion, M+H = 361.08. Example 10 4-(4-Cyano-3-hydroxy-7-phenylsulfanyl-quinolin-2-yl)-4-oxo-butyric acid a) 4-(3-Hydroxy-7-phenylsulfanyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0197] To a round-bottom-flask were added 4-(7-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (352mg, 1.0 mmol), Pd2(dba)3 (35.4 mg, 0.05 mmol), Xantphos (58 mg, 0.1 mmol), benzenethiol (165 mg, 1.5 mmol), and N,N-Diisopropylethylamine (0.35 mL, 2.0 mmol) in anhydrous 1,4-dioxane (5 mL). The mixture was heated at 105 °C under N2 atmosphere for 6 hours. The reaction mixture was then allowed to reach ambient temperature, diluted in 30 mL H2O, treated with 1N HCl to pH = 3, and extracted with ethyl acetate (50 mL x 3). The combined organics were washed with brine (100 mL) and dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 10%) to give the title compound 338 mg. MS-(+)-ion, M+H = 382.04.
b) 4-(4-Bromo-3-hydroxy-7-phenylsulfanyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0198] At room temperature, to a solution of 4-(3-Hydroxy-7-phenylsulfanyl-quinolin-2-yl)-4- oxo-butyric acid ethyl ester (291 mg, 0.76 mmol) and sodium acetate (125 mg, 1.52 mmol) in anhydrous CHCl3 (7 mL) was added bromine (184 mg, 1.14 mmol). After 30 min at room temperature, the reaction was quenched by saturated NaHSO3 aqueous solution and extracted with DCM (15mL x 3). The combined organics were washed with aqueous sodium bicarbonate, brine and dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 10%) to give the title compound.312 mg (~80% purity). MS-(+)-ion, M+H = 461.80. c) 4-(4-Cyano-3-hydroxy-7-phenylsulfanyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0199] A mixture of 4-(4-Bromo-3-hydroxy-7-phenylsulfanyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (311 mg, 0.67 mmol), zinc cyanide (149 mg, 1.35 mmol), tris(dibenzylideneacetone)dipalladium(0) (61 mg, 0.067 mmol), 1,1'-Bis(diphenylphosphino)ferrocene (dppf, 75 mg, 0.135 mmol), and zinc dust (13 mg, 0.20 mmol) in anhydrous dimethylacetamide (5 mL) was heated at 90 °C under N2 atmosphere for 2 hours. After cooling to room temperature, the reaction mixture was diluted with water (25 mL) and ethyl acetate (25 mL).2 mL of 1 N HCl was added to the mixture and it was allowed to stir for 10 min at room temperature. The organic layer was collected. The aqueous layer was further extracted with ethyl acetate (2 x 25 mL). The combined extracts were washed with brine (30 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 30%) to give the title compound, 146 mg. MS-(+)-ion, M+H = 407.04. d) 4-(4-Cyano-3-hydroxy-7-phenylsulfanyl-quinolin-2-yl)-4-oxo-butyric acid [0200] At room temperature, to a solution of 4-(4-Cyano-3-hydroxy-7-phenylsulfanyl-quinolin- 2-yl)-4-oxo-butyric acid ethyl ester (61 mg, 0.15 mmol) in methanol(2 mL) was added sodium hydroxide aqueous solution (1.0 M in water, 0.45 mL, 0.45 mmol). After 18h at room temperature, the reaction was diluted in 15 mL water and extracted with ethyl acetate (10mL x 3). The resulting aqueous layer was treated with 1N HCl to pH = 4, followed by extraction with ethyl acetate (10mL x 3). The combined organic layers were washed with brine and dried over sodium sulfate, filtered and evaporated in vacuo to afford the title compound.23 mg. MS-(+)-ion, M+H = 378.99. Example 11 4-(7-Benzenesulfonyl-4-cyano-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid a) 4-(7-Benzenesulfonyl-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0201] At 0 oC, RuCl3.XH2O (0.02 mmol, 4 mg) was added to the mixture of 4-(3-Hydroxy-7- phenylsulfanyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (150 mg, 0.39 mmol) and NaIO4 (247 mg,
1.17 mmol) in CH3CN (10mL)/H2O (5mL). 20 min later, the reaction was diluted in 20 mL H2O, extracted with ethyl acetate (20 mL x 3). The combined organics were washed with brine (30 mL) and dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 40%) to give the title compound 102 mg. MS-(+)-ion, M+H = 414.04. b) 4-(7-Benzenesulfonyl-4-bromo-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0202] To a solution of 4-(7-Benzenesulfonyl-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (100 mg, 0.24 mmol) in acetonitrile (5 mL) was added N-Bromosuccinimide (68 mg, 0.38 mmol). The mixture was stirred at room temperature for 1h. Silica gel was added to the reaction. The mixture was concentrated under vacuo to get crude; purified by column chromatography using 0-10% ethyl acetate in hexane as eluent gave 84 mg of the title compound. MS-(+)-ion, M+H = 493.81. c) 4-(7-Benzenesulfonyl-4-cyano-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0203] A mixture of 4-(7-Benzenesulfonyl-4-bromo-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (84 mg, 0.17 mmol), zinc cyanide (40 mg, 0.34 mmol), tris(dibenzylideneacetone)dipalladium(0) (16 mg, 0.017 mmol), 1,1'-Bis(diphenylphosphino)ferrocene (dppf, 19 mg, 0.034 mmol), and zinc dust (3.3 mg, 0.051 mmol) in anhydrous dimethylacetamide (3 mL) was heated at 90 °C under N2 atmosphere for 2 hours. After cooling to room temperature, the reaction mixture was diluted with water (15 mL) and ethyl acetate (15 mL).1 mL of 1 N HCl was added to the mixture and it was allowed to stir for 10 min at room temperature. The organic layer was collected. The aqueous layer was further extracted with ethyl acetate (2 x 15 mL). The combined extracts were washed with brine (30 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 30%) to give the title compound, 18 mg. MS-(+)-ion, M+H = 439.00. d) 4-(7-Benzenesulfonyl-4-cyano-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid [0204] At room temperature, to a solution of 4-(7-Benzenesulfonyl-4-cyano-3-hydroxy- quinolin-2-yl)-4-oxo-butyric acid ethyl ester (18 mg, 0.044 mmol) in methanol(2 mL) was added sodium hydroxide aqueous solution (1.0 M in water, 0.45 mL, 0.45 mmol). After 18h at room temperature, the reaction was diluted in 15 mL water and extracted with ethyl acetate (10mL x 3). The resulting aqueous layer was treated with 1N HCl to pH = 4, followed by extraction with ethyl acetate (10mL x 3). The combined organic layers were washed with brine and dried over sodium sulfate, filtered and evaporated in vacuo to afford the title compound.15 mg. MS-(+)-ion, M+H = 411.03.
Example 12 4-[4-Cyano-3-hydroxy-7-(2-methyl-benzyl)-quinolin-2-yl]-4-oxo-butyric acid a) 4-[3-Hydroxy-7-(2-methyl-benzyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0205] At 0°C, to a solution of 4-(7-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (176 mg, 0.45 mmol), Pd(OAc)2 (22.4 mg, 0.10 mmol) and S-Phos (61 mg, 0.15 mmol) in dry THF (3 mL) was added dropwise a solution of 2-methylbenzyl zinc(II) bromide in THF (1.25 mmol, 2.5 mL, 0.5 M) under nitrogen atmosphere. The reaction mixture was stirred at room temperature for 1 hour, then quenched by half saturated NH4Cl aqueous solution (20 mL) and extracted with ethyl acetate (20 mL X 3). The combined organic layers were dried (Na2SO4), concentrated under reduced pressure, and purified by flash column chromatography to give the title compound, 156 mg. MS-(+)-ion, M+H = 378.09. b) 4-[4-Bromo-3-hydroxy-7-(2-methyl-benzyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0206] To a solution of 4-[3-Hydroxy-7-(2-methyl-benzyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester (155 mg, 0.41 mmol) in acetonitrile (5 mL) was added N-bromosuccinimide (109 mg, 0.61 mmol). The mixture was stirred at room temperature for 18h. Silica gel was added to the reaction. The mixture was concentrated under vacuo to get crude; purified by column chromatography using 0-10% ethyl acetate in hexane as eluent gave 122 mg of the title compound. MS-(+)-ion, M+H = 457.88, 455.95. c) 4-[4-Cyano-3-hydroxy-7-(2-methyl-benzyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0207] A mixture of 4-[4-Bromo-3-hydroxy-7-(2-methyl-benzyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester (120 mg, 0.26 mmol), zinc cyanide (61 mg, 0.52 mmol), tris(dibenzylideneacetone)dipalladium(0) (24 mg, 0.026 mmol), 1,1'-Bis(diphenylphosphino)ferrocene (dppf, 29 mg, 0.052 mmol), and zinc dust (5.1 mg, 0.078 mmol) in anhydrous dimethylacetamide (3 mL) was heated at 90 °C under N2 atmosphere for 2 hours. After cooling to room temperature, the reaction mixture was diluted with water (15 mL) and ethyl acetate (15 mL).1 mL of 1 N HCl was added to the mixture and it was allowed to stir for 10 min at room temperature. The organic layer was collected. The aqueous layer was further extracted with ethyl acetate (2 x 15 mL). The combined extracts were washed with brine (30 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 30%) to give the title compound, 46 mg. MS-(+)-ion, M+H = 403.04. d) 4-[4-Cyano-3-hydroxy-7-(2-methyl-benzyl)-quinolin-2-yl]-4-oxo-butyric acid [0208] At room temperature, to a solution of 4-[4-Cyano-3-hydroxy-7-(2-methyl-benzyl)- quinolin-2-yl]-4-oxo-butyric acid ethyl ester (45 mg, 0.09 mmol) in methanol(3 mL) was added sodium hydroxide aqueous solution (1.0 M in water, 0.36 mL, 0.36 mmol). After 5h at room temperature, the reaction was diluted in 15 mL water and extracted with ethyl acetate (10mL x 3). The resulting aqueous layer was treated with 1N HCl to pH = 4, followed by extraction with ethyl acetate (10mL x 3). The
combined organic layers were washed with brine and dried over sodium sulfate, filtered and evaporated in vacuo to afford the title compound.27 mg. MS-(+)-ion, M+H = 375.09. Example 13 4-(4-Cyano-3-hydroxy-8-phenyl-quinolin-2-yl)-4-oxo-butyric acid a) (2-Amino-3-bromo-phenyl)-methanol [0209] To a solution of 2-amino-3-bromo benzoic acid (10 g, 46.2 mmol) in THF (100 mL), LiAlH4 (2.5 g, 69.3 mmol) was added at 0oC and stirred at RT for 8 h, The reaction was quenched using saturated solution of sodium sulfate and filtered through celite bed to yield 7 g of title compound after trituration with hexane. MS: (+) m/z 202, 204 (M+1). b) 2-Amino-3-bromo-benzaldehyde [0210] To a solution of (2-Amino-3-bromo-phenyl)-methanol (7 g, 34.65 mmol) in DCM (200 mL) at room temperature was added MnO2 (30.14 g, 346 mmol) in portions. Reaction mixture was stirred at room temperature for 10 h. Reaction mixture was filtered through a pad of celite and washed with DCM, filtrate was concentrated under vacuo to get crude; The obtained crude was purified by column chromatography (10% EtOAc/hexane) to yield 5 g of the title compound. MS: (+) m/z 200, 202 (M+1). c) 3-Amino-8-bromo-quinoline-2-carboxylic acid ethyl ester [0211] A solution of ethyl bromopyruvate (3.57 mL, 27.5 mmol) in ethanol (25 mL) was added dropwise to a mixture of pyridine (2.2 mL, 27.5 mmol) and ethanol (20 mL) at room temperature for a period of more than 30 minutes and reaction mixture was stirred at rt for 1h to ensure the reaction was complete. The mixture was stirred at 60oC for 2h and was cooled to room temperature. To the mixture was added 2-Amino-3-bromo-benzaldehyde (5 g, 25 mmol) and pyridine (20 mL). The mixture was refluxed at 85oC for 4 hours. Pyrrolidine (5 mL, 62.5 mmol) was added and the mixture was refluxed at 85oC for 4 hours. The reaction mixture was concentrated on rotavapor, water was added to the reaction mixture and extracted with ethyl acetate. The organic layer was separated, dried over sodium sulfate and concentrated to get crude. The obtained crude was purified by column chromatography using 0-2% ethyl acetate in DCM as eluent gave 1 g of the title compound. MS: (+) m/z 295, 297 (M+1). d) 8-Bromo-3-hydroxy-quinoline-2-carboxylic acid ethyl ester [0212] 3-Amino-8-bromo-quinoline-2-carboxylic acid ethyl ester (2 g, 6.77 mmol) was dissolved in anhydrous THF (20 mL) and placed in an ice bath. With vigorous stirring, concentrated H2SO4 (1.08 mL, 20.33 mmol) was slowly added to give a thick suspension. Butyl nitrite (2.3 mL, 20.33 mmol) was then added dropwise, and the resulting suspension was stirred vigorously in the ice bath for 2 h. The mixture was diluted with 10 mL of cold THF and the solid was isolated by filtration and dried under high vacuum for several hours. In a separate flask, glacial acetic acid (20 mL) was heated to 115oC. The solid from above was suspended in glacial acetic acid (20 mL) and added to the pre-heated acetic
acid, and the resulting homogeneous mixture was then stirred at 115-120oC for 16 h. The reaction mixture was allowed to come to room temperature and concentrated to dryness. The residue was re- dissolved in absolute EtOH (30 mL) and placed in ice bath. Thionyl chloride (1 mL) was added, and the mixture was warmed to room temperature and refluxed for 16 h. The mixture was concentrated on rotavapor. Ethyl acetate was added to the reaction mixture and extracted with water and aq. sodium bicarbonate solution. The organic layer was separated, dried over sodium sulfate and concentrated to get crude. The obtained crude was purified by column chromatography using 5% ethyl acetate in DCM as eluent to yield 415 mg of the title compound. MS: (+) m/z 296, 298 (M+1). e) 3-Benzyloxy-8-bromo-quinoline-2-carboxylic acid ethyl ester [0213] Benzyl bromide (2.1 mL, 2.98 g, 17.1 mmol) was added to a mixture of 8-Bromo-3- hydroxy-quinoline-2-carboxylic acid ethyl ester (3.63 g, 12.2 mmol) and cesium carbonate (4.8 g, 14.7 mmol) in anhydrous DMF (25 mL) at room temperature. After 3 hours at room temperature, TLC shows the completion of the reaction. The reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate (4 x 30 mL). The combined extracts were washed with brine (2 x 30 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 30%) to give the title compound, 4.52 g. MS- (+)-ion, M+H = 387.94, 385.89. f) 3-Benzyloxy-8-bromo-quinoline-2-carboxylic acid [0214] At room temperature, to a solution of 4-(3-Benzyloxy-8-bromo-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (4.52 g, 12 mmol) in THF/H2O (60 mL/30 mL) was added lithium hydroxide monohydrate (1.48 g, 36 mmol). After 5h at room temperature, most of the organic solvent was evaporated off.200 mL of water was the reaction mixture, followed by treatment with 1N HCl to pH = 3. The precipitation was filtrated off and dried under vacuum for overnight to afford the title compound. 3.86 g. MS-(+)-ion, M+H = 359.88. g) 3-Benzyloxy-8-bromo-quinoline-2-carbonyl chloride [0215] At 0 °C, to the solution of 3-Benzyloxy-8-bromo-quinoline-2-carboxylic acid (3.964 g, 11 mmol, 1.0 eq) in anhydrous THF (40 mL) was added oxalyl chloride (1.9 mL, 22 mmol, 2.0 eq). The reaction was stirred at room temperature for 2 hour. The solvent was evaporated in vacuo and further dried under high vacuum for 1 hour. The residue was used directly in the next step. h) 4-(3-Benzyloxy-8-bromo-quinolin-2-yl)-3,3-bis-tert-butoxycarbonyl-4-oxo-butyric acid ethyl ester [0216] A solution of 2-tert-Butoxycarbonyl-succinic acid 1-tert-butyl ester 4-ethyl ester (4.98 g, 16.5 mmol) in anhydrous tetrahydrofuran (40 mL) was added to a suspension of sodium hydride (0.66 g, 16.5 mmol, 60% dispersion) in anhydrous tetrahydrofuran (40 mL) at room temperature. The mixture
was then stirred at 40oC for 16 h. After cooling down to room temperature, a solution of 3-Benzyloxy-8- bromo-quinoline-2-carbonyl chloride (11 mmol) in anhydrous tetrahydrofuran (30 mL) was added, and the mixture was stirred at room temperature for 2 h. Then the mixture was treated with aqueous ammonium chloride (100 mL) and extracted with ethyl acetate (100 mL X 3). The combined extract was washed with brine (100 mL), dried over sodium sulfate, and concentrated to a crude residue. The obtained crude was purified by column chromatography using 0-15% ethyl acetate in hexane as eluent to yield 4.3 g of the title compound. MS-(+)-ion, M+H = 644.05, 642.08. i) 4-(3-Benzyloxy-8-bromo-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0217] p-Toluenesulfonic acid monohydrate (0.12 g, 0.66 mmol) was added to a solution of 4- (3-Benzyloxy-8-bromo-quinolin-2-yl)-3,3-bis-tert-butoxycarbonyl-4-oxo-butyric acid ethyl ester (4.28 g, 6.6 mmol) in toluene (30 mL), and the mixture was refluxed for 3 h. After cooling to room temperature, the mixture was treated with saturated aqueous sodium bicarbonate (50 mL) and extracted with ethyl acetate (100 mL X 3). The combined extract was dried over sodium sulfate, and concentrated to a crude residue. The obtained crude was purified by column chromatography using 0-15% ethyl acetate in hexane as eluent to yield 2.62 g of the title compound. MS-(+)-ion, M+H = 443.90, 441.95. j) 4-(8-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0218] The mixture of 4-(3-Benzyloxy-8-bromo-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (2.62 g, 4.8 mmol) and thioanisole (1.8 g, 14.4 mmol) in trifluoroacetic acid (6 mL) was heated at 80°C for 6 hours. After cooling down to room temperature, the reaction mixture was slowly quenched with sodium bicarbonate aqueous solution to pH = 7~8. The mixture was extracted with ethyl acetate (3x100 mL). The combined extracts were washed with brine (100 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 10%) to give the title compound, 1.59 g. MS-(+)-ion, M+H = 353.88, 351.83. k) 4-(3-Hydroxy-8-phenyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0219] A round bottom flask was charged with 4-(8-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (176 mg, 0.5 mmol), phenylboronic acid (98 mg, 0.8 mmol, 1.5 eq), S-Phos (16.5 mg, 0.04 mmol, 0.08 eq), palladium acetate (6.7 mg, 0.03 mmol, 0.06 eq), and tripotassium phosphate (212 mg, 1.0 mmol, 2.0 eq). The flask was evacuated and backfilled with nitrogen three times. Anhydrous toluene (3 mL) and water (18 mg, 1.0 mmol, 2.0 eq) were added to the reaction. The reaction was heated at 100 °C for 6 hours, until TLC shows the completion of the reaction. After cooling back to room temperature, the reaction was diluted with water (50 mL) and acidified to pH = 4 with 1N HCl. The mixture filtrate through celite. The filtrate was extracted with ethyl acetate (3 x 20 mL). The combined extracts were washed with brine (20 mL), dried over sodium sulfate, filtered and evaporated in vacuo to
afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 20%) to give the title compound, 157 mg. MS-(+)-ion, M+H = 350.03. l) 4-(4-Bromo-3-hydroxy-8-phenyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0220] To a solution of 4-(3-Hydroxy-8-phenyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (150 mg, 0.44 mmol) in acetonitrile (5 mL) was added N-bromosuccinimide (117 mg, 0.66 mmol). The mixture was stirred at room temperature for 18 h. Silica gel was added to the reaction. The mixture was concentrated under vacuo to get crude; purified by column chromatography using 0-10% ethyl acetate in hexane as eluent gave 146 mg of the title compound. MS-(+)-ion, M+H = 429.80. m) 4-(4-Cyano-3-hydroxy-8-phenyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0221] A mixture of 4-(4-Bromo-3-hydroxy-8-phenyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (145 mg, 0.34 mmol), zinc cyanide (80 mg, 0.68 mmol), tris(dibenzylideneacetone)dipalladium(0) (31 mg, 0.034 mmol), 1,1'-Bis(diphenylphosphino)ferrocene (dppf, 35 mg, 0.064 mmol), and zinc dust (6.5 mg, 0.1 mmol) in anhydrous dimethylacetamide (4 mL) was heated at 90 °C under N2 atmosphere for 2 hours. After cooling to room temperature, the reaction mixture was diluted with water (15 mL) and ethyl acetate (15 mL).1 mL of 1 N HCl was added to the mixture and it was allowed to stir for 10 min at room temperature. The organic layer was collected. The aqueous layer was further extracted with ethyl acetate (2 x 15 mL). The combined extracts were washed with brine (30 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 30%) to give the title compound, 81 mg. MS- (+)-ion, M+H = 375.04. n) 4-(4-Cyano-3-hydroxy-8-phenyl-quinolin-2-yl)-4-oxo-butyric acid [0222] At room temperature, to a solution of 4-(4-cyano-3-hydroxy-8-phenyl-quinolin-2-yl)-4- oxo-butyric acid ethyl ester (80 mg, 0.21 mmol) in methanol(3 mL) was added sodium hydroxide aqueous solution (1.0 M in water, 1.05 mL, 1.05 mmol). After 5h at room temperature, the reaction was diluted in 15 mL water and extracted with ethyl acetate (10mL x 3). The resulting aqueous layer was treated with 1N HCl to pH = 4, followed by extraction with ethyl acetate (10mL x 3). The combined organic layers were washed with brine and dried over sodium sulfate, filtered and evaporated in vacuo to afford the title compound.27 mg. MS-(+)-ion, M+H = 346.98. Example 14 4-[4-Cyano-7-(2,6-dimethyl-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid a) 4-[7-(2,6-Dimethyl-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0223] A round bottom flask was charged with 4-(7-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (210 mg, 0.6 mmol), 2,6-dimethylphenylboronic acid (125 mg, 0.9 mmol, 1.5 eq), S-Phos (20 mg, 0.048 mmol, 0.08 eq), palladium acetate (8.1 mg, 0.036 mmol, 0.06 eq), and tripotassium
phosphate (254 mg, 1.2 mmol, 2.0 eq). The flask was evacuated and backfilled with nitrogen three times. Anhydrous toluene (4 mL) and water (22 mg, 1.2 mmol, 2.0 eq) were added to the reaction. The reaction was heated at 100 °C for 6 hours, until TLC shows the completion of the reaction. After cooling back to room temperature, the reaction was diluted with water (50 mL) and acidified to pH = 4 with 1N HCl. The mixture filtrate through celite. The filtrate was extracted with ethyl acetate (3 x 20 mL). The combined extracts were washed with brine (20 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 20%) to give the title compound, 152 mg. MS-(+)-ion, M+H = 378.09. b) 4-[4-Bromo-7-(2,6-dimethyl-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0224] To a solution of 4-[7-(2,6-dimethyl-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester (150 mg, 0.39 mmol) in acetonitrile (5 mL) was added N-bromosuccinimide (84 mg, 0.47 mmol). The mixture was stirred at room temperature for 18 h. Silica gel was added to the reaction. The mixture was concentrated under vacuo to get crude; purified by column chromatography using 0-10% ethyl acetate in hexane as eluent gave 125 mg of the title compound. MS-(+)-ion, M+H = 453.95, 455.95. c) 4-[4-Cyano-7-(2,6-dimethyl-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0225] A mixture of 4-[4-bromo-7-(2,6-dimethyl-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo- butyric acid ethyl ester (125 mg, 0.27 mmol), zinc cyanide (63 mg, 0.54 mmol), tris(dibenzylideneacetone)dipalladium(0) (25 mg, 0.027 mmol), 1,1’-bis(diphenylphosphino)ferrocene (dppf, 30 mg, 0.054 mmol), and zinc dust (5.3 mg, 0.081 mmol) in anhydrous dimethylacetamide (3 mL) was heated at 90 °C under N2 atmosphere for 2 hours. After cooling to room temperature, the reaction mixture was diluted with water (15 mL) and ethyl acetate (15 mL).1 mL of 1 N HCl was added to the mixture and it was allowed to stir for 10 min at room temperature. The organic layer was collected. The aqueous layer was further extracted with ethyl acetate (2 x 15 mL). The combined extracts were washed with brine (30 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 30%) to give the title compound, 42 mg. MS-(+)-ion, M+H = 403.14. d) 4-[4-Cyano-7-(2,6-dimethyl-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid [0226] At room temperature, to a solution of 4-[4-cyano-7-(2,6-dimethyl-phenyl)-3-hydroxy- quinolin-2-yl]-4-oxo-butyric acid ethyl ester (41 mg, 0.1 mmol) in methanol(3 mL) was added sodium hydroxide aqueous solution (1.0 M in water, 0.5 mL, 0.5 mmol). After 20h at room temperature, the reaction was diluted in 15 mL water and extracted with ethyl acetate (10mL x 3). The resulting aqueous layer was treated with 1N HCl to pH = 4, followed by extraction with ethyl acetate (10mL x 3). The combined organic layers were washed with brine and dried over sodium sulfate, filtered and evaporated in vacuo to afford the title compound.27 mg. MS-(+)-ion, M+H = 375.04.
Example 15 4-(4-Cyano-3-hydroxy-7-phenoxy-quinolin-2-yl)-4-oxo-butyric acid a) 4-(3-Benzyloxy-7-phenoxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0227] To a round-bottom-flask were added 4-(3-benzyloxy-7-bromo-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (221mg, 0.5 mmol), Pd(OAc)2 (11.2 mg, 0.05 mmol), t-BuXPhos (32 mg, 0.075 mmol), phenol (71 mg, 0.75 mmol), and K3PO4 (212 mg, 1.0 mmol) in anhydrous toluene (4 mL). The mixture was heated at 100 °C under N2 atmosphere for 2 hours. The reaction mixture was then allowed to reach ambient temperature, diluted in 30 mL H2O, treated with 1N HCl to pH = 3, and extracted with ethyl acetate (50 mL x 3). The combined organics were washed with brine (100 mL) and dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 15%) to give the title compound 122 mg. MS-(+)-ion, M+H = 456.10. b) 4-(3-Hydroxy-7-phenoxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0228] The mixture of 4-(3-benzyloxy-7-phenoxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (120 mg, 0.26 mmol) and thioanisole (161 mg, 1.3 mmol) in trifluoroacetic acid (5 mL) was heated at 90°C for 6 hours. After cooling down to room temperature, the reaction mixture was slowly quenched with sodium bicarbonate aqueous solution to pH = 7~8. The mixture was extracted with ethyl acetate (3x20 mL). The combined extracts were washed with brine (20 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 10%) to give the title compound, 74 mg. MS-(+)-ion, M+H = 366.03. c) 4-(4-Bromo-3-hydroxy-7-phenoxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0229] At room temperature, to a solution of 4-(3-hydroxy-7-phenoxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (73 mg, 0.20 mmol) and sodium acetate (33 mg, 0.40 mmol) in anhydrous CHCl3 (4 mL) was added bromine (48 mg, 0.30 mmol). After 30 min at room temperature, the reaction was quenched by saturated NaHSO3 aqueous solution and extracted with DCM (15mL x 3). The combined organics were washed with aqueous sodium bicarbonate, brine and dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 10%) to give the title compound.71 mg (~70% purity). MS-(+)- ion, M+H = 443.95, 445.85. d) 4-(4-Cyano-3-hydroxy-7-phenoxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0230] A mixture of 4-(4-bromo-3-hydroxy-7-phenoxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (70 mg, 0.16 mmol), zinc cyanide (37 mg, 0.32 mmol), tris(dibenzylideneacetone)dipalladium(0) (15 mg, 0.016 mmol), 1,1'-Bis(diphenylphosphino)ferrocene (dppf, 18 mg, 0.038 mmol), and zinc dust
(3.1 mg, 0.048 mmol) in anhydrous dimethylacetamide (3 mL) was heated at 90 °C under N2 atmosphere for 2 hours. After cooling to room temperature, the reaction mixture was diluted with water (15 mL) and ethyl acetate (15 mL).1 mL of 1 N HCl was added to the mixture and it was allowed to stir for 10 min at room temperature. The organic layer was collected. The aqueous layer was further extracted with ethyl acetate (2 x 15 mL). The combined extracts were washed with brine (30 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 30%) to give the title compound, 22 mg. MS- (+)-ion, M+H = 391.09. e) 4-(4-Cyano-3-hydroxy-7-phenoxy-quinolin-2-yl)-4-oxo-butyric acid [0231] At room temperature, to a solution of 4-(4-cyano-3-hydroxy-7-phenoxy-quinolin-2-yl)-4- oxo-butyric acid ethyl ester (20 mg, 0.05 mmol) in methanol(3 mL) was added sodium hydroxide aqueous solution (1.0 M in water, 0.3 mL, 0.3 mmol). After 20h at room temperature, the reaction was diluted in 15 mL water and extracted with ethyl acetate (10mL x 3). The resulting aqueous layer was treated with 1N HCl to pH = 4, followed by extraction with ethyl acetate (10mL x 3). The combined organic layers were washed with brine and dried over sodium sulfate, filtered and evaporated in vacuo to afford the title compound.12 mg. MS-(+)-ion, M+H = 362.98. Example 16 4-(8-Benzyl-4-cyano-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid a) 4-(8-Benzyl-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0232] At 0°C, to a solution of 4-(8-bromo-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (176 mg, 0.5 mmol), Pd(OAc)2 (22.4 mg, 0.1 mmol) and S-Phos (61 mg, 0.15 mmol) in dry THF (3 mL) was added dropwise a solution of benzylzinc(II) bromide in THF (1.25 mmol, 2.5 mL, 0.5 M) under nitrogen atmosphere. The reaction mixture was stirred at room temperature for 1 hour, then quenched by half saturated NH4Cl aqueous solution (20 mL) and extracted with ethyl acetate (20 mL X 3). The combined organic layers were dried (Na2SO4), concentrated under reduced pressure, and purified by flash column chromatography to give the title compound, 136 mg. MS-(+)-ion, M+H = 364.08 b) 4-(8-Benzyl-4-bromo-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0233] To a solution of 4-(8-Benzyl-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (134 mg, 0.37 mmol) in acetonitrile (5 mL) was added N-bromosuccinimide (79 mg, 0.44 mmol). The mixture was stirred at room temperature for 18 h. Silica gel was added to the reaction. The mixture was concentrated under vacuo to get crude; purified by column chromatography using 0-10% ethyl acetate in hexane as eluent gave 99 mg of the title compound. MS-(+)-ion, M+H = 443.80, 441.90.
c) 4-(8-Benzyl-4-cyano-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0234] A mixture of 4-(8-Benzyl-4-bromo-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (98 mg, 0.22 mmol), zinc cyanide (51 mg, 0.44 mmol), tris(dibenzylideneacetone)dipalladium(0) (20 mg, 0.022 mmol), 1,1'-bis(diphenylphosphino)ferrocene (dppf, 24 mg, 0.044 mmol), and zinc dust (4.3 mg, 0.066 mmol) in anhydrous dimethylacetamide (3 mL) was heated at 90 °C under N2 atmosphere for 2 hours. After cooling to room temperature, the reaction mixture was diluted with water (15 mL) and ethyl acetate (15 mL).1 mL of 1 N HCl was added to the mixture and it was allowed to stir for 10 min at room temperature. The organic layer was collected. The aqueous layer was further extracted with ethyl acetate (2 x 15 mL). The combined extracts were washed with brine (30 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 30%) to give the title compound, 42 mg. MS- (+)-ion, M+H = 389.09. d) 4-(8-Benzyl-4-cyano-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid [0235] At room temperature, to a solution of 4-(8-benzyl-4-cyano-3-hydroxy-quinolin-2-yl)-4- oxo-butyric acid ethyl ester (40 mg, 0.05 mmol) in methanol(2 mL) was added sodium hydroxide aqueous solution (1.0 M in water, 0.5 mL, 0.5 mmol). After 20h at room temperature, the reaction was diluted in 15 mL water and extracted with ethyl acetate (10mL x 3). The resulting aqueous layer was treated with 1N HCl to pH = 4, followed by extraction with ethyl acetate (10mL x 3). The combined organic layers were washed with brine and dried over sodium sulfate, filtered and evaporated in vacuo to afford the title compound.25 mg. MS-(+)-ion, M+H = 361.08. Example 17 4-(4-Cyano-3-hydroxy-7-o-tolyl-quinolin-2-yl)-4-oxo-butyric acid a) 4-(3-Hydroxy-7-o-tolyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0236] A round bottom flask was charged with 4-(7-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (176 mg, 0.5 mmol), 2-methylphenylboronic acid (136 mg, 1.0 mmol), S-Phos (16.5 mg, 0.04 mmol), palladium acetate (6.7 mg, 0.03 mmol), and tripotassium phosphate (212 mg, 1.0 mmol). The flask was evacuated and backfilled with nitrogen three times. Anhydrous toluene (4 mL) and water (18 mg, 1.0 mmol) were added to the reaction. The reaction was heated at 100 °C for 6 hours, until TLC shows the completion of the reaction. After cooling back to room temperature, the reaction was diluted with water (50 mL) and acidified to pH = 4 with 1N HCl. The mixture filtrate through celite. The filtrate was extracted with ethyl acetate (3 x 20 mL). The combined extracts were washed with brine (20 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 20%) to give the title compound, 163 mg. MS-(+)-ion, M+H = 364.08.
b) 4-(4-Bromo-3-hydroxy-7-o-tolyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0237] To a solution of 4-(3-Hydroxy-7-o-tolyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (160 mg, 0.44 mmol) in acetonitrile (5 mL) was added N-bromosuccinimide (95 mg, 0.53 mmol). The mixture was stirred at room temperature for 48 h. Silica gel was added to the reaction. The mixture was concentrated under vacuo to get crude; purified by column chromatography using 0-10% ethyl acetate in hexane as eluent gave 165 mg of the title compound. MS-(+)-ion, M+H = 443.85. c) 4-(4-Cyano-3-hydroxy-7-o-tolyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0238] A mixture of 4-(4-bromo-3-hydroxy-7-o-tolyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (165 mg, 0.37 mmol), zinc cyanide (87 mg, 0.74 mmol), tris(dibenzylideneacetone)dipalladium(0) (34 mg, 0.037 mmol), 1,1'-bis(diphenylphosphino)ferrocene (dppf, 41 mg, 0.074 mmol), and zinc dust (7.1 mg, 0.11 mmol) in anhydrous dimethylacetamide (4 mL) was heated at 90 °C under N2 atmosphere for 2 hours. After cooling to room temperature, the reaction mixture was diluted with water (15 mL) and ethyl acetate (15 mL).1 mL of 1 N HCl was added to the mixture and it was allowed to stir for 10 min at room temperature. The organic layer was collected. The aqueous layer was further extracted with ethyl acetate (2 x 15 mL). The combined extracts were washed with brine (30 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (10% - 30%) to give the title compound, 106 mg. MS- (+)-ion, M+H = 389.09. d) 4-(4-Cyano-3-hydroxy-7-o-tolyl-quinolin-2-yl)-4-oxo-butyric acid [0239] At room temperature, to a solution of 4-(4-cyano-3-hydroxy-7-o-tolyl-quinolin-2-yl)-4- oxo-butyric acid ethyl ester (105 mg, 0.27 mmol) in methanol(3 mL) was added sodium hydroxide aqueous solution (1.0 M in water, 1.35 mL, 1.35 mmol). After 20h at room temperature, the reaction was diluted in 35 mL water and extracted with ethyl acetate (10mL x 3). The resulting aqueous layer was treated with 1N HCl to pH = 4, followed by extraction with ethyl acetate (20mL x 3). The combined organic layers were washed with brine and dried over sodium sulfate, filtered and evaporated in vacuo to afford the title compound.76 mg. MS-(+)-ion, M+H = 361.03. Example 18 4-(4-Cyano-3-hydroxy-7-m-tolyl-quinolin-2-yl)-4-oxo-butyric acid a) 4-(3-Hydroxy-7-m-tolyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0240] A round bottom flask was charged with 4-(7-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (176 mg, 0.5 mmol), 3-methylphenylboronic acid (136 mg, 1.0 mmol), S-Phos (16.5 mg, 0.04 mmol), palladium acetate (6.7 mg, 0.03 mmol), and tripotassium phosphate (212 mg, 1.0 mmol). The flask was evacuated and backfilled with nitrogen three times. Anhydrous toluene (4 mL) and water (18 mg, 1.0 mmol) were added to the reaction. The reaction was heated at 100 °C for 6 hours, until
TLC shows the completion of the reaction. After cooling back to room temperature, the reaction was diluted with water (50 mL) and acidified to pH = 4 with 1N HCl. The mixture filtrate through celite. The filtrate was extracted with ethyl acetate (3 x 20 mL). The combined extracts were washed with brine (20 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 20%) to give the title compound, 172 mg. MS-(+)-ion, M+H = 364.08. b) 4-(4-Bromo-3-hydroxy-7-m-tolyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0241] To a solution of 4-(3-hydroxy-7-m-tolyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (172 mg, 0.48 mmol) in acetonitrile (5 mL) was added N-bromosuccinimide (111 mg, 0.62 mmol). The mixture was stirred at room temperature for 48 h. Silica gel was added to the reaction. The mixture was concentrated under vacuo to get crude; purified by column chromatography using 0-10% ethyl acetate in hexane as eluent gave 146 mg of the title compound. MS-(+)-ion, M+H = 443.80, 441.95. c) 4-(4-Cyano-3-hydroxy-7-m-tolyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0242] A mixture of 4-(4-bromo-3-hydroxy-7-m-tolyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (145 mg, 0.33 mmol), zinc cyanide (77 mg, 0.66 mmol), tris(dibenzylideneacetone)dipalladium(0) (30 mg, 0.033 mmol), 1,1'-bis(diphenylphosphino)ferrocene (dppf, 37 mg, 0.066 mmol), and zinc dust (6.5 mg, 0.10 mmol) in anhydrous dimethylacetamide (4 mL) was heated at 90 °C under N2 atmosphere for 2 hours. After cooling to room temperature, the reaction mixture was diluted with water (15 mL) and ethyl acetate (15 mL).1 mL of 1 N HCl was added to the mixture and it was allowed to stir for 10 min at room temperature. The organic layer was collected. The aqueous layer was further extracted with ethyl acetate (2 x 15 mL). The combined extracts were washed with brine (30 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (10% - 30%) to give the title compound, 68 mg. MS- (+)-ion, M+H = 389.07. d) 4-(4-Cyano-3-hydroxy-7-m-tolyl-quinolin-2-yl)-4-oxo-butyric acid [0243] At room temperature, to a solution of 4-(4-cyano-3-hydroxy-7-m-tolyl-quinolin-2-yl)-4- oxo-butyric acid ethyl ester (68 mg, 0.27 mmol) in methanol(3 mL) was added sodium hydroxide aqueous solution (1.0 M in water, 0.9 mL, 0.9 mmol). After 20h at room temperature, the reaction was diluted in 35 mL water and extracted with ethyl acetate (10mL x 3). The resulting aqueous layer was treated with 1N HCl to pH = 4, followed by extraction with ethyl acetate (20mL x 3). The combined organic layers were washed with brine and dried over sodium sulfate, filtered and evaporated in vacuo to afford the title compound.45 mg. MS-(+)-ion, M+H = 361.03.
Example 19 4-(4-Cyano-3-hydroxy-7-p-tolyl-quinolin-2-yl)-4-oxo-butyric acid a) 4-(3-Hydroxy-7-p-tolyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0244] A round bottom flask was charged with 4-(7-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (176 mg, 0.5 mmol), 4-methylphenylboronic acid (136 mg, 1.0 mmol), S-Phos (16.5 mg, 0.04 mmol), palladium acetate (6.7 mg, 0.03 mmol), and tripotassium phosphate (212 mg, 1.0 mmol). The flask was evacuated and backfilled with nitrogen three times. Anhydrous toluene (4 mL) and water (18 mg, 1.0 mmol) were added to the reaction. The reaction was heated at 100 °C for 6 hours, until TLC shows the completion of the reaction. After cooling back to room temperature, the reaction was diluted with water (50 mL) and acidified to pH = 4 with 1N HCl. The mixture filtrate through celite. The filtrate was extracted with ethyl acetate (3 x 20 mL). The combined extracts were washed with brine (20 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 20%) to give the title compound, 161 mg. MS-(+)-ion, M+H = 364.13. b) 4-(4-Bromo-3-hydroxy-7-p-tolyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0245] To a solution of 4-(3-hydroxy-7-p-tolyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (160 mg, 0.44 mmol) in acetonitrile (5 mL) was added N-bromosuccinimide (111 mg, 0.62 mmol). The mixture was stirred at room temperature for 48 h. Silica gel was added to the reaction. The mixture was concentrated under vacuo to get crude; purified by column chromatography using 0-10% ethyl acetate in hexane as eluent gave 146 mg of the title compound. MS-(+)-ion, M+H = 443.85, 441.95. c) 4-(4-Cyano-3-hydroxy-7-p-tolyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0246] A mixture of 4-(4-Bromo-3-hydroxy-7-p-tolyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (118 mg, 0.27 mmol), zinc cyanide (63 mg, 0.54 mmol), tris(dibenzylideneacetone)dipalladium(0) (25 mg, 0.027 mmol), 1,1'-Bis(diphenylphosphino)ferrocene (dppf, 30 mg, 0.054 mmol), and zinc dust (5.3 mg, 0.08 mmol) in anhydrous dimethylacetamide (4 mL) was heated at 90 °C under N2 atmosphere for 2 hours. After cooling to room temperature, the reaction mixture was diluted with water (15 mL) and ethyl acetate (15 mL).1 mL of 1 N HCl was added to the mixture and it was allowed to stir for 10 min at room temperature. The organic layer was collected. The aqueous layer was further extracted with ethyl acetate (2 x 15 mL). The combined extracts were washed with brine (30 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (10% - 30%) to give the title compound, 61 mg. MS- (+)-ion, M+H = 389.04.
d) 4-(4-Cyano-3-hydroxy-7-p-tolyl-quinolin-2-yl)-4-oxo-butyric acid [0247] At room temperature, to a solution of 4-(4-Cyano-3-hydroxy-7-p-tolyl-quinolin-2-yl)-4- oxo-butyric acid ethyl ester (60 mg, 0.16 mmol) in methanol(3 mL) was added sodium hydroxide aqueous solution (1.0 M in water, 0.8 mL, 0.8 mmol). After 20h at room temperature, the reaction was diluted in 15 mL water and extracted with ethyl acetate (10mL x 3). The resulting aqueous layer was treated with 1N HCl to pH = 4, followed by extraction with ethyl acetate (10mL x 3). The combined organic layers were washed with brine and dried over sodium sulfate, filtered and evaporated in vacuo to afford the title compound.43 mg. MS-(+)-ion, M+H = 361.03. Example 20 4-(4-Cyano-3-hydroxy-6-phenoxy-quinolin-2-yl)-4-oxo-butyric acid a) 4-(3-Benzyloxy-6-phenoxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0248] To a round-bottom-flask were added 4-(3-Benzyloxy-6-bromo-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (221mg, 0.5 mmol), Pd(OAc)2 (11.2 mg, 0.05 mmol), t-BuXPhos (32 mg, 0.075 mmol), phenol (71 mg, 0.75 mmol), and K3PO4 (212 mg, 1.0 mmol) in anhydrous toluene (4 mL). The mixture was heated at 100 °C under N2 atmosphere for 2 hours. The reaction mixture was then allowed to reach ambient temperature, diluted in 30 mL H2O, treated with 1N HCl to pH = 3, and extracted with ethyl acetate (50 mL x 3). The combined organics were washed with brine (100 mL) and dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 15%) to give the title compound 146 mg. MS-(+)-ion, M+H = 456.15. b) 4-(3-Hydroxy-6-phenoxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0249] The mixture of 4-(3-Benzyloxy-6-phenoxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (145 mg, 0.32 mmol) and thioanisole (200 mg, 1.6 mmol) in trifluoroacetic acid (3 mL) was heated at 90°C for 6 hours. After cooling down to room temperature, the reaction mixture was slowly quenched with sodium bicarbonate aqueous solution to pH = 7~8. The mixture was extracted with ethyl acetate (3x20 mL). The combined extracts were washed with brine (20 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 10%) to give the title compound, 109 mg. MS-(+)-ion, M+H = 366.03. c) 4-(4-Bromo-3-hydroxy-6-phenoxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0250] To a solution of 4-(3-Hydroxy-6-phenoxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (136 mg, 0.37 mmol) in DMF (4 mL) was added N-Bromosuccinimide (73 mg, 0.41 mmol). The mixture was stirred at room temperature for 1h and then quenched with saturated aqueous sodium sulfite (5 mL) and diluted with 20 mL water. The mixture was extracted with ethyl acetate (3x20 mL). The combined
extracts were washed with brine (20 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 10%) to give the title compound, 83 mg. MS-(+)-ion, M+H = 445.85, 443.90. d) 4-(4-Cyano-3-hydroxy-6-phenoxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0251] A mixture of 4-(4-Bromo-3-hydroxy-6-phenoxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (82 mg, 0.18 mmol), zinc cyanide (42 mg, 0.36 mmol), tris(dibenzylideneacetone)dipalladium(0) (16 mg, 0.018 mmol), 1,1'-Bis(diphenylphosphino)ferrocene (dppf, 20 mg, 0.036 mmol), and zinc dust (3.5 mg, 0.054 mmol) in anhydrous dimethylacetamide (3 mL) was heated at 90 °C under N2 atmosphere for 2 hours. After cooling to room temperature, the reaction mixture was diluted with water (15 mL) and ethyl acetate (15 mL).1 mL of 1 N HCl was added to the mixture and it was allowed to stir for 10 min at room temperature. The organic layer was collected. The aqueous layer was further extracted with ethyl acetate (2 x 15 mL). The combined extracts were washed with brine (30 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (10% - 30%) to give the title compound, 33 mg. MS- (+)-ion, M+H = 391.04. e) 4-(4-Cyano-3-hydroxy-6-phenoxy-quinolin-2-yl)-4-oxo-butyric acid [0252] At room temperature, to a solution of 4-(4-Cyano-3-hydroxy-6-phenoxy-quinolin-2-yl)- 4-oxo-butyric acid ethyl ester (30 mg, 0.077 mmol) in methanol(2 mL) was added sodium hydroxide aqueous solution (1.0 M in water, 0.46 mL, 0.46 mmol). After 20h at room temperature, the reaction was diluted in 15 mL water and extracted with ethyl acetate (10mL x 3). The resulting aqueous layer was treated with 1N HCl to pH = 4, followed by extraction with ethyl acetate (10mL x 3). The combined organic layers were washed with brine and dried over sodium sulfate, filtered and evaporated in vacuo to afford the title compound.17 mg. MS-(+)-ion, M+H = 363.08. Example 21 4-(4-Cyano-3-hydroxy-6-phenylsulfanyl-quinolin-2-yl)-4-oxo-butyric acid a) 4-(3-Hydroxy-6-phenylsulfanyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0253] To a round-bottom-flask were added 4-(6-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (352mg, 1.0 mmol), Pd2(dba)3 (35.4 mg, 0.05 mmol), Xantphos (58 mg, 0.1 mmol), benzenethiol (165 mg, 1.5 mmol), and N,N-Diisopropylethylamine (0.35 mL, 2.0 mmol) in anhydrous 1,4-dioxane (5 mL). The mixture was heated at 105 °C under N2 atmosphere for 6 hours. The reaction mixture was then allowed to reach ambient temperature, diluted in 30 mL H2O, treated with 1N HCl to pH = 3, and extracted with ethyl acetate (50 mL x 3). The combined organics were washed with brine (100 mL) and dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 10%) to give the title compound 356 mg. MS-(+)-ion, M+H = 381.99.
b) 4-(4-Bromo-3-hydroxy-6-phenylsulfanyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0254] To a solution of 4-(3-Hydroxy-6-phenylsulfanyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (196 mg, 0.51 mmol) in DMF (6 mL) was added N-Bromosuccinimide (99 mg, 0.56 mmol). The mixture was stirred at room temperature for 20 min and then quenched with saturated aqueous sodium sulfite (5 mL) and diluted with 20 mL water. The mixture was extracted with ethyl acetate (3x20 mL). The combined extracts were washed with brine (20 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 10%) to give the title compound, 232 mg. MS-(+)-ion, M+H = 461.80. c) 4-(4-Cyano-3-hydroxy-6-phenylsulfanyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0255] A mixture of 4-(4-Bromo-3-hydroxy-6-phenylsulfanyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (230 mg, 0.50 mmol), zinc cyanide (117 mg, 1.0 mmol), tris(dibenzylideneacetone)dipalladium(0) (46 mg, 0.05 mmol), 1,1'-Bis(diphenylphosphino)ferrocene (dppf, 55 mg, 0.10 mmol), and zinc dust (9.7 mg, 0.15 mmol) in anhydrous dimethylacetamide (5 mL) was heated at 90 °C under N2 atmosphere for 2 hours. After cooling to room temperature, the reaction mixture was diluted with water (25 mL) and ethyl acetate (25 mL).2 mL of 1 N HCl was added to the mixture and it was allowed to stir for 10 min at room temperature. The organic layer was collected. The aqueous layer was further extracted with ethyl acetate (2 x 15 mL). The combined extracts were washed with brine (30 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (10% - 30%) to give the title compound, 116 mg. MS-(+)-ion, M+H = 407.04. d) 4-(4-Cyano-3-hydroxy-6-phenylsulfanyl-quinolin-2-yl)-4-oxo-butyric acid [0256] At room temperature, to a solution of 4-(4-Cyano-3-hydroxy-6-phenylsulfanyl-quinolin- 2-yl)-4-oxo-butyric acid ethyl ester (30 mg, 0.07 mmol) in methanol(2 mL) was added sodium hydroxide aqueous solution (1.0 M in water, 0.46 mL, 0.46 mmol). After 20h at room temperature, the reaction was diluted in 15 mL water and extracted with ethyl acetate (10mL x 3). The resulting aqueous layer was treated with 1N HCl to pH = 4, followed by extraction with ethyl acetate (10mL x 3). The combined organic layers were washed with brine and dried over sodium sulfate, filtered and evaporated in vacuo to afford the title compound.26 mg. MS-(+)-ion, M+H = 378.94. Example 22 4-(6-Benzenesulfonyl-4-cyano-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid a) 4-(6-Benzenesulfonyl-4-cyano-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0257] To a solution of 4-(4-Cyano-3-hydroxy-6-phenylsulfanyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (70 mg, 0.17 mmol) in DCM (6 mL) was added meta-chloroperoxybenzoic acid (88 mg,
0.51 mmol). The mixture was stirred at room temperature for 3h and then quenched with saturated aqueous sodium bicarbonate (20 mL). The mixture was extracted with ethyl acetate (3x20 mL). The combined extracts were washed with brine (20 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (50% - 100%) to give the title compound, 53 mg. MS-(+)-ion, M+H = 439.00 b) 4-(6-Benzenesulfonyl-4-cyano-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid [0258] At room temperature, to a solution of 4-(6-Benzenesulfonyl-4-cyano-3-hydroxy- quinolin-2-yl)-4-oxo-butyric acid ethyl ester (52 mg, 0.12 mmol) in methanol(3 mL) was added sodium hydroxide aqueous solution (1.0 M in water, 0.6 mL, 0.6 mmol). After 20h at room temperature, the reaction was diluted in 15 mL water and extracted with ethyl acetate (10mL x 3). The resulting aqueous layer was treated with 1N HCl to pH = 4, followed by extraction with ethyl acetate (10mL x 3). The combined organic layers were washed with brine and dried over sodium sulfate, filtered and evaporated in vacuo to afford the title compound.17 mg. MS-(+)-ion, M+H = 410.97. Example 23 4-[4-Cyano-6-(2,6-dimethyl-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid a) 4-[6-(2,6-Dimethyl-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0259] A round bottom flask was charged with 4-(6-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (176 mg, 0.5 mmol), 2,6-dimethylphenylboronic acid (136 mg, 1.0 mmol), S- Phos (16.5 mg, 0.04 mmol), palladium acetate (6.7 mg, 0.03 mmol), and tripotassium phosphate (212 mg, 1.0 mmol). The flask was evacuated and backfilled with nitrogen three times. Anhydrous toluene (4 mL) and water (18 mg, 1.0 mmol) were added to the reaction. The reaction was heated at 100 °C for 6 hours, until TLC shows the completion of the reaction. After cooling back to room temperature, the reaction was diluted with water (50 mL) and acidified to pH = 4 with 1N HCl. The mixture filtrate through celite. The filtrate was extracted with ethyl acetate (3 x 20 mL). The combined extracts were washed with brine (20 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 20%) to give the title compound, 161 mg. MS-(+)-ion, M+H = 378.09. b) 4-[4-Bromo-6-(2,6-dimethyl-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0260] To a solution of 4-[6-(2,6-Dimethyl-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester (160 mg, 0.42 mmol) in DMF (4 mL) was added N-bromosuccinimide (83 mg, 0.46 mmol). The mixture was stirred at room temperature for 1 hour and then quenched with saturated aqueous sodium sulfite (5 mL) and diluted with 20 mL water. The mixture was extracted with ethyl acetate (3x20 mL). The combined extracts were washed with brine (20 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash
chromatography eluting with ethyl acetate/hexane (0% - 10%) to give the title compound, 173 mg. MS- (+)-ion, M+H = 455.95, 457.90. c) 4-[4-Cyano-6-(2,6-dimethyl-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0261] A mixture of 4-[4-Bromo-6-(2,6-dimethyl-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo- butyric acid ethyl ester (173 mg, 0.38 mmol), zinc cyanide (89 mg, 0.76 mmol), tris(dibenzylideneacetone)dipalladium(0) (35 mg, 0.038 mmol), 1,1'-Bis(diphenylphosphino)ferrocene (dppf, 42 mg, 0.076 mmol), and zinc dust (8.2 mg, 0.13 mmol) in anhydrous dimethylacetamide (4 mL) was heated at 90 °C under N2 atmosphere for 2 hours. After cooling to room temperature, the reaction mixture was diluted with water (25 mL) and ethyl acetate (25 mL).2 mL of 1 N HCl was added to the mixture and it was allowed to stir for 10 min at room temperature. The organic layer was collected. The aqueous layer was further extracted with ethyl acetate (2 x 15 mL). The combined extracts were washed with brine (30 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (10% - 30%) to give the title compound, 92 mg. MS-(+)-ion, M+H = 403.08. d) 4-[4-Cyano-6-(2,6-dimethyl-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid [0262] At room temperature, to a solution of 4-[4-Cyano-6-(2,6-dimethyl-phenyl)-3-hydroxy- quinolin-2-yl]-4-oxo-butyric acid ethyl ester (90 mg, 0.22 mmol) in methanol(3 mL) was added sodium hydroxide aqueous solution (1.0 M in water, 1.1 mL, 1.1 mmol). After 20h at room temperature, the reaction was diluted in 15 mL water and extracted with ethyl acetate (10mL x 3). The resulting aqueous layer was treated with 1N HCl to pH = 4, followed by extraction with ethyl acetate (10mL x 3). The combined organic layers were washed with brine and dried over sodium sulfate, filtered and evaporated in vacuo to afford the title compound.57 mg. MS-(+)-ion, M+H = 375.07. Example 24 4-(4-Cyano-3-hydroxy-7-phenethyl-quinolin-2-yl)-4-oxo-butyric acid a) 4-(3-Hydroxy-7-phenylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0263] To a round-bottom-flask were added 4-(7-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (71 mg, 0.20 mmol), PdCl2(PPh3)2 (28 mg, 0.04 mmol), and tributyl- phenylethynyl-stannane (0.12 mL, 0.32 mmol) in anhydrous DMF (3 mL). The mixture was heated at 120 °C under N2 atmosphere for 2 hours. The reaction mixture was then allowed to reach ambient temperature, diluted in 20 mL H2O, and extracted with ethyl acetate (20 mL x 3). The combined organics were washed with brine (20 mL) and dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 10%) to give the title compound, 77 mg, MS-(+)-ion, M+H = 374.12.
b) 4-(3-Hydroxy-7-phenethyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0264] To a solution of 4-(3-Hydroxy-7-phenylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (77 mg, 0.21 mmol) in ethyl acetate (6 mL) was added Pd/C (11 mg, 0.05eq, 10 wt.%, wet, contains ~51% water). The mixture was vacuumed/refilled with hydrogen gas for three times and attached to a hydrogen gas balloon. After stirring for 16 hr at room temperature, the reaction mixture was filtrated off through celite. The filtrate was evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with EtOAc/Hexane (0% - 20%) to give the title compound, 46 mg, MS-(+)-ion, M+H = 378.10. c) 4-(4-Bromo-3-hydroxy-7-phenethyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0265] To a solution of from 4-(3-Hydroxy-7-phenethyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (38 mg, 0.10 mmol) in DMF (2 mL) was added N-Bromosuccinimide (21 mg, 0.12 mmol). The mixture was stirred at room temperature for 1 hour and then quenched with saturated aqueous sodium sulfite (5 mL) and diluted with 20 mL water. The mixture was extracted with ethyl acetate (3x10 mL). The combined extracts were washed with brine (20 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 10%) to give the title compound, 38 mg. MS-(+)-ion, M+H = 457.93, 455.93. d) 4-(4-Cyano-3-hydroxy-7-phenethyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0266] A mixture of 4-(4-Bromo-3-hydroxy-7-phenethyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (37 mg, 0.08 mmol), zinc cyanide (19 mg, 0.16 mmol), tris(dibenzylideneacetone)dipalladium(0) (7.3 mg, 0.008 mmol), 1,1'-Bis(diphenylphosphino)ferrocene (dppf, 8.9 mg, 0.016 mmol), and zinc dust (1.7 mg, 0.024 mmol) in anhydrous dimethylacetamide (3 mL) was heated at 90 °C under N2 atmosphere for 2 hours. After cooling to room temperature, the reaction mixture was diluted with water (15 mL) and ethyl acetate (15 mL).1 mL of 1 N HCl was added to the mixture and it was allowed to stir for 10 min at room temperature. The organic layer was collected. The aqueous layer was further extracted with ethyl acetate (2 x 15 mL). The combined extracts were washed with brine (30 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (10% - 30%) to give the title compound, 14 mg. MS- (+)-ion, M+H = 403.09. e) 4-(4-Cyano-3-hydroxy-7-phenethyl-quinolin-2-yl)-4-oxo-butyric acid [0267] At room temperature, to a solution of 4-(4-cyano-3-hydroxy-7-phenethyl-quinolin-2-yl)- 4-oxo-butyric acid ethyl ester (12 mg, 0.03 mmol) in methanol(1 mL) was added sodium hydroxide aqueous solution (1.0 M in water, 0.15 mL, 0.15 mmol). After 3h at room temperature, the reaction was diluted in 15 mL water and extracted with ethyl acetate (10mL x 3). The resulting aqueous layer was treated with 1N HCl to pH = 4, followed by extraction with ethyl acetate (10mL x 3). The combined
organic layers were washed with brine and dried over sodium sulfate, filtered and evaporated in vacuo to afford the title compound.3.0 mg. MS-(+)-ion, M+H = 375.09. Example 25 4-(4-Cyano-3-hydroxy-6-phenethyl-quinolin-2-yl)-4-oxo-butyric acid a) 4-(3-Hydroxy-6-phenylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0268] To a round-bottom-flask were added 4-(6-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (176 mg, 0.50 mmol), PdCl2(PPh3)2 (71 mg, 0.2 mmol), and tributyl- phenylethynyl-stannane (0.31 mL, 0.8 mmol) in anhydrous DMF (5 mL). The mixture was heated at 120 °C under N2 atmosphere for 2 hours. The reaction mixture was then allowed to reach ambient temperature, diluted in 20 mL H2O, and extracted with ethyl acetate 2 x 3). The combined organics were washed with brine (20 mL) and dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 10%) to give the title compound, 156 mg, MS-(+)-ion, M+H = 374.08. b) 4-(3-Hydroxy-6-phenethyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0269] To a solution of 4-(3-Hydroxy-6-phenylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (155 mg, 0.42 mmol) in ethyl acetate (8 mL) was added Pd/C (22 mg, 0.05eq, 10 wt.%, wet, contains ~51% water). The mixture was vacuumed/refilled with hydrogen gas for three times and attached to a hydrogen gas balloon. After stirring for 16 hr at room temperature, the reaction mixture was filtrated off through celite. The filtrate was evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with EtOAc/Hexane (0% - 20%) to give the title compound, 112 mg, MS-(+)-ion, M+H = 378.09. c) 4-(4-Bromo-3-hydroxy-6-phenethyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0270] To a solution of from 4-(3-Hydroxy-6-phenethyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (112 mg, 0.30 mmol) in DMF (5 mL) was added N-Bromosuccinimide (64 mg, 0.36 mmol). The mixture was stirred at room temperature for 1 hour and then quenched with saturated aqueous sodium sulfite (5 mL) and diluted with 20 mL water. The mixture was extracted with ethyl acetate (3x20 mL). The combined extracts were washed with brine (20 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 10%) to give the title compound, 114 mg. MS-(+)-ion, M+H = 457.93, 455.93. d) 4-(4-Cyano-3-hydroxy-6-phenethyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0271] A mixture of 4-(4-Bromo-3-hydroxy-6-phenethyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (112 mg, 0.25 mmol), zinc cyanide (59 mg, 0.5 mmol), tris(dibenzylideneacetone)dipalladium(0) (23 mg, 0.025 mmol), 1,1'-Bis(diphenylphosphino)ferrocene (dppf, 28 mg, 0.05 mmol), and zinc dust
(4.9 mg, 0.075 mmol) in anhydrous dimethylacetamide (3 mL) was heated at 90 °C under N2 atmosphere for 2 hours. After cooling to room temperature, the reaction mixture was diluted with water (15 mL) and ethyl acetate (15 mL).1 mL of 1 N HCl was added to the mixture and it was allowed to stir for 10 min at room temperature. The organic layer was collected. The aqueous layer was further extracted with ethyl acetate (2 x 15 mL). The combined extracts were washed with brine (30 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (10% - 30%) to give the title compound, 42 mg. MS- (+)-ion, M+H = 403.09. e) 4-(4-Cyano-3-hydroxy-6-phenethyl-quinolin-2-yl)-4-oxo-butyric acid [0272] At room temperature, to a solution of 4-(4-cyano-3-hydroxy-6-phenethyl-quinolin-2-yl)- 4-oxo-butyric acid ethyl ester (40 mg, 0.1 mmol) in methanol(3 mL) was added sodium hydroxide aqueous solution (1.0 M in water, 0.5 mL, 0.5 mmol). After 3h at room temperature, the reaction was diluted in 15 mL water and extracted with ethyl acetate (10mL x 3). The resulting aqueous layer was treated with 1N HCl to pH = 4, followed by extraction with ethyl acetate (10mL x 3). The combined organic layers were washed with brine and dried over sodium sulfate, filtered and evaporated in vacuo to afford the title compound.15 mg. MS-(+)-ion, M+H = 375.09. Example 26 4-(4-Cyano-3-hydroxy-6-o-tolyl-quinolin-2-yl)-4-oxo-butyric acid a) 4-(3-Hydroxy-6-o-tolyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0273] A round bottom flask was charged with 4-(6-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (176 mg, 0.5 mmol), 2-methylphenylboronic acid (136 mg, 1.0 mmol), S-Phos (16.5 mg, 0.04 mmol), palladium acetate (6.7 mg, 0.03 mmol), and tripotassium phosphate (212 mg, 1.0 mmol). The flask was evacuated and backfilled with nitrogen three times. Anhydrous toluene (4 mL) and water (18 mg, 1.0 mmol) were added to the reaction. The reaction was heated at 100 °C for 6 hours, until TLC shows the completion of the reaction. After cooling back to room temperature, the reaction was diluted with water (50 mL) and acidified to pH = 4 with 1N HCl. The mixture filtrate through celite. The filtrate was extracted with ethyl acetate (3 x 20 mL). The combined extracts were washed with brine (20 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 20%) to give the title compound, 161 mg. MS-(+)-ion, M+H = 364.08. b) 4-(4-Bromo-3-hydroxy-6-o-tolyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0274] To a solution of from 4-(3-hydroxy-6-o-tolyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (175 mg, 0.48 mmol) in DMF (5 mL) was added N-bromosuccinimide (90 mg, 0.51 mmol). The mixture was stirred at room temperature for 1 hour and then quenched with saturated aqueous sodium sulfite (5 mL) and diluted with 20 mL water. The mixture was extracted with ethyl acetate (3x20 mL).
The combined extracts were washed with brine (20 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 10%) to give the title compound, 170 mg. MS-(+)-ion, M+H = 443.90, 441.95. c) 4-(4-Cyano-3-hydroxy-6-o-tolyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0275] A mixture of 4-(4-bromo-3-hydroxy-6-o-tolyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (170 mg, 0.23 mmol) and zinc(II) cyanide (54 mg, 0.46 mmol), tris(dibenzylideneacetone)dipalladium(0) (21 mg, 0.023 mmol), 1,1'-bis(diphenylphosphino)ferrocene (dppf, 25 mg, 0.046 mmol), and zinc dust (4.6 mg, 0.07 mmol) in anhydrous dimethylacetamide (3 mL) was heated at 90 °C under N2 atmosphere for 2 hours. After cooling to room temperature, the reaction mixture was diluted with water (15 mL) and ethyl acetate (15 mL).1 mL of 1 N HCl was added to the mixture and it was allowed to stir for 10 min at room temperature. The organic layer was collected. The aqueous layer was further extracted with ethyl acetate (2 x 15 mL). The combined extracts were washed with brine (30 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (10% - 30%) to give the title compound, 96 mg. MS-(+)-ion, M+H = 389.07. d) 4-(4-Cyano-3-hydroxy-6-o-tolyl-quinolin-2-yl)-4-oxo-butyric acid [0276] At room temperature, to a solution of 4-(4-cyano-3-hydroxy-6-o-tolyl-quinolin-2-yl)-4- oxo-butyric acid ethyl ester (95 mg, 0.25 mmol) in methanol(3 mL) was added sodium hydroxide aqueous solution (1.0 M in water, 1.25 mL, 1.25 mmol). After 18h at room temperature, the reaction was diluted in 25 mL water and extracted with ethyl acetate (10mL x 3). The resulting aqueous layer was treated with 1N HCl to pH = 4, followed by extraction with ethyl acetate (20mL x 3). The combined organic layers were washed with brine and dried over sodium sulfate, filtered and evaporated in vacuo to afford the title compound.52 mg. MS-(+)-ion, M+H = 361.08. Example 27 4-(4-Cyano-3-hydroxy-6-m-tolyl-quinolin-2-yl)-4-oxo-butyric acid a) 4-(3-Hydroxy-6-m-tolyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0277] A round bottom flask was charged with 4-(6-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (176 mg, 0.5 mmol), 3-methylphenylboronic acid (136 mg, 1.0 mmol), S-Phos (16.5 mg, 0.04 mmol), palladium acetate (6.7 mg, 0.03 mmol), and tripotassium phosphate (212 mg, 1.0 mmol). The flask was evacuated and backfilled with nitrogen three times. Anhydrous toluene (4 mL) and water (18 mg, 1.0 mmol) were added to the reaction. The reaction was heated at 100 °C for 6 hours, until TLC shows the completion of the reaction. After cooling back to room temperature, the reaction was diluted with water (50 mL) and acidified to pH = 4 with 1N HCl. The mixture filtrate through celite. The filtrate was extracted with ethyl acetate (3 x 20 mL). The combined extracts were washed with brine (20
mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 20%) to give the title compound, 156 mg. MS-(+)-ion, M+H = 364.08. b) 4-(4-Bromo-3-hydroxy-6-m-tolyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0278] To a solution of from 4-(3-Hydroxy-6-m-tolyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (156 mg, 0.43 mmol) in DMF (5 mL) was added N-Bromosuccinimide (78 mg, 0.44 mmol). The mixture was stirred at room temperature for 1 hour and then quenched with saturated aqueous sodium sulfite (5 mL) and diluted with 20 mL water. The mixture was extracted with ethyl acetate (3x20 mL). The combined extracts were washed with brine (20 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 10%) to give the title compound, 176 mg. MS-(+)-ion, M+H = 443.85, 442.00. c) 4-(4-Cyano-3-hydroxy-6-m-tolyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0279] A mixture of 4-(4-Bromo-3-hydroxy-6-m-tolyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (170 mg, 0.38 mmol) and zinc(II) cyanide (89 mg, 0.76 mmol), tris(dibenzylideneacetone)dipalladium(0) (35 mg, 0.038 mmol), 1,1'-Bis(diphenylphosphino)ferrocene (dppf, 42 mg, 0.076 mmol), and zinc dust (7.4 mg, 0.114 mmol) in anhydrous dimethylacetamide (4 mL) was heated at 90 °C under N2 atmosphere for 2 hours. After cooling to room temperature, the reaction mixture was diluted with water (15 mL) and ethyl acetate (15 mL).1 mL of 1 N HCl was added to the mixture and it was allowed to stir for 10 min at room temperature. The organic layer was collected. The aqueous layer was further extracted with ethyl acetate (2 x 15 mL). The combined extracts were washed with brine (30 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (10% - 30%) to give the title compound, 96 mg. MS-(+)-ion, M+H = 389.07. d) 4-(4-Cyano-3-hydroxy-6-m-tolyl-quinolin-2-yl)-4-oxo-butyric acid [0280] At room temperature, to a solution of 4-(4-Cyano-3-hydroxy-6-m-tolyl-quinolin-2-yl)-4- oxo-butyric acid ethyl ester (95 mg, 0.25 mmol) in methanol(3 mL) was added sodium hydroxide aqueous solution (1.0 M in water, 1.25 mL, 1.25 mmol). After 18h at room temperature, the reaction was diluted in 25 mL water and extracted with ethyl acetate (10mL x 3). The resulting aqueous layer was treated with 1N HCl to pH = 4, followed by extraction with ethyl acetate (20mL x 3). The combined organic layers were washed with brine and dried over sodium sulfate, filtered and evaporated in vacuo to afford the title compound.52 mg. MS-(+)-ion, M+H = 361.03.
Example 28 4-(4-Cyano-3-hydroxy-6-p-tolyl-quinolin-2-yl)-4-oxo-butyric acid a) 4-(3-Hydroxy-6-p-tolyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0281] A round bottom flask was charged with 4-(6-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (106 mg, 0.3 mmol), 4-methylphenylboronic acid (82 mg, 0.6 mmol), S-Phos (9.8 mg, 0.024 mmol), palladium acetate (4.0 mg, 0.018 mmol), and tripotassium phosphate (127 mg, 0.6 mmol). The flask was evacuated and backfilled with nitrogen three times. Anhydrous toluene (4 mL) and water (18 mg, 1.0 mmol) were added to the reaction. The reaction was heated at 100 °C for 6 hours, until TLC shows the completion of the reaction. After cooling back to room temperature, the reaction was diluted with water (50 mL) and acidified to pH = 4 with 1N HCl. The mixture filtrate through celite. The filtrate was extracted with ethyl acetate (3 x 20 mL). The combined extracts were washed with brine (20 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 20%) to give the title compound, 110 mg. MS-(+)-ion, M+H = 364.08. b) 4-(4-Bromo-3-hydroxy-6-p-tolyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0282] To a solution of from 4-(3-Hydroxy-6-p-tolyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (110 mg, 0.3 mmol) in DMF (4 mL) was added N-Bromosuccinimide (55 mg, 0.31 mmol). The mixture was stirred at room temperature for 1 hour and then quenched with saturated aqueous sodium sulfite (5 mL) and diluted with 20 mL water. The mixture was extracted with ethyl acetate (3x20 mL). The combined extracts were washed with brine (20 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 10%) to give the title compound, 116 mg. MS-(+)-ion, M+H = 443.91, 441.94. c) 4-(4-Cyano-3-hydroxy-6-p-tolyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0283] A mixture of 4-(4-Bromo-3-hydroxy-6-p-tolyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (115 mg, 0.26 mmol) and zinc(II) cyanide (61 mg, 0.52 mmol), tris(dibenzylideneacetone)dipalladium(0) (24 mg, 0.026 mmol), 1,1'-Bis(diphenylphosphino)ferrocene (dppf, 29 mg, 0.052 mmol), and zinc dust (5.1 mg, 0.078 mmol) in anhydrous dimethylacetamide (4 mL) was heated at 90 °C under N2 atmosphere for 2 hours. After cooling to room temperature, the reaction mixture was diluted with water (15 mL) and ethyl acetate (15 mL).1 mL of 1 N HCl was added to the mixture and it was allowed to stir for 10 min at room temperature. The organic layer was collected. The aqueous layer was further extracted with ethyl acetate (2 x 15 mL). The combined extracts were washed with brine (30 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (10% - 30%) to give the title compound, 69 mg. MS-(+)-ion, M+H = 389.04.
d) 4-(4-Cyano-3-hydroxy-6-p-tolyl-quinolin-2-yl)-4-oxo-butyric acid [0284] At room temperature, to a solution of 4-(4-Cyano-3-hydroxy-6-p-tolyl-quinolin-2-yl)-4- oxo-butyric acid ethyl ester (68 mg, 0.18 mmol) in methanol(3 mL) was added sodium hydroxide aqueous solution (1.0 M in water, 0.9 mL, 0.9 mmol). After 18h at room temperature, the reaction was diluted in 25 mL water and extracted with ethyl acetate (10mL x 3). The resulting aqueous layer was treated with 1N HCl to pH = 4, followed by extraction with ethyl acetate (20mL x 3). The combined organic layers were washed with brine and dried over sodium sulfate, filtered and evaporated in vacuo to afford the title compound.43 mg. MS-(+)-ion, M+H = 361.08. Example 29 4-(4-Cyano-3-hydroxy-8-o-tolyl-quinolin-2-yl)-4-oxo-butyric acid a) 4-(3-Hydroxy-8-o-tolyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0285] A round bottom flask was charged with 4-(8-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (106 mg, 0.3 mmol), 2-methylphenylboronic acid (82 mg, 0.6 mmol), S-Phos (9.8 mg, 0.024 mmol), palladium acetate (4.0 mg, 0.018 mmol), and tripotassium phosphate (127 mg, 0.6 mmol). The flask was evacuated and backfilled with nitrogen three times. Anhydrous toluene (4 mL) and water (18 mg, 1.0 mmol) were added to the reaction. The reaction was heated at 100 °C for 6 hours, until TLC shows the completion of the reaction. After cooling back to room temperature, the reaction was diluted with water (50 mL) and acidified to pH = 4 with 1N HCl. The mixture filtrate through celite. The filtrate was extracted with ethyl acetate (3 x 20 mL). The combined extracts were washed with brine (20 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 20%) to give the title compound, 116 mg. MS-(+)-ion, M+H = 364.08. b) 4-(4-Bromo-3-hydroxy-8-o-tolyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0286] To a solution of from 4-(3-Hydroxy-8-o-tolyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (115 mg, 0.31 mmol) in DMF (4 mL) was added N-Bromosuccinimide (57 mg, 0.32 mmol). The mixture was stirred at room temperature for 1 hour and then quenched with saturated aqueous sodium sulfite (5 mL) and diluted with 20 mL water. The mixture was extracted with ethyl acetate (3x20 mL). The combined extracts were washed with brine (20 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 10%) to give the title compound, 132 mg. MS-(+)-ion, M+H = 443.85, 441.95. c) 4-(4-Cyano-3-hydroxy-8-o-tolyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0287] A mixture of 4-(4-bromo-3-hydroxy-8-o-tolyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (130 mg, 0.3 mmol) and zinc(II) cyanide (70 mg, 0.6 mmol),
tris(dibenzylideneacetone)dipalladium(0) (27 mg, 0.03 mmol), 1,1'-bis(diphenylphosphino)ferrocene (dppf, 33 mg, 0.06 mmol), and zinc dust (6.0 mg, 0.09 mmol) in anhydrous dimethylacetamide (4 mL) was heated at 90 °C under N2 atmosphere for 2 hours. After cooling to room temperature, the reaction mixture was diluted with water (15 mL) and ethyl acetate (15 mL).1 mL of 1 N HCl was added to the mixture and it was allowed to stir for 10 min at room temperature. The organic layer was collected. The aqueous layer was further extracted with ethyl acetate (2 x 15 mL). The combined extracts were washed with brine (30 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (10% - 30%) to give the title compound, 52 mg. MS-(+)-ion, M+H = 389.09. d) 4-(4-Cyano-3-hydroxy-8-o-tolyl-quinolin-2-yl)-4-oxo-butyric acid [0288] At room temperature, to a solution of 4-(4-Cyano-3-hydroxy-8-o-tolyl-quinolin-2-yl)-4- oxo-butyric acid ethyl ester (50 mg, 0.13 mmol) in methanol(3 mL) was added sodium hydroxide aqueous solution (1.0 M in water, 0.65 mL, 0.65 mmol). After 18h at room temperature, the reaction was diluted in 25 mL water and extracted with ethyl acetate (10mL x 3). The resulting aqueous layer was treated with 1N HCl to pH = 4, followed by extraction with ethyl acetate (20mL x 3). The combined organic layers were washed with brine and dried over sodium sulfate, filtered and evaporated in vacuo to afford the title compound.26 mg. MS-(+)-ion, M+H = 361.08. Example 30 4-(4-Cyano-3-hydroxy-8-m-tolyl-quinolin-2-yl)-4-oxo-butyric acid a) 4-(3-Hydroxy-8-m-tolyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0289] A round bottom flask was charged with 4-(8-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (106 mg, 0.3 mmol), 3-methylphenylboronic acid (82 mg, 0.6 mmol), S-Phos (9.8 mg, 0.024 mmol), palladium acetate (4.0 mg, 0.018 mmol), and tripotassium phosphate (127 mg, 0.6 mmol). The flask was evacuated and backfilled with nitrogen three times. Anhydrous toluene (4 mL) and water (18 mg, 1.0 mmol) were added to the reaction. The reaction was heated at 100 °C for 6 hours, until TLC shows the completion of the reaction. After cooling back to room temperature, the reaction was diluted with water (50 mL) and acidified to pH = 4 with 1N HCl. The mixture filtrate through celite. The filtrate was extracted with ethyl acetate (3 x 20 mL). The combined extracts were washed with brine (20 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 20%) to give the title compound, 105 mg. MS-(+)-ion, M+H = 364.08. b) 4-(4-Bromo-3-hydroxy-8-m-tolyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0290] To a solution of from 4-(3-Hydroxy-8-m-tolyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (104 mg, 0.29 mmol) in DMF (4 mL) was added N-Bromosuccinimide (52 mg, 0.30 mmol). The mixture was stirred at room temperature for 1 hour and then quenched with saturated aqueous sodium
sulfite (5 mL) and diluted with 20 mL water. The mixture was extracted with ethyl acetate (3x20 mL). The combined extracts were washed with brine (20 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 10%) to give the title compound, 115 mg. MS-(+)-ion, M+H = 443.85, 441.90. c) 4-(4-Cyano-3-hydroxy-8-m-tolyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0291] A mixture of 4-(4-Bromo-3-hydroxy-8-m-tolyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (112 mg, 0.25 mmol) and zinc(II) cyanide (59 mg, 0.5 mmol), tris(dibenzylideneacetone)dipalladium(0) (23 mg, 0.025 mmol), 1,1'-Bis(diphenylphosphino)ferrocene (dppf, 28 mg, 0.05 mmol), and zinc dust (4.9 mg, 0.075 mmol) in anhydrous dimethylacetamide (3 mL) was heated at 90 °C under N2 atmosphere for 2 hours. After cooling to room temperature, the reaction mixture was diluted with water (15 mL) and ethyl acetate (15 mL).1 mL of 1 N HCl was added to the mixture and it was allowed to stir for 10 min at room temperature. The organic layer was collected. The aqueous layer was further extracted with ethyl acetate (2 x 15 mL). The combined extracts were washed with brine (30 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (10% - 30%) to give the title compound, 77 mg. MS-(+)-ion, M+H = 389.09. d) 4-(4-Cyano-3-hydroxy-8-m-tolyl-quinolin-2-yl)-4-oxo-butyric acid [0292] At room temperature, to a solution of 4-(4-Cyano-3-hydroxy-8-m-tolyl-quinolin-2-yl)-4- oxo-butyric acid ethyl ester (76 mg, 0.20 mmol) in methanol(3 mL) was added sodium hydroxide aqueous solution (1.0 M in water, 1.0 mL, 1.0 mmol). After 18h at room temperature, the reaction was diluted in 25 mL water and extracted with ethyl acetate (10mL x 3). The resulting aqueous layer was treated with 1N HCl to pH = 4, followed by extraction with ethyl acetate (20mL x 3). The combined organic layers were washed with brine and dried over sodium sulfate, filtered and evaporated in vacuo to afford the title compound.21 mg. MS-(+)-ion, M+H = 361.03. Example 31 4-(4-Cyano-3-hydroxy-8-p-tolyl-quinolin-2-yl)-4-oxo-butyric acid a) 4-(3-Hydroxy-8-p-tolyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0293] A round bottom flask was charged with 4-(8-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (106 mg, 0.3 mmol), 4-methylphenylboronic acid (82 mg, 0.6 mmol), S-Phos (9.8 mg, 0.024 mmol), palladium acetate (4.0 mg, 0.018 mmol), and tripotassium phosphate (127 mg, 0.6 mmol). The flask was evacuated and backfilled with nitrogen three times. Anhydrous toluene (4 mL) and water (18 mg, 1.0 mmol) were added to the reaction. The reaction was heated at 100 °C for 6 hours, until TLC shows the completion of the reaction. After cooling back to room temperature, the reaction was diluted with water (50 mL) and acidified to pH = 4 with 1N HCl. The mixture filtrate through celite. The
filtrate was extracted with ethyl acetate (3 x 20 mL). The combined extracts were washed with brine (20 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 20%) to give the title compound, 89 mg. MS-(+)-ion, M+H = 364.08. b) 4-(4-Bromo-3-hydroxy-8-p-tolyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0294] To a solution of from 4-(3-Hydroxy-8-p-tolyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (88 mg, 0.24 mmol) in DMF (4 mL) was added N-Bromosuccinimide (44 mg, 0.25 mmol). The mixture was stirred at room temperature for 1 hour and then quenched with saturated aqueous sodium sulfite (5 mL) and diluted with 20 mL water. The mixture was extracted with ethyl acetate (3x20 mL). The combined extracts were washed with brine (20 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 10%) to give the title compound, 101 mg. MS-(+)-ion, M+H = 443.85, 441.95. c) 4-(4-Cyano-3-hydroxy-8-p-tolyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0295] A mixture of 4-(4-Bromo-3-hydroxy-8-p-tolyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (99 mg, 0.22 mmol) and zinc(II) cyanide (52 mg, 0.44 mmol), tris(dibenzylideneacetone)dipalladium(0) (20 mg, 0.022 mmol), 1,1'-Bis(diphenylphosphino)ferrocene (dppf, 24 mg, 0.044 mmol), and zinc dust (4.3 mg, 0.066 mmol) in anhydrous dimethylacetamide (3 mL) was heated at 90 °C under N2 atmosphere for 2 hours. After cooling to room temperature, the reaction mixture was diluted with water (15 mL) and ethyl acetate (15 mL).1 mL of 1 N HCl was added to the mixture and it was allowed to stir for 10 min at room temperature. The organic layer was collected. The aqueous layer was further extracted with ethyl acetate (2 x 15 mL). The combined extracts were washed with brine (30 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (10% - 30%) to give the title compound, 54 mg. MS-(+)-ion, M+H = 389.09. d) 4-(4-Cyano-3-hydroxy-8-p-tolyl-quinolin-2-yl)-4-oxo-butyric acid [0296] At room temperature, to a solution of 4-(4-Cyano-3-hydroxy-8-p-tolyl-quinolin-2-yl)-4- oxo-butyric acid ethyl ester (53 mg, 0.14 mmol) in methanol(3 mL) was added sodium hydroxide aqueous solution (1.0 M in water, 0.7 mL, 0.7 mmol). After 18h at room temperature, the reaction was diluted in 25 mL water and extracted with ethyl acetate (10mL x 3). The resulting aqueous layer was treated with 1N HCl to pH = 4, followed by extraction with ethyl acetate (20mL x 3). The combined organic layers were washed with brine and dried over sodium sulfate, filtered and evaporated in vacuo to afford the title compound.23 mg. MS-(+)-ion, M+H = 361.08.
Example 32 4-[4-Cyano-3-hydroxy-7-(2-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid a) 4-[3-Hydroxy-7-(2-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0297] A round bottom flask was charged with 4-(7-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (176 mg, 0.5 mmol), 2-trifluoromethylphenylboronic acid (190 mg, 1.0 mmol), S- Phos (33 mg, 0.08 mmol), palladium acetate (13.4 mg, 0.06 mmol), and tripotassium phosphate (212 mg, 1.0 mmol). The flask was evacuated and backfilled with nitrogen three times. Anhydrous toluene (3 mL) and water (18 mg, 1.0 mmol) were added to the reaction. The reaction was heated at 100 °C for 6 hours, until TLC shows the completion of the reaction. After cooling back to room temperature, the reaction was diluted with water (50 mL) and acidified to pH = 4 with 1N HCl. The mixture filtrate through celite. The filtrate was extracted with ethyl acetate (3 x 20 mL). The combined extracts were washed with brine (20 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 20%) to give the title compound, 195 mg. MS-(+)-ion, M+H = 418.09. b) 4-[4-Bromo-3-hydroxy-7-(2-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0298] To a solution of from 4-[3-Hydroxy-7-(2-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo- butyric acid ethyl ester (193 mg, 0.46 mmol) in DMF (6 mL) was added N-Bromosuccinimide (85 mg, 0.47 mmol). The mixture was stirred at room temperature for 1 hour and then quenched with saturated aqueous sodium sulfite (5 mL) and diluted with 20 mL water. The mixture was extracted with ethyl acetate (3x20 mL). The combined extracts were washed with brine (20 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 10%) to give the title compound, 208 mg. MS- (+)-ion, M+H = 497.86. c) 4-[4-Cyano-3-hydroxy-7-(2-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0299] A mixture of 4-[4-Bromo-3-hydroxy-7-(2-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo- butyric acid ethyl ester (206 mg, 0.40 mmol) and zinc(II) cyanide (94 mg, 0.80 mmol), tris(dibenzylideneacetone)dipalladium(0) (37 mg, 0.04 mmol), 1,1'-Bis(diphenylphosphino)ferrocene (dppf, 44 mg, 0.08 mmol), and zinc dust (7.8 mg, 0.12 mmol) in anhydrous dimethylacetamide (4 mL) was heated at 90 °C under N2 atmosphere for 2 hours. After cooling to room temperature, the reaction mixture was diluted with water (15 mL) and ethyl acetate (15 mL).1 mL of 1 N HCl was added to the mixture and it was allowed to stir for 10 min at room temperature. The organic layer was collected. The aqueous layer was further extracted with ethyl acetate (2 x 15 mL). The combined extracts were washed with brine (30 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude
product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (10% - 30%) to give the title compound, 119 mg. MS-(+)-ion, M+H = 443.00. d) 4-[4-Cyano-3-hydroxy-7-(2-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid [0300] At room temperature, to a solution of 4-[4-Cyano-3-hydroxy-7-(2-trifluoromethyl- phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester (118 mg, 0.27 mmol) in methanol(3 mL) was added sodium hydroxide aqueous solution (1.0 M in water, 1.35 mL, 1.35 mmol). After 18h at room temperature, the reaction was diluted in 25 mL water and extracted with ethyl acetate (10mL x 3). The resulting aqueous layer was treated with 1N HCl to pH = 4, followed by extraction with ethyl acetate (20mL x 3). The combined organic layers were washed with brine and dried over sodium sulfate, filtered and evaporated in vacuo to afford the title compound.73 mg. MS-(+)-ion, M+H = 414.99. Example 33 4-[4-Cyano-3-hydroxy-7-(4-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid a) 4-[3-Hydroxy-7-(4-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0301] A round bottom flask was charged with 4-(7-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (106 mg, 0.3 mmol),4-trifluoromethylphenylboronic acid (114 mg, 0.6 mmol), S- Phos (19.7 mg, 0.048 mmol), palladium acetate (8.1 mg, 0.036 mmol), and tripotassium phosphate (127 mg, 0.6 mmol). The flask was evacuated and backfilled with nitrogen three times. Anhydrous toluene (3 mL) and water (18 mg, 1.0 mmol) were added to the reaction. The reaction was heated at 100 °C for 6 hours, until TLC shows the completion of the reaction. After cooling back to room temperature, the reaction was diluted with water (50 mL) and acidified to pH = 4 with 1N HCl. The mixture filtrate through celite. The filtrate was extracted with ethyl acetate (3 x 20 mL). The combined extracts were washed with brine (20 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 20%) to give the title compound, 68 mg. MS-(+)-ion, M+H = 418.04. b) 4-[4-Bromo-3-hydroxy-7-(4-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0302] To a solution of from 4-[3-Hydroxy-7-(4-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo- butyric acid ethyl ester (65 mg, 0.16 mmol) in DMF (3 mL) was added N-Bromosuccinimide (29 mg, 0.17 mmol). The mixture was stirred at room temperature for 1 hour and then quenched with saturated aqueous sodium sulfite (5 mL) and diluted with 20 mL water. The mixture was extracted with ethyl acetate (3x20 mL). The combined extracts were washed with brine (20 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 10%) to give the title compound, 61 mg. MS- (+)-ion, M+H = 495.76, 497.81.
c) 4-[4-Cyano-3-hydroxy-7-(4-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0303] A mixture of 4-[4-Bromo-3-hydroxy-7-(4-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo- butyric acid ethyl ester (60 mg, 0.12 mmol) and zinc(II) cyanide (28 mg, 0.24 mmol), tris(dibenzylideneacetone)dipalladium(0) (11 mg, 0.012 mmol), 1,1'-Bis(diphenylphosphino)ferrocene (dppf, 13 mg, 0.074 mmol), and zinc dust (2.4 mg, 0.036 mmol) in anhydrous dimethylacetamide (3 mL) was heated at 90 °C under N2 atmosphere for 2 hours. After cooling to room temperature, the reaction mixture was diluted with water (15 mL) and ethyl acetate (15 mL).1 mL of 1 N HCl was added to the mixture and it was allowed to stir for 10 min at room temperature. The organic layer was collected. The aqueous layer was further extracted with ethyl acetate (2 x 15 mL). The combined extracts were washed with brine (30 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (10% - 30%) to give the title compound, 38 mg. MS-(+)-ion, M+H = 443.05. d) 4-[4-Cyano-3-hydroxy-7-(4-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid [0304] At room temperature, to a solution of 4-[4-Cyano-3-hydroxy-7-(4-trifluoromethyl- phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester (35 mg, 0.08 mmol) in methanol(3 mL) was added sodium hydroxide aqueous solution (1.0 M in water, 0.48 mL, 0.48 mmol). After 18h at room temperature, the reaction was diluted in 25 mL water and extracted with ethyl acetate (10mL x 3). The resulting aqueous layer was treated with 1N HCl to pH = 4, followed by extraction with ethyl acetate (20mL x 3). The combined organic layers were washed with brine and dried over sodium sulfate, filtered and evaporated in vacuo to afford the title compound.20 mg. MS-(+)-ion, M+H = 414.99. Example 34 4-[4-Cyano-3-hydroxy-7-(3-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid a) 4-[3-Hydroxy-7-(3-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0305] A round bottom flask was charged with 4-(7-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (176 mg, 0.5 mmol), 3-trifluoromethylphenylboronic acid (190 mg, 1.0 mmol), S- Phos (33 mg, 0.08 mmol), palladium acetate (13.4 mg, 0.06 mmol), and tripotassium phosphate (212 mg, 1.0 mmol). The flask was evacuated and backfilled with nitrogen three times. Anhydrous toluene (3 mL) and water (18 mg, 1.0 mmol) were added to the reaction. The reaction was heated at 100 °C for 6 hours, until TLC shows the completion of the reaction. After cooling back to room temperature, the reaction was diluted with water (50 mL) and acidified to pH = 4 with 1N HCl. The mixture filtrate through celite. The filtrate was extracted with ethyl acetate (3 x 20 mL). The combined extracts were washed with brine (20 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 20%) to give the title compound, 169 mg. MS-(+)-ion, M+H = 417.99.
b) 4-[4-Bromo-3-hydroxy-7-(3-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0306] To a solution of from 4-[3-Hydroxy-7-(3-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo- butyric acid ethyl ester (168 mg, 0.40 mmol) in DMF (6 mL) was added N-Bromosuccinimide (73 mg, 0.41 mmol). The mixture was stirred at room temperature for 1 hour and then quenched with saturated aqueous sodium sulfite (5 mL) and diluted with 20 mL water. The mixture was extracted with ethyl acetate (3x20 mL). The combined extracts were washed with brine (20 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 10%) to give the title compound, 173 mg. MS- (+)-ion, M+H = 497.86, 495.91. c) 4-[4-Cyano-3-hydroxy-7-(3-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0307] A mixture of 4-[4-Bromo-3-hydroxy-7-(3-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo- butyric acid ethyl ester (170 mg, 0.35 mmol) and zinc(II) cyanide (82 mg, 0.70 mmol), tris(dibenzylideneacetone)dipalladium(0) (32 mg, 0.035 mmol), 1,1'-Bis(diphenylphosphino)ferrocene (dppf, 39 mg, 0.07 mmol), and zinc dust (6.8 mg, 0.105 mmol) in anhydrous dimethylacetamide (4 mL) was heated at 90 °C under N2 atmosphere for 2 hours. After cooling to room temperature, the reaction mixture was diluted with water (15 mL) and ethyl acetate (15 mL).1 mL of 1 N HCl was added to the mixture and it was allowed to stir for 10 min at room temperature. The organic layer was collected. The aqueous layer was further extracted with ethyl acetate (2 x 15 mL). The combined extracts were washed with brine (30 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (10% - 30%) to give the title compound, 87 mg. MS-(+)-ion, M+H = 443.05. d) 4-[4-Cyano-3-hydroxy-7-(3-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid [0308] At room temperature, to a solution of 4-[4-Cyano-3-hydroxy-7-(3-trifluoromethyl- phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester (87 mg, 0.20 mmol) in methanol(3 mL) was added sodium hydroxide aqueous solution (1.0 M in water, 1.0 mL, 1.0 mmol). After 18h at room temperature, the reaction was diluted in 25 mL water and extracted with ethyl acetate (10mL x 3). The resulting aqueous layer was treated with 1N HCl to pH = 4, followed by extraction with ethyl acetate (20mL x 3). The combined organic layers were washed with brine and dried over sodium sulfate, filtered and evaporated in vacuo to afford the title compound.37 mg. MS-(+)-ion, M+H = 414.99.
Example 35 4-[4-Cyano-3-hydroxy-7-(2-isopropyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid a) 4-[3-Hydroxy-7-(2-isopropyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0309] A round bottom flask was charged with 4-(7-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (176 mg, 0.5 mmol), 2-isopropylphenylboronic acid (164 mg, 1.0 mmol), S-Phos (33 mg, 0.08 mmol), palladium acetate (13.4 mg, 0.06 mmol), and tripotassium phosphate (212 mg, 1.0 mmol). The flask was evacuated and backfilled with nitrogen three times. Anhydrous toluene (3 mL) and water (18 mg, 1.0 mmol) were added to the reaction. The reaction was heated at 100 °C for 6 hours, until TLC shows the completion of the reaction. After cooling back to room temperature, the reaction was diluted with water (50 mL) and acidified to pH = 4 with 1N HCl. The mixture filtrate through celite. The filtrate was extracted with ethyl acetate (3 x 20 mL). The combined extracts were washed with brine (20 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 20%) to give the title compound, 190 mg. MS-(+)-ion, M+H = 392.14. b) 4-[4-Bromo-3-hydroxy-7-(2-isopropyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0310] To a solution of from 4-[3-Hydroxy-7-(2-isopropyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester (180 mg, 0.46 mmol) in DMF (6 mL) was added N-Bromosuccinimide (85 mg, 0.47 mmol). The mixture was stirred at room temperature for 1 hour and then quenched with saturated aqueous sodium sulfite (5 mL) and diluted with 20 mL water. The mixture was extracted with ethyl acetate (3x20 mL). The combined extracts were washed with brine (20 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 10%) to give the title compound, 192 mg. MS- (+)-ion, M+H = 471.85. c) 4-[4-Cyano-3-hydroxy-7-(2-isopropyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0311] A mixture of 4-[4-Bromo-3-hydroxy-7-(2-isopropyl-phenyl)-quinolin-2-yl]-4-oxo- butyric acid ethyl ester (190 mg, 0.40 mmol) and zinc(II) cyanide (94 mg, 0.80 mmol), tris(dibenzylideneacetone)dipalladium(0) (37 mg, 0.04 mmol), 1,1'-Bis(diphenylphosphino)ferrocene (dppf, 44 mg, 0.08 mmol), and zinc dust (7.8 mg, 0.12 mmol) in anhydrous dimethylacetamide (4 mL) was heated at 90 °C under N2 atmosphere for 2 hours. After cooling to room temperature, the reaction mixture was diluted with water (15 mL) and ethyl acetate (15 mL).1 mL of 1 N HCl was added to the mixture and it was allowed to stir for 10 min at room temperature. The organic layer was collected. The aqueous layer was further extracted with ethyl acetate (2 x 15 mL). The combined extracts were washed with brine (30 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (10% - 30%) to give the title compound, 116 mg. MS-(+)-ion, M+H = 417.14.
d) 4-[4-Cyano-3-hydroxy-7-(2-isopropyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid [0312] At room temperature, to a solution of 4-[4-Cyano-3-hydroxy-7-(2-isopropyl-phenyl)- quinolin-2-yl]-4-oxo-butyric acid ethyl ester (115 mg, 0.28 mmol) in methanol(3 mL) was added sodium hydroxide aqueous solution (1.0 M in water, 1.4 mL, 1.4 mmol). After 18h at room temperature, the reaction was diluted in 25 mL water and extracted with ethyl acetate (10mL x 3). The resulting aqueous layer was treated with 1N HCl to pH = 4, followed by extraction with ethyl acetate (20mL x 3). The combined organic layers were washed with brine and dried over sodium sulfate, filtered and evaporated in vacuo to afford the title compound.75 mg. MS-(+)-ion, M+H = 389.09. Example 36 4-[4-Cyano-3-hydroxy-7-(3-isopropyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid a) 4-[3-Hydroxy-7-(3-isopropyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0313] A round bottom flask was charged with 4-(7-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (176 mg, 0.5 mmol), 3-isopropylphenylboronic acid (164 mg, 1.0 mmol), S-Phos (33 mg, 0.08 mmol), palladium acetate (13.4 mg, 0.06 mmol), and tripotassium phosphate (212 mg, 1.0 mmol). The flask was evacuated and backfilled with nitrogen three times. Anhydrous toluene (3 mL) and water (18 mg, 1.0 mmol) were added to the reaction. The reaction was heated at 100 °C for 6 hours, until TLC shows the completion of the reaction. After cooling back to room temperature, the reaction was diluted with water (50 mL) and acidified to pH = 4 with 1N HCl. The mixture filtrate through celite. The filtrate was extracted with ethyl acetate (3 x 20 mL). The combined extracts were washed with brine (20 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 20%) to give the title compound, 169 mg. MS-(+)-ion, M+H = 392.09. b) 4-[4-Bromo-3-hydroxy-7-(3-isopropyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0314] To a solution of from 4-[3-Hydroxy-7-(3-isopropyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester (169 mg, 0.44 mmol) in DMF (6 mL) was added N-Bromosuccinimide (81 mg, 0.46 mmol). The mixture was stirred at room temperature for 1 hour and then quenched with saturated aqueous sodium sulfite (5 mL) and diluted with 20 mL water. The mixture was extracted with ethyl acetate (3x20 mL). The combined extracts were washed with brine (20 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 10%) to give the title compound, 182 mg. MS- (+)-ion, M+H = 470.15. c) 4-[4-Cyano-3-hydroxy-7-(3-isopropyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0315] A mixture of 4-[4-Bromo-3-hydroxy-7-(3-isopropyl-phenyl)-quinolin-2-yl]-4-oxo- butyric acid ethyl ester (180 mg, 0.38 mmol) and zinc(II) cyanide (89 mg, 0.76 mmol),
tris(dibenzylideneacetone)dipalladium(0) (35 mg, 0.038 mmol), 1,1'-Bis(diphenylphosphino)ferrocene (dppf, 42 mg, 0.076 mmol), and zinc dust (7.4 mg, 0.11 mmol) in anhydrous dimethylacetamide (4 mL) was heated at 90 °C under N2 atmosphere for 2 hours. After cooling to room temperature, the reaction mixture was diluted with water (15 mL) and ethyl acetate (15 mL).1 mL of 1 N HCl was added to the mixture and it was allowed to stir for 10 min at room temperature. The organic layer was collected. The aqueous layer was further extracted with ethyl acetate (2 x 15 mL). The combined extracts were washed with brine (30 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (10% - 30%) to give the title compound, 105 mg. MS-(+)-ion, M+H = 417.09. d) 4-[4-Cyano-3-hydroxy-7-(3-isopropyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid [0316] At room temperature, to a solution of 4-[4-Cyano-3-hydroxy-7-(3-isopropyl-phenyl)- quinolin-2-yl]-4-oxo-butyric acid ethyl ester (102 mg, 0.25 mmol) in methanol(3 mL) was added sodium hydroxide aqueous solution (1.0 M in water, 1.4 mL, 1.4 mmol). After 18h at room temperature, the reaction was diluted in 25 mL water and extracted with ethyl acetate (10mL x 3). The resulting aqueous layer was treated with 1N HCl to pH = 4, followed by extraction with ethyl acetate (20mL x 3). The combined organic layers were washed with brine and dried over sodium sulfate, filtered and evaporated in vacuo to afford the title compound.46 mg. MS-(+)-ion, M+H = 389.04. Example 37 4-[4-Cyano-3-hydroxy-7-(4-isopropyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid a) 4-[3-Hydroxy-7-(4-isopropyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0317] A round bottom flask was charged with 4-(7-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (176 mg, 0.5 mmol), 4-isopropylphenylboronic acid (164 mg, 1.0 mmol), S-Phos (33 mg, 0.08 mmol), palladium acetate (13.4 mg, 0.06 mmol), and tripotassium phosphate (212 mg, 1.0 mmol). The flask was evacuated and backfilled with nitrogen three times. Anhydrous toluene (3 mL) and water (18 mg, 1.0 mmol) were added to the reaction. The reaction was heated at 100 °C for 6 hours, until TLC shows the completion of the reaction. After cooling back to room temperature, the reaction was diluted with water (50 mL) and acidified to pH = 4 with 1N HCl. The mixture filtrate through celite. The filtrate was extracted with ethyl acetate (3 x 20 mL). The combined extracts were washed with brine (20 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 20%) to give the title compound, 86 mg. MS-(+)-ion, M+H = 392.14. b) 4-[4-Bromo-3-hydroxy-7-(4-isopropyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0318] To a solution of from 4-[3-Hydroxy-7-(4-isopropyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester (85 mg, 0.42 mmol) in DMF (4 mL) was added N-Bromosuccinimide (41 mg, 0.23 mmol). The mixture was stirred at room temperature for 1 hour and then quenched with saturated
aqueous sodium sulfite (5 mL) and diluted with 20 mL water. The mixture was extracted with ethyl acetate (3x20 mL). The combined extracts were washed with brine (20 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 10%) to give the title compound, 81 mg. MS- (+)-ion, M+H = 470.15. c) 4-[4-Cyano-3-hydroxy-7-(4-isopropyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0319] A mixture of 4-[4-Bromo-3-hydroxy-7-(4-isopropyl-phenyl)-quinolin-2-yl]-4-oxo- butyric acid ethyl ester (80 mg, 0.17 mmol) and zinc(II) cyanide (40 mg, 0.34 mmol), tris(dibenzylideneacetone)dipalladium(0) (16 mg, 0.017 mmol), 1,1'-Bis(diphenylphosphino)ferrocene (dppf, 19 mg, 0.034 mmol), and zinc dust (3.3 mg, 0.051 mmol) in anhydrous dimethylacetamide (4 mL) was heated at 90 °C under N2 atmosphere for 2 hours. After cooling to room temperature, the reaction mixture was diluted with water (15 mL) and ethyl acetate (15 mL).1 mL of 1 N HCl was added to the mixture and it was allowed to stir for 10 min at room temperature. The organic layer was collected. The aqueous layer was further extracted with ethyl acetate (2 x 15 mL). The combined extracts were washed with brine (30 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (10% - 30%) to give the title compound, 46 mg. MS-(+)-ion, M+H = 417.14. d) 4-[4-Cyano-3-hydroxy-7-(4-isopropyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid [0320] At room temperature, to a solution of 4-[4-Cyano-3-hydroxy-7-(4-isopropyl-phenyl)- quinolin-2-yl]-4-oxo-butyric acid ethyl ester (45 mg, 0.11 mmol) in methanol(3 mL) was added sodium hydroxide aqueous solution (1.0 M in water, 0.55 mL, 0.55 mmol). After 18h at room temperature, the reaction was diluted in 25 mL water and extracted with ethyl acetate (10mL x 3). The resulting aqueous layer was treated with 1N HCl to pH = 4, followed by extraction with ethyl acetate (10mL x 3). The combined organic layers were washed with brine and dried over sodium sulfate, filtered and evaporated in vacuo to afford the title compound.46 mg. MS-(+)-ion, M+H = 389.04. Example 38 4-[4-Cyano-8-(2,6-dimethyl-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid a) 4-[8-(2,6-Dimethyl-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0321] A round bottom flask was charged with 4-(8-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (142 mg, 0.4 mmol), 2,6-dimethylphenylboronic acid (120 mg, 0.8 mmol), S- Phos (26 mg, 0.064 mmol), palladium acetate (11 mg, 0.048 mmol), and tripotassium phosphate (170 mg, 0.8 mmol). The flask was evacuated and backfilled with nitrogen three times. Anhydrous toluene (4 mL) and water (18 mg, 1.0 mmol) were added to the reaction. The reaction was heated at 100 °C for 6 hours, until TLC shows the completion of the reaction. After cooling back to room temperature, the reaction was diluted with water (50 mL) and acidified to pH = 4 with 1N HCl. The mixture filtrate through celite.
The filtrate was extracted with ethyl acetate (3 x 20 mL). The combined extracts were washed with brine (20 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 20%) to give the title compound, 106 mg. MS-(+)-ion, M+H = 378.04. b) 4-[4-Bromo-8-(2,6-dimethyl-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0322] To a solution of from 4-[8-(2,6-Dimethyl-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo- butyric acid ethyl ester (104 mg, 0.28 mmol) in DMF (4 mL) was added N-Bromosuccinimide (51 mg, 0.29 mmol). The mixture was stirred at room temperature for 1 hour and then quenched with saturated aqueous sodium sulfite (5 mL) and diluted with 20 mL water. The mixture was extracted with ethyl acetate (3x20 mL). The combined extracts were washed with brine (20 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 10%) to give the title compound, 102 mg. MS- (+)-ion, M+H = 457.80, 455.90. c) 4-[4-Cyano-8-(2,6-dimethyl-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0323] A mixture of 4-[4-Bromo-8-(2,6-dimethyl-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo- butyric acid ethyl ester (100 mg, 0.25 mmol) and zinc(II) cyanide (58 mg, 0.50 mmol), tris(dibenzylideneacetone)dipalladium(0) (23 mg, 0.025 mmol), 1,1'-Bis(diphenylphosphino)ferrocene (dppf, 28 mg, 0.05 mmol), and zinc dust (4.9 mg, 0.075 mmol) in anhydrous dimethylacetamide (3 mL) was heated at 90 °C under N2 atmosphere for 2 hours. After cooling to room temperature, the reaction mixture was diluted with water (15 mL) and ethyl acetate (15 mL).1 mL of 1 N HCl was added to the mixture and it was allowed to stir for 10 min at room temperature. The organic layer was collected. The aqueous layer was further extracted with ethyl acetate (2 x 15 mL). The combined extracts were washed with brine (30 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (10% - 30%) to give the title compound, 39 mg. MS-(+)-ion, M+H = 403.09. d) 4-[4-Cyano-8-(2,6-dimethyl-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid [0324] At room temperature, to a solution of 4-[4-Cyano-8-(2,6-dimethyl-phenyl)-3-hydroxy- quinolin-2-yl]-4-oxo-butyric acid ethyl ester (39 mg, 0.10 mmol) in methanol(2 mL) was added sodium hydroxide aqueous solution (1.0 M in water, 0.4 mL, 0.4 mmol). After 18h at room temperature, the reaction was diluted in 25 mL water and extracted with ethyl acetate (10mL x 3). The resulting aqueous layer was treated with 1N HCl to pH = 4, followed by extraction with ethyl acetate (10mL x 3). The combined organic layers were washed with brine and dried over sodium sulfate, filtered and evaporated in vacuo to afford the title compound.17 mg. MS-(+)-ion, M+H = 375.09.
Example 39 4-[4-Cyano-7-(3,5-dimethyl-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid a) 4-[7-(3,5-Dimethyl-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0325] A round bottom flask was charged with 4-(7-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (530 mg, 1.5 mmol), 3,5-dimethylphenylboronic acid (450 mg, 3.0 mmol), S- Phos (98 mg, 0.24 mmol), palladium acetate (41 mg, 0.18 mmol), and tripotassium phosphate (636 mg, 3.0 mmol). The flask was evacuated and backfilled with nitrogen three times. Anhydrous toluene (6 mL) and water (60 mg) were added to the reaction. The reaction was heated at 100 °C for 6 hours, until TLC shows the completion of the reaction. After cooling back to room temperature, the reaction was diluted with water (50 mL) and acidified to pH = 4 with 1N HCl. The mixture filtrate through celite. The filtrate was extracted with ethyl acetate (3 x 20 mL). The combined extracts were washed with brine (20 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 20%) to give the title compound, 520 mg. MS-(+)-ion, M+H = 378.09. b) 4-[4-Bromo-7-(3,5-dimethyl-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0326] To a solution of from 4-[7-(3,5-Dimethyl-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo- butyric acid ethyl ester (520 mg, 1.38 mmol) in DMF (20 mL) was added N-Bromosuccinimide (250 mg, 1.4 mmol). The mixture was stirred at room temperature for 1 hour and then quenched with saturated aqueous sodium sulfite (10 mL) and diluted with 30 mL water. The mixture was extracted with ethyl acetate (3x30 mL). The combined extracts were washed with brine (30 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 10%) to give the title compound, 530 mg. MS- (+)-ion, M+H = 456.10, 457.90. c) 4-[4-Cyano-7-(3,5-dimethyl-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0327] A mixture of 4-[4-Bromo-7-(3,5-dimethyl-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo- butyric acid ethyl ester (183 mg, 0.4 mmol) and zinc(II) cyanide (94 mg, 0.8 mmol), tris(dibenzylideneacetone)dipalladium(0) (37 mg, 0.04 mmol), 1,1'-Bis(diphenylphosphino)ferrocene (dppf, 44 mg, 0.08 mmol), and zinc dust (7.8 mg, 0.12 mmol) in anhydrous dimethylacetamide (5 mL) was heated at 90 °C under N2 atmosphere for 2 hours. After cooling to room temperature, the reaction mixture was diluted with water (15 mL) and ethyl acetate (15 mL).1 mL of 1 N HCl was added to the mixture and it was allowed to stir for 10 min at room temperature. The organic layer was collected. The aqueous layer was further extracted with ethyl acetate (2 x 15 mL). The combined extracts were washed with brine (30 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (10% - 30%) to give the title compound, 92 mg. MS-(+)-ion, M+H = 403.09.
d) 4-[4-Cyano-7-(3,5-dimethyl-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid [0328] At room temperature, to a solution of 4-[4-Cyano-7-(3,5-dimethyl-phenyl)-3-hydroxy- quinolin-2-yl]-4-oxo-butyric acid ethyl ester (92 mg, 0.23 mmol) in methanol(4 mL) was added sodium hydroxide aqueous solution (1.0 M in water, 1.1 mL, 1.1 mmol). After 18h at room temperature, the reaction was diluted in 25 mL water and extracted with ethyl acetate (10mL x 3). The resulting aqueous layer was treated with 1N HCl to pH = 4, followed by extraction with ethyl acetate (20mL x 3). The combined organic layers were washed with brine and dried over sodium sulfate, filtered and evaporated in vacuo to afford the title compound.47 mg. MS-(+)-ion, M+H = 375.19. Example 40 4-(4-Cyano-3-hydroxy-8-phenylsulfanyl-quinolin-2-yl)-4-oxo-butyric acid a) 4-(3-Hydroxy-7-phenylsulfanyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0329] To a round-bottom-flask were added 4-(8-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (246 mg, 0.7 mmol), Pd2(dba)3 (50 mg, 0.07 mmol), Xantphos (81 mg, 0.14 mmol), benzenethiol (154 mg, 1.4 mmol), and N,N-Diisopropylethylamine (0.25 mL, 1.4 mmol) in anhydrous 1,4-dioxane (5 mL). The mixture was heated at 105 °C under N2 atmosphere for 6 hours. The reaction mixture was then allowed to reach ambient temperature, diluted in 30 mL H2O, treated with 1N HCl to pH = 3, and extracted with ethyl acetate (50 mL x 3). The combined organics were washed with brine (100 mL) and dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 10%) to give the title compound 230 mg. MS-(+)-ion, M+H = 382.04. b) 4-(4-Bromo-3-hydroxy-8-phenylsulfanyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0330] To a solution of 4-(3-Hydroxy-8-phenylsulfanyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (230 mg, 0.6 mmol) in DMF (6 mL) was added N-Bromosuccinimide (108 mg, 0.61 mmol). The mixture was stirred at room temperature for 20 min and then quenched with saturated aqueous sodium sulfite (5 mL) and diluted with 20 mL water. The mixture was extracted with ethyl acetate (3x20 mL). The combined extracts were washed with brine (20 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 10%) to give the title compound, 252 mg. MS-(+)-ion, M+H = 459.85, 461.85. c) 4-(4-Cyano-3-hydroxy-8-phenylsulfanyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0331] A mixture of 4-(4-Bromo-3-hydroxy-8-phenylsulfanyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (251 mg, 0.54 mmol), zinc cyanide (126 mg, 1.08 mmol), tris(dibenzylideneacetone)dipalladium(0) (49 mg, 0.054 mmol), 1,1'-Bis(diphenylphosphino)ferrocene (dppf, 60 mg, 0.108 mmol), and zinc dust (10.5 mg, 0.112 mmol) in anhydrous dimethylacetamide (5
mL) was heated at 90 °C under N2 atmosphere for 2 hours. After cooling to room temperature, the reaction mixture was diluted with water (25 mL) and ethyl acetate (25 mL).2 mL of 1 N HCl was added to the mixture and it was allowed to stir for 10 min at room temperature. The organic layer was collected. The aqueous layer was further extracted with ethyl acetate (2 x 15 mL). The combined extracts were washed with brine (30 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (10% - 30%) to give the title compound, 128 mg. MS-(+)-ion, M+H = 407.04. d) 4-(4-Cyano-3-hydroxy-8-phenylsulfanyl-quinolin-2-yl)-4-oxo-butyric acid [0332] At room temperature, to a solution of 4-(4-Cyano-3-hydroxy-8-phenylsulfanyl-quinolin- 2-yl)-4-oxo-butyric acid ethyl ester (50 mg, 0.12 mmol) in methanol(2 mL) was added sodium hydroxide aqueous solution (1.0 M in water, 0.6 mL, 0.6 mmol). After 20h at room temperature, the reaction was diluted in 15 mL water and extracted with ethyl acetate (10mL x 3). The resulting aqueous layer was treated with 1N HCl to pH = 4, followed by extraction with ethyl acetate (10mL x 3). The combined organic layers were washed with brine and dried over sodium sulfate, filtered and evaporated in vacuo to afford the title compound.31 mg. MS-(+)-ion, M+H = 379.04. Example 41 4-(8-Benzenesulfonyl-4-cyano-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid a) 4-(8-Benzenesulfonyl-4-cyano-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0333] To a solution of 4-(4-Cyano-3-hydroxy-8-phenylsulfanyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (75 mg, 0.19 mmol) in DCM (6 mL) was added meta-chloroperoxybenzoic acid (99 mg, 0.57 mmol). The mixture was stirred at room temperature for 3h and then quenched with saturated aqueous sodium bicarbonate (20 mL). The mixture was extracted with ethyl acetate (3x20 mL). The combined extracts were washed with brine (20 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (50% - 100%) to give the title compound, 42 mg. MS-(+)-ion, M+H = 438.95. b) 4-(8-Benzenesulfonyl-4-cyano-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid [0334] At room temperature, to a solution of 4-(8-Benzenesulfonyl-4-cyano-3-hydroxy- quinolin-2-yl)-4-oxo-butyric acid ethyl ester (42 mg, 0.10 mmol) in methanol(3 mL) was added sodium hydroxide aqueous solution (1.0 M in water, 0.5 mL, 0.5 mmol). After 20h at room temperature, the reaction was diluted in 15 mL water and extracted with ethyl acetate (10mL x 3). The resulting aqueous layer was treated with 1N HCl to pH = 4, followed by extraction with ethyl acetate (10mL x 3). The combined organic layers were washed with brine and dried over sodium sulfate, filtered and evaporated in vacuo to afford the title compound.22 mg. MS-(+)-ion, M+H = 410.99.
Example 42 4-[7-(3,5-Dimethyl-phenyl)-3-hydroxy-4-trifluoromethyl-quinolin-2-yl]-4-oxo-butyric acid a) 4-[3-Benzyloxy-4-bromo-7-(3,5-dimethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0335] Benzyl bromide (0.13 mL, 185 mg, 1.05 mmol) was added to a mixture of 4-[4-Bromo- 7-(3,5-dimethyl-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester (321 mg, 0.7 mmol) and potassium carbonate (145 mg, 1.05 mmol) in anhydrous DMF (7 mL) at room temperature. After 20 hours at room temperature, TLC shows the completion of the reaction. The reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (4x15 mL). The combined extracts were washed with brine (2x20 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 20%) to give the title compound, 355 mg. MS-(+)-ion, M+H = 546.07, 548.07. b) 4-[3-Benzyloxy-7-(3,5-dimethyl-phenyl)-4-trifluoromethyl-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0336] The mixture of 4-[3-Benzyloxy-4-bromo-7-(3,5-dimethyl-phenyl)-quinolin-2-yl]-4-oxo- butyric acid ethyl ester (350 mg, 0.64 mmol), methyl 2,2-difluoro-2-(fluorosulfonyl)acetate (611 mg, 3.2 mmol), and copper(I) iodide (367 mg, 1.92 mmol), in anhydrous 1-methyl-2-pyrrolidone (10 mL) was heated at 100 °C under N2 atmosphere for 3 hours. After cooling down to room temperature, the reaction mixture was diluted with water (30 mL), quenched with 5 mL 1 N HCl and extracted with ethyl acetate (3 x 30 mL). The combined extracts were washed with brine (50 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 20%) to give the title compound.92 mg, MS-(+)-ion, M+H = 536.11. c) 4-[7-(3,5-Dimethyl-phenyl)-3-hydroxy-4-trifluoromethyl-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0337] The mixture of 4-[3-Benzyloxy-7-(3,5-dimethyl-phenyl)-4-trifluoromethyl-quinolin-2- yl]-4-oxo-butyric acid ethyl ester (90 mg, 0.17 mmol) and thioanisole (105 mg, 0.85 mmol) in trifluoroacetic acid (5 mL) was stirred at room temperature for 2h, the reaction mixture was slowly quenched with sodium bicarbonate aqueous solution to pH = 7~8. The mixture was extracted with ethyl acetate (3x20 mL). The combined extracts were washed with brine (20 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 10%) to give the title compound, 69 mg. MS- (+)-ion, M+H = 446.00.
d) 4-[7-(3,5-Dimethyl-phenyl)-3-hydroxy-4-trifluoromethyl-quinolin-2-yl]-4-oxo-butyric acid [0338] At room temperature, to a solution of 4-[7-(3,5-Dimethyl-phenyl)-3-hydroxy-4- trifluoromethyl-quinolin-2-yl]-4-oxo-butyric acid ethyl ester (67 mg, 0.15 mmol) in methanol(3 mL) was added sodium hydroxide aqueous solution (1.0 M in water, 0.75 mL, 0.75 mmol). After 18h at room temperature, the reaction was diluted in 25 mL water and extracted with ethyl acetate (10mL x 3). The resulting aqueous layer was treated with 1N HCl to pH = 4, followed by extraction with ethyl acetate (20mL x 3). The combined organic layers were washed with brine and dried over sodium sulfate, filtered and evaporated in vacuo to afford the title compound.20 mg. MS-(+)-ion, M+H = 417.99. Example 43 4-(4-Cyano-3-hydroxy-7-phenylethynyl-quinolin-2-yl)-4-oxo-butyric acid a) 4-(3-Hydroxy-7-phenylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0339] To a round-bottom-flask were added 4-(7-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (353 mg, 1.0 mmol), PdCl2(PPh3)2 (142 mg, 0.2 mmol), and tributyl- phenylethynyl-stannane (626 mg, 1.6 mmol) in anhydrous DMF (8 mL). The mixture was heated at 120 °C under N2 atmosphere for 2 hours. The reaction mixture was then allowed to reach ambient temperature, diluted in 50 mL H2O, and extracted with ethyl acetate (50 x 3). The combined organics were washed with brine (50 mL) and dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 10%) to give the title compound, 290 mg, MS-(+)-ion, M+H = 374.09. b) 4-(4-Bromo-3-hydroxy-7-phenylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0340] At 0°C, to a solution of 4-(3-Hydroxy-7-phenylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (270 mg, 0.73 mmol) in DMF (20 mL) was added N-Bromosuccinimide (130 mg, 0.73 mmol). The mixture was stirred then at room temperature for 30 min and quenched with saturated aqueous sodium sulfite (5 mL) and diluted with 20 mL water. The mixture was extracted with ethyl acetate (3x20 mL). The combined extracts were washed with brine (20 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 10%) to give the title compound, 346 mg. MS-(+)-ion, M+H = 453.85. c) 4-(4-Cyano-3-hydroxy-7-phenylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0341] A mixture of 4-(4-Bromo-3-hydroxy-7-phenylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (136 mg, 0.3 mmol), zinc cyanide (70 mg, 0.6 mmol), tris(dibenzylideneacetone)dipalladium(0) (28 mg, 0.03 mmol), 1,1'-Bis(diphenylphosphino)ferrocene (dppf, 33 mg, 0.06 mmol), and zinc dust (6.0 mg, 0.09 mmol) in anhydrous dimethylacetamide (4 mL) was heated at 90 °C under N2 atmosphere for 2 hours. After cooling to room temperature, the reaction
mixture was diluted with water (25 mL) and ethyl acetate (25 mL).2 mL of 1 N HCl was added to the mixture and it was allowed to stir for 10 min at room temperature. The organic layer was collected. The aqueous layer was further extracted with ethyl acetate (2 x 15 mL). The combined extracts were washed with brine (30 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (10% - 30%) to give the title compound, 82 mg. MS-(+)-ion, M+H = 399.04. d) 4-(4-Cyano-3-hydroxy-7-phenylethynyl-quinolin-2-yl)-4-oxo-butyric acid [0342] At room temperature, to a solution of 4-(4-Cyano-3-hydroxy-7-phenylethynyl-quinolin- 2-yl)-4-oxo-butyric acid ethyl ester (80 mg, 0.23 mmol) in methanol(3 mL) was added sodium hydroxide aqueous solution (1.0 M in water, 1.15 mL, 1.05 mmol). After 20h at room temperature, the reaction was diluted in 15 mL water and extracted with ethyl acetate (10mL x 3). The resulting aqueous layer was treated with 1N HCl to pH = 4, followed by extraction with ethyl acetate (10mL x 3). The combined organic layers were washed with brine and dried over sodium sulfate, filtered and evaporated in vacuo to afford the title compound.22 mg. MS-(+)-ion, M+H = 371.08. Example 44 4-(4-Cyano-3-hydroxy-7-o-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid a) 4-(3-Hydroxy-7-o-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0343] To a round-bottom-flask were added 4-(7-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (530 mg, 1.5 mmol), PdCl2(PPh3)2 (53 mg, 0.075 mmol), CuI (29 mg, 015 mmol), Et3N (757 mg, 7.5 mmol), and 1-ethynyl-2-methyl-benzene (348 mg, 3.0 mmol) in anhydrous DMF (8 mL). The mixture was heated at 100 °C under N2 atmosphere for 2 hours. The reaction mixture was then allowed to reach ambient temperature, diluted in 50 mL H2O, treated with 5 mL 1N HCl, and extracted with ethyl acetate (50 mL x 3). The combined organics were washed with brine (50 mL) and dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 20%) to give the title compound, 540 mg, MS-(+)-ion, M+H = 388.04. b) 4-(4-Bromo-3-hydroxy-7-o-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0344] At 0°C, to a solution of 4-(3-Hydroxy-7-o-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (540 mg, 1.4 mmol) in DMF (20 mL) was added N-Bromosuccinimide (253 mg, 1.42 mmol). The mixture was stirred then at room temperature for 30 min and quenched with saturated aqueous sodium sulfite (5 mL) and diluted with 20 mL water. The mixture was extracted with ethyl acetate (3x30 mL). The combined extracts were washed with brine (30 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 20%) to give the title compound, 598 mg. MS-(+)-ion, M+H = 465.90, 468.10.
c) 4-(4-Cyano-3-hydroxy-7-o-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0345] A mixture of 4-(4-Bromo-3-hydroxy-7-o-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (595 mg, 1.3 mmol), zinc cyanide (304 mg, 2.6 mmol), tris(dibenzylideneacetone)dipalladium(0) (119 mg, 0.13 mmol), 1,1'-Bis(diphenylphosphino)ferrocene (dppf, 144 mg, 0.26 mmol), and zinc dust (25 mg, 0.39 mmol) in anhydrous dimethylacetamide (12 mL) was heated at 90 °C under N2 atmosphere for 2 hours. After cooling to room temperature, the reaction mixture was diluted with water (50 mL) and ethyl acetate (50 mL).2 mL of 1 N HCl was added to the mixture and it was allowed to stir for 10 min at room temperature. The organic layer was collected. The aqueous layer was further extracted with ethyl acetate (2 x 30 mL). The combined extracts were washed with brine (50 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (10% - 30%) to give the title compound, 266 mg. MS-(+)-ion, M+H = 413.14. d) 4-(4-Cyano-3-hydroxy-7-o-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid [0346] At room temperature, to a solution of 4-(4-Cyano-3-hydroxy-7-o-tolylethynyl-quinolin- 2-yl)-4-oxo-butyric acid ethyl ester (65 mg, 0.15 mmol) in methanol(3 mL) was added sodium hydroxide aqueous solution (1.0 M in water, 0.75 mL, 0.75 mmol). After 20h at room temperature, the reaction was diluted in 25 mL water and extracted with ethyl acetate (20mL x 3). The resulting aqueous layer was treated with 1N HCl to pH = 4, followed by extraction with ethyl acetate (20mL x 3). The combined organic layers were washed with brine and dried over sodium sulfate, filtered and evaporated in vacuo to afford the title compound.21 mg. MS-(+)-ion, M+H = 385.04. Example 45 4-[4-Cyano-3-hydroxy-7-(2-o-tolyl-ethyl)-quinolin-2-yl]-4-oxo-butyric acid a) 4-(4-Cyano-3-hydroxy-7-o-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0347] To a solution of 4-(4-Bromo-3-hydroxy-7-o-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (200 mg, 0.47 mmol) in ethyl acetate (20 mL) was added Pd/C (25 mg, 0.025eq, 10 wt.%, wet, contains ~51% water). The mixture was vacuumed/refilled with hydrogen gas for three times and attached to a hydrogen gas balloon. After stirring for 4 hr at room temperature, the reaction mixture was filtrated off through celite. The filtrate was evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with EtOAc/Hexane (0% - 20%) to give the title compound, 91 mg, MS-(+)-ion, M+H = 417.09. b) 4-[4-Cyano-3-hydroxy-7-(2-o-tolyl-ethyl)-quinolin-2-yl]-4-oxo-butyric acid [0348] At room temperature, to a solution of 4-(4-Cyano-3-hydroxy-7-o-tolylethynyl-quinolin- 2-yl)-4-oxo-butyric acid ethyl ester (90 mg, 0.21 mmol) in methanol(3 mL) was added sodium hydroxide aqueous solution (1.0 M in water, 1.05 mL, 1.05 mmol). After 3h at room temperature, the reaction was
diluted in 15 mL water and extracted with ethyl acetate (10mL x 3). The resulting aqueous layer was treated with 1N HCl to pH = 4, followed by extraction with ethyl acetate (10mL x 3). The combined organic layers were washed with brine and dried over sodium sulfate, filtered and evaporated in vacuo to afford the title compound.48 mg. MS-(+)-ion, M+H = 389.09. Example 46 4-(4-Cyano-3-hydroxy-7-m-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid a) 4-(3-Hydroxy-7-m-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0349] To a round-bottom-flask were added 4-(7-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (530 mg, 1.5 mmol), PdCl2(PPh3)2 (53 mg, 0.075 mmol), CuI (29 mg, 015 mmol), Et3N (757 mg, 7.5 mmol), and 1-ethynyl-3-methyl-benzene (348 mg, 3.0 mmol) in anhydrous DMF (8 mL). The mixture was heated at 100 °C under N2 atmosphere for 3 hours. The reaction mixture was then allowed to reach ambient temperature, diluted in 50 mL H2O, treated with 5 mL 1N HCl, and extracted with ethyl acetate (50 mL x 3). The combined organics were washed with brine (50 mL) and dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 20%) to give the title compound, 490 mg, MS-(+)-ion, M+H = 388.09. b) 4-(4-Bromo-3-hydroxy-7-m-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0350] At 0°C, to a solution of 4-(3-Hydroxy-7-m-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (490 mg, 1.26 mmol) in DMF (20 mL) was added N-Bromosuccinimide (236 mg, 1.33 mmol). The mixture was stirred then at room temperature for 1 h and quenched with saturated aqueous sodium sulfite (5 mL) and diluted with 20 mL water. The mixture was extracted with ethyl acetate (3x30 mL). The combined extracts were washed with brine (30 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 20%) to give the title compound, 508 mg. MS-(+)-ion, M+H = 465.90, 467.85. c) 4-(4-Cyano-3-hydroxy-7-m-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0351] A mixture of 4-(4-Bromo-3-hydroxy-7-m-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (505 mg, 1.1 mmol), zinc cyanide (257 mg, 2.2 mmol), tris(dibenzylideneacetone)dipalladium(0) (101 mg, 0.11 mmol), 1,1'-Bis(diphenylphosphino)ferrocene (dppf, 122 mg, 0.22 mmol), and zinc dust (21 mg, 0.33 mmol) in anhydrous dimethylacetamide (10 mL) was heated at 90 °C under N2 atmosphere for 2 hours. After cooling to room temperature, the reaction mixture was diluted with water (50 mL) and ethyl acetate (50 mL).2 mL of 1 N HCl was added to the mixture and it was allowed to stir for 10 min at room temperature. The organic layer was collected. The aqueous layer was further extracted with ethyl acetate (2 x 30 mL). The combined extracts were washed with brine (50 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude
product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (10% - 30%) to give the title compound, 239 mg. MS-(+)-ion, M+H = 413.14. d) 4-(4-Cyano-3-hydroxy-7-m-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid [0352] At room temperature, to a solution of 4-(4-Cyano-3-hydroxy-7-m-tolylethynyl-quinolin- 2-yl)-4-oxo-butyric acid ethyl ester (64 mg, 0.15 mmol) in methanol(3 mL) was added sodium hydroxide aqueous solution (1.0 M in water, 0.75 mL, 0.75 mmol). After 20h at room temperature, the reaction was diluted in 25 mL water and extracted with ethyl acetate (20mL x 3). The resulting aqueous layer was treated with 1N HCl to pH = 4, followed by extraction with ethyl acetate (20mL x 3). The combined organic layers were washed with brine and dried over sodium sulfate, filtered and evaporated in vacuo to afford the title compound.42 mg. MS-(+)-ion, M+H = 385.04. Example 47 4-[7-(2-Chloro-phenyl)-4-cyano-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid a) (2-Amino-4-bromo-phenyl)-methanol [0353] To a solution of 2-amino-4-bromo benzoic acid (10 g, 46.2 mmol) in THF (100 ml), LAH (2.5 g, 69.3 mmol) was added at 0oC and stirred at room temperature for 8 h. The reaction was quenched using saturated solution of sodium sulfate and filtered through Celite bed to yield 7 g of the title compound after trituration with hexane. MS: (+) m/z 202, 204 (M+1). b) 2-Amino-4-bromo-benzaldehyde [0354] To a solution of (2-amino-4-bromo-phenyl)-methanol (7 g, 34.65 mmol) in DCM (200 mL) at room temperature was added MnO2 (30.14g, 346 mmol) in portions. Reaction mixture was stirred at room temperature for 10 h. Reaction mixture was filtered through a pad of Celite and washed with DCM. The filtrate was concentrated in vacuo to give the crude product. The obtained crude was purified by column chromatography (10% EtOAc/hexane) to yield 5 g of the title compound. MS: (+) m/z 200, 202 (M+1). c) 3-Amino-7-bromo-quinoline-2-carboxylic acid ethyl ester [0355] A solution of ethyl bromopyruvate (3.57 ml, 27.5 mmol) in ethanol (25 ml) was added dropwise to a mixture of pyridine (2.2ml, 27.5 mmol) and ethanol (20 ml) at room temperature for a period of more than 30 minutes and reaction mixture was stirred at room temperature for 1 h. Then the mixture was stirred at 60oC for 2 h and was cooled to room temperature. To the mixture was added 2- amino-4-bromo-benzaldehyde (5g, 25 mmol) and pyridine (20 ml). The mixture was refluxed at 85oC for 4 hours. Pyrrolidine (5 ml, 62.5 mmol) was added and the mixture was refluxed at 85oC for 4 hours. The reaction mixture was concentrated on rotavapor, mixed with water, and extracted with ethyl acetate. The organic layer was separated, dried over sodium sulfate and concentrated to yield the crude product. The
obtained crude was purified by column chromatography using 0-2% ethyl acetate in DCM as the eluent to give 1 g of the title compound. MS: (+) m/z 295, 297 (M+1). d) 7-Bromo-3-hydroxy-quinoline-2-carboxylic acid ethyl ester [0356] Compound 3-amino-7-bromo-quinoline-2-carboxylic acid ethyl ester (2g, 6.77 mmol) was dissolved in anhydrous THF (20 mL) and placed in an ice bath. With vigorous stirring, concentrated H2SO4 (1.08 mL, 20.33 mmol) was slowly added to give a thick suspension. Butyl nitrite (2.3 mL, 20.33 mmol) was then added dropwise, and the resulting suspension was stirred vigorously in the ice bath for 2 h. The mixture was diluted with 10 mL of cold THF and the solid was isolated by filtration and dried under high vacuum for several hours. In a separate flask, glacial acetic acid (20 mL) was heated to 115oC. The solid from above was suspended in glacial acetic acid (20 mL) and added to the pre-heated acetic acid, and the resulting homogeneous mixture was then stirred at 115-120oC for 16 h. The reaction mixture was cooled to room temperature and concentrated to dryness. The residue was re-dissolved in absolute EtOH (30 mL) and placed in ice bath. Thionyl chloride (1 mL) was added, and the mixture was warmed to room temperature and refluxed for 16h. The mixture was concentrated on rotavapor. Ethyl acetate was added to the reaction mixture and washed with water and aqueous sodium bicarbonate solution. The organic layer was separated, dried over sodium sulfate and concentrated to yield the crude product. The obtained crude was purified by column chromatography using 5% ethyl acetate in DCM as eluent to yield 415 mg of the title compound. MS: (+) m/z 296, 298 (M+1). e) 3-Benzyloxy-7-bromo-quinoline-2-carboxylic acid ethyl ester [0357] A mixture of 7-bromo-3-hydroxy-quinoline-2-carboxylic acid ethyl ester (0.2 g, 0.56 mmol), Cs2CO3 (0.33 g, 1.01 mmol) and benzyl bromide (0.139 g, 0.81 mmol) in tetrahydrofuran (2 mL) was stirred at room temperature for 3 h. The reaction mixture was diluted with water and extracted with ethyl acetate. The organic layer was washed with water and brine, dried over Na2SO4 and evaporated to yield the crude product. The crude was purified by flash column chromatography (using 5-20% EtOAc in heptane) to afford 150 mg of the title compound. MS: (+) m/z 386, 388 (M+1). f) 3-Benzyloxy-7-bromo-quinoline-2-carboxylic acid [0358] To a solution of 3-benzyloxy-7-bromo-quinoline-2-carboxylic acid ethyl ester (150 mg, 0.388 mmol) in THF/H2O (9 mL/0.5 mL) was added lithium hydroxide monohydrate (48 mg, 1.14 mmol, 3.0 eq) and stirred at room temperature for 4 h. The reaction mixture was evaporated in vacuo and diluted in water. The pH of the aqueous layer was adjusted to 4 using 1N HCl, the resulting mixture was filtered, washed with water and dried to obtain the title compound (120 mg). MS: (+) m/z 358, 360 (M+1).
g) 4-(3-Benzyloxy-7-bromo-quinolin-2-yl)-3,3-bis-tert-butoxycarbonyl-4-oxo-butyric acid ethyl ester [0359] A solution of 3-benzyloxy-7-bromo-quinoline-2-carboxylic acid (3.5 g, 9.8 mmol, 1 eq.). oxalyl chloride (2 eq.) and catalytic DMF in THF (35 ml) was stirred at 0oC for 1 h then at room temperature for 1 h. THF was distilled off under vacuum to obtain acid chloride. In a separate flask, NaH (3 eq) was added to a solution of 2-tert-butoxycarbonyl-succinic acid 1-tert-butyl ester 4-ethyl ester (1.5 eq) in anhydrous THF at room temperature and stirred at 40oC for 4 h. The above prepared acid chloride in anhydrous THF was added at room temperature and the reaction mixture stirred at room temperature for 2 h. The reaction was quenched with aqueous ammonium chloride, extracted with EtOAc and purified by flash column chromatography to give 3.1 g of the title compound. MS: (+) m/z 642, 644 (M+1). h) 4-(3-Benzyloxy-7-bromo-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0360] A solution of 4-(3-benzyloxy-7-bromo-quinolin-2-yl)-3,3-bis-tert-butoxycarbonyl-4-oxo- butyric acid ethyl ester (3.1 g, 4.8 mmol, 1 eq) and p-toluenesulfonic acid (99 mg, catalytic amount) in toluene (18.6 ml) was stirred at 120oC for 3 h. The reaction mixture was concentrated and partitioned between EtOAc and water. The organic layer was dried over Na2SO4, concentrated and purified by flash column chromatography to obtain 1.6 g of the title compound. MS: (+) m/z 442, 444 (M+1). i) 4-(7-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0361] A mixture of 4-(3-benzyloxy-7-bromo-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (0.13 g, 0.294 mmol) and thioanisole (0.161 g, 1.47 mmol) in TFA (1.0 mL) was heated at 90oC for 4 h. The reaction mixture was quenched with aqueous sodium bicarbonate solution to pH 8. The mixture was extracted with ethyl acetate, and the ethyl acetate layer was concentrated under reduced pressure and purified by flash column chromatography to yield 60 mg of the title compound. MS: (+) m/z 352, 354 (M+1). j) 4-[7-(2-Chloro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0362] To a solution of 4-(7-bromo-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (179 mg, 0.51 mmol, prepared from 47i) in toluene (3.4 mL) and H2O (18 mg) at room temperature were added 2-chlorophenylboronic acid (119 mg, 0.76 mmol), K3PO4 (216 mg, 1.01 mmol), Pd(OAc)2 (2.3 mg, 0.01 mmol), and S-Phos (10.4 mg, 0.03 mmol) to give a suspension. The reaction mixture was allowed to stir at 100°C for 18 h. After cooled to room temperature, the mixture was diluted with EtOAc (100 mL), filtered through a Celite plug, and rinsed with EtOAc (100 mL). The organic layers were washed with 0.1 N HCl solution and water, dried over MgSO4, and concentrated in vacuo. The residue was purified by ISCO over silica gel, eluting with 2-35% EtOAc / hexanes to give the title compound (178 mg). MS (m/z) 383.9 (M+1)+.
k) 4-[4-Bromo-7-(2-chloro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0363] To a solution of 4-[7-(2-chloro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester (178 mg, 0.46 mmol) in DMF (4.6 mL) at room temperature was added NBS (86.8 mg, 0.48 mmol) to give a suspension. The reaction mixture was stirred at room temperature for 1 h, and diluted with EtOAc (100 mL). The organic layer was washed with Na2S2O3 solution and water, dried over MgSO4, and concentrated in vacuo. The residue was purified by ISCO over silica gel, eluting with 2-35% EtOAc / hexanes to give the product (110 mg). MS (m/z) 461.8, 463.8 (M+1)+. l) 4-[7-(2-Chloro-phenyl)-4-cyano-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0364] To a solution of 4-[4-bromo-7-(2-chloro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester (110 mg, 0.24 mmol) in DMAC (3.4 mL) at room temperature were added Zn(CN)2 (56 mg, 0.48 mmol), Pd2(dba)3 (22 mg, 0.024 mmol), dppf (26 mg, 0.048 mmol), and Zn dust (4.6 mg, 0.07 mmol) to give a suspension. The reaction mixture was allowed to stir at 100°C for 2 hours. After cooled to room temperature, the mixture was diluted with EtOAc (50 mL), filtered through a Celite plug, and rinsed with EtOAc (50 mL). The organic layers were washed with 0.1 N HCl solution and water, dried over MgSO4, and concentrated in vacuo. The residue was purified by ISCO over silica gel, eluting with 2-35% EtOAc / hexanes to give the product (32.4 mg). MS (m/z) 406.9 (M-1)+. m) 4-[7-(2-Chloro-phenyl)-4-cyano-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid [0365] To a solution of the 4-[7-(2-chloro-phenyl)-4-cyano-3-hydroxy-quinolin-2-yl]-4-oxo- butyric acid ethyl ester (32.4 mg, 0.07 mmol) in MeOH (2 mL) and water (0.65 mL) at room temperature was added lithium hydroxide monohydrate (13.3 mg, 0.31 mmol) to give a suspension. The reaction mixture was stirred at room temperature for 24 h, concentrated in vacuo to remove methanol. The residue was dissolved in water (15 mL) and washed with EtOAc(3 x 5 mL). The aqueous solution was acidified by 1N HCl solution, filtered, washed with water, and dried to give the product (20.9 mg). MS (m/z) 378.9 (M-1)+. Example 48 4-[7-(3-Chloro-phenyl)-4-cyano-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid a) 4-[7-(3-Chloro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0366] The title compound was prepared from 4-(7-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from Example 47i) and 3-chlorophenylboronic acid in analogy to Example 47j. MS (m/z) 384.0 (M+1)+. b) 4-[4-Bromo-7-(3-chloro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0367] The title compound was prepared from 4-[7-(3-chloro-phenyl)-3-hydroxy-quinolin-2-yl]- 4-oxo-butyric acid ethyl ester and NBS in analogy to Example 47k. MS (m/z) 461.8, 463.8 (M+1)+.
c) 4-[7-(3-Chloro-phenyl)-4-cyano-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0368] The title compound was prepared from 4-[4-bromo-7-(3-chloro-phenyl)-3-hydroxy- quinolin-2-yl]-4-oxo-butyric acid ethyl ester and Zn(CN)2 in analogy to Example 47l. MS (m/z) 408.9 (M+1)+. d) 4-[7-(3-Chloro-phenyl)-4-cyano-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid [0369] The title compound was prepared from 4-[7-(3-chloro-phenyl)-4-cyano-3-hydroxy- quinolin-2-yl]-4-oxo-butyric acid ethyl ester and LiOH.H2O in analogy to Example 47m. MS (m/z) 380.9 (M+1)+. Example 49 4-[7-(4-Chloro-phenyl)-4-cyano-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid a) 4-[7-(4-Chloro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0370] The title compound was prepared from 4-(7-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from Example 47i) and 4-chlorophenylboronic acid in analogy to Example 47j. MS (m/z) 384.0 (M+1)+. b) 4-[4-Bromo-7-(4-chloro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0371] The title compound was prepared from 4-[7-(4-chloro-phenyl)-3-hydroxy-quinolin-2-yl]- 4-oxo-butyric acid ethyl ester and NBS in analogy to Example 47k. MS (m/z) 461.8, 463.8 (M+1)+. c) 4-[7-(4-Chloro-phenyl)-4-cyano-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0372] The title compound was prepared from 4-[4-bromo-7-(4-chloro-phenyl)-3-hydroxy- quinolin-2-yl]-4-oxo-butyric acid ethyl ester and Zn(CN)2 in analogy to Example 47l. MS (m/z) 408.9 (M+1)+. d) 4-[7-(4-Chloro-phenyl)-4-cyano-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid [0373] The title compound was prepared from 4-[7-(4-chloro-phenyl)-4-cyano-3-hydroxy- quinolin-2-yl]-4-oxo-butyric acid ethyl ester and LiOH.H2O in analogy to Example 47m. MS (m/z) 381.0 (M+1)+.
Example 50 4-[4-Cyano-7-(4-fluoro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid a) 4-[7-(4-Fluoro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0374] The title compound was prepared from 4-(7-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from Example 47i) and 4-fluorophenylboronic acid in analogy to Example 47j. MS (m/z) 368.0 (M+1)+. b) 4-[4-Bromo-7-(4-fluoro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0375] The title compound was prepared from 4-[7-(4-fluoro-phenyl)-3-hydroxy-quinolin-2-yl]- 4-oxo-butyric acid ethyl ester and NBS in analogy to Example 47k. MS (m/z) 445.9, 447.9 (M+1)+. c) 4-[4-Cyano-7-(4-fluoro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0376] The title compound was prepared from 4-[4-bromo-7-(4-fluoro-phenyl)-3-hydroxy- quinolin-2-yl]-4-oxo-butyric acid ethyl ester and Zn(CN)2 in analogy to Example 47l. MS (m/z) 393.0 (M+1)+. d) 4-[4-Cyano-7-(4-fluoro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid [0377] The title compound was prepared from 4-[4-cyano-7-(4-fluoro-phenyl)-3-hydroxy- quinolin-2-yl]-4-oxo-butyric acid ethyl ester and LiOH.H2O in analogy to 47m. MS (m/z) 363.0 (M-1)+. Example 51 4-[4-Cyano-7-(3-fluoro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid a) 4-[7-(3-Fluoro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0378] The title compound was prepared from 4-(7-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from Example 47i) and 3-fluorophenylboronic acid in analogy to Example 47j. MS (m/z) 368.1 (M+1)+. b) 4-[4-Bromo-7-(3-fluoro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0379] The title compound was prepared from 4-[7-(3-fluoro-phenyl)-3-hydroxy-quinolin-2-yl]- 4-oxo-butyric acid ethyl ester and NBS in analogy to Example 47k. MS (m/z) 445.9, 447.8 (M+1)+. c) 4-[4-Cyano-7-(3-fluoro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0380] The title compound was prepared from 4-[4-bromo-7-(3-fluoro-phenyl)-3-hydroxy- quinolin-2-yl]-4-oxo-butyric acid ethyl ester and Zn(CN)2 in analogy to Example 47l. MS (m/z) 393.0 (M+1)+.
d) 4-[4-Cyano-7-(3-fluoro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid [0381] The title compound was prepared from 4-[4-cyano-7-(3-fluoro-phenyl)-3-hydroxy- quinolin-2-yl]-4-oxo-butyric acid ethyl ester and LiOH.H2O in analogy to Example 47m. MS (m/z) 362.9 (M-1)+. Example 52 4-[4-Cyano-7-(2-fluoro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid a) 7-Bromo-3-hydroxy-4-iodo-quinoline-2-carboxylic acid ethyl ester [0382] To a solution of 7-bromo-3-hydroxy-quinoline-2-carboxylic acid ethyl ester (1.31 g, 4.42 mmol, prepared from Example 47d) in CH2Cl2 (44 mL) at room temperature was added I(collidine)PF6 (2.5 g, 4.86 mmol) to give a suspension. The reaction mixture was stirred at room temperature for 1 h, diluted with EtOAc (100 mL), and washed by Na2S2O3 solution and water. The organic layer was dried over MgSO4 and concentrated in vacuo. The residue was purified by ISCO over silica gel, eluting with 2- 35% EtOAc / hexanes to give the product (1.79 g). MS (m/z) 421.7, 423.7 (M+1)+. b) 3-Benzyloxy-7-bromo-4-iodo-quinoline-2-carboxylic acid ethyl ester [0383] To a solution of 7-bromo-3-hydroxy-4-iodo-quinoline-2-carboxylic acid ethyl ester (1.76 g, 4.17 mmol) in DMF (42 mL) at room temperature were added potassium carbonate (1.15 g, 8.34 mmol) and benzyl bromide (1.07 g, 6.25 mmol) to give a suspension. The reaction mixture was stirred at room temperature for 3 h, diluted with EtOAc (100 mL), filtered through a Celite plug, and rinsed with EtOAc (50 mL). The organic layer was washed with 0.1 N HCl solution and water, dried over MgSO4 and concentrated in vacuo. The residue was purified by ISCO over silica gel, eluting with 2-35% EtOAc / hexanes to give the product (1.47 g). MS (m/z) 511.7, 513.7 (M+1)+. c) 3-Benzyloxy-7-bromo-4-cyano-quinoline-2-carboxylic acid ethyl ester [0384] To a solution of 3-benzyloxy-7-bromo-4-iodo-quinoline-2-carboxylic acid ethyl ester (1.26 g, 2.46 mmol) in DMAC (12.3 mL) at room temperature was added CuCN (660 mg, 7.38 mmol) to give a suspension. The reaction mixture was stirred at 140 ºC for 2 h, cooled to room temperature, diluted with EtOAc (100 mL), filtered through a celite plug, and rinsed with EtOAc (100 mL). The organic layer was washed with 0.1 N HCl solution and water, dried over MgSO4 and concentrated in vacuo. The residue was purified by ISCO over silica gel, eluting with 10-50% EtOAc / hexanes to give the product (398 mg). MS (m/z) 410.9, 412.9 (M+1)+. d) 3-Benzyloxy-7-bromo-4-cyano-quinoline-2-carboxylic acid [0385] To a solution of the 3-benzyloxy-7-bromo-4-cyano-quinoline-2-carboxylic acid ethyl ester (398 mg, 0.96 mmol) in THF (7.2 mL) and water (2.5 mL) at room temperature was added lithium hydroxide monohydrate (162 mg, 3.87 mmol). The reaction mixture was stirred at room temperature for
24 h, and concentrated in vacuo. The aqueous solution was acidified by 1N HCl solution, filtered, washed with water, dried to give crude product (371 mg). MS (m/z) 382.9, 384.9 (M+1)+. e) 4-(3-Benzyloxy-7-bromo-4-cyano-quinolin-2-yl)-3,3-bis-tert-butoxycarbonyl-4-oxo-butyric acid ethyl ester [0386] To a solution of the 3-benzyloxy-7-bromo-4-cyano-quinoline-2-carboxylic acid (371 mg, 0.96 mmol) in THF (4.8 mL) was added oxalyl chloride (245 mg, 1.93 mmol) and 1 drop of DMF at 0 ºC. The mixture was stirred at 0 ºC for 1 h, then allowed to warm to room temperature for another 1 h. Removal of solvent and drying under vacuum gave 3-benzyloxy-7-bromo-4-cyano-quinoline-2-carbonyl chloride as the crude product. It was used in the next step without further purification. [0387] To a suspension of 60% NaH (44 mg, 1.83 mol) in THF (4.8 ml) at 0 °C was slowly added a solution of 2-tert-butoxycarbonyl-succinic acid 1-tert-butyl ester 4-ethyl ester (438 mg, 1.45 mol) in THF. The resulting mixture was stirred at 40 °C for 2 h, after which 3-benzyloxy-7-bromo-4- cyano-quinoline-2-carbonyl chloride in THF (1.5 mL) was added. The solution was allowed to stir for 20 h at room temperature. The reaction mixture was quenched with saturated NH4Cl solution and was extracted with EtOAc. The extract was dried over MgSO4 and concentrated in vacuo. The residue was purified by ISCO over silica gel, eluting with 2-50% EtOAc / hexanes, to give the product (451 mg). MS (m/z) 666.9, 669.1 (M+1)+. f) 4-(7-Bromo-4-cyano-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0388] To a solution of 4-(3-benzyloxy-7-bromo-4-cyano-quinolin-2-yl)-3,3-bis-tert- butoxycarbonyl-4-oxo-butyric acid ethyl ester (451 mg, 0.67 mmol) in toluene (6.7 mL) was added p- toluenesulfonic acid monohydrate (64 mg, 0.34 mmol). The reaction mixture was refluxed for 2 h, cooled to room temperature, and diluted with EtOAc (50 mL). The organic layer was washed with NaHCO3 solution and water, dried over MgSO4, and concentrated in vacuo The residue was purified by ISCO over silica gel, eluting with 10-50% EtOAc / hexanes to give the product (167 mg). MS (m/z) 376.9, 378.9 (M+1)+. g) 4-[4-Cyano-7-(2-fluoro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0389] To a solution of 4-(7-bromo-4-cyano-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (116 mg, 0.31 mmol) in toluene (3.1 mL) and H2O (11 mg) at room temperature were added 2- fluorophenylboronic acid (64.5 mg, 0.46 mmol), K3PO4 (131 mg, 1.01 mmol), Pd(OAc)2 (3.4 mg, 0.02 mmol), and S-Phos (12.5 mg, 0.03 mmol). The reaction mixture was allowed to stir at 100°C for 48 h, cooled to room temperature, diluted with EtOAc (50 mL), filtered through a Celite plug, and rinsed with EtOAc (50 mL). The organic layers were washed with 0.1 N HCl solution and water, dried over MgSO4 and concentrated in vacuo. The residue was purified by ISCO over silica gel, eluting with 2-35% EtOAc / hexanes to give the product (70.4 mg). MS (m/z) 393.0 (M+1)+.
[0390] The title compound was prepared from 4-[4-cyano-7-(2-fluoro-phenyl)-3-hydroxy- quinolin-2-yl]-4-oxo-butyric acid ethyl ester and LiOH.H2O in analogy to Example 47m. MS (m/z) 364.9 (M+1)+. Example 53 4-[4-Cyano-3-hydroxy-7-(2-methoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid a) 4-[3-Hydroxy-7-(2-methoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0391] The title compound was prepared from 4-(7-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from 47i) and 2-methoxyphenylboronic acid to give the title compound in analogy to Example 47j. MS (m/z) 380.0 (M+1)+. b) 4-[4-Bromo-3-hydroxy-7-(2-methoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0392] The title compound was prepared from 4-[3-Hydroxy-7-(2-methoxy-phenyl)-quinolin-2- yl]-4-oxo-butyric acid ethyl ester and NBS to give the title compound in analogy to Example 47k. MS (m/z) 457.9, 459.9 (M+1)+. c) 4-[4-Cyano-3-hydroxy-7-(2-methoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0393] The title compound was prepared from 4-[4-Bromo-3-hydroxy-7-(2-methoxy-phenyl)- quinolin-2-yl]-4-oxo-butyric acid ethyl ester and Zn(CN)2 to give the title compound in analogy to Example 47l. MS (m/z) 405.0 (M+1)+. d) 4-[4-Cyano-3-hydroxy-7-(2-methoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid [0394] The title compound was prepared from 4-[4-Cyano-3-hydroxy-7-(2-methoxy-phenyl)- quinolin-2-yl]-4-oxo-butyric acid ethyl ester and LiOH.H2O to give the title compound in analogy to Example 47m. MS (m/z) 377.0 (M+1)+. Example 54 4-[4-Cyano-3-hydroxy-7-(4-methoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid a) 4-[3-Hydroxy-7-(4-methoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0395] The title compound was prepared from 4-(7-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from 47i) and 4-methoxyphenylboronic acid to give the title compound in analogy to Example 47j. MS (m/z) 380.1 (M+1)+.
b) 4-[4-Bromo-3-hydroxy-7-(4-methoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0396] The title compound was prepared from 4-[3-Hydroxy-7-(4-methoxy-phenyl)-quinolin-2- yl]-4-oxo-butyric acid ethyl ester and NBS to give the title compound in analogy to Example 47k. MS (m/z) 457.9, 459.9 (M+1)+. c) 4-[4-Cyano-3-hydroxy-7-(4-methoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0397] The title compound was prepared from 4-[4-Bromo-3-hydroxy-7-(4-methoxy-phenyl)- quinolin-2-yl]-4-oxo-butyric acid ethyl ester and Zn(CN)2 to give the title compound in analogy to Example 47l. MS (m/z) 405.0 (M+1)+. d) 4-[4-Cyano-3-hydroxy-7-(4-methoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid [0398] The title compound was prepared from 4-[4-Cyano-3-hydroxy-7-(4-methoxy-phenyl)- quinolin-2-yl]-4-oxo-butyric acid ethyl ester and LiOH.H2O to give the title compound in analogy to Example 47m. MS (m/z) 377.0 (M+1)+. Example 55 4-[4-Cyano-8-(4-fluoro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid a) (2-Amino-3-bromo-phenyl)-methanol [0399] To a solution of 2-amino-3-bromo benzoic acid (10g, 46.2 mmol) in THF (100ml), LAH (2.5 g, 69.3 mmol) was added at 0oC and stirred at room temperature for 8h. The reaction was quenched using saturated solution of sodium sulfate and filtered through Celite bed to yield 7 g of the title compound after trituration with hexane. MS: (+) m/z 202, 204 (M+1). b) 2-Amino-3-bromo-benzaldehyde [0400] To a solution of (2-Amino-3-bromo-phenyl)-methanol (7 g, 34.65 mmol) in DCM (200 mL) at room temperature was added MnO2 (30.14g, 346 mmol) in portions. Reaction mixture was stirred at room temperature for 10 h. Reaction mixture was filtered through a pad of Celite and washed with DCM. The filtrate was concentrated in vacuo to yield the crude product. The obtained crude was purified by column chromatography (10% EtOAc/hexane) to yield 5 g of the title compound. MS: (+) m/z 200, 202 (M+1). c) 3-Amino-8-bromo-quinoline-2-carboxylic acid ethyl ester [0401] A solution of ethyl bromopyruvate (3.57 ml, 27.5 mmol) in ethanol (25 ml) was added dropwise to a mixture of pyridine (2.2ml, 27.5 mmol) and ethanol (20 ml) at room temperature for a period of more than 30 minutes. The reaction mixture was stirred at room temperature for 1 h, at 60oC for 2 h, and then was cooled to room temperature. To the mixture was added 2-Amino-3-bromo- benzaldehyde (5g, 25 mmol) and pyridine (20 ml). The mixture was refluxed at 85oC for 4 hours.
Pyrrolidine (5 ml, 62.5 mmol) was added and the mixture was refluxed at 85oC for 4 hours. The reaction mixture was concentrated on rotavapor, mixed with water and extracted with ethyl acetate. The organic layer was separated, dried over sodium sulfate and concentrated to yield the crude product. The obtained crude was purified by column chromatography using 0-2% ethyl acetate in DCM as eluent gave 1 g of the title compound. MS: (+) m/z 295, 297 (M+1). d) 8-Bromo-3-hydroxy-quinoline-2-carboxylic acid ethyl ester [0402] 3-Amino-8-bromo-quinoline-2-carboxylic acid ethyl ester (2g, 6.77 mmol) was dissolved in anhydrous THF (20 mL) and placed in an ice bath. With vigorous stirring, concentrated H2SO4 (1.08 mL, 20.33 mmol) was slowly added to give a thick suspension. Butyl nitrite (2.3 mL, 20.33 mmol) was then added dropwise, and the resulting suspension was stirred vigorously in the ice bath for 2 h. The mixture was diluted with 10 mL of cold THF and the solid was isolated by filtration and dried under high vacuum for several hours. In a separate flask, glacial acetic acid (20 mL) was heated to 115oC. The solid from above was suspended in glacial acetic acid (20 mL) and added to the pre-heated acetic acid, and the resulting homogeneous mixture was then stirred at 115-120oC for 16 h. The reaction mixture was allowed to come to room temperature and concentrated to dryness. The residue was re-dissolved in absolute EtOH (30 mL) and placed in ice bath. Thionyl chloride (1 mL) was added, and the mixture was warmed to room temperature and refluxed for 16h. The mixture was concentrated on rotavapor. Ethyl acetate was added to the reaction mixture and washed with water and aqueous sodium bicarbonate solution. The organic layer was separated, dried over sodium sulfate and concentrated to yield the crude product. The obtained crude was purified by column chromatography using 5% ethyl acetate in DCM as eluent to yield 415mg of the title compound. MS: (+) m/z 296, 298 (M+1). e) 3-Benzyloxy-8-bromo-quinoline-2-carboxylic acid ethyl ester [0403] A mixture of compound 8-bromo-3-hydroxy-quinoline-2-carboxylic acid ethyl ester (0.2 g, 0.56 mmol), Cs2CO3 (0.33 g, 1.01 mmol) and benzyl bromide (0.139 g, 0.81 mmol) in tetrahydrofuran (2 mL) was stirred at room temperature for 3 h. The reaction mixture was diluted with water and extracted with ethyl acetate. The organic layer was washed with water and brine, dried over Na2SO4 and evaporated to yield the crude product. The crude was purified by flash column chromatography (using 5- 20% EtOAc in heptane) to afford 150 mg of the title compound. MS: (+) m/z 386, 388 (M+1). f) 3-Benzyloxy-8-bromo-quinoline-2-carboxylic acid [0404] To a solution of compound 3-benzyloxy-8-bromo-quinoline-2-carboxylic acid ethyl ester (150 mg, 0.388 mmol) in THF/H2O (9 mL/0.5 mL) was added lithium hydroxide monohydrate (48 mg, 1.14 mmol, 3.0 eq) and stirred at room temperature for 4 h. The reaction mixture was evaporated in vacuo and diluted with water. The pH of the aqueous layer was adjusted to 4 using 1N HCl. The resulting mixture was filtered, washed with water and dried to obtain the title compound (120 mg). MS: (+) m/z 358, 360 (M+1).
g) 4-(3-Benzyloxy-8-bromo-quinolin-2-yl)-3,3-bis-tert-butoxycarbonyl-4-oxo-butyric acid ethyl ester [0405] A solution of compound 3-benzyloxy-8-bromo-quinoline-2-carboxylic acid (3.5 g, 9.8 mmol, 1 eq.). oxalyl chloride (2 eq.) and catalytic DMF in THF (35 ml) was stirred at 0oC for 1 h, then at room temperature for 1 h. THF was distilled off under vacuum to obtain acid chloride. In a separate flask, NaH (3 eq) was added to a solution of 2-tert-butoxycarbonyl-succinic acid 1-tert-butyl ester 4-ethyl ester (1.5 eq) in anhydrous THF at room temperature and stirred at 40oC for 4 h. The above prepared acid chloride in anhydrous THF was added at room temperature and the reaction mixture stirred at room temperature for 2 h. The reaction was quenched with aqueous ammonium chloride, extracted with EtOAc and purified by flash column chromatography to give 3.1 g of the title compound. MS: (+) m/z 642, 644 (M+1). h) 4-(3-Benzyloxy-8-bromo-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0406] A solution of 4-(3-benzyloxy-8-bromo-quinolin-2-yl)-3,3-bis-tert-butoxycarbonyl-4-oxo- butyric acid ethyl ester (3.1 g, 4.8 mmol, 1 eq) and p-toluenesulfonic acid (99 mg, catalytic amount) in toluene (18.6 ml) was stirred at 120oC for 3 h. The reaction mixture was concentrated and partitioned between EtOAc and water. The organic layer was dried over Na2SO4, concentrated and purified by flash column chromatography to obtain 1.6 g of the title compound. MS: (+) m/z 442, 444 (M+1). i) 4-(8-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0407] A mixture of 4-(3-benzyloxy-8-bromo-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (0.13 g, 0.294 mmol) and thioanisole (0.161 g, 1.47 mmol) in TFA (1.0 mL) was heated at 90oC for 4 h. The reaction mixture was quenched with aqueous sodium bicarbonate solution to pH 8. The mixture was extracted with ethyl acetate, and the ethyl acetate layer was concentrated under reduced pressure and purified by flash column chromatography to yield 60 mg of the title compound. MS: (+) m/z 352, 354 (M+1). j) 4-[8-(4-Fluoro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0408] The title compound was prepared from 4-(8-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester and 4-fluorophenylboronic acid in analogy to Example 47j. MS (m/z) 368.1 (M+1)+. k) 4-[4-Bromo-8-(4-fluoro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0409] The title compound was prepared from 4-[8-(4-fluoro-phenyl)-3-hydroxy-quinolin-2-yl]- 4-oxo-butyric acid ethyl ester and NBS in analogy to Example 47k. MS (m/z) 445.9, 447.8 (M+1)+.
l) 4-[4-Cyano-8-(4-fluoro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0410] The title compound was prepared from 4-[4-bromo-8-(4-fluoro-phenyl)-3-hydroxy- quinolin-2-yl]-4-oxo-butyric acid ethyl ester and Zn(CN)2 in analogy to Example 47l. MS (m/z) 393.1 (M+1)+. m) 4-[4-Cyano-8-(4-fluoro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid [0411] The title compound was prepared from 4-[4-cyano-8-(4-fluoro-phenyl)-3-hydroxy- quinolin-2-yl]-4-oxo-butyric acid ethyl ester and LiOH.H2O in analogy to Example 47m. MS (m/z) 364.9 (M+1)+. Example 56 4-[4-Cyano-8-(3-fluoro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid a) 4-[8-(3-Fluoro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0412] The title compound was prepared from 4-(8-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from Example 55i) and 3-fluorophenylboronic acid in analogy to Example 47j. MS (m/z) 368.1 (M+1)+. b) 4-[4-Bromo-8-(3-fluoro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0413] The title compound was prepared from 4-[8-(3-fluoro-phenyl)-3-hydroxy-quinolin-2-yl]- 4-oxo-butyric acid ethyl ester and NBS in analogy to Example 47k. MS (m/z) 445.9, 447.9 (M+1)+. c) 4-[4-Cyano-8-(3-fluoro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0414] The title compound was prepared from 4-[4-bromo-8-(3-fluoro-phenyl)-3-hydroxy- quinolin-2-yl]-4-oxo-butyric acid ethyl ester and Zn(CN)2 in analogy to Example 47l. MS (m/z) 393.0 (M+1)+. d) 4-[4-Cyano-8-(3-fluoro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid [0415] The title compound was prepared from 4-[4-cyano-8-(3-fluoro-phenyl)-3-hydroxy- quinolin-2-yl]-4-oxo-butyric acid ethyl ester and LiOH.H2O in analogy to Example 47m. MS (m/z) 364.9 (M+1)+.
Example 57 4-[4-Cyano-8-(2-fluoro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid a) 4-[8-(2-Fluoro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0416] The title compound was prepared from 4-(8-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from Example 55i) and 2-fluorophenylboronic acid in analogy to Example 47j. MS (m/z) 368.0 (M+1)+. b) 4-[4-Bromo-8-(2-fluoro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0417] The title compound was prepared from 4-[8-(2-fluoro-phenyl)-3-hydroxy-quinolin-2-yl]- 4-oxo-butyric acid ethyl ester and NBS in analogy to Example 47k. MS (m/z) 445.8, 447.8 (M+1)+. c) 4-[4-Cyano-8-(2-fluoro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0418] The title compound was prepared from 4-[4-bromo-8-(2-fluoro-phenyl)-3-hydroxy- quinolin-2-yl]-4-oxo-butyric acid ethyl ester and Zn(CN)2 in analogy to Example 47l. MS (m/z) 393.0 (M+1)+. d) 4-[4-Cyano-8-(2-fluoro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid [0419] The title compound was prepared from 4-[4-cyano-8-(2-fluoro-phenyl)-3-hydroxy- quinolin-2-yl]-4-oxo-butyric acid ethyl ester and LiOH.H2O in analogy to Example 47m. MS (m/z) 365.0(M+1)+. Example 58 4-[8-(4-Chloro-phenyl)-4-cyano-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid a) 4-[8-(4-Chloro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0420] The title compound was prepared from 4-(8-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from Example 55i) and 4-chlorophenylboronic acid in analogy to Example 47j. MS (m/z) 384.0 (M+1)+. b) 4-[4-Bromo-8-(4-chloro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0421] The title compound was prepared from 4-[8-(4-chloro-phenyl)-3-hydroxy-quinolin-2-yl]- 4-oxo-butyric acid ethyl ester and NBS in analogy to Example 47k. MS (m/z) 461.8, 463.8 (M+1)+. c) 4-[8-(4-Chloro-phenyl)-4-cyano-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0422] The title compound was prepared from 4-[4-bromo-8-(4-chloro-phenyl)-3-hydroxy- quinolin-2-yl]-4-oxo-butyric acid ethyl ester and Zn(CN)2 in analogy to Example 47l. MS (m/z) 408.9 (M+1)+.
d) 4-[8-(4-Chloro-phenyl)-4-cyano-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid [0423] The title compound was prepared from 4-[8-(4-chloro-phenyl)-4-cyano-3-hydroxy- quinolin-2-yl]-4-oxo-butyric acid ethyl ester and LiOH.H2O in analogy to Example 47m. MS (m/z) 380.9 (M+1)+. Example 59 4-[8-(3-Chloro-phenyl)-4-cyano-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid a) 4-[8-(3-Chloro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0424] The title compound was prepared from 4-(8-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from Example 55i) and 3-chlorophenylboronic acid in analogy to Example 47j. MS (m/z) 384.0 (M+1)+. b) 4-[4-Bromo-8-(3-chloro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0425] The title compound was prepared from 4-[8-(3-chloro-phenyl)-3-hydroxy-quinolin-2-yl]- 4-oxo-butyric acid ethyl ester and NBS in analogy to Example 47k. MS (m/z) 461.9, 463.8 (M+1)+. c) 4-[8-(3-Chloro-phenyl)-4-cyano-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0426] The title compound was prepared from 4-[4-bromo-8-(3-chloro-phenyl)-3-hydroxy- quinolin-2-yl]-4-oxo-butyric acid ethyl ester and Zn(CN)2 in analogy to Example 47l. MS (m/z) 408.9 (M+1)+. d) 4-[8-(3-Chloro-phenyl)-4-cyano-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid [0427] To a solution of the 4-[8-(3-chloro-phenyl)-4-cyano-3-hydroxy-quinolin-2-yl]-4-oxo- butyric acid ethyl ester (64 mg, 0.16 mmol) in MeOH (3.9 mL) and water (1.3 mL) at room temperature, was added sodium hydroxide (25 mg, 0.64 mmol) to give a suspension. The reaction mixture was stirred at room temperature. After 4 h, the mixture was concentrated in vacuo to remove methanol. The residue was dissolved in water (15 mL), extracted with EtOAc(3 x 5 mL). The aqueous solution was acidified by 1N HCl solution. The resulting mixture was filtered, washed with water, and dried to give the product (22.5 mg). MS (m/z) 380.9 (M+1)+. Example 60 4-[8-(2-Chloro-phenyl)-4-cyano-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid a) 4-[8-(2-Chloro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0428] The title compound was prepared from 4-(8-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from Example 55i) and 2-chlorophenylboronic acid in analogy to Example 47j. MS (m/z) 384.0 (M+1)+.
b) 4-[4-Bromo-8-(2-chloro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0429] The title compound was prepared 4-[8-(2-chloro-phenyl)-3-hydroxy-quinolin-2-yl]-4- oxo-butyric acid ethyl ester and NBS in analogy to Example 47k. MS (m/z) 461.8, 463.8 (M+1)+. c) 4-[8-(2-Chloro-phenyl)-4-cyano-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0430] The title compound was prepared from 4-[4-bromo-8-(2-chloro-phenyl)-3-hydroxy- quinolin-2-yl]-4-oxo-butyric acid ethyl ester and Zn(CN)2 in analogy to Example 47l. MS (m/z) 408.9 (M+1)+. d) 4-[8-(2-Chloro-phenyl)-4-cyano-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid [0431] The title compound was prepared from 4-[8-(2-chloro-phenyl)-4-cyano-3-hydroxy- quinolin-2-yl]-4-oxo-butyric acid ethyl ester and sodium hydroxide in analogy to Example 59d: MS (m/z) 380.9 (M+1)+. Example 61 4-[4-Cyano-3-hydroxy-8-(4-methoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid a) 4-[3-Hydroxy-8-(4-methoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0432] The title compound was prepared from 4-(8-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from Example 55i) and 4-methoxyphenylboronic acid in analogy to Example 47j. MS (m/z) 380.0 (M+1)+. b) 4-[4-Bromo-3-hydroxy-8-(4-methoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0433] The title compound was prepared from 4-[3-hydroxy-8-(4-methoxy-phenyl)-quinolin-2- yl]-4-oxo-butyric acid ethyl ester and NBS in analogy to Example 47k. MS (m/z) 457.9, 459.9 (M+1)+. c) 4-[4-Cyano-3-hydroxy-8-(4-methoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0434] The title compound was prepared from 4-[4-bromo-3-hydroxy-8-(4-methoxy-phenyl)- quinolin-2-yl]-4-oxo-butyric acid ethyl ester and Zn(CN)2 in analogy to Example 47l. MS (m/z) 405.1 (M+1)+. d) 4-[4-Cyano-3-hydroxy-8-(4-methoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid [0435] The title compound was prepared from4-[4-cyano-3-hydroxy-8-(4-methoxy-phenyl)- quinolin-2-yl]-4-oxo-butyric acid ethyl ester and sodium hydroxide in analogy to Example 59d: MS (m/z) 377.1 (M+1)+.
Example 62 4-[4-Cyano-3-hydroxy-8-(2-methoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid a) 4-[3-Hydroxy-8-(2-methoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0436] The title compound was prepared from 4-(8-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from Example 55i) and 2-methoxyphenylboronic acid in analogy to Example 47j. MS (m/z) 380.1 (M+1)+. b) 4-[4-Bromo-3-hydroxy-8-(2-methoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0437] The title compound was prepared from 4-[3-hydroxy-8-(2-methoxy-phenyl)-quinolin-2- yl]-4-oxo-butyric acid ethyl ester and NBS in analogy to Example 47k. MS (m/z) 457.9, 459.9 (M+1)+. c) 4-[4-Cyano-3-hydroxy-8-(2-methoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0438] The title compound was prepared from 4-[4-bromo-3-hydroxy-8-(2-methoxy-phenyl)- quinolin-2-yl]-4-oxo-butyric acid ethyl ester and Zn(CN)2 in analogy to Example 47l. MS (m/z) 405.1 (M+1)+. d) 4-[4-Cyano-3-hydroxy-8-(2-methoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid [0439] The title compound was prepared from 4-[4-cyano-3-hydroxy-8-(2-methoxy-phenyl)- quinolin-2-yl]-4-oxo-butyric acid ethyl ester and sodium hydroxide in analogy to Example 59d: MS (m/z) 377.0 (M+1)+. Example 63 4-[4-Cyano-3-hydroxy-8-(3-methoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid a) 4-[3-Hydroxy-8-(3-methoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0440] The title compound was prepared from 4-(8-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from Example 55i) and 3-methoxyphenylboronic acid in analogy to Example 47j. MS (m/z) 384.0 (M+1)+. b) 4-[4-Bromo-3-hydroxy-8-(3-methoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0441] The title compound was prepared from 4-[3-hydroxy-8-(3-methoxy-phenyl)-quinolin-2- yl]-4-oxo-butyric acid ethyl ester and NBS in analogy to Example 47k. MS (m/z) 457.9, 459.9 (M+1)+. c) 4-[4-Cyano-3-hydroxy-8-(3-methoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0442] The title compound was prepared from 4-[4-bromo-3-hydroxy-8-(3-methoxy-phenyl)- quinolin-2-yl]-4-oxo-butyric acid ethyl ester and Zn(CN)2 in analogy to Example 47l. MS (m/z) 405.1 (M+1)+.
d) 4-[4-Cyano-3-hydroxy-8-(3-methoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid [0443] The title compound was prepared from 4-[4-cyano-3-hydroxy-8-(3-methoxy-phenyl)- quinolin-2-yl]-4-oxo-butyric acid ethyl ester and sodium hydroxide in analogy to Example 59d: MS (m/z) 377.1 (M+1)+. Example 64 4-[4-Cyano-3-hydroxy-7-(3-methoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid a) 4-[3-Hydroxy-7-(3-methoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0444] The title compound was prepared from 4-(7-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from 47i) and 3-methoxyphenylboronic acid in analogy to Example 47j. MS (m/z) 380.1 (M+1)+. b) 4-[4-Bromo-3-hydroxy-7-(3-methoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0445] The title compound was prepared 4-[3-hydroxy-7-(3-methoxy-phenyl)-quinolin-2-yl]-4- oxo-butyric acid ethyl ester from and NBS in analogy to Example 47k. MS (m/z) 457.9, 459.9 (M+1)+. c) 4-[4-Cyano-3-hydroxy-7-(3-methoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0446] The title compound was prepared from 4-[4-bromo-3-hydroxy-7-(3-methoxy-phenyl)- quinolin-2-yl]-4-oxo-butyric acid ethyl ester and Zn(CN)2 in analogy to Example 47l. MS (m/z) 405.1 (M+1)+. d) 4-[4-Cyano-3-hydroxy-7-(3-methoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid [0447] The title compound was prepared from 4-[4-cyano-3-hydroxy-7-(3-methoxy-phenyl)- quinolin-2-yl]-4-oxo-butyric acid ethyl ester and sodium hydroxide in analogy to Example 59d: MS (m/z) 377.1 (M+1)+. Example 65 4-[4-Cyano-3-hydroxy-7-(4-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid a) 4-[3-Hydroxy-7-(4-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0448] The title compound was prepared from 4-(7-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from 47i) and 4-trifluoromethylphenylboronic acid in analogy to Example 47j. MS (m/z) 418.0 (M+1)+.
b) 4-[4-Bromo-3-hydroxy-7-(4-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0449] The title compound was prepared from 4-[3-hydroxy-7-(4-trifluoromethyl-phenyl)- quinolin-2-yl]-4-oxo-butyric acid ethyl ester and NBS in analogy to Example 47k. MS (m/z) 495.8, 497.8 (M+1)+. c) 4-[4-Cyano-3-hydroxy-7-(4-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0450] The title compound was prepared from 4-[4-bromo-3-hydroxy-7-(4-trifluoromethyl- phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester and Zn(CN)2 in analogy to Example 47l. MS (m/z) 443.0 (M+1)+. d) 4-[4-Cyano-3-hydroxy-7-(4-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid [0451] The title compound was prepared from 4-[4-cyano-3-hydroxy-7-(4-trifluoromethyl- phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester and sodium hydroxide in analogy to Example 59d: MS (m/z) 412.9 (M-1)+. Example 66 4-[4-Cyano-3-hydroxy-7-(3-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid a) 4-[3-Hydroxy-7-(3-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0452] The title compound was prepared from 4-(7-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from 47i) and 3-trifluoromethylphenylboronic acid in analogy to Example 47j. MS (m/z) 418.0 (M+1)+. b) 4-[4-Bromo-3-hydroxy-7-(3-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0453] The title compound was prepared from 4-[3-hydroxy-7-(3-trifluoromethyl-phenyl)- quinolin-2-yl]-4-oxo-butyric acid ethyl ester and NBS in analogy to Example 47k. MS (m/z) 495.8, 497.8 (M+1)+. c) 4-[4-Cyano-3-hydroxy-7-(3-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0454] The title compound was prepared from 4-[4-bromo-3-hydroxy-7-(3-trifluoromethyl- phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester and Zn(CN)2 in analogy to Example 47l. MS (m/z) 443.1 (M+1)+.
d) 4-[4-Cyano-3-hydroxy-7-(3-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid [0455] The title compound was prepared from 4-[4-cyano-3-hydroxy-7-(3-trifluoromethyl- phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester and sodium hydroxide in analogy to Example 59d: MS (m/z) 412.9 (M-1)+. Example 67 4-[4-Cyano-3-hydroxy-7-(2-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid a) 4-[3-Hydroxy-7-(2-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0456] The title compound was prepared from 4-(7-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from 47i) and 2-trifluoromethylphenylboronic acid in analogy to Example 47j. MS (m/z) 418.1 (M+1)+. b) 4-[4-Bromo-3-hydroxy-7-(2-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0457] The title compound was prepared from 4-[3-hydroxy-7-(2-trifluoromethyl-phenyl)- quinolin-2-yl]-4-oxo-butyric acid ethyl ester and NBS in analogy to Example 47k. MS (m/z) 495.8, 497.8 (M+1)+. c) 4-[4-Cyano-3-hydroxy-7-(2-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0458] The title compound was prepared from 4-[4-bromo-3-hydroxy-7-(2-trifluoromethyl- phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester and Zn(CN)2 in analogy to Example 47l. MS (m/z) 443.0 (M+1)+. d) 4-[4-Cyano-3-hydroxy-7-(2-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid [0459] The title compound was prepared from 4-[4-cyano-3-hydroxy-7-(2-trifluoromethyl- phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester and sodium hydroxide in analogy to Example 59d: MS (m/z) 414.9 (M+1)+. Example 68 4-[4-Cyano-3-hydroxy-7-(2-m-tolyl-ethyl)-quinolin-2-yl]-4-oxo-butyric acid a) 4-(4-Cyano-3-hydroxy-7-m-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0460] To a solution of 4-(4-Bromo-3-hydroxy-7-m-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (170 mg, 0.41 mmol) in ethyl acetate (20 mL) was added Pd/C (25 mg, 0.025eq, 10 wt.%, wet, contains ~51% water). The mixture was vacuumed/refilled with hydrogen gas for three times and attached to a hydrogen gas balloon. After stirring for 4 hr at room temperature, the reaction mixture was
filtrated off through celite. The filtrate was evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with EtOAc/Hexane (0% - 20%) to give the title compound, 116 mg, MS-(+)-ion, M+H = 417.09. b) 4-[4-Cyano-3-hydroxy-7-(2-m-tolyl-ethyl)-quinolin-2-yl]-4-oxo-butyric acid [0461] At room temperature, to a solution of 4-(4-Cyano-3-hydroxy-7-m-tolylethynyl-quinolin- 2-yl)-4-oxo-butyric acid ethyl ester (110 mg, 0.26 mmol) in methanol(4 mL) was added sodium hydroxide aqueous solution (1.0 M in water, 1.3 mL, 1.3 mmol). After 8h at room temperature, the reaction was diluted in 15 mL water and extracted with ethyl acetate (10mL x 3). The resulting aqueous layer was treated with 1N HCl to pH = 4, followed by extraction with ethyl acetate (10mL x 3). The combined organic layers were washed with brine and dried over sodium sulfate, filtered and evaporated in vacuo to afford the title compound.46 mg. MS-(+)-ion, M+H = 389.09. Example 69 4-(4-Cyano-3-hydroxy-7-p-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid a) 4-(3-Hydroxy-7-p-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0462] To a round-bottom-flask were added 4-(7-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (530 mg, 1.5 mmol), PdCl2(PPh3)2 (53 mg, 0.075 mmol), CuI (29 mg, 015 mmol), Et3N (757 mg, 7.5 mmol), and 1-ethynyl-4-methyl-benzene (348 mg, 3.0 mmol) in anhydrous DMF (8 mL). The mixture was heated at 100 °C under N2 atmosphere for 3 hours. The reaction mixture was then allowed to reach ambient temperature, diluted in 50 mL H2O, treated with 5 mL 1N HCl, and extracted with ethyl acetate (50 mL x 3). The combined organics were washed with brine (50 mL) and dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 20%) to give the title compound, 520 mg, MS-(+)-ion, M+H = 388.07. b) 4-(4-Bromo-3-hydroxy-7-p-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0463] At 0°C, to a solution of 4-(3-Hydroxy-7-p-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (520 mg, 1.34 mmol) in DMF (15 mL) was added N-Bromosuccinimide (249 mg, 1.41 mmol). The mixture was stirred then at room temperature for 1 h and quenched with saturated aqueous sodium sulfite (5 mL) and diluted with 20 mL water. The mixture was extracted with ethyl acetate (3x30 mL). The combined extracts were washed with brine (30 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 20%) to give the title compound, 405 mg. MS-(+)-ion, M+H = 466.01, 467.81.
c) 4-(4-Cyano-3-hydroxy-7-p-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0464] A mixture of 4-(4-Bromo-3-hydroxy-7-p-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (400 mg, 0.86 mmol), zinc cyanide (201 mg, 1.72 mmol), tris(dibenzylideneacetone)dipalladium(0) (79 mg, 0.086 mmol), 1,1'-Bis(diphenylphosphino)ferrocene (dppf, 94 mg, 0.17 mmol), and zinc dust (17 mg, 0.26 mmol) in anhydrous dimethylacetamide (10 mL) was heated at 90 °C under N2 atmosphere for 2 hours. After cooling to room temperature, the reaction mixture was diluted with water (50 mL) and ethyl acetate (50 mL).2 mL of 1 N HCl was added to the mixture and it was allowed to stir for 10 min at room temperature. The organic layer was collected. The aqueous layer was further extracted with ethyl acetate (2 x 30 mL). The combined extracts were washed with brine (50 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (10% - 30%) to give the title compound, 206 mg. MS-(+)-ion, M+H = 413.02. d) 4-(4-Cyano-3-hydroxy-7-p-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid [0465] At room temperature, to a solution of 4-(4-Cyano-3-hydroxy-7-p-tolylethynyl-quinolin- 2-yl)-4-oxo-butyric acid ethyl ester (76 mg, 0.18 mmol) in methanol(3 mL) was added sodium hydroxide aqueous solution (1.0 M in water, 0.9 mL, 0.9 mmol). After 20h at room temperature, the reaction was diluted in 25 mL water and extracted with ethyl acetate (20mL x 3). The resulting aqueous layer was treated with 1N HCl to pH = 4, followed by extraction with ethyl acetate (20mL x 3). The combined organic layers were washed with brine and dried over sodium sulfate, filtered and evaporated in vacuo to afford the title compound.48 mg. MS-(+)-ion, M+H = 385.02. Example 70 4-[4-Cyano-3-hydroxy-7-(2-p-tolyl-ethyl)-quinolin-2-yl]-4-oxo-butyric acid a) 4-(4-Cyano-3-hydroxy-7-p-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0466] To a solution of 4-(4-Bromo-3-hydroxy-7-p-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (125 mg, 0.3 mmol) in ethyl acetate (6 mL) was added Pd/C (32 mg, 0.04eq, 10 wt.%, wet, contains ~51% water). The mixture was vacuumed/refilled with hydrogen gas for three times and attached to a hydrogen gas balloon. After stirring for 1 day at room temperature, the reaction mixture was filtrated off through celite. The filtrate was evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with EtOAc/Hexane (0% - 20%) to give the title compound, 39 mg, MS-(+)-ion, M+H = 417.12. b) 4-[4-Cyano-3-hydroxy-7-(2-p-tolyl-ethyl)-quinolin-2-yl]-4-oxo-butyric acid [0467] At room temperature, to a solution of 4-(4-Cyano-3-hydroxy-7-p-tolylethynyl-quinolin- 2-yl)-4-oxo-butyric acid ethyl ester (38 mg, 0.1 mmol) in methanol(2 mL) was added sodium hydroxide aqueous solution (1.0 M in water, 0.45 mL, 0.45 mmol). After 8h at room temperature, the reaction was
diluted in 15 mL water and extracted with ethyl acetate (10mL x 3). The resulting aqueous layer was treated with 1N HCl to pH = 4, followed by extraction with ethyl acetate (10mL x 3). The combined organic layers were washed with brine and dried over sodium sulfate, filtered and evaporated in vacuo to afford the title compound.22 mg. MS-(+)-ion, M+H = 389.07. Example 71 4-(4-Cyano-3-hydroxy-8-phenylethynyl-quinolin-2-yl)-4-oxo-butyric acid a) 4-(3-Hydroxy-8-phenylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0468] To a round-bottom-flask were added 4-(8-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (530 mg, 1.5 mmol), PdCl2(PPh3)2 (53 mg, 0.075 mmol), CuI (29 mg, 015 mmol), Et3N (757 mg, 7.5 mmol), and ethynyl-benzene (306 mg, 3.0 mmol) in anhydrous DMF (8 mL). The mixture was heated at 100 °C under N2 atmosphere for 3 hours. The reaction mixture was then allowed to reach ambient temperature, diluted in 50 mL H2O, treated with 5 mL 1N HCl, and extracted with ethyl acetate (50 mL x 3). The combined organics were washed with brine (50 mL) and dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 20%) to give the title compound, 542 mg, MS- (+)-ion, M+H = 374.07. b) 4-(4-Bromo-3-hydroxy-8-phenylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0469] At 0°C, to a solution of 4-(3-Hydroxy-8-phenylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (540 mg, 1.45 mmol) in DMF (15 mL) was added N-Bromosuccinimide (540 mg, 3.1 mmol). The mixture was stirred then at room temperature for 1 h and quenched with saturated aqueous sodium sulfite (5 mL) and diluted with 20 mL water. The mixture was extracted with ethyl acetate (3x30 mL). The combined extracts were washed with brine (30 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 20%) to give the title compound, 320 mg. MS-(+)-ion, M+H = 465.90, 467.85. c) 4-(4-Cyano-3-hydroxy-8-phenylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0470] A mixture of 4-(4-Bromo-3-hydroxy-8-phenylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (320 mg, 0.71 mmol), zinc cyanide (124 mg, 1.06 mmol), tris(dibenzylideneacetone)dipalladium(0) (32 mg, 0.0355 mmol), 1,1'-Bis(diphenylphosphino)ferrocene (dppf, 39 mg, 0.071 mmol), and zinc dust (13.8 mg, 0.21 mmol) in anhydrous dimethylacetamide (7 mL) was heated at 90 °C under N2 atmosphere for 2 hours. After cooling to room temperature, the reaction mixture was diluted with water (30 mL) and ethyl acetate (30 mL).2 mL of 1 N HCl was added to the mixture and it was allowed to stir for 10 min at room temperature. The organic layer was collected. The aqueous layer was further extracted with ethyl acetate (2 x 30 mL). The combined extracts were washed with brine (50 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude
product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (10% - 30%) to give the title compound, 112 mg. MS-(+)-ion, M+H = 399.12. d) 4-(4-Cyano-3-hydroxy-8-phenylethynyl-quinolin-2-yl)-4-oxo-butyric acid [0471] At room temperature, to a solution of 4-(4-Cyano-3-hydroxy-8-phenylethynyl-quinolin- 2-yl)-4-oxo-butyric acid ethyl ester (28 mg, 0.07 mmol) in methanol(1 mL) was added sodium hydroxide aqueous solution (1.0 M in water, 0.42 mL, 0.42 mmol). After 4h at room temperature, the reaction was diluted in 15 mL water and extracted with ethyl acetate (10mL x 3). The resulting aqueous layer was treated with 1N HCl to pH = 4, followed by extraction with ethyl acetate (10mL x 3). The combined organic layers were washed with brine and dried over sodium sulfate, filtered and evaporated in vacuo to afford the title compound.5.8 mg. MS-(+)-ion, M+H = 371.07. Example 72 4-(4-Cyano-3-hydroxy-8-phenethyl-quinolin-2-yl)-4-oxo-butyric acid a) 4-(4-Cyano-3-hydroxy-8-phenethyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0472] To a solution of 4-(4-Cyano-3-hydroxy-8-phenylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (82 mg, 0.2 mmol) in ethyl acetate (10 mL) was added Pd/C (21 mg, 0.04eq, 10 wt.%, wet, contains ~51% water). The mixture was vacuumed/refilled with hydrogen gas for three times and attached to a hydrogen gas balloon. After stirring for 3 h at room temperature, the reaction mixture was filtrated off through celite. The filtrate was evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with EtOAc/Hexane (0% - 20%) to give the title compound, 38 mg, MS-(+)-ion, M+H = 403.07. b) 4-(4-Cyano-3-hydroxy-8-phenethyl-quinolin-2-yl)-4-oxo-butyric acid [0473] At room temperature, to a solution of 4-(4-Cyano-3-hydroxy-7-p-tolylethynyl-quinolin- 2-yl)-4-oxo-butyric acid ethyl ester (38 mg, 0.1 mmol) in methanol(2 mL) was added sodium hydroxide aqueous solution (1.0 M in water, 0.5 mL, 0.5 mmol). After 8h at room temperature, the reaction was diluted in 15 mL water and extracted with ethyl acetate (10mL x 3). The resulting aqueous layer was treated with 1N HCl to pH = 4, followed by extraction with ethyl acetate (10mL x 3). The combined organic layers were washed with brine and dried over sodium sulfate, filtered and evaporated in vacuo to afford the title compound.26 mg. MS-(+)-ion, M+H = 375.02.
Example 73 4-[4-Cyano-3-hydroxy-7-(4-trifluoromethoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid a) 4-[3-Hydroxy-7-(4-trifluoromethoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0474] The title compound was prepared from 4-(7-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from 47i) and 4-trifluoromethoxyphenylboronic acid in analogy to Example 47j. MS (m/z) 434.0 (M+1)+. b) 4-[4-Bromo-3-hydroxy-7-(4-trifluoromethoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0475] The title compound was prepared from 4-[3-hydroxy-7-(4-trifluoromethoxy-phenyl)- quinolin-2-yl]-4-oxo-butyric acid ethyl ester and NBS in analogy to Example 47k. MS (m/z) 511.8, 513.8 (M+1)+. c) 4-[4-Cyano-3-hydroxy-7-(4-trifluoromethoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0476] The title compound was prepared from 4-[4-bromo-3-hydroxy-7-(4-trifluoromethoxy- phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester and Zn(CN)2 in analogy to Example 47l. MS (m/z) 456.9 (M-1)+. d) 4-[4-Cyano-3-hydroxy-7-(4-trifluoromethoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid [0477] The title compound was prepared from 4-[4-cyano-3-hydroxy-7-(4-trifluoromethoxy- phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester and sodium hydroxide in analogy to Example 59d: MS (m/z) 431.0 (M+1)+. Example 74 4-[4-Cyano-3-hydroxy-7-(3-trifluoromethoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid a) 4-[3-Hydroxy-7-(3-trifluoromethoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0478] The title compound was prepared from 4-(7-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from 47i) and 3-trifluoromethoxyphenylboronic acid in analogy to Example 47j. MS (m/z) 384.0 (M+1)+. b) 4-[4-Bromo-3-hydroxy-7-(3-trifluoromethoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0479] The title compound was prepared from 4-[3-hydroxy-7-(3-trifluoromethoxy-phenyl)- quinolin-2-yl]-4-oxo-butyric acid ethyl ester and NBS in analogy to Example 47k. MS (m/z) 511.8, 513.8 (M+1)+.
c) 4-[4-Cyano-3-hydroxy-7-(3-trifluoromethoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0480] The title compound was prepared from 4-[4-bromo-3-hydroxy-7-(3-trifluoromethoxy- phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester and Zn(CN)2 in analogy to Example 47l. MS (m/z) 459.0 (M+1)+. d) 4-[4-Cyano-3-hydroxy-7-(3-trifluoromethoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid [0481] The title compound was prepared from 4-[4-cyano-3-hydroxy-7-(3-trifluoromethoxy- phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester and sodium hydroxide in analogy to Example 59d: MS (m/z) 431.0 (M+1)+. Example 75 4-[4-Cyano-3-hydroxy-7-(2-trifluoromethoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid a) 4-[3-Hydroxy-7-(2-trifluoromethoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0482] The title compound was prepared from 4-(7-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from 47i) and 2-trifluoromethoxyphenylboronic acid in analogy to Example 47j. MS (m/z) 434.0 (M+1)+. b) 4-[4-Bromo-3-hydroxy-7-(2-trifluoromethoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0483] The title compound was prepared from 4-[3-hydroxy-7-(2-trifluoromethoxy-phenyl)- quinolin-2-yl]-4-oxo-butyric acid ethyl ester and NBS in analogy to Example 47k. MS (m/z) 511.8, 513.8 (M+1)+. c) 4-[4-Cyano-3-hydroxy-7-(2-trifluoromethoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0484] The title compound was prepared from 4-[4-bromo-3-hydroxy-7-(2-trifluoromethoxy- phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester and Zn(CN)2 in analogy to Example 47l. MS (m/z) 459.0 (M+1)+. d) 4-[4-Cyano-3-hydroxy-7-(2-trifluoromethoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid [0485] The title compound was prepared from 4-[4-cyano-3-hydroxy-7-(2-trifluoromethoxy- phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester and sodium hydroxide in analogy to Example 59d: MS (m/z) 431.0 (M+1)+.
Example 76 4-(4-Cyano-3-hydroxy-7-naphthalen-1-yl-quinolin-2-yl)-4-oxo-butyric acid a) 4-(3-Hydroxy-7-naphthalen-1-yl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0486] The title compound was prepared from 4-(7-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from 47i) and 1-naphthaleneboronic acid to give the title compound in analogy to Example 47j. MS (m/z) 400.0 (M+1)+. b) 4-(4-Bromo-3-hydroxy-7-naphthalen-1-yl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0487] The title compound was prepared from 4-(3-hydroxy-7-naphthalen-1-yl-quinolin-2-yl)-4- oxo-butyric acid ethyl ester and NBS in analogy to Example 47k. MS (m/z) 477.9, 479.9 (M+1)+. c) 4-(4-Cyano-3-hydroxy-7-naphthalen-1-yl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0488] The title compound was prepared from 4-(4-bromo-3-hydroxy-7-naphthalen-1-yl- quinolin-2-yl)-4-oxo-butyric acid ethyl ester and Zn(CN)2 in analogy to Example 47l. MS (m/z) 423.1 (M-1)+. d) 4-(4-Cyano-3-hydroxy-7-naphthalen-1-yl-quinolin-2-yl)-4-oxo-butyric acid [0489] The title compound was prepared from 4-(4-cyano-3-hydroxy-7-naphthalen-1-yl- quinolin-2-yl)-4-oxo-butyric acid ethyl ester and sodium hydroxide in analogy to Example 59d: MS (m/z) 397.0 (M+1)+. Example 77 4-(4-Cyano-3-hydroxy-8-o-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid a) 4-(3-Hydroxy-8-o-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0490] To a round-bottom-flask were added 4-(8-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (530 mg, 1.5 mmol), PdCl2(PPh3)2 (53 mg, 0.075 mmol), CuI (29 mg, 015 mmol), Et3N (757 mg, 7.5 mmol), and 1-ethynyl-2-methyl-benzene (348 mg, 3.0 mmol) in anhydrous DMF (8 mL). The mixture was heated at 100 °C under N2 atmosphere for 3 hours. The reaction mixture was then allowed to reach ambient temperature, diluted in 50 mL H2O, treated with 5 mL 1N HCl, and extracted with ethyl acetate (50 mL x 3). The combined organics were washed with brine (50 mL) and dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 20%) to give the title compound, 551 mg, MS-(+)-ion, M+H = 388.07.
b) 4-(4-Bromo-3-hydroxy-8-o-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0491] At 0°C, to a solution of 4-(3-Hydroxy-8-o-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (550 mg, 1.4 mmol) in DMF (15 mL) was added N-Bromosuccinimide (540 mg, 3.1 mmol). The mixture was stirred then at room temperature for 1 h and quenched with saturated aqueous sodium sulfite (5 mL) and diluted with 20 mL water. The mixture was extracted with ethyl acetate (3x30 mL). The combined extracts were washed with brine (30 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 20%) to give the title compound, 132 mg. MS-(+)-ion, M+H = 465.96. c) 4-(4-Cyano-3-hydroxy-8-o-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0492] A mixture of 4-(4-Bromo-3-hydroxy-8-o-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (325 mg, 0.70 mmol), zinc cyanide (124 mg, 1.06 mmol), tris(dibenzylideneacetone)dipalladium(0) (32 mg, 0.0355 mmol), 1,1'-Bis(diphenylphosphino)ferrocene (dppf, 39 mg, 0.071 mmol), and zinc dust (13.8 mg, 0.21 mmol) in anhydrous dimethylacetamide (7 mL) was heated at 90 °C under N2 atmosphere for 2 hours. After cooling to room temperature, the reaction mixture was diluted with water (30 mL) and ethyl acetate (30 mL).2 mL of 1 N HCl was added to the mixture and it was allowed to stir for 10 min at room temperature. The organic layer was collected. The aqueous layer was further extracted with ethyl acetate (2 x 30 mL). The combined extracts were washed with brine (50 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (10% - 30%) to give the title compound, 162 mg. MS-(+)-ion, M+H = 413.07. d) 4-(4-Cyano-3-hydroxy-8-o-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid [0493] At room temperature, to a solution of 4-(4-Cyano-3-hydroxy-8-o-tolylethynyl-quinolin- 2-yl)-4-oxo-butyric acid ethyl ester (41 mg, 0.1 mmol) in methanol(1 mL) was added sodium hydroxide aqueous solution (1.0 M in water, 0.5 mL, 0.5 mmol). After 16h at room temperature, the reaction was diluted in 15 mL water and extracted with ethyl acetate (10mL x 3). The resulting aqueous layer was treated with 1N HCl to pH = 4, followed by extraction with ethyl acetate (10mL x 3). The combined organic layers were washed with brine and dried over sodium sulfate, filtered and evaporated in vacuo to afford the title compound.27 mg. MS-(+)-ion, M+H = 385.07. Example 78 4-[4-Cyano-3-hydroxy-8-(2-o-tolyl-ethyl)-quinolin-2-yl]-4-oxo-butyric acid a) 4-[4-Cyano-3-hydroxy-8-(2-o-tolyl-ethyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0494] To a solution of 4-(4-Cyano-3-hydroxy-8-o-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (120 mg, 0.3 mmol) in ethyl acetate (10 mL) was added Pd/C (16 mg, 0.02eq, 10 wt.%,
wet, contains ~51% water). The mixture was vacuumed/refilled with hydrogen gas for three times and attached to a hydrogen gas balloon. After stirring for 6 h at room temperature, the reaction mixture was filtrated off through celite. The filtrate was evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with EtOAc/Hexane (0% - 20%) to give the title compound, 67 mg, MS-(+)-ion, M+H = 417.12. b) 4-[4-Cyano-3-hydroxy-8-(2-o-tolyl-ethyl)-quinolin-2-yl]-4-oxo-butyric acid [0495] At room temperature, to a solution of 4-[4-Cyano-3-hydroxy-8-(2-o-tolyl-ethyl)- quinolin-2-yl]-4-oxo-butyric acid ethyl ester (62 mg, 0.15 mmol) in methanol(2 mL) was added sodium hydroxide aqueous solution (1.0 M in water, 0.75 mL, 0.75 mmol). After 18h at room temperature, the reaction was diluted in 15 mL water and extracted with ethyl acetate (10mL x 3). The resulting aqueous layer was treated with 1N HCl to pH = 4, followed by extraction with ethyl acetate (10mL x 3). The combined organic layers were washed with brine and dried over sodium sulfate, filtered and evaporated in vacuo to afford the title compound.46 mg. MS-(+)-ion, M+H = 389.07. Example 79 4-(4-Cyano-3-hydroxy-8-m-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid a) 4-(3-Hydroxy-8-m-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0496] To a round-bottom-flask were added 4-(8-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (530 mg, 1.5 mmol), PdCl2(PPh3)2 (53 mg, 0.075 mmol), CuI (29 mg, 015 mmol), Et3N (757 mg, 7.5 mmol), and 1-ethynyl-3-methyl-benzene (348 mg, 3.0 mmol) in anhydrous DMF (8 mL). The mixture was heated at 100 °C under N2 atmosphere for 3 hours. The reaction mixture was then allowed to reach ambient temperature, diluted in 50 mL H2O, treated with 5 mL 1N HCl, and extracted with ethyl acetate (50 mL x 3). The combined organics were washed with brine (50 mL) and dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 20%) to give the title compound, 503 mg, MS-(+)-ion, M+H = 388.07. b) 4-(4-Bromo-3-hydroxy-8-m-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0497] At 0°C, to a solution of 4-(3-Hydroxy-8-m-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (440 mg, 1.15 mmol) and acetic acid (645 mg, 10.75 mmol) in DMF (15 mL) was added N-Bromosuccinimide (463 mg, 2.6 mmol). The mixture was stirred then at [0498] room temperature for 1 h and quenched with saturated aqueous sodium sulfite (5 mL) and diluted with 20 mL water. The mixture was extracted with ethyl acetate (3x30 mL). The combined extracts were washed with brine (30 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 20%) to give the title compound, 220 mg. MS-(+)-ion, M+H = 465.91, 467.96.
c) 4-(4-Cyano-3-hydroxy-8-m-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0499] A mixture of 4-(4-Bromo-3-hydroxy-8-m-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (295 mg, 0.64 mmol), zinc cyanide (117 mg, 1.0 mmol), tris(dibenzylideneacetone)dipalladium(0) (29 mg, 0.032 mmol), 1,1'-Bis(diphenylphosphino)ferrocene (dppf, 35 mg, 0.064 mmol), and zinc dust (13 mg, 0.2 mmol) in anhydrous dimethylacetamide (7 mL) was heated at 90 °C under N2 atmosphere for 2 hours. After cooling to room temperature, the reaction mixture was diluted with water (30 mL) and ethyl acetate (30 mL).2 mL of 1 N HCl was added to the mixture and it was allowed to stir for 10 min at room temperature. The organic layer was collected. The aqueous layer was further extracted with ethyl acetate (2 x 30 mL). The combined extracts were washed with brine (50 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (10% - 30%) to give the title compound, 166 mg. MS-(+)-ion, M+H = 413.07. d) 4-(4-Cyano-3-hydroxy-8-m-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid [0500] At room temperature, to a solution of 4-(4-Cyano-3-hydroxy-8-m-tolylethynyl-quinolin- 2-yl)-4-oxo-butyric acid ethyl ester (41 mg, 0.1 mmol) in methanol(1 mL) was added sodium hydroxide aqueous solution (1.0 M in water, 0.5 mL, 0.5 mmol). After 16h at room temperature, the reaction was diluted in 15 mL water and extracted with ethyl acetate (10mL x 3). The resulting aqueous layer was treated with 1N HCl to pH = 4, followed by extraction with ethyl acetate (10mL x 3). The combined organic layers were washed with brine and dried over sodium sulfate, filtered and evaporated in vacuo to afford the title compound.27 mg. MS-(+)-ion, M+H = 385.07. Example 80 4-[4-Cyano-3-hydroxy-8-(2-m-tolyl-ethyl)-quinolin-2-yl]-4-oxo-butyric acid a) 4-[4-Cyano-3-hydroxy-8-(2-m-tolyl-ethyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0501] To a solution of 4-(4-Cyano-3-hydroxy-8-m-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (120 mg, 0.3 mmol) in ethyl acetate (10 mL) was added Pd/C (16 mg, 0.02eq, 10 wt.%, wet, contains ~51% water). The mixture was vacuumed/refilled with hydrogen gas for three times and attached to a hydrogen gas balloon. After stirring for 6 h at room temperature, the reaction mixture was filtrated off through celite. The filtrate was evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with EtOAc/Hexane (0% - 20%) to give the title compound, 74 mg, MS-(+)-ion, M+H = 417.12. b) 4-[4-Cyano-3-hydroxy-8-(2-m-tolyl-ethyl)-quinolin-2-yl]-4-oxo-butyric acid [0502] At room temperature, to a solution of 4-[4-Cyano-3-hydroxy-8-(2-m-tolyl-ethyl)- quinolin-2-yl]-4-oxo-butyric acid ethyl ester (70 mg, 0.17 mmol) in methanol(2 mL) was added sodium hydroxide aqueous solution (1.0 M in water, 0.85 mL, 0.85 mmol). After 18h at room temperature, the
reaction was diluted in 15 mL water and extracted with ethyl acetate (10mL x 3). The resulting aqueous layer was treated with 1N HCl to pH = 4, followed by extraction with ethyl acetate (10mL x 3). The combined organic layers were washed with brine and dried over sodium sulfate, filtered and evaporated in vacuo to afford the title compound.49 mg. MS-(+)-ion, M+H = 389.07. Example 81 4-(4-Cyano-3-hydroxy-8-p-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid a) 4-(3-Hydroxy-8-p-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0503] To a round-bottom-flask were added 4-(8-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (530 mg, 1.5 mmol), PdCl2(PPh3)2 (53 mg, 0.075 mmol), CuI (29 mg, 015 mmol), Et3N (757 mg, 7.5 mmol), and 1-ethynyl-4-methyl-benzene (348 mg, 3.0 mmol) in anhydrous DMF (8 mL). The mixture was heated at 100 °C under N2 atmosphere for 3 hours. The reaction mixture was then allowed to reach ambient temperature, diluted in 50 mL H2O, treated with 5 mL 1N HCl, and extracted with ethyl acetate (50 mL x 3). The combined organics were washed with brine (50 mL) and dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 20%) to give the title compound, 521 mg, MS-(+)-ion, M+H = 388.12. b) 4-(4-Bromo-3-hydroxy-8-p-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0504] At 0°C, to a solution of 4-(3-Hydroxy-8-p-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (520 mg, 1.35 mmol) and acetic acid (810 mg, 13.5 mmol) in DMF (15 mL) was added N- Bromosuccinimide (505 mg, 2.8 mmol). The mixture was stirred then at room temperature for 1 h and quenched with saturated aqueous sodium sulfite (5 mL) and diluted with 20 mL water. The mixture was extracted with ethyl acetate (3x30 mL). The combined extracts were washed with brine (30 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 20%) to give the title compound, 135 mg. MS-(+)-ion, M+H = 465.92, 467.90. c) 4-(4-Cyano-3-hydroxy-8-p-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester [0505] A mixture of 4-(4-Bromo-3-hydroxy-8-p-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (295 mg, 0.64 mmol), zinc cyanide (117 mg, 1.0 mmol), tris(dibenzylideneacetone)dipalladium(0) (29 mg, 0.032 mmol), 1,1'-Bis(diphenylphosphino)ferrocene (dppf, 35 mg, 0.064 mmol), and zinc dust (13 mg, 0.2 mmol) in anhydrous dimethylacetamide (7 mL) was heated at 90 °C under N2 atmosphere for 2 hours. After cooling to room temperature, the reaction mixture was diluted with water (30 mL) and ethyl acetate (30 mL).2 mL of 1 N HCl was added to the mixture and it was allowed to stir for 10 min at room temperature. The organic layer was collected. The aqueous layer was further extracted with ethyl acetate (2 x 30 mL). The combined extracts were washed with brine (50 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude
product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (10% - 30%) to give the title compound, 166 mg. MS-(+)-ion, M+H = 413.07. d) 4-(4-Cyano-3-hydroxy-8-p-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid [0506] At room temperature, to a solution of 4-(4-Cyano-3-hydroxy-8-p-tolylethynyl-quinolin- 2-yl)-4-oxo-butyric acid ethyl ester (20 mg, 0.05 mmol) in methanol(1 mL) was added sodium hydroxide aqueous solution (1.0 M in water, 0.3 mL, 0.3 mmol). After 16h at room temperature, the reaction was diluted in 15 mL water and extracted with ethyl acetate (10mL x 3). The resulting aqueous layer was treated with 1N HCl to pH = 4, followed by extraction with ethyl acetate (10mL x 3). The combined organic layers were washed with brine and dried over sodium sulfate, filtered and evaporated in vacuo to afford the title compound.10 mg. MS-(+)-ion, M+H = 385.02. Example 82 4-[4-Cyano-7-(4-fluoro-3-methyl-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid a) 4-[7-(4-Fluoro-3-methyl-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0507] The title compound was prepared from 4-(7-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from 47i) and 4-fluoro-3-methylphenylboronic acid in analogy to Example 47j. MS (m/z) 382.1 (M+1)+. b) 4-[4-Bromo-7-(4-fluoro-3-methyl-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0508] The title compound was prepared from 4-[7-(4-fluoro-3-methyl-phenyl)-3-hydroxy- quinolin-2-yl]-4-oxo-butyric acid ethyl ester and NBS in analogy to Example 47k. MS (m/z) 459.9, 461.9 (M+1)+. c) 4-[4-Cyano-7-(4-fluoro-3-methyl-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0509] The title compound was prepared from 4-[4-bromo-7-(4-fluoro-3-methyl-phenyl)-3- hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester and Zn(CN)2 in analogy to Example 47l. MS (m/z) 407.1 (M+1)+. d) 4-[4-Cyano-7-(4-fluoro-3-methyl-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid [0510] The title compound was prepared from 4-[4-cyano-7-(4-fluoro-3-methyl-phenyl)-3- hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester and sodium hydroxide in analogy to Example 59d: MS (m/z) 379.0 (M+1)+.
Example 83 4-[4-Cyano-7-(2-fluoro-3-methyl-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid a) 4-[7-(2-Fluoro-3-methyl-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0511] The title compound was prepared from 4-(7-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from 47i) and 2-fluoro-3-methylphenylboronic acid in analogy to Example 47j. MS (m/z) 382.1 (M+1)+. b) 4-[4-Bromo-7-(2-fluoro-3-methyl-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0512] The title compound was prepared from 4-[7-(2-fluoro-3-methyl-phenyl)-3-hydroxy- quinolin-2-yl]-4-oxo-butyric acid ethyl ester and NBS in analogy to Example 47k. MS (m/z) 459.9, 461.9 (M+1)+. c) 4-[4-Cyano-7-(2-fluoro-3-methyl-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0513] The title compound was prepared from 4-[4-bromo-7-(2-fluoro-3-methyl-phenyl)-3- hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester and Zn(CN)2 in analogy to Example 47l. MS (m/z) 407.0 (M+1)+. d) 4-[4-Cyano-7-(2-fluoro-3-methyl-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid [0514] The title compound was prepared from 4-[4-cyano-7-(2-fluoro-3-methyl-phenyl)-3- hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester and sodium hydroxide in analogy to Example 59d: MS (m/z) 379.0 (M+1)+. Example 84 4-[4-Cyano-7-(2-fluoro-5-methyl-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid a) 4-[7-(2-Fluoro-5-methyl-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0515] The title compound was prepared from 4-(7-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from 47i) and 2-fluoro-5-methylphenylboronic acid in analogy to Example 47j. MS (m/z) 382.1 (M+1)+. b) 4-[4-Bromo-7-(2-fluoro-5-methyl-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0516] The title compound was prepared from 4-[7-(2-fluoro-5-methyl-phenyl)-3-hydroxy- quinolin-2-yl]-4-oxo-butyric acid ethyl ester and NBS in analogy to Example 47k. MS (m/z) 459.9, 461.9 (M+1)+.
c) 4-[4-Cyano-7-(2-fluoro-5-methyl-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0517] The title compound was prepared from 4-[4-bromo-7-(2-fluoro-5-methyl-phenyl)-3- hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester and Zn(CN)2 in analogy to Example 47l. MS (m/z) 407.1 (M+1)+. d) 4-[4-Cyano-7-(2-fluoro-5-methyl-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid [0518] The title compound was prepared from 4-[4-cyano-7-(2-fluoro-5-methyl-phenyl)-3- hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester and sodium hydroxide in analogy to Example 59d: MS (m/z) 379.0 (M+1)+. Example 85 4-[4-Cyano-3-hydroxy-8-(4-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid a) 4-[3-Hydroxy-8-(4-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0519] The title compound was prepared from 4-(8-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from Example 55i) and 4-trifluoromethylphenylboronic acid in analogy to Example 47j. MS (m/z) 418.0 (M+1)+. b) 4-[4-Bromo-3-hydroxy-8-(4-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0520] The title compound was prepared from 4-[3-hydroxy-8-(4-trifluoromethyl-phenyl)- quinolin-2-yl]-4-oxo-butyric acid ethyl ester and NBS in analogy to Example 47k. MS (m/z) 495.8, 497.8 (M+1)+. c) 4-[4-Cyano-3-hydroxy-8-(4-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0521] The title compound was prepared from 4-[4-bromo-3-hydroxy-8-(4-trifluoromethyl- phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester and Zn(CN)2 in analogy to Example 47l. MS (m/z) 443.0 (M+1)+. d) 4-[4-Cyano-3-hydroxy-8-(4-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid [0522] The title compound was prepared from 4-[4-cyano-3-hydroxy-8-(4-trifluoromethyl- phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester and sodium hydroxide in analogy to Example 59d: MS (m/z) 415.0 (M+1)+.
Example 86 4-[4-Cyano-3-hydroxy-8-(3-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid a) 4-[3-Hydroxy-8-(3-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0523] The title compound was prepared from 4-(8-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from Example 55i) and 3-trifluoromethylphenylboronic acid in analogy to Example 47j. MS (m/z) 418.0 (M+1)+. b) 4-[4-Bromo-3-hydroxy-8-(3-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0524] The title compound was prepared from 4-[3-hydroxy-8-(3-trifluoromethyl-phenyl)- quinolin-2-yl]-4-oxo-butyric acid ethyl ester and NBS in analogy to Example 47k. MS (m/z) 495.8, 497.8 (M+1)+. c) 4-[4-Cyano-3-hydroxy-8-(3-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0525] The title compound was prepared from 4-[4-bromo-3-hydroxy-8-(3-trifluoromethyl- phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester and Zn(CN)2 in analogy to Example 47l. MS (m/z) 443.1 (M+1)+. d) 4-[4-Cyano-3-hydroxy-8-(3-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid [0526] The title compound was prepared from 4-[4-cyano-3-hydroxy-8-(3-trifluoromethyl- phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester and sodium hydroxide in analogy to Example 59d: MS (m/z) 415.0 (M+1)+. Example 87 4-[4-Cyano-3-hydroxy-8-(2-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid a) 4-[3-Hydroxy-8-(2-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0527] The title compound was prepared from 4-(8-bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from Example 55i) and 2-trifluoromethylphenylboronic acid in analogy to Example 47j. MS (m/z) 418.0 (M+1)+. b) 4-[4-Bromo-3-hydroxy-8-(2-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0528] The title compound was prepared from 4-[3-hydroxy-8-(2-trifluoromethyl-phenyl)- quinolin-2-yl]-4-oxo-butyric acid ethyl ester and NBS in analogy to Example 47k. MS (m/z) 495.8, 497.7 (M+1)+.
c) 4-[4-Cyano-3-hydroxy-8-(2-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0529] The title compound was prepared from 4-[4-bromo-3-hydroxy-8-(2-trifluoromethyl- phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester and Zn(CN)2 in analogy to Example 47l. MS (m/z) 443.0 (M+1)+. d) 4-[4-Cyano-3-hydroxy-8-(2-trifluoromethyl-phenyl)-quinolin-2-yl]-4-oxo-butyric acid [0530] The title compound was prepared from 4-[4-cyano-3-hydroxy-8-(2-trifluoromethyl- phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester and sodium hydroxide in analogy to Example 59d: MS (m/z) 415.0 (M+1)+. Example 88 4-[4-Cyano-3-hydroxy-8-(2-p-tolyl-ethyl)-quinolin-2-yl]-4-oxo-butyric acid a) 4-[4-Cyano-3-hydroxy-8-(2-p-tolyl-ethyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0531] To a solution of 4-(4-Cyano-3-hydroxy-8-p-tolylethynyl-quinolin-2-yl)-4-oxo-butyric acid ethyl ester (40 mg, 0.1 mmol) in ethyl acetate (5 mL) was added Pd/C (5 mg, 0.03eq, 10 wt.%, wet, contains ~51% water). The mixture was vacuumed/refilled with hydrogen gas for three times and attached to a hydrogen gas balloon. After stirring for 6 h at room temperature, the reaction mixture was filtrated off through celite. The filtrate was evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with EtOAc/Hexane (0% - 20%) to give the title compound, 21 mg, MS-(+)-ion, M+H = 417.17. b) 4-[4-Cyano-3-hydroxy-8-(2-p-tolyl-ethyl)-quinolin-2-yl]-4-oxo-butyric acid [0532] At room temperature, to a solution of 4-[4-Cyano-3-hydroxy-8-(2-p-tolyl-ethyl)- quinolin-2-yl]-4-oxo-butyric acid ethyl ester (19 mg, 0.05 mmol) in methanol(1 mL) was added sodium hydroxide aqueous solution (1.0 M in water, 0.3 mL, 0.3 mmol). After 18h at room temperature, the reaction was diluted in 15 mL water and extracted with ethyl acetate (10mL x 3). The resulting aqueous layer was treated with 1N HCl to pH = 4, followed by extraction with ethyl acetate (10mL x 3). The combined organic layers were washed with brine and dried over sodium sulfate, filtered and evaporated in vacuo to afford the title compound.11 mg. MS-(+)-ion, M+H = 389.07. Example 89 4-[8-(2-Chloro-phenylethynyl)-4-cyano-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid a) 4-[8-(2-Chloro-phenylethynyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0533] To a round-bottom-flask were added 4-(8-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (530 mg, 1.5 mmol), PdCl2(PPh3)2 (53 mg, 0.075 mmol), CuI (29 mg, 015 mmol),
Et3N (757 mg, 7.5 mmol), and 1-Chloro-2-ethynyl-benzene (411 mg, 3.0 mmol) in anhydrous DMF (8 mL). The mixture was heated at 100 °C under N2 atmosphere for 3 hours. The reaction mixture was then allowed to reach ambient temperature, diluted in 50 mL H2O, treated with 5 mL 1N HCl, and extracted with ethyl acetate (50 mL x 3). The combined organics were washed with brine (50 mL) and dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 20%) to give the title compound, 542 mg, MS-(+)-ion, M+H = 408.07. b) 4-[4-Bromo-8-(2-chloro-phenylethynyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0534] At 0°C, to a solution of 4-[8-(2-Chloro-phenylethynyl)-3-hydroxy-quinolin-2-yl]-4-oxo- butyric acid ethyl ester (550 mg, 1.2 mmol) in DMF (20 mL) was added 2-Bromo-isoindole-1,3-dione (380 mg, 1.68 mmol). The mixture was stirred then at room temperature for 18 h and quenched with saturated aqueous sodium sulfite (5 mL) and diluted with 20 mL water. The mixture was extracted with ethyl acetate (3x30 mL). The combined extracts were washed with brine (30 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (0% - 20%) to give the title compound, 486 mg. MS- (+)-ion, M+H = 487.81. c) 4-[8-(2-Chloro-phenylethynyl)-4-cyano-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0535] A mixture of 4-[4-Bromo-8-(2-chloro-phenylethynyl)-3-hydroxy-quinolin-2-yl]-4-oxo- butyric acid ethyl ester (485 mg, 1.0 mmol), zinc cyanide (234 mg, 2.0 mmol), tris(dibenzylideneacetone)dipalladium(0) (92 mg, 0.1 mmol), 1,1'-Bis(diphenylphosphino)ferrocene (dppf, 110 mg, 0.2 mmol), and zinc dust (20 mg, 0.3 mmol) in anhydrous dimethylacetamide (10 mL) was heated at 80 °C under N2 atmosphere for 2 hours. After cooling to room temperature, the reaction mixture was diluted with water (30 mL) and ethyl acetate (30 mL).2 mL of 1 N HCl was added to the mixture and it was allowed to stir for 10 min at room temperature. The organic layer was collected. The aqueous layer was further extracted with ethyl acetate (2 x 30 mL). The combined extracts were washed with brine (50 mL), dried over sodium sulfate, filtered and evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with ethyl acetate/hexane (10% - 30%) to give the title compound, 211 mg. MS-(+)-ion, M+H = 432.97. d) 4-[8-(2-Chloro-phenylethynyl)-4-cyano-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid [0536] At room temperature, to a solution of 4-[8-(2-Chloro-phenylethynyl)-4-cyano-3- hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester (87 mg, 0.2 mmol) in methanol(3 mL) was added sodium hydroxide aqueous solution (1.0 M in water, 1.0 mL, 1.0 mmol). After 16h at room temperature, the reaction was diluted in 25 mL water and extracted with ethyl acetate (10mL x 3). The resulting aqueous layer was treated with 1N HCl to pH = 4, followed by extraction with ethyl acetate (10mL x 3).
The combined organic layers were washed with brine and dried over sodium sulfate, filtered and evaporated in vacuo to afford the title compound.56 mg. MS-(+)-ion, M+H = 405.02. Example 90 4-{8-[2-(2-Chloro-phenyl)-ethyl]-4-cyano-3-hydroxy-quinolin-2-yl}-4-oxo-butyric acid a) 4-{8-[2-(2-Chloro-phenyl)-ethyl]-4-cyano-3-hydroxy-quinolin-2-yl}-4-oxo-butyric acid ethyl ester [0537] To a solution of 4-[8-(2-Chloro-phenylethynyl)-4-cyano-3-hydroxy-quinolin-2-yl]-4- oxo-butyric acid ethyl ester (130 mg, 0.3 mmol) in ethyl acetate (10 mL) was added Pd/C (24 mg, 0.03eq, 10 wt.%, wet, contains ~51% water). The mixture was vacuumed/refilled with hydrogen gas for three times and attached to a hydrogen gas balloon. After stirring for 6 h at room temperature, the reaction mixture was filtrated off through celite. The filtrate was evaporated in vacuo to afford the crude product. This material was purified by flash chromatography eluting with EtOAc/Hexane (0% - 20%) to give the title compound, 62 mg, MS-(+)-ion, M+H = 437.02. b) 4-{8-[2-(2-Chloro-phenyl)-ethyl]-4-cyano-3-hydroxy-quinolin-2-yl}-4-oxo-butyric acid [0538] At room temperature, to a solution of 4-{8-[2-(2-Chloro-phenyl)-ethyl]-4-cyano-3- hydroxy-quinolin-2-yl}-4-oxo-butyric acid ethyl ester (56 mg, 0.13 mmol) in methanol(3 mL) was added sodium hydroxide aqueous solution (1.0 M in water, 0.65 mL, 0.65 mmol). After 18h at room temperature, the reaction was diluted in 25 mL water and extracted with ethyl acetate (10mL x 3). The resulting aqueous layer was treated with 1N HCl to pH = 4, followed by extraction with ethyl acetate (10mL x 3). The combined organic layers were washed with brine and dried over sodium sulfate, filtered and evaporated in vacuo to afford the title compound.35 mg. MS-(+)-ion, M+H = 409.02. Example 91 4-[4-Cyano-3-hydroxy-8-(4-trifluoromethoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid a) 4-[3-Hydroxy-8-(4-trifluoromethoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0539] The title compound was prepared from 4-(8-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from Example 55i) and 4-trifluoromethoxyphenylboronic acid in analog to Example 47j : MS (m/z) 433.9 (M+1)+. b) 4-[4-Bromo-3-hydroxy-8-(4-trifluoromethoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0540] The title compound was prepared from 4-[3-Hydroxy-8-(4-trifluoromethoxy-phenyl)- quinolin-2-yl]-4-oxo-butyric acid ethyl ester and NBS in analog to Example 47k: MS (m/z) 511.7, 513.8 (M+1)+.
c) 4-[4-Cyano-3-hydroxy-8-(4-trifluoromethoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0541] The title compound was prepared from 4-[4-Bromo-3-hydroxy-8-(4-trifluoromethoxy- phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester and Zn(CN)2 in analog to Example 47l : MS (m/z) 459.0 (M+1)+. d) 4-[4-Cyano-3-hydroxy-8-(4-trifluoromethoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid [0542] The title compound was prepared from 4-[4-Cyano-3-hydroxy-8-(4-trifluoromethoxy- phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester and sodium hydroxide to give the title compound in analog to Example 59d: MS (m/z) 431.0 (M+1)+. Example 92 4-[4-Cyano-3-hydroxy-8-(3-trifluoromethoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid a) 4-[3-Hydroxy-8-(3-trifluoromethoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0543] The title compound was prepared from 4-(8-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from Example 55i) and 3-trifluoromethoxyphenylboronic acid in analog to Example 47j : MS (m/z) 434.0 (M+1)+. b) 4-[4-Bromo-3-hydroxy-8-(3-trifluoromethoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0544] The title compound was prepared from 4-[3-Hydroxy-8-(3-trifluoromethoxy-phenyl)- quinolin-2-yl]-4-oxo-butyric acid ethyl ester and NBS in analog to Example 47k: MS (m/z) 511.8, 513.8 (M+1)+. c) 4-[4-Cyano-3-hydroxy-8-(3-trifluoromethoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0545] The title compound was prepared from 4-[4-Bromo-3-hydroxy-8-(3-trifluoromethoxy- phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester and Zn(CN)2 in analog to Example 47l : MS (m/z) 458.9 (M+1)+. d) 4-[4-Cyano-3-hydroxy-8-(3-trifluoromethoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid [0546] The title compound was prepared from 4-[4-Cyano-3-hydroxy-8-(3-trifluoromethoxy- phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester and sodium hydroxide in analog to Example 59d: MS (m/z) 431.1 (M+1)+.
Example 93 4-[4-Cyano-3-hydroxy-8-(2-trifluoromethoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid a) 4-[3-Hydroxy-8-(2-trifluoromethoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0547] The title compound was prepared from 4-(8-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from Example 55i) and 2-trifluoromethoxyphenylboronic acid in analog to Example 47j : MS (m/z) 434.0 (M+1)+. b) 4-[4-Bromo-3-hydroxy-8-(2-trifluoromethoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0548] The title compound was prepared from 4-[3-Hydroxy-8-(2-trifluoromethoxy-phenyl)- quinolin-2-yl]-4-oxo-butyric acid ethyl ester and NBS in analog to Example 47k: MS (m/z) 511.8, 513.8 (M+1)+. c) 4-[4-Cyano-3-hydroxy-8-(2-trifluoromethoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0549] The title compound was prepared from 4-[4-Bromo-2-hydroxy-8-(2-trifluoromethoxy- phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester and Zn(CN)2 in analog to Example 47l : MS (m/z) 459.0 (M+1)+. d) 4-[4-Cyano-3-hydroxy-8-(2-trifluoromethoxy-phenyl)-quinolin-2-yl]-4-oxo-butyric acid [0550] The title compound was prepared from 4-[4-Cyano-3-hydroxy-8-(2-trifluoromethoxy- phenyl)-quinolin-2-yl]-4-oxo-butyric acid ethyl ester and sodium hydroxide in analog to Example 59d: MS (m/z) 431.0 (M+1)+. Example 94 4-[4-Cyano-8-(2-fluoro-4-methoxy-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid a) 4-[8-(2-Fluoro-4-methoxy-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0551] The title compound was prepared from 4-(8-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from Example 55i) and 2-Fluoro-4-methoxyphenylboronic acid in analog to Example 47j : MS (m/z) 398.1 (M+1)+. b) 4-[4-Bromo-8-(2-fluoro-4-methoxy-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0552] The title compound was prepared from 4-[8-(2-Fluoro-4-methoxy-phenyl)-3-hydroxy- quinolin-2-yl]-4-oxo-butyric acid ethyl ester and NBS in analog to Example 47k: MS (m/z) 475.9, 477.9 (M+1)+.
c) 4-[4-Cyano-8-(2-fluoro-4-methoxy-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0553] The title compound was prepared from 4-[4-Bromo-8-(2-fluoro-4-methoxy-phenyl)-3- hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester and Zn(CN)2 in analog to Example 47l : MS (m/z) 423.0 (M+1)+. d) 4-[4-Cyano-8-(2-fluoro-4-methoxy-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid [0554] The title compound was prepared from 4-[4-Cyano-8-(2-fluoro-4-methoxy-phenyl)-3- hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester and sodium hydroxide in analog to Example 59d: MS (m/z) 395.0 (M+1)+. Example 95 4-[4-Cyano-8-(2,4-difluoro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid a) 4-[8-(2,4-Difluoro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0555] The title compound was prepared from 4-(8-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from Example 55i) and 2,4-difluorophenylboronic acid in analog to Example 47j : MS (m/z) 386.0 (M+1)+. b) 4-[4-Bromo-8-(2,4-difluoro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0556] The title compound was prepared from 4-[8-(2,4-Difluoro-phenyl)-3-hydroxy-quinolin- 2-yl]-4-oxo-butyric acid ethyl ester and NBS in analog to Example 47k: MS (m/z) 463.9, 465.9 (M+1)+. c) 4-[4-Cyano-8-(2,4-difluoro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0557] The title compound was prepared from 4-[4-Bromo-8-(2,4-difluoro-phenyl)-3-hydroxy- quinolin-2-yl]-4-oxo-butyric acid ethyl ester and Zn(CN)2 in analog to Example 47l : MS (m/z) 411.0 (M+1)+. d) 4-[4-Cyano-8-(2,4-difluoro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid [0558] The title compound was prepared from 4-[4-Cyano-8-(2,4-difluoro-phenyl)-3-hydroxy- quinolin-2-yl]-4-oxo-butyric acid ethyl ester and sodium hydroxide in analog to Example 59d: MS (m/z) 383.0 (M+1)+.
Example 96 4-[4-Cyano-8-(2,5-difluoro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid a) 4-[8-(2,5-Difluoro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0559] The title compound was prepared from 4-(8-Bromo-3-hydroxy-quinolin-2-yl)-4-oxo- butyric acid ethyl ester (prepared from Example 55i) and 2,5-difluorophenylboronic acid in analog to Example 47j: MS (m/z) 386.1 (M+1)+. b) 4-[4-Bromo-8-(2,5-difluoro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0560] The title compound was prepared from 4-[8-(2,5-Difluoro-phenyl)-3-hydroxy-quinolin- 2-yl]-4-oxo-butyric acid ethyl ester and NBS in analog to Example 47k: MS (m/z) 463.8, 465.8 (M+1)+. c) 4-[4-Cyano-8-(2,5-difluoro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid ethyl ester [0561] The title compound was prepared from 4-[4-Bromo-8-(2,5-difluoro-phenyl)-3-hydroxy- quinolin-2-yl]-4-oxo-butyric acid ethyl ester and Zn(CN)2 in analog to Example 47l : MS (m/z) 411.0 (M+1)+. d) 4-[4-Cyano-8-(2,5-difluoro-phenyl)-3-hydroxy-quinolin-2-yl]-4-oxo-butyric acid [0562] The title compound was prepared from 4-[4-Cyano-8-(2,5-difluoro-phenyl)-3-hydroxy- quinolin-2-yl]-4-oxo-butyric acid ethyl ester and sodium hydroxide in analog to Example 59d: MS (m/z) 383.0 (M+1)+. [0563] Each of the following compounds were prepared according to Example 96, described above, using the appropriate starting materials.
Example 118 4-(4-cyano-8-(3-fluoropyridin-4-yl)-3-hydroxyquinolin-2-yl)-4-oxobutanoic acid a) ethyl 4-[3-(benzyloxy)-8-(3-fluoropyridin-4-yl)quinolin-2-yl]-4-oxobutanoate [0564] A mixture of ethyl 4-[3-(benzyloxy)-8-bromoquinolin-2-yl]-4-oxobutanoate (2.40 g, 5.43 mmol, 1 equiv), 3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (1.82 g, 8.13 mmol, 1.5 equiv), K3PO4 (3.46 g, 16.3 mmol, 3.0 equiv) and Pd(dppf)Cl2 (0.401 g, 0.541 mmol, 0.1 equiv) in dioxane (20 mL) and H2O (2 mL) was stirred for 3 h at 100 °C under nitrogen atmosphere. The mixture was allowed to cool down to room temperature. The reaction was quenched by the addition of water (20 mL) at room temperature. The resulting mixture was extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with brine (3 x 50 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / EA (1:1) to afford ethyl 4-[3-(benzyloxy)-8-(3-fluoropyridin- 4-yl)quinolin-2-yl]-4-oxobutanoate (1 g, 46%). MS (m/z) 459.16 (M+H).1H NMR (400 MHz, DMSO-d6) δ 8.69 (d, J = 1.8 Hz, 1H), 8.56 (dd, J = 4.8 Hz, 1.1 Hz, 1H), 8.22 (s, 1H), 8.09 (dd, J = 7.7 Hz, 2.0 Hz, 1H), 7.84 – 7.76 (m, 2H), 7.66 (dd, J = 6.2 Hz, 4.8 Hz, 1H), 7.58 – 7.52 (m, 2H), 7.43 (t, J = 7.4 Hz, 2H), 7.38 – 7.31 (m, 1H), 5.36 (s, 2H), 4.02 (q, J = 7.1 Hz, 2H), 3.92 (s, 2H), 2.57 (t, J = 6.5 Hz, 2H), 1.20 – 1.12 (m, 4H). b) ethyl 4-[8-(3-fluoropyridin-4-yl)-3-hydroxyquinolin-2-yl]-4-oxobutanoate [0565] A mixture of ethyl 4-[3-(benzyloxy)-8-(3-fluoropyridin-4-yl) quinolin-2-yl]-4- oxobutanoate (1.01 g, 2.18 mmol, 1.0 equiv) and thioanisole (1.35 g, 10.9 mmol, 5.0 equiv) in TFA (11 mL) was stirred for overnight at 90°C. After cooling to room temperature, the mixture was acidified to pH 7 with saturated aqueous NaHCO3 and extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with brine (3 x 10 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / EA (1:1) to afford ethyl 4-[8-(3-fluoropyridin-4-yl)-3-hydroxyquinolin-2-yl]-4- oxobutanoate (450 mg, 56%). MS (m/z) 369.12 (M+H).1H NMR (300 MHz, DMSO-d6) δ 10.81 (s, 1H), 8.70 (d, J = 1.9 Hz, 1H), 8.57 (d, J = 4.9 Hz, 1H), 8.06 (dd, J = 7.0 Hz, 2.8 Hz, 1H), 7.97 (s, 1H), 7.83 – 7.74 (m, 2H), 7.68 (dd, J = 6.3 Hz, 4.8 Hz, 1H), 4.05 (q, J = 7.1 Hz, 2H), 2.62 (t, J = 6.6 Hz, 2H), 1.16 (t, J = 7.1 Hz, 3H). c) ethyl 4-(4-bromo-8-(3-fluoropyridin-4-yl)-3-hydroxyquinolin-2-yl)-4-oxobutanoate [0566] A mixture of ethyl 4-[8-(3-fluoropyridin-4-yl)-3-hydroxyquinolin-2-yl]-4-oxobutanoate (200 mg, 0.181 mmol, 1.0 equiv) and NBS (35.4 mg, 0.199 mmol, 1.1 equiv) in DMF (0.5 mL) was stirred for 2 h at room temperature. The reaction was quenched with ice water and extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with brine (3 x 10 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified
by silica gel column chromatography, eluted with PE / EA (5:1) to afford ethyl 4-(4-bromo-8-(3- fluoropyridin-4-yl)-3-hydroxyquinolin-2-yl)-4-oxobutanoate (160 mg, 74%). MS (m/z) 447.03 (M+H). d) ethyl 4-[4-cyano-8-(3-fluoropyridin-4-yl)-3-hydroxyquinolin-2-yl]-4-oxobutanoate [0567] A mixture of ethyl 4-[4-bromo-8-(3-fluoropyridin-4-yl)-3-hydroxyquinolin-2-yl]-4- oxobutanoate (160 mg, 0.358 mmol, 1.0 equiv), Zn(CN)2 (126 mg, 1.07 mmol, 3.0 equiv), Pd2(dba)3 (32.8 mg, 0.0361 mmol, 0.1 equiv), Zn (46.8 mg, 0.716 mmol, 2.0 equiv) and dppf (39.5 mg, 0.0721 mmol, 0.2 equiv) in DMA (1 mL) was stirred for 1 h at 75°C under nitrogen atmosphere. The resulting mixture was diluted with water (20 mL) and extracted with EtOAc (3 x 10 mL). The combined organic layers were washed with brine (3 x 10 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. This resulted in ethyl 4-[4-cyano-8-(3-fluoropyridin-4-yl)-3- hydroxyquinolin-2-yl] -4-oxobutanoate (80 mg, 26%). MS (m/z) 394.11 (M+H). e) 4-[4-cyano-8-(3-fluoropyridin-4-yl)-3-hydroxyquinolin-2-yl]-4-oxobutanoic acid [0568] A mixture of ethyl 4-[4-cyano-8-(3-fluoropyridin-4-yl)-3-hydroxyquinolin-2-yl]-4- oxobutanoate (90.0 mg, 0.229 mmol, 1.0 equiv) and LiOH.H2O (28.8 mg, 0.687 mmol, 3.0 equiv) in THF (0.75 mL) and H2O (0.25 mL) was stirred for 1 h at room temperature. The mixture was acidified to pH 6 with HCl (2 M). The filtrate was concentrated under reduced pressure. The residue was purified by Prep-HPLC with following conditions (2#SHIMADZU (HPLC-01): Column, X Bridge Shield RP18 OBD Column, 19*150 mm, 5µm; mobile phase, water (0.05% FA) and CH3CN (40% CH3CN up to 60% in 8 min); Detector, UV 220 nm to afford 4-[4-cyano-8-(3-fluoropyridin-4-yl)-3-hydroxyquinolin-2-yl]- 4-oxobutanoic acid (5 mg, 7%). MS (m/z) 366.20 (M+H).1H NMR (300 MHz, DMSO-d6) δ 8.80 – 8.51 (m, 2H), 8.20 – 8.02 (m, 2H), 7.95 (d, J = 7.1 Hz, 1H), 7.68 (t, J = 5.6 Hz, 1H), 2.57 (t, J = 6.5 Hz, 2H), 1.24 (s, 1H). Example 119 4-(4-cyano-8-(3,5-difluoropyridin-4-yl)-3-hydroxyquinolin-2-yl)-4-oxobutanoic acid a) 3-(benzyloxy)-2-(4-ethoxy-4-oxobutanoyl)quinolin-8-ylboronic acid [0569] Into a 100 mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, were added ethyl 4-[3-(benzyloxy)-8-bromoquinolin-2-yl]-4-oxobutanoate (1 g, 2.26 mmol, 1.0 equiv.), Pin2B2 (860 mg, 3.390 mmol, 1.5 equiv.) KOAc (670 mg, 6.780 mmol, 3.0 equiv.) and Pd(dppf)Cl2 (170 mg, 0.226 mmol, 0.1 equiv.), dioxane (10 mL) at room temperature. The mixture was stirred for overnight at 100°C under nitrogen atmosphere. After cooling to room temperature, the mixture was diluted with water (100 mL) and extracted with EtOAc (3 x 75 mL). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / EA (1:1) to give of 3- (benzyloxy)-2-(4-ethoxy-4-oxobutanoyl)quinolin-8-ylboronic acid (700 mg, 76%). MS (m/z) 408.23 (M+H).1H NMR (300 MHz, DMSO-d6) δ 9.12 (s, 2H), 8.26 (s, 1H), 8.16 (dd, J = 6.8, 1.5 Hz, 1H), 8.05
(dd, J = 8.3, 1.5 Hz, 1H), 7.71 (dd, J = 8.2, 6.8 Hz, 1H), 7.60 – 7.49 (m, 2H), 7.47 – 7.31 (m, 4H), 5.38 (s, 2H), 4.06 (q, J = 7.1 Hz, 3H), 3.39 (t, J = 7.5, 5.2 Hz, 2H), 2.70 (t, J = 6.3 Hz, 2H), 1.17 (t, J = 7.1 Hz, 3H). b) ethyl 4-[3-(benzyloxy)-8-(3,5-difluoropyridin-4-yl)quinolin-2-yl]-4-oxobutanoate [0570] Into a 100 mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, were added 3-(benzyloxy)-2-(4-ethoxy-4-oxobutanoyl)quinolin-8-ylboronic acid (800 mg, 1.96 mmol, 1 equiv.), 4-bromo-3,5-difluoropyridine (457 mg, 2.35 mmol, 1.2 equiv.), Pd(dppf)Cl2 (143 mg, 0.19 mmol, 0.1 equiv.), K2CO3 (814 mg, 5.89 mmol, 3.0 equiv.), dioxane (15 mL) and H2O (1.5 mL) at room temperature. The above mixture was stirred for overnight at 100°C under nitrogen atmosphere. After cooling to room temperature, the mixture was diluted with water (100 mL) and extracted with EtOAc (3 x 75 mL). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / EA (1:1) to give ethyl 4-[3-(benzyloxy)-8-(3,5- difluoropyridin-4-yl)quinolin-2-yl]-4-oxobutanoate (200 mg, 21%). MS (m/z) 477.48 (M+H). c) ethyl 4-[8-(3,5-difluoropyridin-4-yl)-3-hydroxyquinolin-2-yl]-4-oxobutanoate [0571] Into a 100 mL round-bottom flask, were added ethyl 4-[3-(benzyloxy)-8-(3,5- difluoropyridin-4-yl)quinolin-2-yl]-4-oxobutanoate (200 mg, 0.42 mmol, 1 equiv.), thioanisole (208 mg, 1.68 mmol, 4 equiv.) and TFA (3 mL) at room temperature. The above mixture was stirred overnight at 90oC. After cooling to room temperature, the mixture neutralized to pH 7 with saturated NaHCO3 (aq.). The aqueous layer was extracted with EtOAc (3 x 50 mL). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / EA (1:1) to give ethyl 4-[8-(3,5- difluoropyridin-4-yl)-3-hydroxyquinolin-2-yl]-4-oxobutanoate (130 mg, 80%). MS (m/z) 387.35 (M+H). 1H NMR (300 MHz, DMSO-d6) δ 10.81 (s, 1H), 8.70 (s, 2H), 8.11 (dd, J = 7.4, 2.4 Hz, 1H), 7.99 (s, 1H), 7.87 – 7.77 (m, 2H), 4.04 (q, J = 7.1 Hz, 2H), 3.25 (t, J = 6.6 Hz, 2H), 2.60 (t, J = 6.6 Hz, 2H), 1.16 (t, J = 7.1 Hz, 3H). d) ethyl 4-[4-bromo-8-(3,5-difluoropyridin-4-yl)-3-hydroxyquinolin-2-yl]-4-oxobutanoate [0572] Into a 100 mL round-bottom flask, were added ethyl 4-[8-(3,5-difluoropyridin-4-yl)-3- hydroxyquinolin-2-yl]-4-oxobutanoate (130 mg, 0.33 mmol, 1 equiv.) and NBS (62 mg, 0.35 mmol, 1.05 equiv.), CH3CN (5 mL). The mixture was stirred for 2 h at room temperature. The reaction was quenched by the addition of NH4Cl (aq.) (50 mL) and extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with brine (3 x 30 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / EA (1:1) to give ethyl 4-[4-bromo-8-(3,5-difluoropyridin-4-yl)-3-hydroxyquinolin-2-yl]- 4-oxobutanoate (110 mg 70%). MS (m/z) 465.25 (M+H).1H NMR (300 MHz, Chloroform-d) δ 11.78 (s,
1H), 8.55 (s, 2H), 8.34 (dd, J = 8.6, 1.3 Hz, 1H), 7.86 (dd, J = 8.6, 7.1 Hz, 1H), 7.75 (d, J = 7.1 Hz, 1H), 4.17 (q, J = 7.1 Hz, 2H), 3.43 (t, J = 6.4 Hz, 2H), 2.70 (t, J = 6.5 Hz, 2H), 1.29 (t, J = 7.1 Hz, 3H). e) ethyl 4-[4-cyano-8-(3,5-difluoropyridin-4-yl)-3-hydroxyquinolin-2-yl]-4-oxobutanoate [0573] Into a 100 mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, were added ethyl 4-[4-bromo-8-(3,5-difluoropyridin-4-yl)-3-hydroxyquinolin-2-yl]-4- oxobutanoate (110 mg, 0.236 mmol, 1 equiv.), Zn(CN)2 (55 mg, 0.472 mmol, 2 equiv.), Pd2(dba)3 (21 mg, 0.024 mmol, 0.1 equiv.), Zn (0.8 mg, 0.012 mmol, 0.05 equiv.) and dppf (13 mg, 0.024 mmol, 0.1 equiv.), DMA (2 mL). The mixture was stirred for 6 h at 75°C under nitrogen atmosphere. After cooling to room temperature, the mixture was diluted with water (50 mL) and extracted with EtOAc (3 x 25 mL). The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reversed-phase flash chromatography with the following conditions: column, C18 silica gel; mobile phase, CH3CN in water (0.1% TFA), 30% to 70% gradient in 10 min; detector, UV 254 nm to give ethyl 4-[4-cyano-8-(3,5-difluoropyridin-4-yl)-3- hydroxyquinolin-2-yl]-4-oxobutanoate (20 mg 20 %). MS (m/z) 412.36 (M+H). f) 4-[4-cyano-8-(3,5-difluoropyridin-4-yl)-3-hydroxyquinolin-2-yl]-4-oxobutanoic acid [0574] Into a 100 mL round-bottom flask, were added ethyl 4-[4-cyano-8-(3,5-difluoropyridin- 4-yl)-3-hydroxyquinolin-2-yl]-4-oxobutanoate (20 mg, 0.05 mmol, 1 equiv.), LiOH.H2O (4 mg, 0.19 mmol, 4 equiv.), THF (3 mL), MeOH (3 mL) and H2O (1 mL) at room temperature. The resulting mixture was stirred for 2 h at room temperature. The mixture was neutralized to pH 7 with HCl (2 M) and extracted with EtOAc (3 x 15mL). The resulting mixture was concentrated under reduced pressure. The crude product (15 mg) was purified by Prep-HPLC with the following conditions, C18 silica gel; mobile phase, CH3CN in water (0.1% FA), 30% to 70% gradient in 10 min; detector, UV 254 nm to give of 4-[4-cyano-8-(3,5-difluoropyridin-4-yl)-3-hydroxyquinolin-2-yl]-4-oxobutanoic acid (6 mg 36%). MS (m/z) 383.31 (M+H).1H NMR (400 MHz, DMSO-d6) δ 12.06 (s, 2H), 8.72 (s, 2H), 8.09 (d, J = 8.3 Hz, 1H), 8.01 (t, J = 7.7 Hz, 1H), 7.92 (d, J = 7.1 Hz, 1H), 3.15 (t, J = 6.6 Hz, 2H), 2.53 (t, 2H). Example 120 4-(4-cyano-3-hydroxy-8-(6-(trifluoromethoxy)pyridin-3-yl)quinolin-2-yl)-4-oxobutanoic acid a) ethyl 4-[3-(benzyloxy)-8-[6-(trifluoromethoxy)pyridin-3-yl]quinolin-2-yl]-4-oxobutanoate [0575] Into a 100 mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, were added 3-(benzyloxy)-2-(4-ethoxy-4-oxobutanoyl)quinolin-8-ylboronic acid (500 mg, 1.22 mmol, 1 equiv.), 5-bromo-2-(trifluoromethoxy)pyridine (356 mg, 1.47 mmol, 1.2 equiv.), K2CO3 (509 mg, 3.68 mmol, 3.0 equiv.), 1,4-dioxane (10 mL) and H2O (1 mL). The mixture was stirred overnight at 100°C under nitrogen atmosphere. After cooling to room temperature, the mixture was diluted with water (100 mL) and extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with brine (3 x 15 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under
reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / EA (1:1) to give ethyl 4-[3-(benzyloxy)-8-[6-(trifluoromethoxy)pyridin-3-yl]quinolin-2-yl]-4- oxobutanoate (450 mg 69%). MS (m/z) 525.50 (M+H).1H NMR (300 MHz, DMSO-d6) δ 8.71 (d, J = 2.4 Hz, 1H), 8.45 (dd, J = 8.5, 2.5 Hz, 1H), 8.22 (s, 1H), 8.04 (dd, J = 8.0, 1.7 Hz, 1H), 7.92 – 7.73 (m, 2H), 7.56 (d, J = 7.3 Hz, 2H), 7.47 – 7.29 (m, 4H), 5.36 (s, 2H), 4.03 (q, J = 7.1 Hz, 2H), 3.30 (t, 2H), 2.61 (t, J = 6.5 Hz, 2H), 1.14 (t, J = 7.1 Hz, 3H). b) ethyl 4-{3-hydroxy-8-[6-(trifluoromethoxy)pyridin-3-yl]quinolin-2-yl}-4-oxobutanoate [0576] Into a 100 mL round-bottom flask, were added ethyl 4-[3-(benzyloxy)-8-[6- (trifluoromethoxy)pyridin-3-yl]quinolin-2-yl]-4-oxobutanoate (450 mg, 0.85 mmol, 1 equiv.), thioanisole (532 mg, 4.29 mmol, 5 equiv.), TFA (5 mL). The mixture was stirred overnight at 90oC. After cooling to room temperature, the mixture was neutralized to pH 7 with saturated NaHCO3 (aq.). The aqueous layer was extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with brine (3 x 15 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / EA (1:1) to give ethyl 4-{3-hydroxy-8-[6-(trifluoromethoxy)pyridin-3-yl]quinolin-2-yl}-4-oxobutanoate (280 mg 75%). MS (m/z) 435.37 (M+H).1H NMR (400 MHz, Chloroform-d) δ 11.04 (s, 1H), 8.68 (d, J = 2.4 Hz, 1H), 8.26 (dd, J = 8.4, 2.4 Hz, 1H), 7.82 (dd, J = 8.0, 1.8 Hz, 1H), 7.76 (s, 1H), 7.73 – 7.61 (m, 2H), 7.20 (d, J = 8.4 Hz, 1H), 4.18 (q, J = 7.1 Hz, 2H), 3.62 – 3.54 (m, 2H), 2.76 (t, J = 6.4 Hz, 2H), 1.30 (t, J = 7.2 Hz, 3H), c) ethyl 4-{4-bromo-3-hydroxy-8-[6-(trifluoromethoxy)pyridin-3-yl]quinolin-2-yl}-4-oxobutanoate [0577] Into a 100 mL round-bottom flask, were added ethyl 4-{3-hydroxy-8-[6- (trifluoromethoxy)pyridin-3-yl]quinolin-2-yl}-4-oxobutanoate (280 mg, 0.64 mmol, 1 equiv.), NBS (120 mg, 0.67 mmol, 1.05 equiv.), CH3CN (5 mL). The mixture was stirred for 2 h at room temperature. The reaction was quenched by the addition of NH4Cl (aq.) (50 mL) and extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with brine (3 x 30 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / EA (1:1) to give ethyl 4-{4-bromo-3-hydroxy-8-[6- (trifluoromethoxy)pyridin-3-yl]quinolin-2-yl}-4-oxobutanoate (250 mg 75%). MS (m/z) 514.27 (M+H). 1H NMR (300 MHz, DMSO-d6) δ 11.54 (s, 1H), 8.72 (d, J = 2.5 Hz, 1H), 8.47 (dd, J = 8.5, 2.5 Hz, 1H), 8.20 (dd, J = 6.5, 3.4 Hz, 1H), 8.05 – 7.89 (m, 2H), 7.44 (d, J = 8.5 Hz, 1H), 4.06 (q, J = 7.1 Hz, 2H), 3.47 (t, J = 6.7 Hz, 2H), 2.67 (t, J = 6.7 Hz, 2H), 1.17 (t, J = 7.1 Hz, 3H). d) ethyl 4-{4-cyano-3-hydroxy-8-[6-(trifluoromethoxy)pyridin-3-yl]quinolin-2-yl}-4-oxobutanoate [0578] Into a 100 mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, were added ethyl 4-{4-bromo-3-hydroxy-8-[6-(trifluoromethoxy)pyridin-3-yl]quinolin-2-yl}-4- oxobutanoate (250 mg, 0.48 mmol, 1 equiv.), Zn(CN)2 (114 mg, 0.974 mmol, 2 equiv.), Zn (1.5 mg, 0.024 mmol, 0.05 equiv.), Pd2(dba)3 (44 mg, 0.049 mmol, 0.1 equiv.), dppf (26 mg, 0.049 mmol, 0.1
equiv.), DMA (3 mL). The mixture was stirred for 1 h at 75°C under nitrogen atmosphere. The resulting mixture was diluted with water (20 mL) and extracted with EtOAc (3 x 10 mL). The combined organic layers were washed with brine (3 x 10 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reversed-phase flash chromatography with the following conditions: column, C18 silica gel; mobile phase, CH3CN in water (0.1% TFA), 10% to 50% gradient in 10 min; detector, UV 254 nm. This resulted in ethyl 4-{4-cyano-3- hydroxy-8-[6-(trifluoromethoxy)pyridin-3-yl]quinolin-2-yl}-4-oxobutanoate (110 mg 49%). MS (m/z) 460.38 (M+H).1H NMR (300 MHz, DMSO-d6) δ 8.72 (d, J = 2.4 Hz, 1H), 8.45 (dd, J = 8.5, 2.5 Hz, 1H), 8.11 – 7.97 (m, 3H), 7.46 (d, J = 8.5 Hz, 1H), 4.06 (q, J = 7.1 Hz, 2H), 3.43 (t, J = 6.7 Hz, 1H), 2.67 (t, J = 6.6 Hz, 2H), 1.18 (t, J = 7.1 Hz, 3H). e) 4-{4-cyano-3-hydroxy-8-[6-(trifluoromethoxy)pyridin-3-yl]quinolin-2-yl}-4-oxobutanoic acid [0579] Into a 100 mL round-bottom flask, were added ethyl 4-{4-cyano-3-hydroxy-8-[6- (trifluoromethoxy)pyridin-3-yl]quinolin-2-yl}-4-oxobutanoate (100 mg, 0.22 mmol, 1 equiv.), LiOH.H2O (15 mg, 0.6 mmol, 3 equiv.), THF (3 mL) and H2O (1 mL). The resulting mixture was stirred for 1 h at room temperature. The mixture was neutralized to pH 7 with HCl (2 M) and extracted with EtOAc (3 x 15 mL). The resulting mixture was concentrated under reduced pressure. The crude product was purified by Prep-HPLC with the following conditions, C18 silica gel; mobile phase, CH3CN in water (0.1% FA), 30% to 70% gradient in 10 min; detector, UV 254 nm to give of 4-{4-cyano-3-hydroxy-8-[6- (trifluoromethoxy)pyridin-3-yl]quinolin-2-yl}-4-oxobutanoic acid (30 mg 31%). MS (m/z) 432.33 (M+H).1H NMR (400 MHz, DMSO-d6) δ 12.15 (s, 2H), 8.72 (d, J = 2.4 Hz, 1H), 8.45 (dd, J = 8.5, 2.5 Hz, 1H), 8.15 – 7.88 (m, 3H), 7.45 (d, J = 8.5 Hz, 1H), 3.39 (t, J = 6.5 Hz, 2H), 2.60 (t, J = 6.5 Hz, 2H). BIOLOGICAL EXAMPLES Biological Example 1 [0580] Enzymatic activity was determined based on the capture of 14CO2 released by the decarboxylation of [1-14C] αKG (Zhang et al., Anal. Biochem., 1998, vol.271, pp.137-142). [1-14C] alphaketoglutarate (αKG) was from Perkin-Elmer, H3K4me3 and H3K9me3 peptides were from Mimotopes. All other reagents were from Sigma. Reaction mixtures included the following components: Fe(SO4), [1-14C] αKG, non-labeled αKG, ascorbate, peptide-substrate (H3K4me3: H- ARTK(me3)QTARKSTGGKAPRKQLA-OH. H3K9me3: H-ARTKQTARK(me3)STGGKAPRKQLA- OH), NaCl, Tween-20 and catalase in 25 mM HEPES buffer, pH 7.4. The enzymatic reactions were initiated by addition of recombinant human KDM5B or KDM4A enzyme (truncated enzyme produced in house by method and using sequence disclosed in Ng et al, Nature 448:87-91, 2007). The reactions were performed in 96-well microtiter plates (20 µL total assay volume) (Greiner #650201).14CO2 was captured on a glass fiber filter paper (Cat. No. IH-201-A, Inotech Biosystems International) soaked with saturated Ba(OH)2 that was laid on top of the 96-well plate. A microtiter plate sealer film (Thermal Seal cat# T7961100) was applied to the filter paper. The plate and filter paper were sandwiched between two
custom made aluminum plates (Advanced Component Manufacturing, Burlingame, CA) and transferred to a 37 °C oven and allowed to incubate for 1 hour. After incubation, the filter paper was dried in a 103 °C oven for 40-60 minutes. To determine percent turnover, aliquots of the reaction mixture were spotted onto the filter paper and the filter paper was dried again. The dry filter paper was exposed to a storage phosphor screen for 24-72 hours and the images recorded using a Typhoon FLA 7000 Imager (Amersham Biosciences, Piscataway, NJ). Integrated spot intensities corresponding to control reactions lacking the enzyme were subtracted from integration results for enzyme containing reactions and data were converted to enzyme dependent percent 14CO2 release. All enzymatic reactions were run in duplicates. [0581] For IC50 determination, a 3-fold dilution series of compound was prepared and added to the reaction mixture (final 1 % DMSO, v/v) prior to enzyme addition. The final reagent concentrations were: 10 µM Fe(SO4), 10 µM [1-14C] αKG, 90 µM non-labeled αKG, 2 mM ascorbate, 50 µM peptide substrate, 75 mM NaCl, 0.01 % Tween-20 and ~2 units/µL catalase. IC50s were determined by non-linear fitting using Grafit version 7.0. Data for compounds disclosed herein is shown in Table 2. TABLE 2
Biological Example 2 a) Cell-Based Assay for KDM5 inhibitors [0582] COS-7 monkey kidney fibroblasts (ATCC, Manassas VA) were seeded into collagen- coated 96-well culture dishes and incubated overnight at 37°C, 5% CO2 in standard culture medium, e.g., Dulbecco's Modified Eagle Medium containing 10% fetal bovine serum. The next day, cells were transfected with an expression plasmid for Myc-His-tagged KDM5B (Origene, Rockville MD) for 3h before replacing the transfection medium with fresh culture medium and treating with vehicle or compound. [0583] After 18h incubation, the cell culture treatment medium was removed and cell layers were fixed using 4% formaldehyde in Dulbecco’s Phosphate Buffered Saline (DPBS), then permeabilized with 0.25% Triton X-100, and then blocked using a suitable blocking agent e.g., Odyssey Blocking Buffer (LICOR, Lincoln NE). Cell layers were then incubated overnight with primary antibodies for detection of MYC (Thermo Fisher Scientific, Waltham MA) and tri-methylated Lysine 4 of Histone 3 (H3K4me3) (Cell Signaling Technology, Danvers MA). The next day cell layers were washed and incubated with appropriate fluorescently labeled secondary antibodies. Finally, nuclei were stained using 4′,6-diamidino-2-phenylindole (DAPI). b) Imaging and Analyses of Cell-Based Assay for KDM5 Inhibitors [0584] In one analysis method, fold increases in H3K4me3 levels per cell were assessed. A suitable cell imaging system e.g., Cytation5 (Biotek, Winooski VT) was used to scan cell layers that had
been immunostained for MYC and H3K4me3. Scanned objects were gated using DAPI (cells) and binned according to MYC-KDM5B expression levels (low, medium, or high). H3K4me3 levels were quantified per cell. Mean fold increases in H3K4me3 in compound-treated cells relative to vehicle- treated cells were calculated for each MYC-KDM5B expressing bin (low, medium, or high). [0585] In another analysis method, the percentages of MYC-KDM5B-overexpressing cells with H3K4me3 levels above a pre-determined threshold were calculated. A suitable cell imaging system e.g., Incucyte ZOOM (Sartorius, Germany) was used to scan cell layers that had been immunostained for MYC-KDM5B and H3K4me3. Cells highly overexpressing MYC-KDM5B were gated based on MYC staining levels and then the percentages of cells within vehicle- and compound-treated groups with H3K4me3 levels above a set threshold were determined. Compound-dependent increases in percentages of cells above the pre-determined H3K4me3 threshold were calculated.
Claims
WHAT IS CLAIMED IS: 1. A compound of formula I:
or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, wherein: n is 0, 1, 2, 3, or 4; R1 is hydrogen, -P(O)(OR20)2, -CH2P(O)(OR20)2, -P(O)(R20)(OR20), -CH2P(O)(R20)(OR20), -P(O)(N(R20)2)(OR20), -CH2P(O)(N(R20)2)(OR20), -P(O)(R20)(N(R20)2), -CH2P(O)(R20)(N(R20)2), -C(O)R20, -C(O)N(R21)(R22), -CH2P(O)(N(R20)2)2, or -P(O)(N(R20)2)2; R2 is -OH, -OR5, -OCH2P(O)(OR20)2, -OCH2P(O)(R20)(N(R20)2), -OCH2P(O)(R20)(OR20), -OCH2P(O)(N(R20)2)(OR20), -OCH2P(O)(N(R20)2)2, -N(R21)(R22), -N(R20)C(O)R20, -N(R20)C(O)OR20, -N(R20)C(O)N(R21)(R21), -N(R20)S(O)2(R20), -NR20S(O)2N(R21)(R22), or -NR20S(O)2O(R20); R3 is hydrogen, halo, cyano, or C1-6 haloalkyl; each R4 is independently halo, cyano, -L-C1-6 alkyl, -L-C2-6 alkenyl, -L-C2-6 alkynyl, -L-C1-6 haloalkyl, -L-C3-10 cycloalkyl, -L-heterocyclyl, -L-aryl, or -L-heteroaryl; wherein each alkyl, alkenyl, alkynyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl of R4 is independently optionally substituted with 1-5 R14; L is a bond, C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, -C1-6 heteroalkylene, -O-, -S-, -S(O)-, -S(O)2-, -NR16-, -C(O)NR16-, -NR16C(O)-, -C(O)-, -OC(O)-, -C(O)O-, -NR16S(O)-, -S(O)NR16-, -NR16S(O)NR16-, -NR16S(O)2-, -S(O)2NR16-, -NR16S(O)2NR16-, -NR16C(O)NR16-, -OC(O)NR16-, or -NR16C(O)O-; wherein each C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, or -C1-6 heteroalkylene of L is independently optionally substituted with 1-5 R14; each R5 is independently C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, heterocyclyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl of R5 is independently optionally substituted with 1-5 R15; each of R6, R7, R8, and R9 are independently hydrogen, deuterium, C1-6 alkyl, or C1-6 haloalkyl; each R14 and R15 are independently hydroxy, halo, cyano, -NO2, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-10 cycloalkyl, heterocyclyl, aryl, benzyl, heteroaryl, -N(R16)2, -C(O)R16, -C(O)OR16, -S-R16, S(O)R16, -NR16S(O)R16, -S(O)N(R16)2, -NR16S(O)N(R16)2, -S(O)2R16, -NR16S(O)2R16, -S(O)2N(R16)2, -NR16S(O)2N(R16)2, -NR16C(O)N(R16)2, -C(O)N(R16)2, -NR16C(O)R16, -OC(O)N(R16)2, or -NR16C(O)OR16;
each R16 is independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 heteroalkyl, C3-10 cycloalkyl, heterocyclyl, aryl, or heteroaryl; wherein each C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 heteroalkyl, C3-10 cycloalkyl, heterocyclyl, aryl, or heteroaryl of R16 is independently optionally substituted with 1-5 halo, cyano, -NO2, oxo, -SF5, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-10 cycloalkyl, aryl, benzyl, heteroaryl, or heterocyclyl; or two R16 together with the atom to which they are attached form a heterocyclyl; wherein said heterocyclyl is independently optionally substituted with 1-5 R30; each R20 is independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, aryl, heteroaryl, or heterocyclyl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl is independently optionally substituted with 1-5 R30; or two R20together with the atom to which they are attached form a heterocyclyl; wherein said heterocyclyl is independently optionally substituted with 1-5 R30; each R21 and R22 is independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, aryl, heteroaryl or heterocyclyl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl is independently optionally substituted with 1-5 R30 groups; or R20and R21 together with the nitrogen to which they are attached form a heterocyclyl; wherein said heterocyclyl is independently optionally substituted with 1-5 R30; or R21and R22 together with the nitrogen to which they are attached form a heterocyclyl; wherein said heterocyclyl is independently optionally substituted with 1-5 R30; each R30 is independently oxo, thioxo, hydroxy, halo, -NO2, -N3, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C1-6 haloalkyl, aryl, heteroaryl, heterocyclyl, -O(C1-6 alkyl), -O(C2-6 alkenyl), -O(C2-6 alkynyl), -O(C3-10 cycloalkyl), -O(C1-6 haloalkyl), -O(aryl), -O(heteroaryl), -O(heterocyclyl), -NH2, -NH(C1-6 alkyl), -NH(C2-6 alkenyl), -NH(C2-6 alkynyl), -NH(C3-10 cycloalkyl), -NH(C1-6 haloalkyl), -NH(aryl), -NH(heteroaryl), -NH(heterocyclyl), -N(C1-6 alkyl)2, -N(C3-10 cycloalkyl)2, -N(C2-6 alkenyl)2, -N(C2-6 alkynyl)2, -N(C3-10 cycloalkyl)2, -N(C1-6 haloalkyl)2, -N(aryl)2, -N(heteroaryl)2, -N(heterocyclyl)2, -N(C1-6 alkyl)(C3-10 cycloalkyl), -N(C1-6 alkyl)(C2-6 alkenyl), -N(C1-6 alkyl)(C2-6 alkynyl), -N(C1-6 alkyl)(C3-10 cycloalkyl), -N(C1-6 alkyl)(C1-6 haloalkyl), -N(C1-6 alkyl)(aryl), -N(C1-6 alkyl)(heteroaryl), -N(C1-6 alkyl)(heterocyclyl), -C(O)(C1-6 alkyl), -C(O)(C2-6 alkenyl), -C(O)(C2-6 alkynyl), -C(O)(C3-10 cycloalkyl), -C(O)(C1-6 haloalkyl), -C(O)(aryl), -C(O)(heteroaryl), -C(O)(heterocyclyl), -C(O)O(C1-6 alkyl), -C(O)O(C2-6 alkenyl), -C(O)O(C2-6 alkynyl), -C(O)O(C3-10 cycloalkyl), -C(O)O(C1-6 haloalkyl), -C(O)O(aryl), -C(O)O(heteroaryl), -C(O)O(heterocyclyl), -C(O)NH2, -C(O)NH(C1-6 alkyl), -C(O)NH(C2-6 alkenyl), -C(O)NH(C2-6 alkynyl), -C(O)NH(C3-10 cycloalkyl), -C(O)NH(C1-6 haloalkyl), -C(O)NH(aryl), -C(O)NH(heteroaryl), -C(O)NH(heterocyclyl), -C(O)N(C1-6 alkyl)2, -C(O)N(C3-10 cycloalkyl)2, -C(O)N(C2-6 alkenyl)2, -C(O)N(C2-6 alkynyl)2, -C(O)N(C3-10 cycloalkyl)2, -C(O)N(C1-6 haloalkyl)2, -C(O)N(aryl)2, -C(O)N(heteroaryl)2,
-C(O)N(heterocyclyl)2, -NHC(O)(C1-6 alkyl), -NHC(O)(C2-6 alkenyl), -NHC(O)(C2-6 alkynyl), -NHC(O)(C3-10 cycloalkyl), -NHC(O)(C1-6 haloalkyl), -NHC(O)(aryl), -NHC(O)(heteroaryl), -NHC(O)(heterocyclyl), -NHC(O)O(C1-6 alkyl), -NHC(O)O(C2-6 alkenyl), -NHC(O)O(C2-6 alkynyl), -NHC(O)O(C3-10 cycloalkyl), -NHC(O)O(C1-6 haloalkyl), -NHC(O)O(aryl), -NHC(O)O(heteroaryl), -NHC(O)O(heterocyclyl), -NHC(O)NH(C1-6 alkyl), -NHC(O)NH(C2-6 alkenyl), -NHC(O)NH(C2-6 alkynyl), -NHC(O)NH(C3-10 cycloalkyl), -NHC(O)NH(C1-6 haloalkyl), -NHC(O)NH(aryl), -NHC(O)NH(heteroaryl), -NHC(O)NH(heterocyclyl), -SH, -S(C1-6 alkyl), -S(C2-6 alkenyl), -S(C2-6 alkynyl), -S(C3-10 cycloalkyl), -S(C1-6 haloalkyl), -S(aryl), -S(heteroaryl), -S(heterocyclyl), -NHS(O)(C1-6 alkyl), -N(C1-6 alkyl)(S(O)(C1-6 alkyl), -S(O)N(C1-6 alkyl)2, -S(O)(C1-6 alkyl), -S(O)(NH)(C1-6 alkyl), -S(O)(C2-6 alkenyl), -S(O)(C2-6 alkynyl), -S(O)(C3-10 cycloalkyl), -S(O)(C1-6 haloalkyl), -S(O)(aryl), -S(O)(heteroaryl), -S(O)(heterocyclyl), -S(O)2(C1-6 alkyl), -S(O)2(C2-6 alkenyl), -S(O)2(C2-6 alkynyl), -S(O)2(C3-10 cycloalkyl), -S(O)2(C1-6 haloalkyl), -S(O)2(aryl), -S(O)2(heteroaryl), -S(O)2(heterocyclyl), -S(O)2NH(C1-6 alkyl), or -S(O)2N(C1-6 alkyl)2; wherein each alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl of R30 is optionally substituted with one to four substituents independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, -OH, -NH2, -NH(C1-6 alkyl), -NH(C3-10 cycloalkyl), -NH(C1-6 haloalkyl), -NH(aryl), -NH(heteroaryl), -NH(heterocyclyl), -N(C1-6 alkyl)2, -N(C3-10 cycloalkyl)2, -NHC(O)(C3-10 cycloalkyl), -NHC(O)(C1-6 haloalkyl), -NHC(O)(aryl), -NHC(O)(heteroaryl), -NHC(O)(heterocyclyl), -NHC(O)O(C1-6 alkyl), -NHC(O)O(C2-6 alkynyl), -NHC(O)O(C3-10 cycloalkyl), -NHC(O)O(C1-6 haloalkyl), -NHC(O)O(aryl), -NHC(O)O(heteroaryl), -NHC(O)O(heterocyclyl), -NHC(O)NH(C1-6 alkyl), -S(O)(NH)(C1-6 alkyl), S(O)2(C1-6 alkyl), -S(O)2(C3-10 cycloalkyl), -S(O)2(C1-6 haloalkyl), -S(O)2(aryl), -S(O)2(heteroaryl), -S(O)2(heterocyclyl), -S(O)2NH(C1-6 alkyl), -S(O)2N(C1-6 alkyl)2, -O(C1-6 alkyl), -O(C3-10 cycloalkyl), -O(C1-6 haloalkyl), -O(aryl), -O(heteroaryl), or -O(heterocyclyl).
2. The compound of claim 1, wherein R3 is hydrogen, cyano, or C1-6 haloalkyl.
4. The compound of any preceding claim , wherein n is 0 or 1.
5. The compound of any preceding claim , wherein n is 1.
6. The compound of any preceding claim, wherein R6, R7, R8, and R9 are hydrogen.
7. The compound of any preceding claim, wherein R1 is hydrogen.
8. The compound of any preceding claim, wherein R2 is -OH.
9. The compound of any preceding claim, wherein R4 is cyano, -L-C3-10 cycloalkyl, -L-heterocyclyl, -L-aryl, or -L-heteroaryl; wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl of R4 is optionally substituted with 1-3 R14.
10. The compound of any preceding claim, wherein R4 is cyano, -L-cycloalkyl, -L-aryl, or -L- heteroaryl; wherein the cycloalkyl, aryl, or heteroaryl of R4 is optionally substituted with 1-3 R14.
11. The compound of any preceding claim, wherein L is a bond, C1-2 alkylene, C2 alkynylene, -O-, -S-, or -S(O)2-.
12. The compound of any preceding claim, wherein R4 is cyano, -L-cycloalkyl, -L-aryl, or -L- heteroaryl; wherein the cycloalkyl, aryl, or heteroaryl of R4 is optionally substituted with 1-3 R14; and L is a bond, C1-2 alkylene, C2 alkynylene, -O-, -S-, or -S(O)2-.
13. The compound of claim 12, wherein each R14 is independently selected from the group consisting of halo, cyano, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, and aryl.
14. The compound of any preceding claim, wherein R4 is cyano, -L-cycloalkyl, -L-aryl, or -L- heteroaryl; wherein the cycloalkyl, aryl, or heteroaryl of R4 is optionally substituted with 1-3 R14 independently selected from the group consisting of halo, cyano, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, and C1-6 haloalkoxy; and L is a bond, C1-2 alkylene, C2 alkynylene, -O-, -S-, or -S(O)2-.
15. The compound of any preceding claim, wherein R4 is cyano, phenyl, 2-fluorophenyl, 3- fluorophenyl, 4-fluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-methylphenyl, 3- methylphenyl, 4-methylphenyl, 2,6-dimethylphenyl, 3,5-dimethylphenyl, 2-trifluoromethylphenyl, 3- trifluoromethylphenyl, 4-trifluoromethylphenyl, 2-isopropylphenyl, 3-isopropylphenyl, 4- isopropylphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2-trifluoromethoxyphenyl, 3- trifluoromethoxyphenyl, 4-trifluoromethoxyphenyl, naphthalen-1-yl, 4-fluoro-3-methylphenyl, 2-fluoro- 3-methylphenyl, 2-fluoro-5-methylphenyl, 2-p-tolyl-ethyl, 2-chloro-phenylethynyl, 2-(2-chloro-phenyl)- ethyl, 2-fluoro-4-methoxy-phenyl, 2,4-difluoro-phenyl, 2,5-difluoro-phenyl, 2-fluoro-3-methoxyphenyl, 1,1'-biphenyl]-2-yl, 1,1'-biphenyl]-3-yl, 1,1'-biphenyl]-4-yl, 2,4-dimethylphenyl, 2,5-dimethylphenyl, 2- chloro-4-(trifluoromethoxy)phenyl, 2-fluoro-3-methylphenyl, 2-fluoro-4-methoxyphenyl, 2-fluoro-5- methoxyphenyl, 2-fluoro-5-methylphenyl, 2-methyl-4-(trifluoromethoxy)phenyl, 3,4-dimethylphenyl, 3,5-difluorophenyl, 3,5-difluoropyridin-4-yl, 3-cyanophenyl, 3-fluoropyridin-4-yl, 4-cyanophenyl, 4- fluoro-3-methylphenyl, 6-(trifluoromethoxy)pyridin-3-yl, or cyclopropyl.
16. The compound of any preceding claim, wherein: R1 is hydrogen; R2 is -OH; R3 is hydrogen, cyano, or C1-6 haloalkyl; and
each of R6, R7, R8, and R9 is hydrogen.
17. The compound of claim 1, wherein: R1 is hydrogen; R2 is -OH; R3 is hydrogen, cyano, or C1-6 haloalkyl; each of R6, R7, R8, and R9 is hydrogen; and R4 is cyano, phenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2-chlorophenyl, 3- chlorophenyl, 4-chlorophenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 2,6-dimethylphenyl, 3,5-dimethylphenyl, 2-trifluoromethylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 2- isopropylphenyl, 3-isopropylphenyl, 4-isopropylphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4- methoxyphenyl, 2-trifluoromethoxyphenyl, 3-trifluoromethoxyphenyl, 4-trifluoromethoxyphenyl, naphthalen-1-yl, 4-fluoro-3-methylphenyl, 2-fluoro-3-methylphenyl, 2-fluoro-5-methylphenyl, 2-p-tolyl- ethyl, 2-chloro-phenylethynyl, 2-(2-chloro-phenyl)-ethyl, 2-fluoro-4-methoxy-phenyl, 2,4-difluoro- phenyl, 2,5-difluoro-phenyl, 2-fluoro-3-methoxyphenyl, 1,1'-biphenyl]-2-yl, 1,1'-biphenyl]-3-yl, 1,1'- biphenyl]-4-yl, 2,4-dimethylphenyl, 2,5-dimethylphenyl, 2-chloro-4-(trifluoromethoxy)phenyl, 2-fluoro- 3-methylphenyl, 2-fluoro-4-methoxyphenyl, 2-fluoro-5-methoxyphenyl, 2-fluoro-5-methylphenyl, 2- methyl-4-(trifluoromethoxy)phenyl, 3,4-dimethylphenyl, 3,5-difluorophenyl, 3,5-difluoropyridin-4-yl, 3- cyanophenyl, 3-fluoropyridin-4-yl, 4-cyanophenyl, 4-fluoro-3-methylphenyl, 6- (trifluoromethoxy)pyridin-3-yl, or cyclopropyl.
18. A compound selected from Table 1, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof.
19. A pharmaceutical composition comprising one or more compounds of any preceding claim and a pharmaceutically acceptable excipient.
20. The pharmaceutical composition of claim 19, further comprising at least one additional therapeutic agent.
21. A method of inhibiting the activity of histone lysine demethylase, the method comprising bringing into contact histone lysine demethylase and an inhibitory-effective amount of a pharmaceutical composition of claim 19 or claim 20.
22. A method of treating, pretreating, or delaying onset of a condition associated with histone lysine demethylase, the method comprising administering to a patient a therapeutically effective amount of a pharmaceutical composition of claim 19 or claim 20.
23. A method of treating, pretreating, or delaying onset of a condition associated with undesirable cellular proliferation, the method comprising administering to a patient a therapeutically effective amount of a pharmaceutical composition of claim 19 or claim 20.
24. The method of claim 23, wherein the condition is cancer.
25. The method of claim 23, wherein the condition is a neoplasm, a tumor, or leukemia.
26. The method of claim 23, wherein the condition is histocytoma, glioma, astrocytoma, osteoma, lung cancer, small cell lung cancer, gastrointestinal cancer, bowel cancer, colon cancer, breast carinoma, ovarian carcinoma, prostate cancer, testicular cancer, liver cancer, kidney cancer, bladder cancer, pancreas cancer, brain cancer, sarcoma, osteosarcoma, Kaposi's sarcoma, or melanoma.
27. The method of claim 23, wherein the condition is depression, schizophrenia, Huntington disease, autism, Alzheimer’s, obsessive compulsive disorder, posttraumatic stress syndrome, bulimia nervosa, Tourette’s syndrome, bipolar disorder, serotonin syndrome, anxiety disorder, Rubinstein-Taybi syndrome, Fragile-X syndrome, Coffm-Lowry syndrome, Rett syndrome, Alpha-thalassemia/mental retardation syndrome X-linked, Immunodeficiency-centromeric instability-facial abnormalities syndrome, myotonic dystrophy, Prader-Willi syndrome, Angleman syndrome, addiction, or a learning or memory disorder.
28. A method of preventing or treating hepatitis B virus (HBV), the method comprising administering to a patient a therapeutically effective amount of a pharmaceutical composition of claim 19 or claim 20.
29. A method of preventing or treating a viral infection, the method comprising administering to a patient a therapeutically effective amount of a pharmaceutical composition of claim 19 or claim 20.
30. The method of claim 29, wherein the viral infection involves reactivation of a virus after latency in the patient.
31. The method of claim 29 or 30, wherein the viral infection is due to a herpesvirus.
32. The method of claim 31, wherein the herpesvirus is herpes simplex virus type 1, herpes simplex virus type 2, varicella zoster virus, cytomegalovirus, Epstein-Barr, or Kaposi's Sarcoma-Associated herpesvirus.
33. The method of any one of claims 29-32, wherein the patient has undergone, is undergoing, or will undergo, immunosuppression.
34. The method of any one of claims 29-33, wherein the method prevents or treats viral-induced encephalitis, viral-induced keratitis, or reduces the severity of infection.
35. The method of any one of claims 29-34, wherein the patient is an immunocompromised mammal.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163238042P | 2021-08-27 | 2021-08-27 | |
US63/238,042 | 2021-08-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023028341A1 true WO2023028341A1 (en) | 2023-03-02 |
Family
ID=83457486
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2022/041742 WO2023028341A1 (en) | 2021-08-27 | 2022-08-26 | Compounds, compositions and methods for histone lysine demethylase inhibition |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023028341A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017143011A1 (en) * | 2016-02-16 | 2017-08-24 | Chrysalis, Inc. | Histone demethylase inhibitors |
WO2017214413A1 (en) * | 2016-06-08 | 2017-12-14 | Chrysalis, Inc. | Imidazo[1,2-a]pyridine derivatives as histone demethylase inhibitors |
WO2022047230A1 (en) * | 2020-08-28 | 2022-03-03 | Fibrogen, Inc. | Compounds, compositions and methods for histone lysine demethylase inhibition |
-
2022
- 2022-08-26 WO PCT/US2022/041742 patent/WO2023028341A1/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017143011A1 (en) * | 2016-02-16 | 2017-08-24 | Chrysalis, Inc. | Histone demethylase inhibitors |
WO2017214413A1 (en) * | 2016-06-08 | 2017-12-14 | Chrysalis, Inc. | Imidazo[1,2-a]pyridine derivatives as histone demethylase inhibitors |
WO2022047230A1 (en) * | 2020-08-28 | 2022-03-03 | Fibrogen, Inc. | Compounds, compositions and methods for histone lysine demethylase inhibition |
Non-Patent Citations (15)
Title |
---|
"Handbook of Experimental Immunology", 1986, BLACKWELL SCIENTIFIC PUBLICATIONS |
"March's Advanced Organic Chemistry", 2001, JOHN WILEY, AND SONS |
"Organic Reactions", vol. 1, 1991, JOHN WILEY |
"PCR (Introduction to Biotechniques Series", 1997, SPRINGER VERLAG |
"Short Protocols in Molecular Biology", 1999, JOHN WILEY & SONS |
"Synthesis of Optically Active a-Amino Acids", vol. 1, 1989, COLD SPRING HARBOR LABORATORY PRESS |
EVANS ET AL., J. AMER. CHEM. SOC., vol. 112, 1990, pages 4011 - 4030 |
HAN ET AL., ONCOTARGET, vol. 8, no. 5, 2017, pages 8980 - 8991 |
KUO ET AL., CLIN EPIGENETICS, vol. 10, no. 1, 2018, pages 107 |
LOENARZSCHOFIELD, NAT CHEM BIOL, vol. 4, no. 3, 2008, pages 152 - 6 |
NG ET AL., NATURE, vol. 448, 2007, pages 87 - 91 |
OZER ET AL., NAT CHEM BIOL, vol. 3, no. 3, 2007, pages 144 - 53 |
TANG ET AL., ONCOTARGET, vol. 6, no. 14, 2015, pages 12723 - 39 |
WILLIAMS ET AL., J. AMER. CHEM. SOC., vol. 113, 1991, pages 9276 - 9286 |
ZHANG ET AL., ANAL. BIOCHEM., vol. 271, 1998, pages 137 - 142 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6820836B2 (en) | Phenylquinolinone derivative as a mutant isocitrate dehydrogenase inhibitor | |
CN114008033A (en) | Glucagon-like peptide 1 receptor agonists | |
TWI526440B (en) | Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-(4-(4-ethyl-piperazin-1-yl)-phenylamino)-pyrimidin-4-yl}-1-methyl-urea and salts thereof | |
JP5247681B2 (en) | 2,4-Diaminopyrimidines as inhibitors of cell cycle kinases | |
WO2013027168A1 (en) | Novel heterocyclic compounds as bromodomain inhibitors | |
JP2007514775A (en) | Stereoisomers and stereoisomer mixtures of 1- (2,4-pyrimidinediamino) -2-cyclopentanecarboximide synthesis intermediates | |
TW200838526A (en) | Carboxylic acid derivatives | |
EP2152672A1 (en) | Novel sulphoximine-substituted quinazoline and quinazoline derivatives as kinase inhibitors | |
WO2016011979A1 (en) | 2,4-disubstituted 7h-pyrrolo[2,3-d]pyrimidine derivative, preparation method and medicinal use thereof | |
KR20100022456A (en) | Novel 1,2,3,4-tetrahydroquinoxaline derivative which has, as substituent, phenyl group having sulfonic acid ester structure or sulfonic acid amide structure introduced therein and has glucocorticoid receptor-binding activity | |
WO2006034491A2 (en) | Phenyl-substituted quinoline and quinazoline compounds for the treatment of diabetes | |
US9624218B2 (en) | Pyrido[2,3-d]pyrimidin-4-one compounds as tankyrase inhibitors | |
WO2014029831A1 (en) | Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity | |
JP2020522517A (en) | Heteroaromatic compounds as vanin inhibitors | |
JP2021500334A (en) | Amine-substituted heterocyclic compounds as EHMT2 inhibitors, salts thereof, and methods for synthesizing them. | |
KR20170054421A (en) | Tetrahydroquinoline derivatives as bromodomain inhibitors | |
JPWO2009041559A1 (en) | Indazole acrylic acid amide compound | |
KR20030086327A (en) | Novel Cyano-Substituted Dihydropyrimidine Compounds and Their Use to Treat Diseases | |
TWI424998B (en) | Triazolo[1,5-a]quinolines as adenosine a3 receptor ligands | |
CN112313207B (en) | Cyano-substituted pyridine and cyano-substituted pyrimidine compounds, and preparation methods and applications thereof | |
US20160016933A1 (en) | Isoquinolines as potassium ion channel inhibitors | |
WO2004009556A1 (en) | 4-(substituted aryl)-5-hydroxyisoquinolinone derivative | |
EP4204400A1 (en) | Compounds, compositions and methods for histone lysine demethylase inhibition | |
WO2023028341A1 (en) | Compounds, compositions and methods for histone lysine demethylase inhibition | |
JP7214053B2 (en) | 6-Methoxy-3,4-dihydro-1H-isoquinoline compounds useful for treating diabetes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22777773 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |